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TUESDAY, OCTOBER 20, 2009
PALAIS DES CONGRÈS DE VERSAILLES
OPENING SESSION
19:00 Greetings:
Mr. François de Mazières. Versailles, France
Mayor of Versailles
Prof. Dominique Maraninchi, Boulogne-Billancourt, France
President, Institut National du Cancer
Dr. Margaret Foti, Philadelphia, USA
Chief Executive Officer – American Association for Cancer Research
Prof. Fabien Calvo, Boulogne-Billancourt, France
Scientific Director – Institut National du Cancer
Opening Lectures:
19:30 Isaac P. Witz, Tel Aviv, Israel – Introductory Lecture
The Tumor Microenvironment: The Making of a Paradigm
19:50 Jeffrey W. Pollard, New York, USA – Keynote Lecture
Macrophages and Metastasis
20:30 Welcome Reception – Sponsored by the City of Versailles
WEDNESDAY, OCTOBER 21, 2009
PLENARY SESSION 1: Regulation of Gene Expression in Tumor and Non-Tumor Cells in the Microenvironment
AUDITORIUM RICHELIEU
Session Dedicated to the Memory of Mary A. Pikovski
Chairperson: Margaret Foti, Philadelphia, PA, USA
08:30 Moshe Oren, Rehovot, Israel
Involvement of the p53 Tumor Suppressor in Tumor-Stroma Interactions
08:55 Avraham Raz, Detroit, MI, USA
Cleavage of Galectin-3 by Matrix Metalloproteinases Regulates Breast Cancer Progression and Metastasis
09:20 Valerie Marie Weaver, San Francisco, CA, USA
Extracellular Matrix Remodeling Forces Tumor Progression
09:45 Yoel Kloog, Tel Aviv, Israel
Intercellular Transfer of Ras and microRNAs: New Mechanisms of Non-Autonomous Protein Functions
and Post-Transcriptional Control
10:10 Mary Hendrix, Chicago, IL, USA
Reprogramming Metastatic Tumor Cells with an Embryonic Microenvironment: Convergence of Embryonic and
Tumorigenic Signaling Pathways
10:35–11:00 Coffee – Sponsored by TEVA Pharmaceutical Industries Ltd
S20PLENARY SESSION 2: Therapeutic Targeting of Tumor-Microenvironment Interactions: Pre Clinical and Clinical Studies
AUDITORIUM RICHELIEU
Chairperson: Fabien Calvo, Boulogne-Billancourt, France
11:00 Jacques Pouysségur, Nice, France
Hypoxia and Tumor progression: New Metabolic Anti-Cancer Targets
11:25 Amato Giaccia, Stanford, CA, USA
Identifying New Anti-Cancer Therapeutics Using Synthetic Lethality
11:50 Frances R. Balkwill, London, UK
Targeting Cancer-Related Inflammation
12:15 Benjamin Sredni, Ramat Gan, Israel
Interference with VLA4 and Microenvironmental Interactions by the Tellurium Compound AS101 Results in the
Sensitization of AML Cells to Chemotherapy
12:40 Eitan Yefenof, Jerusalem, Israel
Sensitizing Hemopoietic Malignant Cells to Glucocorticoid Induced Apoptosis by Protein Kinase Inhibitors
13:05 Yona Keisari, Tel Aviv, Israel
Treatment of Solid Malignant Tumors by Intra-Tumoral Diffusing Alpha-Emitting Sources: Role of Tumor Micro-
and Macro-Environmental Traits
13:30–14:45 Business Meeting and Lunch – Auditorium Richelieu
PLENARY SESSION 3: Interactions of Tumor Cells with Microenvironmental Cells and Molecules
AUDITORIUM RICHELIEU
Chairperson: Wolf H. Fridman, Paris, France
14:45 Yves A. DeClerck, Los Angeles, CA, USA
Interleukin-6 and the Tumor Microenvironment
15:10 Adit Ben-Baruch, Tel Aviv, Israel
Inflammatory Chemokines in Malignancy: Regulation by Microenvironmental and Intrinsic Factors
15:35 Eli Keshet, Jerusalem, Israel
Angiogenic Accessory Cells: VEGF-induced Recruitment and Re-programming
16:00 Robert Kerbel, Toronto, ON, Canada
Therapy-Induced Alteration of the Tumor Microenvironment: Impact of Bone Marrow Derived Cells
16:25 Margareta M. Mueller, Heidelberg, Germany
Characterization of Factors Activating Gr-1+ Inflammatory Cells in Squamous Cell Carcinoma Towards a Tumor-
supporting, Pro-angiogenic Phenotype
16:50–17:15 Coffee – Sponsored by “Cancer Microenvironment” the
official journal of the International Cancer Microenvironment Society
S21PLENARY SESSION 4: Inflammation & Protective Immunity in the Tumor Microenvironment I
AUDITORIUM RICHELIEU
Chairperson: Eiichi Tahara, Hiroshima, Japan
17:15 Catherine Sautès-Fridman, Paris, France
Role of Inflammation and Immune Privilege Microenvironment in Tumor Development
17:40 Salem Chouaib, Villejuif, France
Interaction of CTLs with Stroma Components: Endothelial Cell
Cross-Recognition by Specific CTL and Influence of Hypoxic Stress
18:05 Ron N. Apte, Beer-Sheva, Israel
The Role of IL-1R, TLR2 and TLR4 Signaling in the Malignant Process
20:00 Conference Dinner
THURSDAY, OCTOBER 22, 2009
SYMPOSIUM 1: Regulation of Gene Expression in the Tumor Microenvironment I
AUDITORIUM RICHELIEU
Chairperson: Ruth Lupu, Rochester, MN, USA
08:30 Andrei Thomas-Tikhonenko, Philadelphia, PA, USA
Attenuation of TGFβ Signaling by c-Myc-regulated microRNAs
08:50 Ruth Lupu, Rochester, MN, USA
Knockout of Heregulin (HRG) Expression Reverts Paclitaxel-Resistance and Promotes Mesenchymal Epithelial
Transition (MET) of Triple Negative Breast Cancer Cells
09:10 Stefano Indraccolo, Padova, Italy
Decoding Tumor-Host Interactions in Dormancy: Notch3-mediated Regulation of MKP-1 Promotes Tumor Cell
Survival
09:22 Tanya Kalin, Cincinnati, OH, USA
Role of Foxm1 Transcription Factor in Tumor Microenvironment
09:34 Florence Brellier, Basel, Switzerland
Tenascin-W is Overexpressed in Glioma-Associated Blood Vessels and Stimulates Angiogenesis in vitro
09:46 Hagit Turm, Jerusalem, Israel
Protease activated receptor1, PAR1 Acts via a Novel Ga13-DVL Axis to Stabilize b-catenin Levels
09:58 Matthew Farren, Buffalo, NY, USA
Tumor-Mediated Suppression of Myeloid to Dendritic Cell (DC) Differentiation via down Regulation of Protein
Kinase C βII (PKCβII) Expression
10:10 Chandana Koorella, Buffalo, NY, USA
Myeloma Cell Survival and Importance of Crosstalk between Notch1-Jagged2
and CD28-B7 Pathways in Dendritic Cells
10:22 Olatz Crende, Leioa, Bizkaia, Spain
Interleukin-18-Dependent Genes of Highly Metastatic Human Melanoma
S2210:34 Gwendal Lazennec, Montpellier, France
Interleukin-8 Expression Is Regulated by Histone Deacetylases through NF-kB Pathway in Breast Cancer
10:46 Zendra Zehner, Richmond, VA, USA
Differential Expression of MicroRNA-17-3p Reverts Morphology of Prostate Cells in lrECM Gels, Reduces Tumor
Growth in vivo and Correlates with Prostate Tumor Expression by LCM Analysis
10:58–11:30 Coffee
SYMPOSIUM 2: Interactions of Tumor Cells with Microenvironmental Cells & Molecules I
ROOM LULLI
Chairperson: Raffaella Giavazzi, Milan, Italy
08:30 Jacques Huot, Québec, QC, Canada
Regulation of Colon Cancer Metastasis by Death Receptor-3 and E-selectin
08:50 Izhak Haviv, Prahran, Vic, Australia
The Origin of Carcinoma-Associated Fibroblasts
09:10 Lu-Yuan Li, Tianjin, China
VEGI, an Endogenous Antiangiogenic Cytokine, Inhibits Hematopoietic Stem Cell Differentiation into Endothelial
Progenitor Cell
09:22 Beatriz Arteta, Leioa, Bizkaia, Spain
Colon Carcinoma Cell Interaction with Liver Sinusoidal Endothelium Inhibits Organ-Specific Anti-Tumor Immunity
via Interleukin-1-Induced Mannose Receptor
09:34 David Allard, Cambridge, UK
Reversal of the Transformed Phenotype and Normalisation of Oncogene-Regulated Genes through Contact with
Normal Cells
09:46 Claudia Andl, Nashville, TN, USA
Fibroblast-Dependent Epithelial Cell Invasion in a Reconstruct Model for Esophageal Cancer
09:58 Catherine Muller, Toulouse, France
Cancer-Associated Adipocytes: New Key Players in Breast Tumour Invasion
10:10 Charlotte Anderberg, Stockholm, Sweden
Paracrine Signaling by PDGF-CC Promotes Tumor Growth by Recruitment of Cancer-associated Fibroblasts
Secreting Osteopontin
10:22 Didier Dréau, Charlotte, NC, USA
Interplay between Stroma Chemokines and Endothelin-1 in Breast Cancer Cell Migration and Monocyte Recruitment
10:34 Ellen Van Obberghen-Schilling, Nice, France
Autocrine Fibronectin is Essential for Matrix Assembly, Integrin Usage and Adherens Junction Formation in
Endothelial Cells
10:46 Pampee Young, Nashville, TN, USA
Tumor-Derived, Low-Level TNFa Expression Augments the Formation of Tumor-Promoting Myeloid Subtype of
Vascular Leukocytes Through the Upregulation of Integrin a5 and Enhanced Binding to Fibronectin
10:58–11:30 Coffee
S23SYMPOSIUM 3: Inflammation & Protective Immunity in the Tumor Microenvironment I
ROOM COLBERT
Chairperson: Jan Bubenik, Prague, Czech Republic
08:30 Sharon Evans, Buffalo, NY, USA
Overcoming Obstacles to Cancer Immunity at the T Cell – Tumor Microvascular Checkpoint
08:50 Jan Bubenik, Prague, Czech Republic
Depletion of Treg Cells Enhances Inhibition of Tumour Growth by Cyclophosphamide Derivatives and IL-12-
producing Cellular Vaccines
09:10 Melody Swartz, Lausanne, Switzerland
Lymph Node Mimicry by Tumors Induces Immunological Tolerance
09:30 Paola Larghi, Rozzano, Italy
Role of P50 NF-kappaB in Dendritic Cell Functions
09:42 Marie-Laure Arcangeli, Marseille, France
JAM-B and JAM-C: Ying and Yang of Metastasis and Anti-Tumor Immune Response
09:54 Nadira Delhem, Lille, France
Epstein Barr Virus Infection in Hodgkin’s Lymphoma: A Mechanism Facilitating Induced Regulatory T Cells
Recruitment
10:06 Rinat Rotem-Yehudar, Yavne , Israel
CT-011, a Humanized Monoclonal Antibody, Interacts with the PD-1 Receptor and Modulates Survival and
Trafficking Signals in Effector/memory T Lymphocytes
10:18 Jean Edouard Gairin, Toulouse, France
Tumor Cell Plasticity under Immune Micro-Environment Pressure
10:30 Guerric Epron, Rennes, France
Macrophages, IL-15, and Follicular Lymphoma: Towards a Better Understanding of the Interface Between Tumor B
Cells and their Microenvironment
10:42 Riad Abes, Paris, France
Anti-Tumor Treatment of Tumor-Bearing Immunocompetent Mice with Anti-CD20 mAb Induces an Adaptive
Immune Response that can be Strengthened by IL-2 Infusion
10:54–11:30 Coffee
SYMPOSIUM 4: Molecular Pathways in the Tumor Microenvironment I
AUDITORIUM RICHELIEU
Chairperson: Michael Micksche, Vienna, Austria
11:30 Mircea Ivan, Indianapolis, IN, USA
Hypoxia-Regulated MicroRNAs, New Players in Tumorigenesis
11:50 Pierre Sonveaux, Brussels, Belgium
Role of Lactate as a Fuel in a Unique Microenvironmentally Controlled Metabolic Symbiont
12:02 Emily Chen, Stony Brook, NY, USA
Hypoxia Tolerance and Breast Cancer Metastasis
S2412:14 Shoukat Dedhar, Vancouver, BC, Canada
Silencing Hypoxia Mediated Expression of Carbonic Anhydrase IX Induces Regression of Primary Breast Tumor
Growth and Metastasis
12:26 Ludwig Dubois, Maastricht, The Netherlands
Specific Sulfonamide Inhibitors of CA IX are able to Image Hypoxia Response and Enhance the in vivo Therapeutic
Effect of Conventional Cancer Treatments
12:38 Marina Konopleva, Houston, TX, USA
Targeting Hypoxic Microenvironment in Acute Lymphocytic Leukemia (ALL)
12:50 Nathalie M. Mazure, Nice, France
Mitochondrial VDAC3 Splice Variant is Induced in Hypoxia and Protects from Apoptosis
13:02 Sarah Crawford, New Haven, CT, USA
Biomechanical Model of Stress-Dependent Formation of Tissue Organizing Structures (TOS) Associated with Solid
Tumor Formation, Invasion and Metastasis
13:14 Paola Mazzarelli, Rome, Italy
EGFR Signaling Mediates Metabolism-Dependent Epigenetic Control in a Model of Human Breast Cancer. CPT1A
is a Novel Partner of Histone Deacetylase 1 in Cell Death Escaping Mechanisms
13:26 Constantinos Koumenis, Philadelphia, PA, USA
The GCN2-ATF4 Pathway is a Key Determinant of Tumor Cell Survival and Proliferation in Response to Amino
Acid and Glucose Deprivation
Afternoon free
SYMPOSIUM 5: The Role of the Tumor Microenvironment in Tumor Progression I
ROOM LULLI
Chairperson: Avraham Raz, Detroit, MI, USA
11:30 Dave Hoon, Santa Monica, CA, USA
Epigenetic Regulation of SPARC in Tumor Microenvironment Stromal Cells is Associated with Vascular Status of
Early Stage Colon Cancer
11:50 Ugo Cavallaro, Milan, Italy
The New Identity of L1: from a Neural Adhesion Molecule to a Central Modulator of Tumor/Microenvironment
Crosstalk?
12:10 David Barron, Houston, TX, USA
Further Defining Reactive Stroma in Prostate Cancer
12:22 Virginie Dangles-Marie, Paris, France
Newly Characterised ex vivo Colospheres as a Three-Dimensional Colon Cancer Cell Model of Tumour
Aggressiveness
12:34 Steven Mittelman, Los Angeles, CA, USA
Adipocytes Protect Acute Lymphoblastic Leukemia Cells from Chemotherapy
12:46 Dimitris Kletsas, Athens, Greece
Human Lung Fibroblasts Prematurely Senescent after Exposure to Ionizing Radiation Enhance the Growth of
Malignant Epithelial Cells in vitro and in vivo.
12:58 Ann-Charlotte Johansson, Linköping, Sweden
Cancer-Associated Fibroblasts Protect Head and Neck Squamous Cell Carcinoma Cells from Cetuximab-Induced
Cytotoxicity
S2513:10 Magdalena Dutsch-Wicherek, Krakow, Poland
RCAS1 Protein Involvement in Creation of Suppressive Tumor Microenvironment in Salivary Gland Adenocarcinoma
13:22 Sumanta Goswami, Bronx, NY, USA
Tumor Microenvironment Induced Drug and Radio Resistance in Invasive Breast Cancer Cells
Afternoon free
SYMPOSIUM 6: Phenotypic & Functional Alterations in the Tumor Microenvironment
ROOM COLBERT
Chairperson: Theresa L. Whiteside, Pittsburgh, PA, USA
11:30 Viktor Umansky, Heidelberg, Germany
Immunosuppressive Tumor Microenvironment in ret Transgenic Mouse Melanoma Model
11:50 Theresa L. Whiteside, Pittsburgh, PA, USA
Mechanisms of Tumor-escape from the Immune System: Adenosine-producing Treg, Exosomes and Tumor-
associated TLRs
12:10 Curzio Rüegg, Lausanne, Switzerland
Radiation-Induced Modifications of the Tumor Microenvironment Promote Metastasis
12:30 Dan Mercola, Irvine, CA, USA
The Microenvironment Adjacent to Prostate Cancer Exhibits Numerous Differential Expression Changes that are
Useful for Diagnosis without Tumor Cells
12:50 Raj Tiwari, Valhalla, NY, USA
Bone Marrow Endothelial Progenitor Cells are Systemic Sensors of Breast Cancer
13:02 Nancy Boudreau, San Francisco, CA, USA
Stabilization of the Breast Tumor Microenvironment Using Hox Genes
13:14 Jing Yang, Houston, TX, USA
Macrophages are an Important Component of Myeloma Microenvironment and Protect Myeloma Cells from
Chemotherapy Drug-Induced Apoptosis
13:26 Ralph R. Weichselbaum, Chicago, IL, USA
Blockade of TNFα Signaling in Tumor-associated Macrophages: a New Radiosensitizing Strategy
Afternoon free
FRIDAY, OCTOBER 23, 2009
SYMPOSIUM 7: Regulation of Gene Expression in the Tumor Microenvironment II
AUDITORIUM RICHELIEU
Chairperson: Eva Klein, Stockholm, Sweden
08:30 Eva Klein, Stockholm, Sweden
The Role of Microenvironment on the Regulation of Epstein-Barr Virus Latent Gene Expression
08:50 Ben-Zion Katz, Tel-Aviv, Israel
Adhesive Interactions Regulate Transcriptional Diversity in Malignant B-cells
09:10 Kerstin Junker, Jena, Germany
Changes in Epigenetic Expression Patterns of Tumour Associated Fibroblasts (TAF)
S2609:22 Emilie Buache, Illkirch, France
Cancer Cell-adipocyte Cross-talk: Role of Matrix Metalloproteinase-11/stromelysin-3
09:34 Corinne Bousquet, Toulouse, France
Forced Hemidesmosome Assembly as a Novel Mechanism for Somatostatin Receptor sst2 Tumor Suppressive
Activity in Pancreatic Cancer
09:46 Vincent Frontera, Marseille, France
Anti-JAM-C Tumor Growth Inhibition Occurs through Modulation of Thrombomodulin Expressing Stromal Cells
09:58 Véronique Machelon, Clamart, France
Identification of Glucocorticoid-Induced Leucine Zipper as a Key Regulator of Tumor Cell Proliferation in Epithelial
Ovarian Cancer
10:10 Sarah Pringels, Ghent, Belgium
Correlated Expression Analysis of VEGF Family Members and Lipid Inflammatory Mediators in Human Colon
Polyps and Carcinomas and Liver Metastases
10:22 Gertraud Orend, Strasbourg, France
Tenascin-C in the Tumor Microenvironment Triggers Oncogenic Signaling
10:34 Rami Aqeilan, Jerusalem, Israel
WWOX Expression Suppresses Tumorigenecity by Inducing Apoptosis and Attenuating Migration of Metastatic
Cells
10:46 Jozefa Wesierska-Gadek, Vienna, Austria
Oncogenes do not Fully Override the Cellular Programme: Pronounced Impact of Cellular Microenvironment
10:58–11:30 Coffee
SYMPOSIUM 8: Interactions of Tumor Cells with Microenvironmental Cells & Molecules II
ROOM LULLI
Chairperson: Angelo Messina, Catania, Italy
08:30 Karin Joehrer, Innsbruck, Austria
The Role of Myeloma-Derived Chemokine CCL27 on Tumor Progression and Immune Escape
08:50 Medhat Shehata, Vienna, Austria
Reconstitution of PTEN Activity and Inhibition of the PI3-K/Akt Signaling Prevent the Pro-Survival Effect of Bone
Marrow Microenvironment and Induce Apoptosis in CLL Cells
09:10 Harry L. Ioachim, New York, NY, USA
Interactions of Microenvironment with Carcinomas Depend on Tumor Type, Grade and Stage
09:22 Abdelilah Aboussekhra, Riyadh, Saudi Arabia
Role of the Tumor Suppressor p16 Protein in Tumor-Stromal Interactions in Breast Cancer
09:34 Michael Elkin, Jerusalem, Israel
Role of Heparanase in Colitis Associated Cancer
09:46 Karen Hunter, New York, NY, USA
The Role of Heparanase in Promoting Multistage Pancreatic Islet Tumorigenesis
09:58 Margarida Bernardo, Detroit, MI, USA
Maspin Restores Redifferentiation of Prostate Cancer Cells in Collagen I
10:10 Lingtao Wu, Los Angeles, CA, USA
Osteoblastic Maturation-dependent Microenvironment Mediated by Retinoid Signaling Inhibits Proliferation and
Induces Terminal Differentiation of Leukemia Cells
S2710:22 Laura Gibson, Morgantown, WV, USA
VE-cadherin Regulates Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Sensitivity
to Apoptosis
10:34 Ayaka M. Silverman, Los Angeles, CA, USA
Galectin-3 Binding Protein Produced by Neuroblastoma Cells Stimulates the Expression of Interleukin-6 in the
Tumor Microenvironment
10:46 Hao-Wei Wang, New York, NY, USA
Tumor-Derived IL-4 Upregulates Cathepsin Activity in Tumor-Associated Macrophages to Promote Cancer
Development and Progression
10:58–11:30 Coffee
SYMPOSIUM 9: Inflammation & Protective Immunity in the Tumor Microenvironment II
ROOM COLBERT
Chairperson: Jan Żeromski, Poznan, Poland
08:30 Michal Baniyash, Jerusalem, Israel
Chronic Inflammation-Induced Immunosuppression: Micro and Macro Environmental Factors and Implications for
Cancer Therapy
08:50 Jan Żeromski, Poznan, Poland
Functional Studies on Toll-Like Receptor Expression on Cell Lines of Laryngeal Carcinoma
09:10 Karin de Visser, Amsterdam, The Netherlands
Functional Assessment of the Inflammatory Tumor Microenvironment during Spontaneous Breast Cancer
Progression and Metastasis Formation
09:22 Moshe Elkabets, Beer-Sheva, Israel
A Novel Tumor-Derived Inflammatory Myeloid Suppressor Cell Subset Inhibits Anti-Tumor Activity of T and NK
Cells
09:34 Isabelle Cremer, Paris, France
Triggering of TLR7 and 8 on Human Lung Cancer Induces Cell Survival and Chemoresistance
09:46 Guillaume Sarrabayrouse, Nantes, France
Tumor-Specific CD4CD8ab T Cells Infiltrating Human Colorectal Tumors
09:58 Vladislava O. Melnikova, Houston, TX, USA
The Signaling Pathway PAR1-PAFR-MUC18 Links Inflammation with Melanoma Metastasis
10:10 Samuel Lundin, Gothenburg, Sweden
Extensive Upregulation of Proinflammatory Cytokines in the Gastric Mucosa of Stomach Cancer Patients
10:22 Pi-Ling Chang, Birmingham, AL, USA
Host Osteopontin Maintains an Acute Inflammatory Response in the Tumor Microenvironment to Suppress Extrinsic
Cancer Cell Progression
10:34 Esther N. Arwert, Cambridge, UK
Tumour Formation Initiated by Nondividing Epidermal Cells via an Inflammatory Infiltrate
10:46 Aline M. Betancourt, New Orleans, LA, USA
The Human Pro-inflammatory Antimicrobial Peptide LL-37 Supports Ovarian Tumor Progression by the
Recruitment of Multipotent Mesenchymal Stromal Cells and other Immunosuppressive Cells
10:58–11:30 Coffee
S28SYMPOSIUM 10: The Role of the Tumor Microenvironment in Tumor Progression II
AUDITORIUM RICHELIEU
Chairperson: Ruth J. Muschel, Oxford, UK
11:30 Dario Marchetti, Houston, TX, USA
Heparanase: A Critical Determinant of Breast Cancer Metastasis to Brain
11:50 Adriana Haimovitz-Friedman, New York, NY, USA
A Ceramide Rheostat Balances Angiogenesis and Anti-angiogenesis
12:10 Yoav Leiser, Haifa, Israel
Heparanase Role in Oral Cancer Prognosis and Cellular Differentiation
12:22 Mariagrazia Uguccioni, Bellinzona, Switzerland
Perivascular Expression of CXCL9 and CXCL12 in Primary Central Nervous System Lymphoma: Chemokine
Synergism Controls Cell Infiltration and Positioning
12:34 Sivan Izraely, Tel-Aviv, Israel
A Molecular Signature of Melanoma Brain Metastasis: Development and Characterization of a Novel Human
Melanoma Mouse Model
12:46 Ashleigh Hill, Belfast, Northern Ireland, UK
Characterization of Interleukin-8 Promoted Protease Expression and Activity in Relation to Prostate Cancer
Metastasis to the Bone
12:58 Lukas Hawinkels, Leiden, The Netherlands
MMP-14 (MT1-MMP) Mediated Endoglin Shedding Regulates Tumour Angiogenesis
13:10 Shelly Maman, Tel-Aviv, Israel
Neuroblastoma Macro- and Micro-Metastasis: Interactions with the Microenvironment
13:22 Yong Li, Sydney, NSW, Australia
Co-expression of Invasive Markers (uPA, CD44) and Multiple Drug Resistance Proteins (MDR1, MRP2) is
Correlated with Epithelial Ovarian Cancer Progression
13:34–14:30 Lunch
SYMPOSIUM 11: Therapeutic Targeting of the Tumor Microenvironment – Pre-clinical and Clinical Studies I
ROOM LULLI
Chairperson: Daniel Zagury, Paris, France
11:30 Daniel Zagury, Paris, France
Kinoid Vaccine, a New Immunotherapeutic Generation to Target Tumor Released Ectopic Cytokines
11:50 Albrecht Reichle, Regensburg, Germany
Comparative Uncovering of Tumors’ Systems Biology by Modular Targeting of Tumor-Associated Inflammation
12:10 Raymond Frade, Evry, France
Tumor Micoenvironment Is Controled by Procathepsin L Secretion:A New GeneTherapy to Inhibit Progression of
Tumors Induced by Human Melanoma Cells
12:22 Michael Andreeff, Houston, TX, USA
Disruption of Leukemia/Stroma Cell Interactions by CXCR4 Antagonists Enhances Chemotherapy and Signal
Transduction-Induced Apoptosis in Leukemias
S2912:34 Shijie Cai, Oxford, UK
Role of Tetrahydrobiopterin in Regulation of Tumor Angiogenesis Mediated by PI3K/Akt, eNOS and Ras Pathway
12:46 Katherine Cook, Winston-Salem, NC, USA
Angiotensin-(1-7) Inhibits Breast Tumor Growth in an Orthotopic Murine Model by Reducing Angiogenesis and
Fibrosis
12:58 Patricia E. Gallagher, Winston-Salem, NC, USA
Angiotensin-(1-7) Inhibits VEGF and PlGF to Reduce Tumor Angiogenesis in Triple Negative Breast Cancer in an
Orthotopic Mouse Model
13:10 Charlotta Dabrosin, Linköping, Sweden
Tamoxifen and the Lignan Enterolactone Increase in vivo Levels of IL-1Ra and Decrease Tumor Angiogenesis in
Estrogen Dependent Breast Cancer Explants
13:22–14:30 Lunch
SYMPOSIUM 12: Proteomics, Imaging & Biomarkers of the Tumor Microenvironment
ROOM COLBERT
Chairperson: Yona Keisari, Tel Aviv, Israel
11:30 Francesca Botta, Lausanne, Switzerland
Non Invasive Molecular Monitoring of Tumor Angiogenesis
11:42 John D. Lewis, London, ON, Canada
Intravital Imaging of Human Prostate Cancer Using Bombesin-Targeted Viral Nanoparticles
11:54 Christopher Gerner, Vienna, Austria
Novel Multiple Myeloma Biomarker Candidates Identified in the Secretome of Bone Marrow Fibroblasts and
Endothelial Cells
12:06 Thomas Mohr, Vienna, Austria
How do Endothelial Cells Shape the Tissue Microenvironment? A Proteomic Approach.
12:18 Astrid Enkelmann, Jena, Germany
Changes in Proteomic Expression Patterns of Tumour Associated Fibroblasts (TAF) by Interaction with Urinary
Bladder Carcinoma Cells
12:30 Arie Admon, Haifa, Israel
The Serum Soluble HLA Class I Peptidome as a Source for Cancer Biomarkers and a Possible Modulator of the
Tumor Microenvironment
SYMPOSIUM 13: Molecular Pathways in the Tumor Microenvironment II
ROOM COLBERT
Chairperson: Ben-Zion Katz, Tel-Aviv, Israel
12:42 Nitza Lahat, Haifa, Israel
Hypoxia and PMA-Induced Maturation Inhibit TIMP-2 Secretion from Human Monocytes and Enhance
Angiogenesis
12:54 Kasper Rouschop, Maastricht, The Netherlands
The Unfolded Protein Response Protects Cells during Hypoxia through Preservation of Autophagic Capacity
S3013:06 Nic Savaskan, Berlin, Germany
Molecular and Cellular Characterization of the Brain Tumor Microenvironment with Focus on Peritumoral Brain
Swelling
13:18 David Waugh, Belfast, Northern Ireland, UK
Importance of Differential Stress-Induced CXC-chemokine Expression and Signalingin Regulating Cancer and
Stromal Cell Function in PTEN-deficient Prostate Tumours
13:30–14:30 Lunch
PLENARY SESSION 5: Inflammation & Protective Immunity in the Tumor Microenvironment II
AUDITORIUM RICHELIEU
Chairperson: Menashe Bar-Eli, Houston, TX, USA
14:30 Alberto Mantovani, Milan, Italy
Cancer-Related Inflammation: The Seventh Hallmark of Cancer
14:55 Laurence Zitvogel, Villejuif Cedex, France
How Anticancer Therapies Switch on the Immune System?
15:20 Lisa M. Coussens, San Francisco, CA, USA
Inflammation and Cancer: Insights into Organ-specific Immune Regulation of Cancer Development
15:45 Jerome Galon, Paris, France
Intratumoral Immune Reaction: A Novel Paradigm for Cancer
16:10 Claire Lewis, Sheffield, UK
Regulation of Macrophage Function by the Tumor Microenvironment: Role of Hypoxia and Angiopoietin-2
16:35–17:00 Coffee
PLENARY SESSION 6: The Role of the Microenvironment in Tumor Progression
AUDITORIUM RICHELIEU
Chairperson: Suresh Mohla, Bethesda, MD, USA
17:00 Kornelia Polyak, Boston, MA, USA
Regulation of In Situ to Invasive Breast Carcinoma Transition
17:25 Adriana Albini, Milano, Italy EACR sponsored speaker
Role of the Tumour Microenvironment in Angiogenesis and in Prediction of Breast Cancer Metastasis
17:50 Yosef Yarden, Rehovot, Israel
Molecular Basis of Growth Factor-Induced Mammary Cell Migration: Implications to HER2-positive Breast Cancer
18:15 David Lyden, New York, NY, USA
The Metastatic Niche: Adapting the Foreign Soil
18:40 Israel Vlodavsky, Haifa, Israel
Heparanase: One Molecule with Multiple Functions in Cancer Progression
S31SATURDAY, OCTOBER 24, 2009
SYMPOSIUM 14: Interactions of Tumor Cells with Microenvironmental Cells III
AUDITORIUM RICHELIEU
Chairperson: Fernando Vidal-Vanaclocha, Leioa, Bizkaia, Spain
08:30 Maty Tzukerman, Haifa, Israel
Microenvironment-Dependent Support of Self Renewing Ovarian Cancer Stem Cells
08:50 Fernando Vidal-Vanaclocha, Leioa, Bizkaia, Spain
Hepatomimetic Properties of Colon Cancer Cells: Microenvironmental Regulation and Clinical Implications
09:10 Marcelo Ehrlich, Tel Aviv, Israel
Disabled-2 a Potential Integrator of TGF-β Signaling and Trafficking in Epithelial to Mesenchymal Transition and
Dedifferentiated Tumor Cell Lines
09:30 Andrei Bakin, Buffalo, NY, USA
Integrins in EMT and Tumor Microenvironment
09:50 Ruth J. Muschel, Oxford, UK
Vascular Co-option in Brain Metastasis
10:10–10:30 Coffee
SYMPOSIUM 14 (cont’d)
10:30 Judith Leibovici, Tel- Aviv, Israel
The Aging Host Microenvironment May Reduce Tumor Progression by Reducing Genomic Instability
10:42 Roy-Akira Saito, Stockholm, Sweden
FoxF1 Regulates Tumor-promoting Properties of Cancer-associated Fibroblasts in Lung Cancer
10:54 Li Yang, Bethesda, MD, USA
Effect and Regulation of Gr-1+CD11b+ Immature Myeloid Cells in Tumor Microenvironment and Beyond
11:06 Jillian L. Werbeck, Columbus, OH, USA
Ets2 in Lung Fibroblasts Promotes the Growth of Metastatic Breast Cancer Cells
11:18 Qing Yi, Houston, TX, USA
C-reactive Protein Protects Myeloma Cells from Apoptosis via Activating ITAM-containing FcgRII
11:30 Rosandra Kaplan, New York, NY, USA
Bone Marrow-Derived Hematopoietic Progenitor Cells as Mediators of Metastasis
11:42 Ezio Laconi, Cagliari, Italy
The Microenvironment of Hepatic Nodules is Necessary for Tumor Progression
SYMPOSIUM 15: The Role of Microenvironmental Molecules in Tumor Progression
ROOM LULLI
Symposium sponsored by Roche, France
Chairperson: Dave Hoon, Santa Monica, CA, USA
08:30 Elena Voronov, Beer Sheva, Israel
The Differential Role of Microenvironmental IL-1α and IL-1β in Tumor Angiogenesis
S3208:50 Sabina Pucci, Rome, Italy
VEGF-A165A and IL-6 in Human Colon Cancer: A Microenvironment Cooperation Leading to Cell Death Escape
through microRNAS Dysregulation
09:02 Ji Ming Wang, Frederick, MD, USA
Receptor “Hijacking” by Malignant Glioma Cells: A Tactic for Tumor Progression
09:14 Masataka Majima, Sagamihara, Kanagawa, Japan
Recruitment of Mast Cells to the Tumor Microenvironment via a High Affinity Leukotriene B4 Recepter Signaling
Enhances Tumor-Associated Angiogenesis and Tumor Growth
09:26 Antonia Patsialou, Bronx, NY, USA
Invasion of Human Breast Cancer Cells In Vivo Requires both Paracrine and Autocrine Loops Involving the Colony
Stimulating Factor-1 Receptor
09:38 Abdel-Majid Khatib, Paris, France
Regulation of Tumorigenesis, Angiogenesis and Metastasis by the Proprotein Convertases (PCs)
09:50 Camille Laurent, Toulouse, France
Characterization of the Immunological Microenvironment in Follicular Lymphoma
10:02–10:30 Coffee
SYMPOSIUM 15 (Cont’d)
10:30 Steven Mason, New York, NY, USA
The Proteolytic Cascade in Metastasis
10:42 Laura Fung, London, ON, Canada
EGFL7 Protein Expression Effects Tumor Progression by Influencing the Rate of Angiogenesis
10:54 Laurie McCauley, Ann Arbor, MI, USA
A Novel Role for Megakaryocytes in the Bone Marrow Microenvironment of Prostate Cancer Metastasis
11:06 Amitava Chatterjee, Kolkata, India
Culture of Human Laryngeal Carcinoma Cell Line Hep-2 in Presence of Fibronectin Increases MMP-9 Expression
with the Involvement of Multiple Signaling Pathways
11:18 Miranda Ween, Adelaide, South Australia, Australia
Transforming Growth Factor Induced Protein TGFβI Promotes Ovarian Cancer Cell Motility and Adhesion to
Peritoneal Cells
11:30 Grégoire Mignot, Dijon, France
Membrane Hsp72 from Tumor-Derived Exosomes Mediates p-Stat3 Dependent Function of Myeloid Suppressor
Cells through the TLR2-MyD88 Pathway
11:42 Cornelia Trimble, Baltimore, MD, USA
Immune Cell Homing in Preinvasive HPV Disease
SYMPOSIUM 16: Therapeutic Targeting of Tumor-Microenvironment Interactions – Pre-clinical and Clinical Studies II
ROOM COLBERT
Chairperson: W. Gillies McKenna, Oxford, UK
08:30 W. Gillies McKenna, Oxford, UK
Tumor Conditioning: Modulation of the Tumour Microenvironment by Signalling Inhibition as a Strategy for
Improving Cancer Therapy
S3308:50 Yoshiaki Kubota, Tokyo, Japan
M-CSF Inhibition Selectively Targets Pathological Angiogenesis and Lymphangiogenesis
09:12 Sheng-Bin Peng, Indianapolis, IN, USA
Pre-Clinical Evaluation of a Potent and Selective CXCR4 Peptide Antagonist Currently in Phase 1 Trials for Cancer
09:24 Tanaya Shree, New York, NY, USA
Inhibition of Cathepsin Proteases Synergizes with Maximum-Dose and Low-Dose Chemotherapy to Block Malignant
Progression in a Mouse Model of Metastatic Breast Cancer
09:36 Carlton Donald, Atlanta, GA, USA
The Effect of the PAX2 Oncogene on the Tumor Microinvironment, Tumor Progression and its Potential as a
Therapeutic Target for Prostate Cancer
09:48 Jian Wang, Bergen, Norway
Targeting the Tumor Stroma - a Novel Therapeutic Strategy Based on Separate Analysis of the Malignant and
Stromal Cell Compartments in Brain Tumors
10:00–10:30 Coffee
SYMPOSIUM 16 (Cont’d)
10:30 Jenny Worthington, Coleraine, UK
Does Hypoxia Play a Role in the Failure of Androgen Ablation Therapy for Prostate Cancer?
10:42 Mark Pines, Bet Dagan, Israel
Inhibition of Fibroblast-to-myofibroblast Transition as a Modality for Cancer Treatment: Effect of Halofuginone
10:54 Michael P. Lisanti, Philadelphia, PA, USA
Stromal Caveolin-1 Predicts Recurrence and Clinical Outcome in DCIS and Human Breast Cancers
11:06 F. Javier Oliver, Armilla, Granada, Spain
Antimetastasic Action of Parp Inhibition in Melanoma trough Counteracting Angiogenesis and emt Transition
11:18 Silke Haubeiss, Stuttgart, Germany
Targeting Cancer-Associated Fibroblasts (CAFs) with Small Molecule Inhibitors to Enhance Sensitivity of Tumors to
Conventional Chemotherapy
11:30 Lucy Allen, Amersham, Buckinghamshire, UK
Monitoring Tumour Response to the Anti-angiogenic Therapy Sunitinib with an F18-labeled Angiogenesis Imaging
Agent
CLOSING PLENARY SESSION
AUDITORIUM RICHELIEU
Chairperson: Isaac P. Witz, Tel Aviv, Israel
12:00 Poster Session – presentation of best posters and awarding
of prizes
13:00 Jan-Willem van de Loo, Brussels, Belgium
European Commission
Funding for Translational Research on the Tumour Microenvironment through EU Programmes
13:15 Concluding remarks
13:30 Adjourn
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Macrophages and Metastasis
Jeffrey W. Pollard
1
1Department of Developmental and Molecular Biology, Albert
Einstein College of Medicine, NY, NY, USA
Non-malignant cells within the tumor microenvironment play
important roles in modulating tumor progression to malignancy.
Many of these cells are derived from the hematopoietic system.
Particularly abundant are macrophages whose density in many
different human tumor types is usually positively correlated with
poor prognosis suggesting that macrophages are tumor promoting.
Studies in mouse models reinforce this idea since genetic or
chemical ablation of macrophages results in a reduction in tumor
progression and metastasis (1) (2). Functional studies have
identified several tumor-promoting functions for macrophages in
primary tumors. These include promotion of angiogenesis, tumor
cell invasion, migration and intravasation. In some cases the
signaling molecules that are produced by macrophages have been
identified at least in the context of these mouse models of breast
cancer (3, 4). In addition to these effects of macrophages at the
primary tumor site we have recently identified a sub-population of
macrophages that are required for metastatic seeding and
persistent growth at distant sites. These data together with that of
others, suggest that targeting macrophages and their unique
signaling pathways could offer new therapeutic strategies against
metastatic disease.
1. Pollard, J. W. (2004) Nature Reviews Cancer 4, 71 – 78.
2. Joyce, J. A. & Pollard, J. W. (2009) Nat Rev Cancer 9, 239–
252.
3. Condeelis, J. & Pollard, J. W. (2006) Cell 124, 263–266.
4. Lin, E. Y., Li, J. F., Gnatovskiy, L., Deng, Y., Zhu, L., Grzesik,
D. A., Qian, B., Xue, X. N., & Pollard, J. W. (2006) Cancer
research 66, 11238–11246.
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Involvement of the p53 Tumor Suppressor
in Tumor-Stroma Interactions
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The tumor suppressor functions of p53 have been extensively
studied within tumor cells and cells that are at risk of becoming
tumorous. However, recent studies indicate that p53 also
possesses non cell-autonomous tumor suppressor activities.
Thus, we report that p53 can exert its tumor suppressor activity
also within the stromal compartment of the tumor. Consequent-
ly, co-injection of p53-null fibroblasts together with PC3
human prostate cancer cells selectively augments tumor growth,
while wild type fibroblasts fail to exert a similar effect. p53-
deficient fibroblasts produce elevated levels of secreted proteins
such as SDF-1/CXCL12, which may facilitate tumor growth
and spread. Conversely, tumor-associated mutant p53 isoforms
increase the expression of SDF-1 in fibroblasts. In addition to
quenching SDF-1 production by stromal fibroblasts, p53 also
represses the expression of the SDF-1 receptor CXCR4. Of
note, siRNA-mediated downregulation of SDF-1 production
attenuates the ability of p53-null fibroblasts to augment tumor
growth. Quenching p53 function in adjacent stromal fibroblasts
may therefore provide tumor cells with a selective growth
advantage. Indeed, we found that epithelial tumor cells can
repress p53 activation in fibroblasts. This ability is acquired
when epithelial cells undergo neoplastic transformation. Inter-
estingly, this p53-repressive effect of tumor cells is exerted
more readily in cancer-associated fibroblasts (CAFs). All these
findings implicate p53 in a non cell-autonomous tumor
suppressor mechanism, exerted from stromal cells and affecting
adjacent tumor cells. Activation of stromal p53 might therefore
attenuate tumor progression even if the cancer cells themselves
do not harbor wt p53 anymore
O3
Cleavage of Galectin-3 by Matrix Metalloproteinases
Regulates Breast Cancer Progression and Metastasis
Avraham Raz
1
1Karmanos Cancer Institute, Wayne State University School of
Medicine, Detroit, MI, USA
For reasons largely unknown, Caucasian women are at a
significantly higher risk of developing breast cancer than
Asian women. Over a decade ago, mutations in BRCA1/2
were identified as genetic risk factors; however, the discovery
of additional breast cancer genes and genes contributing to
racial disparities are lacking. We report a functional germline
mutation (polymorphism) in the galectin-3 gene at position
191 (rs4644) substituting proline with histidine (P64H), which
results in susceptibility to matrix metalloproteinase (MMP)
cleavage and acquisition of resistance to drug-induced apopto-
sis. This substitution correlates with incidence of breast cancer
and racial disparity. Of note, Cleavage of galectin-3 by MMPs
is related to progression of breast and prostate cancer. We
show that galectin-3 regulated functions like chemotaxis,
chemoinvasion, heterotypic aggregation, epithelial-endothelial
cell interactions and angiogenesis are dependent in part on
cleavage of the N terminus of galectin-3 followed by its
release in the tumor microenvironment. Breast carcinoma cells
harboring cleavable galectin-3 species showed increased
chemotaxis towards collagen IV, invasion through Matrigel
and heterotypic interactions with endothelial cells resulting in
angiogenesis and 3-D morphogenesis in vitro compared to cells
harboring non-cleavable galectin-3. Wound healing studies
employing a novel cell culture insert showed increased migration
and phosphorylation of focal adhesion kinase in endothelial cells
migrating towards H64 cells compared to P64 cells. Using 3-
S37dimensional co-cultures of endothelial cells with breast cells
harboring galectin-3 peptides, we show that amino acids 1-62
and 33–250 stimulate migration and interaction of cells with the
endothelial cells. Immunohistochemical analysis of blood vessel
density and galectin-3 cleavage in a breast cancer progression
tissue array support the in vitro findings. These results indicate
that cleavage of galectin-3 in tumor microenvironment leads to
breast cancer angiogenesis and progression.
In conclusion, we provide novel data implicating a galectin-3
germline nonsynonymous functional polymorphism in breast
cancer progression and metastasis.
O4
Extracellular Matrix Remodeling Forces Tumor
Progression
Valerie Marie Weaver
1
1Department of Surgery, UCSF, San Francisco, CA, USA
Tumor progression is accompanied by a desmoplastic response
that is characterized by significant extracellular matrix (ECM)
remodeling. We have been studying the role of matrix metal-
loproteinase and lysyl oxidase-mediated collagen cross-linking
in ECM remodeling and tissue desmoplasia during breast tumor
progression. Thus far we have established a positive association
between lysyl oxidase-dependent collagen cross-linking, the
accumulation of linear, oriented collagen fibrils, tissue fibrosis
and tissue stiffening during breast transformation. We have
demonstrated that either pharmacological or antibody-mediated
inhibition of lysyl oxidase-induced collagen cross-linking
prevents tissue fibrosis, reduces tissue stiffening, enhances
tumor latency and decreases tumor incidence in both the
MMTV-Neu and PyMT transgenic mouse models of breast
cancer. We also observed that inducing lysyl oxidase-dependent
collagen cross-linking promotes tissue desmoplasia, stiffens the
tissue and promotes the malignant transformation and invasion
of an oncogenically-primed premalignant mammary epithelium.
Experiments using three dimensional organotypic models
showed that collagen cross-linking per se promotes the invasive
behavior of an oncogenically-modified mammary epithelial
tissue but is insufficient to induce invasion in normal tissues.
Because we previously observed that ECM stiffness can
enhance growth factor-dependent mammary epithelial cell
(MEC) proliferation and survival and will disrupt mammary
tissue morphogenesis by promoting integrin clustering, focal
adhesion maturation, integrin-dependent signaling through
ERK, and cell-generated force (Paszek et al., Cancer Cell
2005) we explored functional associations between ECM cross-
linking and stiffness and integrin signaling. We could show that
lysyl oxidase-dependent breast transformation in vivo and ECM
cross-linking in culture are functionally-linked to increased
actomyosin contractility and focal adhesion assembly and
signaling, elevated PI3Kinase activity and reduced PTEN
expression and activity. These findings underscore the impor-
tance of ECM remodeling in tumor progression and identify
mechanical force as a novel molecular mediator and tumori-
genesis. (Supported by grants from the Department of Energy
DE-FG02-07ER64420, DOD BCRP W81XWH-05-1-330, and
NIH CA078731A2)
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Intercellular Transfer of Ras and microRNAs: New Mechanisms
of Non-Autonomous Protein Functions and Post-Transcriptional
Control
Oded Rechavi
1, Yaniv Erlich
2, Hila Avram
3, Fedor V. Kaginov
2,
Itamar Goldstein
3, Gregory J. Hannon
2, Yoel Kloog
1
1Department of Neurobiology, The George S. Wise Faculty of Life
Sciences, Tel-Aviv University, Tel Aviv, Israel,
2Watson School of
Biological Sciences, Howard Hughes Medical Institute, Howard
Hughes Medical Institute Cold Spring Harbor Laboratory, Cold
Spring Harbor, NY, USA,
3Immunology Program, Cancer Re-
search Center, Chaim Sheba Medical Center, Tel Hashomer,
Ramat Gan, Israel
Lipidated Ras proteins are highly mobile and redistribute rapidly
between the plasma membrane and endomembranes. We postulated
that this high mobility might allow also functional “proteome
mixing” among interacting cells, particularly between immune cells.
If so, then this would support the notion that no cell is an island, and
that even these “unsplittable” units are actually non-autonomous. We
will present results on cell-contact-dependent intercellular transfer of
proteins including oncogenic H-Ras and of microRNAs. Acquisition
of oncogenic H-RasG12V by natural killer (NK) and T lymphocytes
had important biological functions in the adopting lymphocytes
including ERK phosphorylation, increased interferon-γ and tumor
necrosis factor-α secretion, enhanced lymphocyte proliferation, and
augmented NK-mediated target cell killing. We also will show that
upon cell contact, T cells acquire from B cells small RNAs, which
impact expression of target genes in the recipient T cells. Both
synthetic microRNA (miRNA) mimetics and viral miRNAs
expressed by infected B cells can be transferred into T cells. Such
mechanisms may allow cell non-autonomous post-transcriptional
control, a process, which could be exploited by tumors or virus-
infected cells.
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Reprogramming Metastatic Tumor Cells with an Embryonic
Microenvironment: Convergence of Embryonic and Tumorigenic
Signaling Pathways
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Embryonic stem cells sustain a microenvironment that facilitates a
balance of self-renewal and differentiation. Aggressive cancer cells,
expressing a multipotent, embryonic cell-like phenotype, engage in a
dynamic reciprocity with a microenvironment that promotes plastic-
S38ity and tumorigenicity. However, the cancer associated milieu lacks
the appropriate regulatory mechanisms to maintain a normal cellular
phenotype. Previous work from our laboratory reported that
aggressive melanoma and breast carcinoma express the embryonic
morphogenNodal,whichisessentialforhumanembryonicstemcells
(hESC) pluripotency. Based on the aberrant expression of this
embryonic plasticity gene by tumor cells, this current study tested
whether these cells could respond to regulatory cues controlling the
Nodal signaling pathway, which might be sequestered within the
microenvironment of hESCs, resulting in the suppression of the
tumorigenic phenotype. Specifically, we discovered that metastatic
tumor cells do not express the inhibitor to Nodal, Lefty, allowing
them to overexpress this embryonic morphogen in an unregulated
manner. However, exposure of the tumor cells to a hESC
microenvironment (containing Lefty) leads to a dramatic down-
regulation in their Nodal expression concomitant with a reduction in
clonogenicity and tumorigenesis accompanied by an increase in
apoptosis. Furthermore, this ability to suppress the tumorigenic
phenotype isdirectly associated withthe secretion of Lefty, exclusive
to hESCs, because it is not detected in other stem cell types, normal
celltypes,ortrophoblasts.Thetumor-suppressiveeffectsofthehESC
microenvironment, by neutralizing the expression of Nodal in
aggressive tumor cells, provide previously unexplored therapeutic
modalities for cancer treatment.
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Hypoxia and Tumor progression: New Metabolic Anti-Cancer
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Nutrient sensing is a fundamental process for life. In its absence,
fast growing cells of the developing embryo and of expanding
tumors would rapidly outstrip essential nutrients and die. In fact
cells sense and respond to variations in the concentration of key
nutrients. However, early on in evolution, oxygen sensing has
emerged, as a central control mechanism of energy metabolism
and vasculogenesis. At the heart of this regulatory system is the
Hypoxia-Inducible Factor, HIF, which controls, among other gene
products, the expression of VEGF-A and Angiopoïetin-2, two key
angiogenic factors in vertebrates. This finding has placed the
hypoxia-signaling pathway at the forefront of nutritional control.
HIF controls glycolysis, intracellular pH (pHi), angiogenesis, cell
migration and invasion, and so has become recognized as a strong
promoter of tumor growth.
We will highlight some of the HIF-induced gene products that
participate in tumor adaptation, resistance and progression in a
nutrient-depleted and acidic microenvironment.
First we will demonstrate that the two HIF-induced ‘BH3-only’-
proteins (BNIP3, BNIP3L/NIX), in contrast to current belief, do
not trigger cell death but, by inducing macro-autophagy, stimulate
tumor cell survival.
Second, we will show how tumor cells by expressing two HIF-
dependent membrane-bound carbonic anhydrases, CAIX and
CAXII, acidify the extracellular milieu, and ensure a more alkaline
intracellular pH favoring migration, survival and growth in a
hostile acidic microenvironment.
Third, HIF-induced glycolysis in most hypoxic tumor cells is
essential to ensure maintenance of ATP levels for growth and cell
survival. Two MonoCarboxylate Transporters MCT-1 and MCT-4,
stabilized in the plasma membrane by the common chaperon
basigin/CD147, play a key role in cancer metabolism.
We propose that appropriate exploitation of these HIF-regulated
proteins and new validated cancer targets, which control exacer-
bated tumor metabolism and intracellular pH, will be at the
forefront of anti-cancer therapy.
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Identifying New Anti-Cancer Therapeutics
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Synthetic lethality results when two nonallelic mutations that by
themselves are not lethal, answer in cell death when combined. To
screen for small molecules that acted in a synthetic lethal manner to
the loss of VHL, we needed a means of tracking cell growth in
microwellplates whenexposed toalibrary of smallmolecules.Renal
carcinoma cell lines with naturally occurring VHL mutations and
their genetically matched wild-type VHL counterparts were stably
labeledwithenhancedyellow fluorescentprotein(EYFP). Cellswere
then seeded onto 384-well plates and allowed to attach overnight.
Baseline fluorescence readings were obtained and a compound
library was added at a concentration of 5 μM. Fluorescence intensity
was read once a day for four days. An increase in fluorescence
intensity was used as a surrogate marker for cell growth. The most
promising compounds that inhibited growth of VHL-deficient cells
but still had an increase in fluorescence of cells with wild-type VHL
were validated by a short-term XTT assay, which measures cellular
metabolic activity as a surrogate for cell viability. Those compounds
that were confirmed by XTT were then subjected to clonogenic
survival assays to further verify specificity for killing VHL-deficient
cells. From this screen, we identified several small molecules, which
demonstrated selective toxicity against cells that had lost VHL
compared to isogenic matched cell lines with wild-type VHL both in
vitro and in vivo. One of these small molecules kills VHL deficient
cells by inducing autophagy and another kills by inhibiting glucose
uptake and retention. Both of these small molecules illustrate the
power of using synthetic lethality inmammalian cells todevelop new
therapeutic strategies.
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Targeting Cancer-Related Inflammation
Fran Balkwill
1
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The cells and mediators of inflammation form a major part of the
epithelial tumour microenvironment. In some cancers, inflammatory
conditions precede development of malignancy; in others, oncogenic
change drives a tumour-promoting inflammatory milieu. Whatever
its origin, this ‘smouldering’ inflammation aids proliferation and
survival of malignant cells, stimulates angiogenesis and metastasis;
subverts adaptive immunity, and alters response to hormones and
chemotherapy. Cytokines are major mediators of communication
between cells in the inflammatory tumour microenvironment and
may be important therapeutic targets in cancer patients.
The inflammatory cytokine TNF-a and its receptors are involved in
tumour promotion andprogression insomeexperimental cancers and
both are found in human cancer biopsies. Mice deficient in TNF-a or
TNFR1 are resistant to skin carcinogenesis; TNF-a drives an
autocrine cytokine network in ovarian cancer, stimulating production
of other cytokines by malignant cells, and TNF-a is important in
maintaining the tumour-associated macrophage, TAM, phenotype in
ovarian cancer. We hypothesised that neutralising its activity would
be of therapeutic benefit and tested this in Phase I/II clinical cancer
trials of TNF-a antagonists. We obtained a signal of clinical activity,
with stable disease and some partial responses achieved in patients
with advanced renal and ovarian cancer.
Interleukin 6 is another inflammatory cytokine that is implicated
in cancer progression and host tumour communication. A Phase II
trial of a therapeutic antibody against IL-6 in ovarian cancer
patients is now complete. Again we see a signal of activity in the
clinical trial and have identified potential biomarkers of response.
Finally, we have evidence that TNF-a and IL-6 signalling
pathways are intricately linked with other pathways involved in
host tumour communication, including CXCR4, CXCL12, Notch
receptors and ligands.
O10
Interference with VLA4 and Microenvironmental
Interactions by the Tellurium Compound AS101 Results
in the Sensitization of AML Cells to Chemotherapy
Benjamin Sredni
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Drug resistance is induced by the attachment of the integrin
receptor VLA-4 on leukemic cells to its ligand fibronectin. We
show that the tellurium compound ammonium trichloro(dioxo-
ethylene-O,O’-)tellurate AS101, sensitizes AML cells to ARA-C
or DNR. Sensitization of AML cells to chemotherapy by AS101
was similar to that obtained by neutralizing anti VLA antibodies.
Sensitization to chemotherapy by AS101 could be obtained in
leukemic cells expressing VLA-4, from AML patients, while not
sensitizing those not expressing this integrin. Treatment of AML
cells plated on FN with AS101 and chemotherapy, significantly
decreased pAkt and Bcl-2 when AML cells were co-treated by
AS101, the decrease correlated with the sensitizing effect of
AS101. Suggesting that treatment with AS101 may interfere with
the sequence of events in AML in which high VLA-4 in leukemic
cells reduces their chemosensitivity through interaction with FN,
resulting in a poor induction of remission, ultimately leading to
recurrence and short survival.
O11
Sensitizing Hemopoietic Malignant Cells to Glucocorticoid
Induced Apoptosis by Protein Kinase Inhibitors
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Glucocorticoids (GCs) are widely used in the therapy of
lymphomas and lymphoblastic leukemias owing to their apopto-
genic effects on these cancerous cells. A major impediment of
GC therapy is the acquisition of apoptotic resistance to GC
treatment. Also, certain lymphomas and leukemias are a priori
resistant to GC. Therefore, a desirable goal is to develop
strategies that confer GC-sensitivity on GC-resistant cells. We
observed that the broad-acting protein kinase (PK) inhibitor
Staurosporine (STS) confers GC-sensitivity on several GC-
resistant lymphoma cells. GC-resistant lymphoma cells express
elevated levels of anti-apoptotic Bcl-2 or Bcl-XL. Transfection
with Bcl-2 or Bcl-XL in sensitive cells confers resistance to GC-
induced apoptosis. STS overcomes the anti-apoptotic properties
of Bcl-2 but not of Bcl-XL. STS acts at several levels. It induces
the expression of the pro-apoptotic Nur77 orphan receptor,
which offsets the anti-apoptotic effects of Bcl-2. STS also leads
to phosphorylation of Bim by an ERK-dependent mechanism
which results in Bim upregulation. In addition, STS inhibits
PIЗK/Akt, leading to the activation of GSK3. Inhibition of GSK3
by its specific inhibitor SB216763 or by overexpression of a
dominant negative GSK3 attenuated the effect of STS. Our study
demonstrates a central role for GSK3a in promoting GC-induced
apoptosis. We found that GSK3a is sequestered to the glucocor-
ticoid receptor (GR) in the absence of ligand, but dissociates
from the GR complex upon exposure to GC to promote
apoptosis. GC-resistance in lymphoma cells can be relieved by
inhibiting the PI3K-Akt survival pathway, which exerts a
negative effect on GSK3. Our data demonstrate that lymphoma
and leukemia therapy can be improved if GCs are combined with
Protein Kinase inhibitors that shift the cell’s kinome in favor of
apoptosis-prone phenotype.
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Treatment of Solid Malignant Tumors by Intra-Tumoral
Diffusing Alpha-Emitting Sources: Role of Tumor Micro- and
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Alpha radiation is a most lethal form of radiation whose short range
limits itsusefor cancer treatment. Wedevelopeda practical solution to
treat the entire tumor with this short range radiation using intratumoral
wires, with radium-224 atoms fixed below their surface. As radium-
224 decays, it releases into the tumor, by recoil, short-lived atoms
which spread inside the tumor and release their lethal alpha particles.
We termed this treatment Diffusing Alpha-emitters Radiation Therapy
(DART). In previous studies we demonstrated DART’s ability to
control tumor development and extend survival of mice bearing
mouse or human-derived tumors, from various histological origins.
Tumors of different histotypes responded differently to the treatment,
with squamous cell carcinoma (SCC) derived tumors being the most
sensitive and pancreatic cell derived tumors the most resistant.
The extent of tumor damage may be affected by several
characteristics:
1. Factors that affect the spread of radioactive atoms and their
clearance from the tumor, i.e., fibrotic tissue, blood vessels,
compactness.
2. Tumor cell characteristics, governing sensitivity to radiation,
i.e., cell repair mechanisms.
Dosimetric measurements of the intra-tumoral spread of radioactivity
in different tumor models revealed biologically significant doses
(asymptoticallyexceeding10Gy)ofPb-212overaregionafewmmin
size. The average region diameter was largest in SCC tumors, smallest
in pancreatic tumors and intermediate for colon and lung tumors.
Measurements of the mean lethal dose (D0) for human and mouse
pancreatic, SCC and colon carcinomas irradiated by alpha
particles, showed that SCC cells are about twice as radiosensitive
to alpha radiation as all other cell lines examined.
Intratumoral tissue necrosis and tumor growth retardation are in
correlation with the distribution of released alpha emitting isotopes
and with the radiosensitivity of tumor cells. Further attempts are
made to correlate radiosensitivity with DNA repair mechanisms.
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Interleukin-6 and the Tumor Microenvironment
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The contribution of cytokines to the tumor microenvironment and to
inflammation in cancer has been the focus of much recent attention.
Amongthe cytokinesthatplay a pro-tumorigenic role incancer isIL-
6,apleiotropiccytokineproducedbystromalandinflammatorycells.
In many cancers, like multiple myeloma and neuroblastoma, the
expression of IL-6 is increased and higher levels are indicators of
poorer clinical outcome. Tumor cellsstimulatethe expressionof IL-6
by stromal cells through adhesion dependent and adhesion indepen-
dent mechanisms. The latter seems to predominate in neuroblastoma.
We have shown that Cox-2 mediated production of PGE2 and the
expression of Galectin-3 binding protein by neuroblastoma cells are
potent mechanisms of IL-6 induction in bone marrow-derived
mesenchymal cells and monocytes. IL-6 has multiple effects on
cancer progression. In the bone marrow it stimulates the maturation
and activation of osteoclast precursor cells and promotes osteolytic
bone metastasis. IL-6 also has a paracrine effect on neuroblastoma
cells which express the 2 subunits of the IL-6 receptor (IL-6R/gp80
andgp130)thatarenecessaryforIL-6-mediatedactivation ofERK1/
2 and STAT-3. Signaling is potentiated by soluble IL-6R/gp80 that
stabilizes IL-6 and acts as a potent agonist. IL-6 stimulates
the proliferation of tumor cells and enhances their survival in the
presence of cytotoxicity drugs like etoposide (an inducer of the
mitochondrial apoptotic pathway) by increasing the expression of
the anti-apoptotic proteins Bcl-2, Bcl-XL and survivin. This effect is
dependent on STAT-3 activation. In neuroblastoma, IL-6 is rarely
expressed by tumor cells and commonly expressed by bone
marrow-derived mesenchymal cells in the bone marrow and
monocytes/macrophages in primary tumors, which are also a source
of sIL-6R. Thus stromal expression of IL-6 contributes to the
protective role that the bone marrow microenvironment has against
the cytotoxic effect of chemotherapy on tumor cells. IL-6 or IL-6
mediated signaling could therefore represent valuable targets for
therapeutic intervention.
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The inflammatory milieu of tumors affects considerably cancer
development and progression. Inflammatory chemokines, including
CCL2 and CCL5 are major contributors to breast malignancy. The
two chemokines are expressed by the tumor cells in ~60–70% of
biopsies of breast cancer patients, but are minimally detected in
normal breast epithelial duct cells. In this study, we have analyzed
molecularmotif/sthatregulatethesecretionofCCL5bybreasttumor
cells. We focused on a specific region located at the 40 s loop of the
chemokine. This region was essential for the release of CCL5 by the
S41tumor cells, and for the trafficking of vesicles containing the chemo-
kine from the endoplasmic reticulum to post-golgi regions and to
secretion. Our studies have also identified the mechanisms by which
this motif regulates the release of CCL5 by the tumor cells. Also, we
determined the regulation of CCL2 and CCL5 secretion by inflamma-
tory cytokines in breast tumors. Our analyses indicate that TNFa and
IL-1b are expressedby thetumorcellsin90%of breast cancerpatients,
and that both cytokines potently promote the release of CCL2 and
CCL5 by breast tumor cells and by normal breast epithelial cells.
Combined with additional findings that provided evidence to
interactions between inflammatorycytokines and chemokines in breast
cancer, we suggest that TNFa and IL-1b that are found at the tumor
microenvironment are important up-regulators of CCL2 and CCL5
release in early and advanced stages of disease, as well as of
progression-related processes. Together, our findings identified micro-
environmental and intrinsic properties that regulate the release of the
pro-malignancy chemokines CCL2 and CCL5 by breast tumor cells,
and consequently affect disease development and progression.
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Adult angiogenesis, in general, and tumor angiogenesis, in particular,
heavily rely on myeloid cells recruited from the bone marrow and
homing to the respective target organ or tumor. There, they act as
paracrine accessory cell without whom angiogenesis is greatly
compromised. Using transgenic systems designed for conditional
gain- or loss of function of VEGF we thrive to elucidate the pivotal
role of VEGF in the recruitment of pro-angiogenic monocytes and
their re-programming. Previously, we have shown that VEGF
functions in homing monocytes to the target tissue from which it
emanates, in their perivascular positioning, and in their retention
therein. The current study addresses dynamic changes that recruited
monocytes undergo under the influence of local VEGF. Specifically,
we provide evidence supporting thenotionthatangiogenicmonocytes
do not represent a dedicated subset of cells but rather ‘regular’ Gr1+
monocytes that are nevertheless ‘educated’by VEGF tobecome more
pro-angiogenic and, importantly, also pro-arteriogenic ‘professional’
cells. These conclusions are mostly based on following the fate, gene
expression profiles and functional performance of genetically-tagged
monocytesadoptively-transferredintothecirculationofmiceinwhich
VEGF has been induced in selected organs.
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A common problem associated with cancer therapy using various
cytotoxic drugs, including chemotherapy, or other treatments, e.g.
radiation, is the property of responding tumors to rapidly
repopulate and recover from such therapies (Kim & Tannock,
Nat Rev Cancer 2005). This can significantly compromise the
progression free and overall survival benefits induced by such
therapies. Historically, tumor repopulation has been viewed
primarily, or exclusively, as an intrinsic tumor cell phenomenon.
However, we have obtained evidence for various therapy-induced
host responses that can alter the tumor microenvironment in such a
way so as to accelerate tumor repopulation after administering
therapies such as maximum tolerated dose (MTD) chemotherapy
or ‘vascular disrupting agents’ (Y Shaked et al. Science 2006; ibid
Cancer Cell 2008). These host responses consist of the rapid
systemic induction of a variety of growth factors, cytokines, and
chemokines such as SDF-1 and G-CSF, among others, which then
induce mobilization of a variety of bone marrow derived cell
(BMDC) types, including circulating endothelial progenitor cells
(CEPs). Such cells subsequently home to and invade the drug
treated tumors, in potentially large numbers. The molecular
mechanisms responsible for CEP tumor homing and retention at
the tumor site are under investigation, and several molecular entities
have been implicated including CXCR4/SDF-1, a4b1 integrin, G-
CSF, and VE-cadherin. As a result, targeting such molecules to
prevent the invasion of tumors by BMDCs becomes a therapeutic
option, e.g. targeting CXCR4 or a4b1 concurrently with certain
cytotoxic therapies. In addition, certain antiangiogenic drugs such as
anti-VEGF(R-2) antibodies may function, at least in part, to enhance
MTD chemotherapy or VDA therapy by reducing aspects of the host
bone marrow ‘tumor response’, either by preventing mobilization,
tumor homing, or retention at the tumor site.
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Inflammatory cell infiltration as an essential contributor to tumor
development and progression has gained increasing acceptance. Data
from our HaCaT model system for human skin squamous cell
carcinoma (SCC) clearly emphasize that a tumor-promoting micro-
environment including an activated inflammatory infiltrate is
indispensable for tumor formation and progression. In this model as
well as in a syngeneic mouse skin SCC model we could demonstrate
thatthe recruitmentofGr-1+cellsintothe malignantstromaprecedes
persistent angiogenesis. We were able to show that CD11b+/Gr1+
immature myeloid cells constitute the majority of the tumor
associatedinflammatoryinfiltrateinSCCsofbothimmunocompetent
C57Bl/6 and athymic nude mice. In athymic nude mice depletion of
Gr-1+ cells strongly inhibited tumor growth, angiogenesis and
invasion. Interestingly, the depletion of Gr-1+ cells correlates with
the reduction of MMP-9 in the malignant stroma. These findings
S42imply that CD11b+/Gr-1+ cells have a tumor supporting role other
than being suppressors of an anti-tumor T-cell response. Our current
work focuses on the characterization of the functional contribution of
Gr-1+ cells to tumor progression and identifies the factors that
activate Gr-1+ cells within the tumor microenvironment.
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Lung cancer develops at the mucosal airway interface. The
respiratory epithelium is in contact with the outside environment
and exposed continuously to a broad range of pathogen agents
includingviruses.WedescribetheexpressionofTLRsinhumanlung
tumor cells (Non Small Cell Lung Carcinoma) and show that the
stimulationbyTLR7andTLR8agonistsleadstoincreasedtumorcell
survival and chemoresistance. Transcriptional analysis suggests a
TLR chronic stimulation of tumor cells in situ. These data indicate
that TLR signaling during infection could directly favour tumor
development. Primary intraocular lymphoma (PIOL) is a high grade
non-Hodgkin lymphoma which develops in an immunoprivileged
site. Using a murine model of intraocular B cell lymphoma we detect
an impaired Th1-Tc1 profile and Th17 cells inthe eye concomitant to
a high proportion of CD4+CD25+Foxp3+ T-cells. Systemic deple-
tion of naturally occurring regulatory T cells induces only a slight
decrease of the tumor burden suggesting that nTregs is one of the
immune suppressive mechanisms occurring in this microenviron-
ment. Other immune privilege mechanisms are under study.
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Stress
Salem Chouaib
1, Houssem Benlalam
1, Muhammed Zaeem N.
1
1Institut Gustave Roussy, Villejuif, France
Cellular interactions in the tumor stroma play a major role in
cancer progression but can also induce tumor rejection. To explore
the role of endothelial cells in these interactions, we used an in
vitro 3D collagen matrix model containing a cytotoxic T
lymphocyte CTL clone autologous tumor cells and an endothelial
cell line that are all derived from the same tumor. We
demonstrated that specific killing of the endothelial cells by the
CTL clone required the autologous tumor cells and involved
antigen cross-presentation. The formation of gap-junctions be-
tween endothelial and tumor cells is required for antigenic peptide
transfer to endothelial cells that are then recognized and eliminated
by CTL. We provided evidence indicating that gap-junctions
facilitate an effective CTL-mediated destruction of endothelial
cells from the tumor microenvironment which may contribute to
the control of tumor progression.
How a better understanding of the crosstalk between killer cells
and stroma components including hypoxic stress may lead to the
development of novel therapeutic strategies will be discussed.
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IL-1 is a pleiotropic pro-inflammatory and immunostimulatory
cytokine with diverse effects on malignant processes. At tumor
sites, IL-1 is produced by microenvironmental cellular elements as
well as by the malignant cells, in response to tissue damage
products recognized by TLR receptors on innate cells. We have
recently shown the involvement of TLR2 and TLR4 in IL-1
production and in the control of malignant processes. The IL-1
family consists of two agonistic proteins, namely IL-1α and IL-1β,
and one antagonistic protein, the IL-1 receptor antagonist (IL-1Ra),
which is a physiological inhibitor of pre-formed IL-1. Recombinant
IL-1α and IL-1β bind to the same receptor and exert the same
biological activities. However, in the physiological milieu, IL-1α
and IL-1β differ dramatically in the sub-cellular compartments in
which they are active; IL-1α is mainly active as a cell-associated
cytokine (cytosolic and membrane-associated forms), while IL-1β is
active only in its mature secreted form. We have previously shown
that IL-1α expression on the membrane of tumor cells increases
their immunogenicity and leads to tumor eradication, while tumor
cells which actively secrete IL-1β are more malignant than control
cells and also induce anergy mediated by MDSC. 3-MCA-indcued
chemical carcinogenesis was further used in IL-1 KO mice. It was
shown that IL-1β-mediated inflammation is essential in the process
of 3-MCA carcinogenesis, while microenvironmental IL-1β syner-
gizes with tumor cell-derived IL-1β in determining the malignant
phenotype of transplantable tumors. Expression of cell-associated
IL-1α by the malignant cells or the host increases the immunoge-
nicity of the tumor or controls immunoediting of the arising
malignant cells, respectively. Altogether, the results show the
differential effects of IL-1β and IL-1α in malignant processes and
point to the therapeutic feasibility of using the IL-1Ra in tumor
therapy to neutralize soluble IL-1 (mainly IL-1β), in addition to its
use in treatment of autoimmune diseases, such as Rheumatoid
arthritis.
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TGFβ produced within the tumor plays an important role in tissue
homeostasis and strongly affects both the stromal and the neoplastic
compartments. Some tumors (e.g., colon adenocarcinomas with
microsatellite instability) sustain and preserve mutations in the
TGFβ-R2, making them refractory to this growth inhibitor. In other
cases, the molecular mechanisms underlying resistance to TGFβ are
less clear. Previously, we had developed a mouse model of colon
cancer based on p53-null murine colonocytes sequentially trans-
formed with Ki-Ras- and c-Myc oncogenes. In this genetically
complex system, c-Myc does not appear to be a primary determinant
of cell proliferation. Instead it strongly promotes the angiogenic
phenotype,atleastpartly throughdownregulationof thrombospondin-
1 and related thrombospondin type I repeat (TSR) proteins such as
clusterin (Thomas-Tikhonenko et al, Cancer Res 2004; Dews et al,
Nature Genetics 2006). Many of these Myc-downregulated proteins
are concertedly upregulated by TGFβ, leading us to hypothesize that
c-Myc somehow attenuates TGFβ signaling. Since Myc can repress
gene expression by activating the miR-17-92 microRNA cluster, we
asked whether the six microRNAs comprising this cluster directly
target components of TGFβsignaling. We discovered that at least two
key signaling molecules, TGFβ-R2 and Smad4 are indeed down-
regulated by miR-17-92. In addition, down-regulation of
thrombospondin-1, which is a direct target of miR-17-92, hinders
the release of TGFβ from the complex with the latent TGFβ-binding
protein 1 (LTBP1.) Consequently, in tumors with Myc- and miR-17-
92 overexpression TGFβ signaling is significantly reduced and the
robust angiogenic phenotype ensues. Our findings help explain how
tumor cells become resistant to TGFβ and identify relevant molecular
intermediates that can be targeted therapeutically.
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The growth factor Heregulin (HRG) is expressed in about 30% of
breast cancer tumors, and induces tumorigenicity and metastasis of
breast cancer cells. We have demonstrated previously that HRG
overexpression renders breast cancer cells resistance to the
microtubule-interfering agent Taxol, a drug of choice for the
treatment of metastatic breast cancer. The mechanism by which
HRG induces Taxol resistance is largely unknown. It is also
known that triple negative breast cancer tumors do express high
levels of HRG and unfortunately they do not respond to HRG. Our
studies were aimed at targeting HRG with the goal of achieving a
therapeutic target as well as restoring the response to Taxol, while
preventing the formation of metastasis. Thus, we knocked-down
HRG expression in three different breast cancer cell lines: MDA-
MB-23, HS578T and BT549. Our data demonstrates that HRG
expression is an absolute requirement for the anchorage-
independent growth for triple negative breast cancer cells, since
none of the breast cancer cells MDA-MB-231, HS578T and
BT549 stable expressing the silencing (shRNA) for HRG, were
capable of forming colony in soft agar. Furthermore, these cells,
not only no longer were not anchorage-independent were no
longer resistant to Taxol, to the contrary the shRNA/HRG cells
were exquisitely sensitive to Taxol, to induce growth inhibition
and apoptosis. More importantly, we observed that the disorga-
nized structured observed in 3D matrigel culture observed for
triple negative cells, was completely abolished once HRG was
knockdown and a very organized structure. These characteristics
resembled an EMT (epithelial-mesenchymal epithelial transition
(MET). This should be deemed a potential target in developing
therapies for triple negative breast carcinomas.
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While it has been recently recognized that signals between
endothelial and cancer cells may drive escape from tumor dormancy,
little is known regarding the molecular mechanisms behind this
phenomenon. Recently, we demonstrated that the Notch ligand Dll4,
induced by angiogenic factors in endothelial cells, triggers Notch3
activation in neighbouring T-ALL leukaemia cells and promotes
tumorigenesis. Here we show that MKP-1 levels - a broadly
expressed dual specificity phosphatase - are controlled by Notch3
by a non-transcriptional mechanism involving regulation of MKP-1
protein stability. Notch3 and MKP-1 levels are consistently up-
regulated in aggressive compared to dormant tumors, which is
accompanied by opposite variations in the levels of active p38 and
ERK1-2 - two canonical MKP-1 targets. A good correlation between
Notch3 and MKP-1 levels was observed in T-ALL primary samples
from patientsand ina panelof T-ALL cell lines.Inhibition of Notch3
by RNA interference or GSI treatment, or stimulation by the Dll4
ligand had marked effects on MKP-1 levels in T-ALL cells in vitro.
Attenuation of MKP-1 levels by shRNA did not affect proliferation,
whereas it significantly increased T-ALL cell death following drug
treatment or serum starvation. Importantly, tumorigenesis of MKP-1
deficient T-ALL cells was markedly impaired compared to controls.
Our results elucidate a novel mechanism downstream of Notch3 by
which the direct interplay between endothelial and tumor cells
promotes survival of T-ALL cells.
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The Forkhead Box m1 (Foxm1) protein is induced in a majority of
human cancers, including non-small cell lung cancers. Increased
Foxm1 expression is associated with poor prognosis. However,
specific requirements for the Foxm1 in each cell type of the cancer
lesion during lung tumor formation remain unknown. In this study,
we examined the role of Foxm1 in tumor microenvironment using
conditional knockout mouse models with Foxm1 deficiency in
macrophages (LysM-Cre Foxm1
fl/fl mice; macFoxm1
−/−)o r
endothelial cells (Tie2-Cre Foxm1
fl/fl mice; enFoxm1
−/−). Lung
tumors in mice were induced using two experimental protocols: 3-
methylcholanthrene (MCA) / butylated hydroxytoluene (BHT) or
urethane. Conditional deletion of Foxm1 from macrophages
caused a significant decrease in lung inflammation during
induction of lung tumors, leading to reduction in the number and
size of lung adenomas. Decreased lung tumorigenesis in mac-
Foxm1
−/− mice was associated with diminished proliferation of
tumor cells, decreased numbers of tumor-associated macrophages
and reduced expression of pro-inflammatory cytokines in the lung
and bronchoalveolar lavage fluid. Furthermore, we demonstrated
that Foxm1
−/− mice displayed a dramatic decrease in proliferation
and migration of macrophages in vivo and in vitro. In our studies,
we also demonstrated that deletion of Foxm1 from endothelial
cells resulted in accelerated lung tumorigenesis. The increased
numbers and sizes of lung tumors in enFoxm1
−/− mice resulted from
increased endothelial leakage and infiltration of inflammatory cells
into lung tissue. The enFoxm1
−/− mice displayed increased tumor cell
proliferation and increased mRNA levels of cell cycle regulator cMyc
and cyclin D1. Deletion of Foxm1 from endothelial cells caused
reduced expression of Foxf1 and Foxf2 transcription factors, both of
which are critical regulators of endothelial cell functions and VEGF
signaling. Altogether, our studies demonstrated that Foxm1 plays a
dual role in tumor microenvironment: it controls cellular permeability
in endothelial cells and induces inflammation and migration of
macrophages into lung tumors.
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Aggressiveness of a tumor does not only reflect intrinsic features of
cancer cells. The microenvironment hosting the tumor also actively
participates in regulating tumor cell proliferation, migration, and
invasion. Among the extracellular matrix proteins enriched in stroma
of carcinomas are the tenascin family members tenascin-C and
tenascin-W. Whereas tenascin-C overexpression in gliomas has been
widely reported to correlate with adverse prognosis, the status of
tenascin-W in brain tumors has not been investigated. We analyzed
protein levels of tenascin-Win 38 human gliomas (29 glioblastomas,
5 astrocytomas, and 4 oligodendromas) and found expression of
tenascin-W in more than 80% of all tumor samples, whereas no
tenascin-W could be detected in control brain tissues. Immunohisto-
chemical co-stainings of tenascin-W and von Willebrand factor
revealed that tenascin-W is localized around blood vessels exclu-
sively in tumor samples. To assess if tenascin-W influences the
behavior of endothelial cells in vitro, Human Umbilical Vein
Endothelial Cells (HUVEC) were seeded on a collagen substratum
including tenascin-W. The presence of tenascin-W increased the
proportion of elongated cells and augmented the mean speed of
migration of the cell population. Furthermore, tenascin-W triggered
sprouting of HUVEC spheroids to a similar extent as the pro-
angiogenic factor tenascin-C. Our study thus identifies tenascin-W
as a candidate biomarker for brain tumor angiogenesis that could be
used as molecular target for therapy irrespective of the glioma
subtype.
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We have previously shown a novel link between human protease-
activated-receptor1 (hPar1) and b-catenin stabilization. The over-
expression of hPar1 leads to a striking stabilization of b-catenin, a
well established core process of the Wnt signaling pathway. Here
we elucidate the mechanism linking PAR1 to b-catenin oncogenicity.
PAR1 is selectively associated with activated Ga13, recruiting next
dishevelled (DVL), an upstream Wnt signaling protein. Using
constructs exhibiting either individually distinct DVL domains (e.g.,
DIX, PDZ and DEP) or depleted DVL sites or a GST-DVL-DIX
column, we showed that the DIX domain associates with Ga13.T h e
impact of DVL involvement in PAR1 induced b-catenin stabiliza-
tion is underscored by the marked reduction of PAR1-induced
Matrigel invasion and the decrease in b-catenin level caused by
DVL-SiRNA lentiviral construct. Activation of PAR1 also promotes
the binding of b-arrestin 2 to DVL, playing a role in PAR1 induced
DVL phosphorylation dynamics. While infection of SiRNA-LRP5/6
potently reduces Wnt3a mediated b-catenin expression, no effect is
observed on PAR1 induced b-catenin stabilization. PAR1-induced
b-catenin expression is also caused by the Wnt antagonists SFRP-2
or SFRP-5. Collectively, our data show that PAR1 mediates b-
catenin stabilization independently of Wnts, Frizzled and the co-
receptor LRP5/6. We hereby propose a novel path of PAR1 induced
Ga13-DVL axis in cancer and b-catenin stabilization.
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Cancer induced immune suppression contributes to tumor out-
growth and immune escape and occurs, in part, due to tumor-
mediated dysregulation of DC differentiation. This results in fewer
dendritic cells and an accumulation of immature myeloid cells,
themselves actively immunosuppressive. Tumors mediate im-
paired DC differentiation by secreting factors (e.g. VEGF) that
hyperactivate Stat3 in DC progenitors, though the molecular
mechanisms by which Stat3 signaling inhibits DC differentiation
are poorly defined. We have previously shown that PKCβII is
essential in myeloid progenitor to DC differentiation and that
knock down or inhibition of PKCβII blocks DC differentiation.
Here, we investigate the idea that tumors inhibit DC differentiation
by down regulating PKCβII expression in myeloid progenitor
cells via Stat3 hyperactivation.
Culture in human or murine tumor conditioned media (TCM)
decreased PKCβII protein levels by 51% and 48% in a human
myeloid progenitor cell line (KG1), respectively. Additionally,
culture of KG1 in TCM significantly decreased PKCβII mRNA
transcript levels (38-fold reduction, p<0.01). PKCβII down
regulation was associated with decreased DC differentiation:
culture of KG1 in TCM significantly reduced phorbol ester driven
DC differentiation (assessed by T cell stimulatory ability, p<0.01).
TCM significantly down regulated PKCβ promoter driven
transcription in KG1, compared to cells grown in normal media
(7-fold reduction, p<0.01). Importantly, TCM induced Stat3
phosphorylation in KG1. To test the role of Stat3 activity on
PKCβII expression, we generated clones stably expressing wild
type and constitutive active Stat3 constructs in a second myeloid
progenitor cell line (K562). Compared to K562, PKCβII mRNA
transcript levels were significantly down regulated (>10-fold) in
clones stably expressing the constitutive active Stat3 construct (p<
0.05) while PKCβII protein levels were reduced 75–95%. Taken
together, these observations argue that tumors inhibit DC
differentiation by inducing down regulation of PKCβII expression
in myeloid progenitor cells via Stat3 hyperactivation.
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Multiple myeloma is a neoplasm of bone marrow resident plasma
cells characterized by a critical interaction between myeloma cells
and bone marrow stromal cells, which produce IL-6, supporting
myeloma cell survival. However, the molecular and cellular
components involved in myeloma induced IL-6 production remain
largely uncharacterized. At the cellular level, dendritic cells (DC)
in the bone marrow microenvironment and at the molecular level
the CD28-B7 and Notch1-Jagged2 pathways were separately
implicated by us in myeloma induced IL-6 production. While
N o t c hs i g n a l i n gl e a d i n gt oI L - 6p r o d u c t i o ni nD Ci sw e l l
understood, the mechanism of “backsignaling” via B7, a ligand
with a short cytoplasmic tail, is largely uncharacterized. To gain
insight into B7 signaling, DC were stimulated with CD28Ig in the
presence or absence of an inhibitor of Notch signaling, gamma
secretase inhibitor (GSI). DC treated with CD28Ig alone produced
significantly higher levelsof IL-6 when compared toDCtreated with
CD28Ig and GSI. GSI specifically targeted Notch signaling as
observed by decreased expression of Notch gene targets: Hes1 and
Deltex4. Also, decreased IL-6 levels in presence of GSI were not due
to the decrease in B7 expression on DC. To specifically implicate the
importance of Notch1 and Jagged2, we blocked them using
antibodies and observed a similar decrease in IL-6 production upon
blocking Notch1 signaling. Our results suggest that CD28 mediated
IL-6 production is dependent on Notch1 signaling and crosstalk
between the Notch1-Jagged2 and CD28-B7 pathways leads to IL-6
production by DC. We are examining a potential direct/ indirect
mechanism of crosstalk in myeloma induced IL-6 production.
Targeting IL-6 induced by crosstalk between these two pathways
promptsnot onlyclinical evaluationtoimprove MM patient outcome
but also extends to advancing knowledge in T-cell biology.
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Because immune-stimulating effects of interleukin (IL)-18 have
anti-neoplastic properties, IL-18 has been proposed as an adjuvant
therapy against cancer. However, IL-18 increases in the blood of
cancer patients and has been associated with metastatic recurrence
in some cancer types. Melanoma cells heterogeneously express IL-
18 receptors and consistent with its potential prometastatic action,
we reported that experimental melanoma metastases are prevented
in both ICE-deficient mice lacking secreted IL-18 and IL-18-
binding protein-treated mice. Moreover, IL-18 promotes melano-
ma metastasis at multiple steps, including stimulating the capillary
arrest of circulating tumor cells, immune escape, angiogenesis,
and tumor cell proliferation. However, at the moment, the
molecular mechanisms underlying IL-18-dependent melanoma me-
S46tastasis have not been elucidated. The aim of this study was to identify
molecular mediators of IL-18 by exploring the melanoma cell gene
display induced by this cytokine. We compared global gene
expression between untreated and IL-18-treated melanomas using a
high-throughput human 36 K cDNA microarray platform. Total RNA
from four primary cultured human melanoma cell lines was used: two
VLA-4-expressing highly-metastatic cell lines (A375 and 1182
melanoma), and two non-VLA-4 expressing low metastatic cell lines
(526 and 624-28 melanoma). Gene profile was determined by cDNA
microarray and real-time PCR. We found around 50 genes over-
expressed (ANOVA, p<0.05) in IL-18-treated highly metastatic
versus low-metastatic melanoma cells. Some of these genes were also
co-expressed by effect of soluble VCAM-1 on highly metastatic but
not on low-metastatic melanoma cells. None of these genes were
expressed by melanoma patients that did not metastasize to distant
sites within 4 years after diagnosis, while majority of them were
expressed in melanomas associated with high risk of metastasis and
death. In summary, we identified the biological and clinical relevance
of IL-18-dependent genes for highly metastatic VLA-4-expressing
human melanoma, and suggest molecular pathways relevant to
melanomametastasisintheinflammatorymicroenvironmentofIL-18.
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We have recently reported that IL-8/CXCL8 was overexpressed in
invasive estrogen receptor (ERalpha)-negative breast cancer cells,
compared to ERa-positive breast cancer cells. We now demon-
strate that histone deacetylases (HDAC) play an essential role in
the regulation of IL-8 gene expression in ERalpha-positive MCF-7
breast cancer cells. Treatment of MCF-7 cells with the HDAC
inhibitor trichostatin A (TSA) led to a strong up-regulation of IL-
8 protein and RNA levels in MCF-7 cells. The up-regulation of
IL-8 in MCF-7 cells was time - and concentration dependent.
Moreover, run-on and transfection experiments demonstrated that
IL-8 induction by HDAC inhibitors was transcriptional and
involved mainly NF-kB site of IL-8 promoter. These observations
are corroborated by an up-regulation of NF-kB activity in MCF-7
cells in the presence of TSA. In addition, blocking NF-kB
pathway by adenoviral delivery of a dominant-negative IkB or
IKK2 mutant abolished IL-8 gene induction by histone deacety-
lase inhibitors. HDAC inhibitors triggered IKK phosphorylation,
up-regulated p65 nuclear translocation, while decreasing the
protein levels of IkBalpha, which accounts for NF-kB activation.
TSA increased the acetylation of Histone H3 on IL-8 promoter in
a time-dependent manner. In summary, our results demonstrate
that NF-kB pathway repression by HDAC is responsible for the
low expression of IL-8 in ERalpha-positive breast cancer cells.
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Differential Expression of MicroRNA-17-3p Reverts Morphology
of Prostate Cells in lrECM Gels, Reduces Tumor Growth in vivo
and Correlates with Prostate Tumor Expression by LCM
Analysis
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MicroRNAs (miRs) are a novel class of RNAs with important roles
in regulating gene expression at the level of protein synthesis. To
identify miRs controlling prostate tumor progression, we utilized
humanprostatesublinesderivedfromtheimmortalizedP69cellline,
which differed in their tumorigenic properties in vivo. When grown
embedded in lrECM gels (3D) these sublines displayed drastically
different morphologies correlating with their behavior in vivo. The
non-tumorigenic P69 subline grew as multiceullular acini with a
defined lumen and basal/polar expression of relevant marker
proteins. M12, a highly tumorigenic, metastatic derivative, grew
as a disorganized mass of cells with no polarization, whereas the
F6 subline, a weakly tumorigenic, non-metastatic M12 variant,
reverted to organized acini. These sublines also differed in
expression of vimentin, which was high in M12, but low in F6
and P69 sublines with E-cadherin exhibiting the opposite expres-
sion pattern. A miR array screen of M12 and F6 cell lines grown in
2D versus 3D revealed several miRs, which were differentially
expressed. Of these miRs, miR-17-3p was found to target vimentin.
Reduction of vimentin expression either by stable expression of a
vimentin-specific siRNA or miR-17-3p in the M12 subline
decreased vimentin levels and reverted growth to organized,
polarized acini in lrECM gels. In vitro motility and invasion assays
suggested a decrease in tumorigenic behaviour as confirmed by
reduced tumor growth in male athymic, nude mice. qRT-PCR
analysis of RNA extracted from laser capture microdissected
(LCM) material of human prostatectomy specimens (FFPE)
established that miR-17-3p levels were reduced 90% in tumor
cells of Gleason pattern 3, 4 and 5 compared to hyperplastic
glandular epithelium, normal glandular epithelium, hyperplastic
stroma or normal stroma. Altogether these results suggest that miR-
17-3p functions as a tumor suppressor, representing a novel, new
target to block prostate tumor progression.
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S47The adhesion of circulating cancer cells to endothelial cells (EC) is
a prerequisite for their extravasation and metastatic dissemination.
We have shown that E-selectin, a major endothelial adhesion
receptor, interacts with Death Receptor-3 (DR3), present on colon
carcinoma cells, to promote their adhesion to EC and to increase
their motile and survival potentials (Gout et al. Cancer Res. 2006
and CEM, 2008). We also found that E-selectin and TL1A, the
cognate ligand of DR3, trigger the tyrosine phosphorylation of
DR3 in a Src family kinase (SFK)-dependent manner. Moreover,
we obtained evidence indicating that interaction between DR3 and
E-selectin or TL1A induces the activation of the PI3K/Akt
pathway in HT-29 colon carcinoma cells. We further discovered
that p65/RelA, the anti-apoptotic subunit of NFkB, is rapidly
phosphorylated at Ser 536 in response to E-selectin or TL1A and
found that the phosphorylation occurs downstream of PI3K/Akt.
These findings suggest that E-selectin and TL1A induced-activation
of DR3 confers a metastatic advantage to colon cancer cells by
inducing SFK-dependent tyrosine phosphorylation of DR3 and by
activating the pro-survival PI3K/Akt/NFkBp65 axis. Interestingly,
the activation of E-selectin induces a remodeling of EC that is
associated with disruption of the adherens junctions. This leads to
increased interendothelial spaces enabling transendothelial migration
(Tremblay et al Oncogene 2006). Using a laminar flow chamber, we
identified three distinct mechanisms by which cancer cells interact
with E-selectin to initiate their diapedesis: formation of a mosaic
between cancer cells and EC, paracellular diapedesis at the junction
of three EC,and transcellular diapedesis(Tremblay et al.Cancer Res.
2008). We conclude that E-selectin-mediated adhesion of colon
cancer cells regulates metastasis by conferring inherent invasive
potentialtocancercellsfollowing binding toDR3 andby remodeling
the endothelium in a way that facilitates diapedesis. Supported by the
Canadian Cancer Society and the Canadian Institutes for Health
Research. NP, SG and PLT have equally contributed to this study.
O33
The Origin of Carcinoma-Associated Fibroblasts
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Recent evidence on the genomic integrity of non-malignant cells
surrounding carcinoma cells has reinvigorated the discussion about
the originof the alteredphenotype exhibited bycarcinomaassociated
fibroblasts (CAF). Many hypotheses have been proposed for the
origin of these altered cells, including standard connective tissue
acute phase and stress response, fibroblast senescence, reciprocal
interactions with the cancer cells, fibroblast specific somatic
mutations, differentiation precursors and infiltrating mesenchymal
stem cells. We have addressed each of those options experimentally
and found evidence for reciprocal interaction between tumour
associated macrophages and cancer associated fibroblasts are
elevated in patients, with an associated poor outcome. This supports
current understanding of cancer etiology, based on previous animal
models, as well as offers novel avenues for therapy.
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VEGI, an Endogenous Antiangiogenic Cytokine,
Inhibits Hematopoietic Stem Cell Differentiation
into Endothelial Progenitor Cell
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Endothelial progenitor cells (EPC) play a critical role in post-natal and
tumor vasculogenesis. Vascular endothelial growth inhibitor (VEGI;
TNFSF15) has been shown to inhibit endothelial cell proliferation by
inducing apoptosis. We report here that VEGI inhibits the differenti-
ation of EPC from mouse bone marrow-derived Sca1+ mononuclear
cells. Analysis of EPC markers indicates a significant decline of the
expression of endothelial cell markers, but not stem cell markers, on
VEGI-treated cells. Consistently, the VEGI-treated cells exhibit a
decreased capability to adhere, migrate and form capillary-like
structures on Matrigel. In addition, VEGI induces apoptosis of
differentiated EPC but not early stage EPC. When treated with VEGI,
an increase of phospho-Erk and a decrease of phospho-Akt are
detected in early stage EPC, while activation of NF-κB, JNK and
caspase-3 are seen in differentiated EPC. Furthermore, VEGI induced
apoptosis of differentiated EPC is, at least partly, mediated by death
receptor-3 (DR3), which is detected on differentiated EPC only. VEGI
induced apoptosis signals can be inhibited by neutralizing antibodies
against DR3 or recombinant extracellular domain of DR3. These
findings indicate that VEGI may participate in the modulation of post-
natal vasculogenesis by inhibiting EPC differentiation.
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Mannose receptor (ManR)-mediated liver sinusoidal endothelial cell
(LSEC) endocytosis plays a primary role in antigen presentation and
innate immunity, but its role in hepatic metastasis is unknown. We
studied ManR-mediated endocytosis during C26 colorectal cancer cell
S48interaction with LSEC and its immunological implications in the
hepatic metastasismicroenvironment.Labeled mannan or ovalbumin
uptake and anti-mouse ManR immunohistochemistry were used to
study ManR expression and endocytosis in vivo, in vitro, and by
confocal microscopy. Several IL-1 inhibitors and cyclooxygenase
(COX)-2 inhibitor Celecoxib were used to analyze the role of IL-1
and COX-2 in ManR regulation. Anti-mouse ManR antibodies and
ManR knockout (ManR
−/−)m i c ew e r eu s e dt oi d e n t i f yM a n R -
dependent mechanisms during anti-tumor immune response of liver
sinusoidal lymphocytes (LSL) interacting with tumor-activated
LSEC. Both ManR expression and endocytosis increased in
tumor-activated LSEC through a two-step mechanism including:
1) Release of COX-2-dependent IL-1-stimulating factor(s) by LFA-
1-expressing C26 cells in response to ICAM-1, which was over
expressed and secreted by tumor-activated LSEC; and 2) wide-
spread upregulation of ManR expression and endocytosis in LSEC
by tumor-induced paracrine IL-1. In addition, LSL that had
interacted with tumor-activated LSEC in vivo decreased their anti-
tumor cytotoxicity and IFN-gamma secretion while increased IL-10
release to their supernatant ex vivo. IFN-gamma/IL-10 ratio also
decreased in the hepatic blood from tumor-injected mice. Immune-
suppressant effects of tumor-activated LSEC on LSL were
abrogated in both LSEC from ManR
−/− mice and tumor-activated
LSEC given anti-mouse ManR antibodies. In summary, ICAM 1-
induced tumor COX-2 led to regional anti-tumor immunity
inhibition during hepatic colorectal metastasis via IL-1-induced
ManR. ManR constituted a common mediator for prometastatic
effects of IL-1, COX-2 and ICAM-1 in the liver. Rise of both
hepatic IFNgamma:IL-10 ratio and anti-tumor cytotoxicity via
ManR blockade is consistent with reported antimetastatic effects
of IL-1, COX-2 and ICAM-1 inhibitors. These results support
ManR as a molecular target for hepatic colorectal metastasis
therapy.
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During the initial growth of a tumour, interactions between the
initiating cells which carry an oncogenic mutation and the
immediate surrounding normal cells can suppress the growth of
the oncogenic cells. This phenomenon of neighbour suppression
has been studied in fibroblasts in vitro and we have extended the
observation to epithelial cells and their transformed derivatives
from a variety of tissues confirming a general relevance to cancer
as >90% of cancers originate from epithelial cells. We confirm the
contact-dependent nature of suppression in epithelial cells and
determine the nature of the cell cycle arrest. To identify molecular
effectors involved in this form of growth arrest, we studied
pancreatic epithelial cells as >90% of pancreatic cancers carry a
mutation in Kras as the initiating oncogenic event. To identify the
molecular mechanism of neighbour suppression we analysed
normal mouse pancreatic ductal epithelial cells, matched deriva-
tives expressing physiological levels of oncogenic Kras
G12D and
co-cultures of these cells. Although expression of the oncogene,
Kras, was not affected in co-cultures where the transformed
growth was suppressed, gene expression profiling identified genes
responsive to expression of Kras
G12D along with a subset which
were normalised upon co-culture with normal cells. Thus a subset
of oncogene-responsive genes are normalised in conditions where
the transformed phenotype is suppressed. Analysis of normal and
tumourous human pancreatic tissue and mice with varying degrees
of mosaicism for Kras
G12D oncogene expression shows the
importance of the phenomenon and this subset of oncogene-
regulated and normalisation-competent genes in an in vivo setting.
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The aim of our study is to analyze the effects of epithelial-
mesenchymal crosstalk on cancer cell migration and invasion. Based
on previous findings that 70% of esophageal tumors demonstrate the
coordinated loss of E-cadherin and TGFβreceptorII (TβRII), we
established an in vitro model using immortalized human esophageal
keratinocytes, expressing dominant-negative mutants of E-cadherin
and TβRII (ECdnT). To allow the analysis of epithelial and
mesenchymal crosstalk, epithelial reconstructs were utilized by
seeding ECdnT cells on an extracellular matrix with embedded
fibroblast. We found that the ECdnT cells invade into the
underlying collagen/matrigel matrix with embedded fibroblasts,
but not in Boyden chamber invasion assays in the absence of
fibroblasts. Crosstalk between the epithelial compartment and the
surrounding microenvironment is essential for mediating invasion.
Biochemical analysis of the fibroblasts in co-culture indicates an
activated status, potentially through secretion of TGFβ1b yt h e
ECdnT cells. While we observed these expression changes in the
fibroblasts in response to the genotype of the epithelial cells, we
also identified reciprocal changes in the epithelial cells themselves:
Gene expression analysis of invasive and non-invasive areas of
ECdnT cells in the organotypic epithelial reconstruct cultures
identified cathepsin B and CD44 to be upregulated in invasive
cells. The increase of cathepsin B expression in ECdnT cells
appears to be an upstream event in the signaling cascade
culminating in cell invasion, as cathepsin B can cleave and activate
TGFβ1. CD44 activation is in part mediated through TGFβ1. We
show then, that CD44 co-localizes with MMP-2 and MMP-9 to
invasive areas and facilitates matrix degradation allowing for cell
invasion into the underlying collagen/matrigel layer. In summary,
we demonstrate here that the epithelial loss of E-cadherin and
TβRII leads to an impaired balance of the epithelial-mesenychmal
crosstalk resulting in the activation of fibroblasts and the induction
of invasion through a fibroblast-secreted factor.
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Most of the studies on epithelial-stroma interactions during
breast cancer cell invasion have focused on fibroblasts,
endothelial and inflammatory cells. Very little attention has
been given to adipocytes, although it is obvious that in
numerous organs including breast, early local tumour invasion
results in immediate proximity of cancer cells to adipocytes.
Until recently, adipocytes were considered as an energy storage
depot, but there is now clear evidence that their ability to secrete
many adipokines could potentially influence tumour behaviour.
Using an original 2D co-culture system where adipocytes and
tumour cell are separated by an insert, we show a crosstalk
between the two cell types. Tumour co-cultivated during 3 to
5 days with adipocytes exhibit an increase in both migratory and
invasive capacities and incomplete EMT. This pro-invasive
effect was not recapitulated with “naïve” adipocyte-conditioned
medium (Ad-CM), but was recapitulated when tumour cells
were grown in the presence of Ad-CM obtained from adipocytes
previously grown in the presence of cancer cells. In fact,
adipocytes cultivated with cancer cells exhibit profound changes
with delipidation and decreased of adipocyte markers associated
to a concomitant expression of an activated phenotype marked
by overexpression of proteases (including MMP-11) and pro-
inflammatory cytokines (IL-6, Il-1β). Furthermore our results
show that these two cytokines are involved in the observed pro-
invasive effect. More importantly, these results have been
confirmed in human breast tumours using both immunohisto-
chemistry and qPCR (comparison of adipocytes isolated from
tumorectomy or mammoplasty in a series of 28 patients). In
conclusion, our data demonstrate for the first time that tumour-
surrounding adipocytes cooperate with breast tumour cells to
provide an invasive phenotype. These results might explain the
poor prognosis of breast cancer in obese women that frequently
exhibit extended tumour at diagnosis suggesting an effect of
adipose tissue on early step of tumour invasion
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Immunohistochemical staining for PDGF-CC has revealed prom-
inent expression by tumor cells in different human skin cancers,
including melanoma, but not in normal skin. To investigate the
significance of PDGF-CC expression, we transfected B16 mela-
noma cells with PDGFC. The growth rate of B16 cells expressing
PDGFC (B16PDGFC) was unaffected in vitro. However, tumors
from B16PDGFC cells grew significantly faster compared to
control tumors (B16ctrl). By injecting B16 tumors into PDGFRα/
GFP reporter mice, we detected a thicker fibrous capsule
surrounding B16PDGFC tumors and an increased number of
infiltrating PDGFRα-expressing stromal cells. Stromal cells were
analysed using coimmunostaining for PDGFRα and the fibroblast
markers FSP-1 and α-SMA. Cells positively labeled for FSP1
were prevalent throughout the B16PDGFC tumors, while
PDGFRα expression was restricted to cells at the edge of tumors.
We demonstrated, by the use of antibody arrays, that B16PDGFC
tumors contained increased levels of the extracellular matrix
protein SPP1 (osteopontin), which was found to be expressed by
fibroblasts. To investigate the effect of SPP1 in vivo, we coinjected
B16 cells with mouse embryonic fibroblasts (MEFs) from wild
type (wtMEF) or SPP1 knockout (KOMEF) mice. B16/wtMEF
tumors exhibited a significant growth advantage compared to
injection of B16 cells alone. In contrast, KOMEFs were not able
to confer any growth advantage to B16 tumors. We conclude that
expression of PDGFC in B16 melanoma cells results in increased
tumor growth rate mediated by attraction of a PDGFRα-
expressing population of cancer-associated fibroblasts, which
secrete growth-promoting and proangiogenic factors such as
SPP1. The results from the present study encourage therapeutic
targeting of support functions performed by cell types populating
the tumor stroma; a therapeutic strategy that may prove comple-
mentary to conventional treatments.
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Stroma facilitates breast tumor cell migration, a key step in
metastases by modulating the microenvironment. The different
molecules including chemokines, cytokines and enzymes pro-
duced by stroma cells that remodel the extracellular environment
of breast tumor have yet to be fully elucidated. Endothelin-1 has
been shown to promote tumor growth, tumor inflammation and the
development of metastases. Here, we present data demonstrating
the role of chemical environment produced by stroma cells on
tumor cell migration. In particular we show the indirect role of
endothelin-1 in the recruitment of monocytes. 3D cultures using
mammary epithelial cells (NMuMG) in combination with pre-
adipocytes (D1) were grown in various extracellular matrix
conditions. Following 5-day incubation, the number and area of
structures were quantified. When co-cultured with D1 pre-
adipocytes, D1 cells surrounded NMuMG epithelial cells and
formed acinar structures with lumen formation. Both the number
and area of acinar structures in cultures grown in Matrigel
® and
collagen in combination with agarose were higher than those
observed in cultures grown in either agarose, Matrigel
® or
collagen alone (p<0.05). In 3D conditions, while NMuMG cells
migrated towards conditioned media (CM) derived from NMuMG
and D1 cells, 4 T1 cells migrated towards CM derived from
MOVAS and NMuMG. In 2D conditions, D1 CM increased
migration of NMuMG cells but not 4 T1 cells. Furthermore,
4T1CM and CM from 4 T1 cells stimulated with ET-1 but not ET-
1 alone or CM from 4 T1 cells treated with an inhibitor of the
endothelin converting enzymes inhibition promoted J774 mono-
cyte chemotaxis and cell invasion (p<0.05). These results further
underline the key role of the interplay of stroma and tumor cells
secretion within the tumor microenvironment in the development
of breast cancer metastases.
This work was supported by grants from the Department of
Defense Era of Hope Program and the National Science
Foundation.
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The importance of the extracellular matrix (ECM) in tumor
development, progression and invasive behavior is becoming
increasingly clear. Not only does the ECM provide an adhesive
substrate for malignant and non-malignant cells, it initiates a host of
cellular responses by activating surface receptors of the integrin
family. Alternatively spliced fibronectin (FN) variants containing
extra FN type 3 repeats, referred to as cellular or “oncofetal” FN, are
major constituentsof the extracellular matrixsurrounding angiogenic
blood vessels and carcinoma-activated fibroblasts. Whereas cellular
FN is virtually absent from normal adult tissue, a massive
upregulation is observed in highly angiogenic and invasive tumors,
suggesting that cellular FN and signaling components that control its
expression, assembly and rigidification may represent key targets for
anti-tumoral therapies. We have examined the role and functional
redundancyofcellularFNvariantsED-Band ED-A(Extra Domains-
B and -A) in vascular endothelial cells by isoform-selective RNA
interference. FN-depleted cells fail to assemble a subendothelial
matrixindicatingthat FN fibrillogenesis isa cell autonomousprocess
in endothelial cells in which basal secretion of FN is tightly coupled
to integrin-dependent assembly. Isoform-specific FN knock down
altersintegrinusageandimpactsondownstreamsignalingeventsthat
regulate cytoskeletal organization, motility, cell-cell adhesion and
capillary morphogenesis on a basement membrane matrix. In cells
lacking FN, the integrin beta subunit partner ILK (Integrin-linked
Kinase) shifts from alpha5beta1 fibrillar adhesions to alphavbeta3
adhesive structures. This integrin switch is accompanied by the
disruption of adherens junctions and abrogation of loss of monolayer
integrity. Altogether, these results highlight the importance of
autocrine FN for angiogenic blood vessel remodeling and allow us
to propose that cellular FN expression provides a spatially and
temporally restricted control of vascular network formation and
stability.
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Tumor associated myeloid cells are believed to promote tumor
development by stimulating tumor growth, angiogenesis, invasion
and metastasis. These tumor-associated myeloid cells are believed to
be a heterogeneous population. There is growing data from multiple
laboratories that tumor associated myeloid cells that co-express
endothelial and myeloid markers represent a pro-angiogenic subtype
of tumor associated myeloid cell known as vascular leukocytes.
Recently, we demonstrated that tumor-derived TNFa promotes local
tumor growth and vascularity, in part by increasing numbers of
tumor-associated vascular leukocytes (Can Res. 2009; 69:338). We
wished to explore the mechanism by which TNFa mediates
endothelial differentiation of myeloid cells. Published studies have
shown that fibronectin is a critical promoter of endothelial
differentiation of blood mononuclear cells in vitro.W eh a v ef o u n d
that TNFa treatment of monocytes significantly increased expres-
S51sion of a5b1 integrin, a major fibronectin receptor, leading to a
consequent 4-fold increase in fibronectin adhesion. Furthermore,
TNFa-treated monocytes upregulated expression of endothelial
markers, VEGFR2 and VE-cadherin. Interestingly, a5 subunit
inhibitory antibodies blocked adhesion to fibronectin as well as
blocked the consequent upregulation of VEGFR2 and VE-cadherin,
implying a role for outside-in signaling by the a5b1 integrin after
binding fibronectin. Finally, treatment of mouse tumors with anti-a5
antibodies reduced accumulation of tumor vascular leukocytes and
inhibited tumor growth. Our studies suggest that tumor-cell derived
TNFa constitutes a tumor microenvironment signal that promotes
differentiation of tumor-associated monocytes towards a proangio-
genic/ provasculogenic myeloid-endothelial phenotype via upregu-
lation of the fibronectin receptor a5b1.
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Trafficking of tumor-reactive T lymphocytes across microvascular
barriers in tumor tissues is a critical juncture in the effector phase of T
cell-mediated cancer immunity. While the multistep adhesion events
directing lymphocyte trafficking to lymphoid organs and sites of
inflammation are well defined, the mechanisms governing entry of
blood-borne Tcells into tumor tissues are largely unexplored. Here we
demonstrate that steady-state homing of tumor-specific CD8 T cells
across tumor vessels is limited by insufficient intravascular expression
of the prototypical trafficking molecule, intercellular adhesion
molecule-1 (ICAM-1). However, T cell trafficking to tumor sites
could be substantially improved during systemic thermal therapy via a
trans-signaling mechanism in which interleukin-6 (IL-6), together
with a soluble form of the IL-6 receptor binding subunit, triggers
ICAM-1 induction on tumor vessels. ICAM-1–dependent early entry
of tumor-specific CD8 effector Tcells is further shown to be causally
linked to apoptosis of tumor cell targets. These findings indicate that
therapeutic targeting of the tumor vasculature for T cell trafficking
holds promise for improving cancer immunity and Tcell-based tumor
immunotherapy. This work is supported by grants from the NIH (R01
CA79765 and P01 CA094045), and the Roswell Park Alliance
Foundation.
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Genetically modified cellular vaccines were found to be efficient
against cancer both in experimental models (Bubenik, Curr.
Cancer Drug Targets 8: 180–186, 2008) and in tumour-bearing
patients (Russel et al., J.Immunother. 31: 812–819, 2008). It has
been shown in various systems that the efficacy of conventional
therapeutic modalities can be increased by their combination with
relevant immunostimulatory vaccines as well as by depletion of
immunosuppressive immunocytes (Zitvogel et al., Nature Rev.
Immunology, 8: 59–73, 2008). The aim of this communication is
to demonstrate that depletion of immunoregulatory immunocytes
(T reg cells and immature myeloid cells) can enhance the efficacy
of genetically (IL-12) modified cellular vaccines administered
either alone or in combination with low doses of the cyclophos-
phamide derivative CBM-4A in the experimental model of HPV
16-induced murine tumours mimicking human HPV 16-associated
neoplasms such as cervical carcinomas. The conclusion of this
communication is that IL-12-producing cellular vaccines are good
as adjuvant for CBM-4A treatment, since they can enhance the
curative effect of the cyclophosphamide derivative and repair the
CBM-4A produced defects in the immunocyte cytotoxicity and
proliferative responses.
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Tumor manipulation of the host immune response is critical for
invasion and metastasis. Here we introduce a mechanism by which
tumors escape immune recognition by mimicking the natural
tolerance-maintaining functions of the lymph node. We recently
showed that some invasive human tumors secrete low levels of
CCL21, which is known as a lymphoid chemokine because of its
high expression in the lymph node and role in attracting antigen-
presenting cells and naïve T cells to the node for T cell education.
Here, we engineered three variants of the murine B16 melanoma:
CCL21knockdown,CCL21overexpressing,andcontrol-transfected.
We found that control tumors – and CCL21-overexpressing but not
knockdown variants – attracted lymphoid tissue inducers and
developed lymphoid-like features including a reticular stromal
network, complement-regulating protein Crry, and HEV-like vessels.
Within this quasi-lymphoid environment, both the cytokine milieu
and T cell populations were polarized towards a regulatory
phenotype, while tumors lacking CCL21 induced tumor antigen-
specific immunity. The CCL21 mediated immune tolerization was
complement-dependent and systemic, with the presence of a control
tumor protecting a distant CCL21-knockdown tumor from immune
recognition. We suggest that “lymph node mimicry” gives tumors an
advantage: by attracting naïve T cells and guiding their education in
the immunosuppressive tumor environment, CCL21-secreting
tumors can shift the host immune response from immunogenic to
tolerogenic, facilitating growth and invasion.
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Tumor growth is supported by tumor stroma, which is made by
matrix and infiltrating cells, such as tumor associated macro-
phages (TAM) and tumor associated dendritic cells (TADC). We
have recently reported that TAM display massive nuclear
localization of the p50 NF-kB inhibitory homodimer, which
correlates with impaired inflammatory functions. The functional
significance of this observation was demonstrated in p50 NF-kB
deficient mice, which displayed tumor growth inhibition. More
recently, in order to evaluate whether this tolerogenic mechanisms
may target other compartments of the immune system, we
characterized the role of p50 NF-kB in dendritic cell (DC)
functions, during their differentiation and maturation.
Our data clearly show that p50 NF-kB plays a non redundant role
in DC survival and APC functions. p50 NF-kB has pro-apoptotic
functions in bone marrow derived DC, as its absence leads to a
reduced rate of apoptosis/necrosis in DC activated for 48 h with
LPS. Moreover, LPS-matured p50 -/- DC display higher expres-
sion of MHC molecules, as well as higher secretion of pro-
inflammatory cytokines such as IL-1b, TNF-a and IL-18. This
correlates with the enhanced capability of p50-/- DC to activate T
cell responses, in vitro and in vivo.
Therefore, our data suggest that targeting p50 NF-kB activity may
represent a strategy to enhance selective functions of DC, with
potential application in anti-tumour vaccination strategies.
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The adhesion molecules JamB and JamC belong to the Ig superfamily
and have been shown to interact together. Through its expression on
endothelial cells, JamC has been involved in the regulation of immune
response, tumor growth and inflammation as demonstrated by several
studies using blocking antibodies and transgenic mice
123 . Recently,
high expression of JamC on fibrosarcoma has been correlated with
increased metastatic potential of tumor cells. Whether this result
simply reflects the adhesive property of JamC with JamB on
endothelial cells or is due to a more complex regulation of
inflammation and anti-tumor immune response remains to be
established. Using B16F10 melanoma cells, which express JamC
but not JamB, we show that silencing JamC in tumor cells inhibits
proliferation, but that subcutaneous growth of B16F10 tumor is not
affected in JamB
−/− mice suggesting that JamC controls cell
proliferation independently of JamB engagement. In contrast,
pulmonary metastasis are greatly reduced in JamB
−/− mice, indicating
that JamC expressed on tumor cells interacts with JamB expressed on
endothelial cells. However, we cannot exclude that the lack of JamB
expression also favors a better control of metastasis by the immune
system since our results show that metastasis of B16F10 expressing
ovalbumin are totally cured by cytolytic T cells directed against
ovalbumin without the need of priming. Ongoing experiments aim to
define whether JamB and/or JamC are involved in cytolytic T cell
recruitment and activation at metastatic sites. This will help to
decipher if preventing metastasis with anti-JamC treatment will be
counter-balanced by adverse effects on the immune system.
1 M. Aurrand-Lions et al., J Immunol 174 (10), (2005).
2 C. Lamagna et al., Cancer research 65 (13), (2005).
3 C. Zimmerli et al., J Immunol 182 (8), (2009).
4 C. Fuse et al., J Biological Chemistry 282 (11), (2007).
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Purpose:
CD4
+ helper and regulatory T cells play important but opposing
roles in regulating host immune responses against Hodgkin’s
Lymphoma (HL). In 20–40% of patients with HL, Epstein Barr
Virus (EBV) is present in the neoplastic cells, however very little
is known about regulatory mechanisms induced in presence of
EBV. Here, we described associations of regulatory T cells (Treg)
with EBV-positive and EBV-negative Hodgkin’s lymphoma.
Methods:
In a retrospective, population-based study, patients with Hodgkin’s
lymphoma were reclassified according to the WHO classification,
and EBV status was assessed by in-situ hybridisation of EBV-
encoded small RNAs. Using quantitative real time PCR, we first
analyzed gene expression of chemokines, immunosuppressive
cytokines and regulatory T cells markers on RNA isolated from
nodes of 20 EBV-positive HL patients and from 20 EBV-negative
HL patients. We also investigated presence of regulatory T cell
markers in PBMCs and sequential tonsil biopsies of HL patients.
Results:
We described in nodes of EBV-positive HL patients, a significant
increase of gene expression for the major immunosuppressive
cytokine: IL-10 which was correlated with an increased gene
S53expression of several markers of regulatory T cells (CD4+CD25+,
Fox P3,CTLA4, GITR). This increase was confirmed by immuno-
histochemical on frozen nodes biopsies and by flow cytometry on
PBMCs of HL patients. Moreover, we also described an over-
expressionof CCL17 and CCL22 which attractTh2 and regulatoryT
cells and may evade immune surveillance by Th1 cells.
Conclusion:
This study suggests direct evidence of regulatory Tcells particularly
in EBV positive Hodgkin’s Lymphoma and a pivotal role of these
cells in controlling the immune response in the context of viral
infection. These results will provide fundamental insights into the
mechanisms of tumor immune surveillance and escape, and yield
novel approaches to therapy of cancer.
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Introduction:
PD-1 (Program Death-1), an immune inhibitory receptor and its
ligands PD-L1 and PD-L2, participate in peripheral tolerance and
play key role in immune suppression and evasion mechanisms in a
variety of human malignancies. PD-1 inhibits activation signals and
functionsasapro-apoptoticreceptorineffectorlymphocytes.CT-011
is a humanized monoclonal antibody that interacts with PD-1 and
modulates the immune response eliciting effective activities of Tand
NK cells against experimental targets in cultures and inanimal tumor
models. CT-011 completed a Phase I single dose, dose escalation
clinical study in patients with advanced stage hematological
malignancies demonstrating acceptable safety and tolerability at all
tested dosage levels and clinical beneficial responses in 33% of the
patients including 1 pt with CR, 4 pts with DS and 1 pt with MR.
Results:
HerewedemonstratethatCT-011bindsaconservedepitopeonthePD-
1 receptor and blocks its function. CT-011 (1ug/ml) inhibits spontane-
ous or FAS-mediated cell death processes and enhances the survival of
human antigen- challenged effector/memory CD4+CD45RO
+lymphocytes via the PI3K pathway. Consistent with its enhancing
effect on lymphocyte survival, the antibody increases the intracellular
levels of BclXL, a survival protein and reduces the levels of activated
caspase 8 in CD4+CD45RO+ but not in CD4+CD45RO- suggesting
that it modulates two apparently separated apoptotic pathways in
specific subsets of T lymphocytes. Furthermore, antigen- challenged
CD4+CD45RO+lymphocytes incubated in the presence of CT-011
(1ug/ml) have shown increased trafficking in SDF-1 gradient in a
chemotaxis test, noted even at high concentration levels of SDF-1
(500 ng/ml).
Conclusions:
CT-011 binds a unique conserved epitope on the PD-1 receptor and
blocks its activity. This specific interaction results in intracellular
signaling affecting the survival and trafficking properties of antigen-
challenged effector/memory CD4+CD45RO+ lymphocytes. The
function of PD-1 and PD-L1 has been demonstrated to be one of
the leading causes of immune suppression in cancer patients.
Accordingly, CT-011 is being studied in several malignancies,
including, Phase II clinical studies in diffuse large B cell lymphoma
and metastatic colorectal cancer.
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The role of immune cellular and molecular effectors in the detection
and elimination of tumor cells is clearly established. However, the
high incidence of cancer in humans shows the inefficacy of the
immune system to control this process. Indeed, the immune system
not only stimulates neoplasia by triggering inflammation, but also
seems to participate to the escape or resistance of tumor cells to innate
and / or adaptive immunity. Melanoma, refractory to most chemo-
therapies and immunotherapeutic strategies, represents a clinical and
experimental model of choice to develop innovative approaches
integrating both chemo and immuno-therapeutic knowledges. One
mechanism used by tumor cells to escape to immune recognition is
down-regulation of the antigen-presenting machinery. Many tumor
cells have low or absent expression of major histocompatibility
complex class I (MHC-I) molecules.Exploringtheroleoftheimmune
systeminthemodulationoftumorcellsphenotype,wediscoveredthat
MHC-I
low tumor cells re-expressed MHC-I molecules in presence of
syngeneic spleen cells (NSC). Cell-cell contact between tumor cells
and NSC was necessary and resulted in IFNg production and a
consequent increased MHC-I expression. The effector cells respon-
s i b l ef o rt h ei n c r e a s e dI F N - gp r o duction were identified as CD4
+
CD1d-independent NKT, NK1.1
+ NK cells and CD4
+ CD11c
+DCs.
We used a model of murine melanoma graft (B16F10) and showed
that MHC-I induction occurs also in vivo and coincides with
recruitment of lymphoid cells. gdTcells and NK cells contributed to
the induction of the expression of MHC-I molecules on B16F10
tumor cells. Our results show the plasticity of a tumor cell under the
influence of immune microenvironment. Deciphering the role of
early interactions between tumor and immune cells in term of tumor
phenotype modification may allow innovative pharmacological
strategies to interfere with this regulation.
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S54Follicular lymphoma (FL), the most common indolent B-cell
lymphoma, involves an initial t(14;18) translocation leading to Bcl-2
anti-apoptotic protein overexpression. Additional genetic events could
lead to its transformation into an aggressive lymphoma. However,
clinicalbehaviorinFLisessentiallydeterminedbythegeneexpression
profile of the microenvironment rather than by inherent properties of
the tumor cells themselves. In agreement, an increased number of
macrophages is associated with a poor prognosis in FL whereas they
support the growth of DLBCL cells in vitro. We thus decided to
unravel the role of macrophages in FL with a specific focus on
interleukin-15 (IL-15), a cytokine mainly expressed by macrophages,
dendritic cells, and stromal cells that is trans-presented on cell
membranes associated with IL-15RA high-affinity receptor, and is a
well-described T and NK cell growth factor. We demonstrated that
whereas exogenous IL-15 promoted the survival of unpurified normal
B cells, resting purified B cells could not respond to this cytokine.
Nonetheless, after CD40-triggering or coculture with autologous T
cells, normal and FL-derived B cells became responsive to IL-15 that
enhanced their proliferation, in association with a phosphorylation of
STAT5. Normal and FL B-cell growth was also increased when
cocultured with monocytes and this feeder effect was reinforced by
IL-15. Furthermore, targeting IL15 and IL15RA in monocytes by
siRNA decreased monocyte-mediated B-cell growth. Specific deple-
tion of CD14
pos cells among tonsil cells decreased normal B-cell
growth in presence or not of IL-15, confirming the essential role
played by myeloid cells in this context. Finally, confocal microscopy
revealed the presence of IL-15RA at the cell interface between
monocytes and B cells. Collectively, these data depict for the first
time IL-15 as a B-cell growth factor within normal and FL B-cell
niches and describe a potent new therapeutic target.
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The long-lasting responses observed in some lymphoma patients
treated with rituximab suggests that this antibody induces an anti-
tumor immune response. We have investigated whether anti-CD20
treatment of CD20
+ tumor bearing mice can trigger a adaptive
immune response and whether it is possible to potentiate it by
subsequent IL-2 infusion. C57Bl/6 mice were i.v. injected with EL4
tumor cells expressing human CD20 and treated with i.p. injections
of the anti-CD20 mouse mAb CAT-13. Whereas all untreated
animals died before Day 35, about 60–70% of CAT-13-treated mice
survived. The surviving mice were then challenged at Day 70 by a
new i.v. injection of either EL4-huCD20 or EL4 cells without any
mAb treatment. All EL4-challenged-mice died before Day 26, while
about 50–60% of EL4-huCD20-challenged mice were still alive at
Day 70. Furthermore, a single i.v. injection of spleen cells isolated
from these surviving animals into naive recipients injected with
EL4-huCD20 cells 24 h later was sufficient to protect the latter
animals.These data suggest that anti-CD20 mAb treatment induces a
long-lasting adaptive immune response. Since IL-2 can exert an
anti-tumor effect through the activation of T cells in some cancers,
we injected IL-2 to the surviving CAT-13-treated mice just after
having challenged them with EL4-huCD20 cells. After 70 days, an
increase of the survival rate of IL-2 infused animals was observed as
compared to animals challenged with EL4-huCD20 cells only.
Thus, IL-2 injection at distance from mAb treatment may strengthen
the immune response against EL4-huCD20 tumor cells induced by
this treatment. In conclusion, our work shows that an anti-CD20
mAb treatment can induce a long-lasting adaptive immune response
that can be manipulated with IL-2.
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Adaptation to decreased oxygen tension is critical for the tumorigenic
process and involves a complex network of genes. Our recent studies
revealed that the hypoxic responseisnot restricted to expressed genes.
Several microRNAs, including miR-210 and miR-373, represent
direct targets of HIF and preliminary data indicate that they play
important roles in the response to extended hypoxic stress. miR-210 is
upregulated in a variety of solid tumors, it is positively correlated with
a hypoxia signature in vivo, and confers a negative prognosis inbreast
cancer. Therefore this miR may represent a key component for cancer
cell adaptation to the tumor microenvironment.
Clonogenic assays in a variety of cancer cell backgrounds demon-
strate that miR-210 supports cell survival and proliferation during
hypoxicstressandwearestudyingcriticaltargetgenesthatcontribute
to this effect. The impact of miR-210 manipulation on hypoxic
expression profiles reveals for the first time pathways that are
regulated viamiR-dependent mechanismsand of relevance fortumor
biology, such as mitochondrial ROS generation (the iron-sulfur
cluster scaffold homolog ISCU). Additionally, miR-210 and 373
directly target DNA repair genes such as Rad52 and Rad23b,
potentially contributing to the well-established correlation between
hypoxia and DNA damage. We developed models for addressing
the role of miR-210 in tumorigenesis, using stable miR-
overexpressing breast cancer cells xenografts, and by performing
in vivo miR inactivation using locked nucleic acids probes (LNAs).
These strategies are aimed to interfere with the ability of cells to
survive and proliferate in a hypoxic microenviroment, and could
provide the starting point for miR-based therapeutic developments.
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The glycolytic activity of hypoxic cells creates a gradient of lactate that
mirrors the gradient of oxygen in tumors. In human tumors, high levels
of lactate predict the likelihood of tumor recurrence, metastasis, and
poor survival. We recently addressed the intrinsic contribution of the
lactate anion to tumor growth and report that lactate is key for a
metabolic symbiosis in tumors. The symbiosis involves the recycling
of lactate, released by glycolytic tumor cells, as an oxidative fuel for
oxygenated tumor cells. The preferential use of lactate over glucose to
fuel tumor cell respiration renders glucose available to fuel the
glycolytic metabolism of hypoxic tumor cells. We further identified
monocarboxylate transporter 1 (MCT1), selectively expressed at the
plasma membrane of oxygenated tumor cells, as the prominent path for
lactate uptake. We successfully disrupted the metabolic symbiosis by
inhibiting MCT1 with a specific siRNA or with the selective inhibitor
α-cyano-4- hydroxycinnamate (CHC), causing a switch from lactate-
fueled respiration to glycolysis in oxygenated tumor cells. As a
consequence, CHC delivery to tumor-bearing mice causes hypoxic/
glycolytic tumor cell death by virtue of glucose starvation and the
remaining oxygenated tumor cells may be targeted by radiotherapy.
Validation of this new therapeutic strategy using three different tumor
m o d e l sa n dM C T 1e x p r e s s i o ni na na r r a yo fp r i m a r yh u m a nt u m o r s
provide clinical significance to anticancer MCT1 inhibition.
Reference: Sonveaux P. et al. Targeting lactate-fueled respiration
selectively kills hypoxic tumor cells in mice. J. Clin. Invest.
2008;118:3930–42.
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The tumor microenvironment, particularly hypoxia, has been demon-
strated to have tremendous impact on tumor progression and patient
prognosis. In patients, hypoxic tumors tend to be more aggressive,
resistant to radiation therapy, and therefore likely to recur locally or
metastasize. Although the development of hypoxia tolerance in
tumors seems to predict poor prognosis, mechanisms contributing to
hypoxia tolerance remain to be elucidated. To study hypoxia tolerance
in breast cancer progression, we isolated sub-populations of breast
cancer cells that survived under severe hypoxic conditions. Particu-
larly, we identified a novel sub-population of breast cancer cells that
exhibited more aggressive and invasive phenotypes after exposure to
repetitive cycles of hypoxia and reoxygenation. We also observed that
tumor cells isolated from 3D selection (grown as spheres) are more
resistant to hypoxia stress than 2D selection (grown as monolayer).
Therefore,thehypoxiaculturemicroenvironmentappearstobe ableto
drive the selection of an aggressive subpopulation of breast cancer
cells. In addition to increased aggressive phenotypes, we found that
regulation of mTOR signaling is critical to the survival of the non-
adherent breast cancer sub-population under hypoxia. This aggressive
sub-population showed increasing sensitivity to rapamycin compared
to the total breast cancer cell population. Furthermore, augmented Akt
and mTOR signaling were found in the non-adherent breast cancer
sub-population even when they are grown under normal growth
condition. Such aggressive cancer cells are difficult to target by
chemotherapy and are likely to repopulate the tumor after cytotoxic
treatment. Therefore, we anticipate that improved anti-cancer treat-
m e n tc o u l db ea c h i e v e di fm e t h o d sw e r ei d e n t i f i e dt ot a r g e tt h i ss u b -
population. Our ultimate goal is to understand the heterogencity of
hypoxia responses in breast cancer sub-populations, and their role in
breast tumor progression and metastasis. We will also examine
collaborations of signaling pathways essential to confer hypoxia
tolerance in sub-populations of breast cancer cells.
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Mortality from cancer is primarily due to the formation of distant
metastases. However, the molecular properties of primary tumours
that dictate metastatic potential are poorly understood. Here we show
that spontaneously metastasizing breast tumors are distinguished by
the expression of a group of hypoxia inducible genes that include
carbonic anhydrases (CA) IX and XII and vascular endothelial
growth factor C (VEGF-C). Primary tumors with high metastatic
potential are distinguished by large areas of hypoxia and necrosis,
higher numbers of apoptotic cells, high CAIX expression, and well
formed intratumoral lymphatic vessels relative to non-metastatic
tumors which are highly vascularized, and do not have intratumoral
lymphatic vessels. The metastatic, but not the non-metastatic cells
can induce CAIX and regulate extracellular acidification under
hypoxia. Gene silencing of CAIX expression in the metastatic cells
resulted in increased cell death in hypoxia in vitro and in dramatic
regression of primary tumor growth in vivo and complete inhibition
of formation of spontaneous metastases. Examination of CAIX
expression in 3,630 primary human breast cancers with long term
follow-up revealed CAIX to be an independent poor prognostic
biomarker for distant metastases and for overall survival. Our
findings strongly implicate hypoxic tumor microenvironments and
lymphangiogenesis as drivers of metastatic potential. We have also
identified CAIX as a targetable biomarker for breast cancer
S56metastatic potential, allowing for the identification and selection of
patients for treatment with CAIX inhibitors.
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Background and Purpose:
Hypoxia is an important micro-environmental parameter that influen-
ces tumor progression and treatment efficacy. The hypoxia target
carbonic anhydrase IX (CA IX) is associated with poor prognosis and
therapy resistance and is an important regulator of tumor pH. Several
studies suggest it may be a potential imaging and therapeutic target.
Recently, sulfonamide inhibitors (CAI) that bind and inhibit CA IX
only during hypoxia have been developed. The aim of this study was to
investigate the in vivo CAI binding properties using fluorescent
imaging and the possible therapeutic gain of combining specific CAI
with irradiation.
Material and Methods:
NMRI-nu mice were inoculated subcutaneously into the lateral flank
with HT-29 colorectal carcinoma cells. Non-invasive imaging was
performed at several time points after CAI#1 (fluorescein-thioureido-
homosulfanilamide) injection with our without modifying the tumor
oxygen concentration levels. Tumor growth and potential treatment
toxicity was monitored after injection of CAI#2 (indanesulfonamide)
combined with irradiation (single tumor dose 10 Gy).
Results:
In vivofluorescenceimagingrevealedforthefirsttimespecificCAI#1
accumulation (P=0.008 compared with controls) in delineated tumor
areas dependent on the oxygen concentration. Treatment of animals
with CAI#2 alone resulted in a significant growth delay (P=0.024).
Single irradiation treatment also demonstrated an increased specific
doubling time evaluated at 4 times the starting tumor volume (P<
0.001). The specific doubling time was further increased by
combining CAI#2 with irradiation (P=0.016). No significant toxicity
was observed, neither for the single, neither for the combined
treatment schedules.
Conclusions:
These in vivo results confirm previous data showing that in vitro CAI
binding occurs only under hypoxia. Furthermore, CAI as a single
treatment is able to significantly reduce tumor growth, which was
further enhanced by combining with irradiation, promising for further
clinical testing.
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The main therapeutic challenge in the treatment of acute lymphocytic
leukemia is the development of strategies aimed at overcoming
resistance to chemotherapy. While intensive chemotherapy nduce
remissions in 90% patients, there has been little improvement in
reducing the risk of leukemia relapse. Recent studies indicate that
interactions between leukemia cells and bone marrow (BM) microen-
vironment promote leukemia cell survival and confer resistance to
drugs commonly used to treat ALL. We have focused on the role of
hypoxia asa natural physiologic componentof BMmicroenvironment.
Our data using the metabolic marker pimonidazole suggest that the
hypoxic BM niche in leukemias is greatly expanded, contrary to the
discrete, subendosteal or perivascular niches found in normal hema-
topoiesis. BM hypoxia promotes a switch to glycolytic metabolism and
contributes to the resistance of leukemic cells in BM niches. These
events are at least in part mediated via transcription factor HIF-1α.
ExpressionofHIF-1αanditstargetgene CAIXwasdetectedin68%of
primary ALL samples (n=53), while it was sparingly expressed in few
hematopoietic cells in normal BM, and inversely associated with
patients’ survival (p=0.023). HIF-1α is induced under hypoxic
conditions in co-cultures with bone marrow-derived stromal cells
(MSC) through mTOR and MAPK pathways. Silencing of HIF-1α
with siRNA, or blockade of mTOR signaling with rapamycin
derivatives reduced expression of the glucose transporter Glut-1
and diminished glucose flux, decreased glycolytic rate and ATP
production and sensitized leukemic cells to pro-apopotic effects of
chemotherapeutic agentsunderhypoxicconditions. Infurthersupport
of the role of hypoxia, utilization of the hypoxia-activated pro-drug
(PR-104) resulted in cures of a proportion of NOD/Scid/IL2Rg-KO
mice transplanted with primary human leukemia. Altogether, these
findingsstronglysupportaroleforhypoxicBMmicroenvironmentin
the chemoresistance of ALL cells and provide a mechanism-based
rationale for eliminating resistant ALL progenitor cells.
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S57It is well-established that cells exposed to the limiting oxygen
microenvironment (hypoxia) of tumors acquire resistance to chemo-
therapy, through mechanisms not fully understood. We noted that
numerous cell lines showed protection from apoptotic stimuli,
staurosporine or etoposide, when exposed to long-term hypoxia (72
hours). In addition, these cells had unusually enlarged mitochondria.
Here we reveal that mitochondria of hypoxia-induced chemotherapy-
resistant cells undergo a hypoxia-inducible factor-dependent and
mitofusin 1-mediated change in morphology from a tubular network
to an enlarged phenotype. An imbalance in mitochondrial fusion/
fission occurs since silencing of the mitochondrial fusion protein
mitofusin 1 reestablished a tubular morphology. Enlarged mitochon-
dria conserved their transmembrane potential and ATP production,
and contained an as yet undetected short isoform of the voltage-
dependent anion channel VDAC3. Hypoxic cells were insensitive to
staurosporine- and etoposide-induced cell death, but the silencing of
VDAC3 restored sensitivity. Our results demonstrate that hypoxia, by
inducing mitochondrial fusion, confers selective protection from
apoptosis through expression of a short isoform of VDAC3 that
allows maintenance of ATP and cell survival in hypoxia.
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Research studies on early stage solid tumor formation in our
laboratory led to the identification of a novel class of cell derived
vesicles released by cell budding or fission that play a critical role in
this process, termed “tissue organizing structures” (TOS). These
trypsin-resistant, membrane-delimited particles, approximately 2
micron diameter, are produced by diverse cell types, both normal
and malignant, and contain genetic material. Documented activities
include a critical role in orchestrating solid tumor formation in vitro
and the induction of cell morphogenesis following fusion with
neighboring cells. Proposed mechanisms of cell transformation
include horizontal gene transfer and a novel mechanism termed
“insertional membrane editing”. Recent studies in this laboratory
have focused on the biophysical components of the cell microenvi-
ronment that may contribute to the formation of these novel
structures. This research extends previously elaborated biomechan-
ical models of malignant transformation by implicating a specific
biological/structural response with direct physiological conse-
quences to biophysical forces initiated by tissue structure
interactions. In this model, TOS formation is initiated by the
stress-dependent restructuring of the cytoarchitecture initiated
by the change in cell division parameters of individual cells
that produce a tissue-encompassing regional integrated biome-
chanical response intrinsically linked to the formation of cell
structures (TOS). The formation of TOS tubules and the
migration of these entities drive the organization of the local
cell population to generate a new architectural entity, the solid
tumor. This is the first biomechanical/structural model of solid
tumor formation, invasion and metastasis that integrates current
biophysical theories of solid tumor formation with the forma-
tion of specific biological cell structures responsible for many
of the genetic, physiological and biochemical parameters that
characterize malignant transformation.
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Control in a Model of Human Breast Cancer. CPT1A is a Novel
Partner of Histone Deacetylase 1 in Cell Death Escaping
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The altered metabolism of tumor cells may be a potential means
by which these cells evade programmed cell death, favouring
survival and tumoral growth. In particular, lipid metabolism is
markedly altered in the tumoral context. Neoplastic cells use
endogenously synthesized fatty acids to satisfy their metabolic
necessities and fatty acids synthase (FASN), the major enzyme
required for the synthesis of fatty acids, is up-regulated in a wide
array of solid tumors. Experiments of RNA interference-
knockdown have confirmed its role as metabolic oncogene. ErbB2
receptor, amplified in 25% of breast cancers, has been recognized
as activator of FASN promoter. Thus, Epidermal growth factor
receptor (EGFR) family system, activated in tumor microenviro-
ment, could influence FASN activity via Her2 activation.
We previously studied human breast carcinomas and breast cancer cell
lines (SK-BR3, BT474, MCF-7) with or without Her2 gene
amplification confirming that FASN was over-expressed in a high
percentofcasesandthatFASNexpressionlevelscouldbeindicatorsof
Her2 transduction activity (unpublished data). On the other hand, we
found an inhibition offatty-acids b-oxidation in the tumoral context. In
particular carnitine palmitoyl transferase I (CPT I), the rate-limiting
enzyme in the transport of long-chain fatty acids for b-oxidation, was
significantly decreased in the mitochondria and it strikingly localized
in the nuclei of tumoral samples, where it could be implicated in the
epigenetic regulation of transcription by its link to HDAC1.
Here we report that the silencing of CPT1A nuclear expression by
small interfering RNAs is a sufficient condition to induce apoptosis in
MCF-7 breast cancer cells. The apoptosis triggered by RNA
interference correlates with reduction of HDAC activity and hyper-
acetylation of histone- and non histone-proteins, involved in cancer-
relevant death pathways. Moreover, the CPT1A knockdown induces
downstream effects on pro-apoptotic genes (up-regulation) and
invasion and metastasis related genes (down-modulation), as shown
by microarray analysis. In a breast cancer model, these results provide
evidence of a mechanism linking the increased biosynthesis of fatty
acids induced by Her2/Neu signaling to the down-regulation of
mitochondrial CPT1A. This enzyme can shuttle into the nucleus
regulating at epigenetic level pro-survival and cell-death escape genes.
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The GCN2-ATF4 Pathway is a Key Determinant
of Tumor Cell Survival and Proliferation in Response
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The basic leucine-zipper (bZip) transcription factor ATF4 has been
shown to regulate the expression of mRNAs involved in amino
acid metabolism, cellular redox homeostasis and anti-stress
responses. It is translationally upregulated upon phosphorylation
of the translation factor eIF2a by cytoplasmic kinase GCN2 under
amino acid starvation and the endoplasmic reticulum (ER) kinase
PERK under ER stress and hypoxia. ATF4 is overexpressed in
clinical samples of human tumors and co-localizes with hypoxic
regions, suggesting that it may play an important role in tumor
progression. Here we report that knockdown of ATF4 in tumor
cells results in significant inhibition of survival and proliferation,
despite an initial activation of an autophagic response and that this
inhibition was more pronounced under hypoxic stress. These
effects are ameliorated by supplementation of tumor cells with
non-essential amino acids (NEAA), but not with antioxidants.
Asparagine, but not any other NEAA, is sufficient to recapitulate
this rescue effect. Knockdown of ATF4 significantly reduces the
levels of asparagine synthetase (ASNS) and overexpression of
ASNS reverses the proliferation block and increases survival of
ATF4 knockdown cells. Both amino acid and glucose deprivation
activate the upstream eIF2a kinase GCN2 to upregulate ATF4 and
target genes involved in amino acid transport and synthesis.
Abrogation of ATF4 or GCN2 levels significantly inhibits trans-
formed cell proliferation and tumor growth in vivo. Since the
GCN2-eIF2a-ATF4 pathway is critical for maintaining amino acid
homeostasis under different stresses, targeting this pathway
represents a novel anti-tumor approach.
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Stromal cells are integral components of the tumor microenvironment
(TM) in early stage colon cancer progression. An important protein
that is activated and secreted by both tumor and stromal cells during
tumor progression is SPARC (secreted protein acidic and rich in
cysteine). The relation of SPARC expressed by tumors and adjacent
TM stromal cells is poorly understood. SPARC is secreted in the
extracellular matrix of tumors and has many cellular regulatory
functions including angiogenesis. The objective was to determine
SPARC activity in TM stromal cells in relation to lymphovascular
invasion(LVI) activity of the primary tumor. To assess SPARC role in
the TM of primary colon cancer we examined patients whose tumors
were histopathology grouped based on LVI. Immunohistochemistry
(IHC) analysis with anti-SPARC of 82 primary colon tumors had no
significant differences of SPARC regardless of LVI status. Examina-
tion of adjacent stromal cells in the TM SPARC expression levels
variedconsiderably.InfurtheranalysisofLVI(-)(n=35)andLVI(+)(n=
37) colon tumors, it was demonstrated in the former group TM
stromal cells had significantly (p<0.0001) elevated SPARC.
Epigenetic regulation of SPARC gene was then assessed in the
stromal cells using microdissected archival paraffin-embedded
tissues through assessment of SPARC gene CpG island region
methylation status in the promoter region by MassARRAY
quantitative sequencing. The analysis demonstrated concurrent
activity of hypermethylation of specific CpG islands that were
significantly (p<0.0001) correlated to LVI status and SPARC
expression. The methylation sequencing analysis showed signifi-
cant hypermethylation of specific CpG islands correlated to
SPARC downregulation. Analysis of angiogenesis activity was
carried out by assessment of stromal cells with anti-VEGF-A Ab.
VEGF-A levels in the stromal cells were inversely correlated (p=
0.005) with SPARC protein levels. The studies demonstrate
SPARC activity of TM stromal is epigenetically regulated and
significantlycorrelatedwithLVIactivity ofcolon primarytumors.
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The immunoglobulin-like cell adhesion molecule L1 is a cell
surface molecule that mediates various essential processes in the
nervous system, as demonstrated by the broad spectrum of
neurological defects in mice and humans carrying deletions or
mutations in the L1 gene. L1 is also expressed in several non-
neural cell types where, however, its function has remained
elusive. In particular L1 is aberrantly expressed in various tumor
types, and its expression often correlates with poor prognosis. We
have focused on epithelial ovarian carcinoma (EOC), one of the
most fatal malignancies in which many of the pathobiological
mechanisms have not been elucidated yet. L1 exhibits a peculiar
expression pattern in EOC lesions, and exerts a cell context-
dependent role, with a clear pro-malignant function. Moreover, L1
appears as a hallmark of pathological vessels, as we found the
molecule to be expressed in the vasculature associated to both
neoplastic and inflammatory vessels, and to be induced in
endothelial cells by inflammatory and angiogenic stimuli. Our
data pointed to L1 also as a marker of certain hematopoietic cell
lineages. The functional relevance of these observations was tested
in a conditional knockout mouse model, which revealed the causal
S59role of L1 in the transendothelial migration of immune cells and in
their trafficking in vivo, two processes strictly related to cancer
progression. Hence, L1 is present in invasive tumor cells, in
cancer-associated vasculature and in inflammatory cells, and in all
these cell types its function is consistent with a pro-malignant role
through the modulation of tumor-host interactions. These obser-
vations provide the rationale to explore L1 targeting as a strategy
to interfere with the tumor-promoting action of some microenvi-
ronment components.
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Myofibroblasts make up reactive stroma associated with prostate,
mammary, lung, colon, and stomach carcinoma, suggesting that
this cell type plays a critical role in a generalized response to
injury. Our lab has shown a direct correlation of degree of reactive
stroma with both severity and biochemical recurrence of human
prostate cancer. The precise origin of myofibroblasts and their
mechanism of recruitment in cancer are unknown. Recent studies
in wound repair suggest that at sites of reactive stroma they
originate from fibrocytes derived from circulating CD34+ hema-
topoietic progenitor cells. TGF-β has emerged as a key factor in
mediating the recruitment and differentiation of fibrocytes to sites
of wounding, however its corresponding role in cancer has not
been examined.
To further understand the role of reactive stroma in adenocarcinoma,
we analyzed several tissue microarrays containing patient matched
normal and cancer regions that were subjected to a dual labeling
immunohistochemistry approach. Recent data suggest that prostate
cancer reactive stroma originates from vimentin+/CD34+/CD14+
progenitor cells that are juxtaposed to the sub-basal lamina surface at
thestromal-epithelialjunction.Moreover,xenograftmodelingstudies
suggest that reactive stroma originates from bone marrow derived
cells that may be of the monocyte series. Mechanistic studies
examining TGF-β overexpression in vivo demonstrate age-
dependent changes that mimic human reactive stroma. Transgenic
mice exhibited focal collagenous micronodules that appear to
correlated with TGF-β1 expression. Intraluminal fibroplasia with
influx of inflammatory cells was also present in various regions of
transgenic prostate. We propose a model of reactive stroma
potential, affected by activation of local progenitors and subsequent
recruitment of circulating progenitors to initiate and sustain a
reactive microenvironment adjacent to cancer foci. We propose that
this microenvironment is selective for more aggressive cancer
phenotypes and is therefore a potential target for more advanced
prognostics and novel therapeutics.
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New models continue to be required to improve our understanding
of colorectal cancer progression. The impact of microenvironment -
like cell-cell interactions, extracellular matrix- on cell phenotype is
now well described and multicellular three-dimensional tumour
spheroids have been shown to closely mimic phenotype character-
istics of in vivo solid tumours. In this context, we characterized
here a three-dimensional multicellular tumour model we named
colospheres, directly obtained from mechanically dissociated colonic
primary tumours and correlated with metastatic potential.
Colorectal primary tumours (n=203) and 120 paired non-tumoral
colon mucosa were mechanically disaggregated into small fragments
for short-term cultures. Colospheres, exclusively formed by viable
cancer cells, were obtained in only one day from 98 tumours (47%).
Inversely, non-tumoral colonic mucosa never generated colospheres.
The colosphere forming capacity was statistically significantly
associated to tumour aggressiveness, according to AJCC stage
analysis. Further characterization was performed using colospheres,
generated from a human colon cancer xenograft, and spheroids,
formed on agarose by the paired cancer cell line.
Despite close morphology, colospheres displayed higher invasivity
thanspheroids.SpheroidsandcolospheresmigratedintoMatrigelbut
MMP-2 and MMP-9 activity was detected only in colospheres.
Mouse subrenal capsule assay revealed the unique tumorigenic and
metastatic phenotype of colospheres. Besides, colospheres and
parental xenograft reproduced similar CD44 and CD133 expression
in which CD44
+ cells represented a minority subset of the CD133
+
population. Different growth conditions (ex vivo versus in vitro)
involve distinct microenvironments, which consequently could
participate in explaining these differences.
The present colospheres provide an ex vivo three-dimensional
model, potentially useful for studying metastatic process, and
underline the interest of studying different 3D microtumours with
a different microenvironment origin.
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We have previously shown that obesity is an independent
predictor of leukemia (ALL) relapse. We have also found that
obese mice transplanted with syngeneic ALL have poorer
survival after treatment with vincristine, Nilotinib, or L-
asparaginase, even when these agents are dosed proportional to
body weight. Since ALL cells were found in the fat pads of
relapsed mice, and adipocytes are a significant component of the
bone marrow microenvironment, we investigated the role of
adipocytes in ALL drug resistance.
We developed an in vitro co-culture system in which human
or murine ALL cells were cultured together with adipocytes
(differentiated 3 T3 L1s). Undifferentiated 3 T3-L1 fibroblasts
were used as a control. Adipocytes protected murine preB
ALL cells (“8093”) from the anti-leukemic effects of all
chemotherapeuties tested (vincristine, dexamethasone, niloti-
nib, daunorubicin, and L-asparaginase). This occurred inde-
pendent of cell contact. Most significant was the protection by
adipocytes against daunorubicin; after a 3-day exposure to 35
nM daunorubicin, there were 3.2±0.3 vs. 0.4±0.1 x 10
5 viable
cells in transwells over adipocytes vs. fibroblasts (p<0.005).
This protection was also observed with murine bone marrow
derived adipocytes (OP9), human immortalized adipocytes
(Chub S7s), and human SD-1, RCH ACV, and BV-173 leukemia
cells.
Further experiments demonstrated that media conditioned by
adipocytes did not protect ALL cells from daunorubicin. However,
media conditioned by the presence of both adipocytes and ALL
cells simultaneously conferred a high degree of resistance to the
leukemia cells (1.3±0.4 x 10
5 viable cells, vs. <0.1x10
5 in all
other media types, p<0.05).
In summary, adipocytes protect ALL cells from multiple chemo-
therapies in vitro. Adipocytes take part in a two-way communi-
cation with ALL cells which leads to the secretion of factor(s) that
confer resistance to daunorubicin. Adipose tissue may contribute
to increased ALL relapse in obese patients.
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Cellular senescence is considered to be a potent anticancer
mechanism. However, it has been proposed that senescent stroma
cells may enhance the growth of adjacent malignant epithelial cells.
Exposure of tumours to repeated low doses of γ-irradiation is a
common treatment regime in several tissues. However, the effect of
this stress to the neighboring stromal cells and the interaction of the
latter with cancer cells have not been adequately investigated. In this
study, wehave exposed confluent cultures of human lung fibroblasts,
derived from normal or cancer-associated regions, to repeated
subcytotoxic doses of 4 Gy of γ-irradiation. We have found that a
singledoseimmediatelyactivatesaDNAdamageresponse,asshown
by the activation of the ATM/Chk2/p53/p21
WAF1 axis, leading to an
intense cell cycle arrest. After a series of doses (total dose approx.
50 Gy), followed by cell subculturing, cellular senescence was
accelerated, as shown by morphological alterations, growth arrest,
p21
WAF1 and p16
INK4a upregulation and senescence-associated β
galactosidase staining. This process was found to be p53-dependent.
Next, we studied the effect of these prematurely senescent cells on
the growth of human malignant lung cell lines (A549 and H1299).
Medium conditioned by young and prematurely senescent cells has
no major effect on the proliferation of all three cell lines. However,
in co-culture studies we have found that the growth of cancer cells
was strongly enhanced when cultured on senescent cells. In
addition, in immunocompromised (SCID) mice γ-irradiation-
induced senescent cells, similarly to replicative senescent fibro-
blasts, intensely promoted A549 cells to form tumours; this process
was partly dependent on the upregulation of matrix metalloproteases
in senescent cells. These findings support the idea that replicative-
or stress-induced-senescence may contribute to tumourigenesis.
This work has been partly supported by ΚΕΣΥ.
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Head and neck squamous cell carcinoma (HNSCC) is the sixth
most common cancer with 650 000 new cases worldwide every
year. The epidermal growth factor receptor (EGFR) is frequently
overexpressed in HNSCC, thus, the anti-EGFR antibody cetux-
imab (Erbitux®) has been introduced in the treatment of this
disease. Cancer-associated fibroblasts (CAFs), which are the major
component of the stromal compartment, are known to support
tumor growth and progression. It has also been suggested that
CAFs could reduce the sensitivity of tumor cells to certain anti-
cancer treatments. Therefore, their effect on cetuximab response in
HNSCC cell lines was investigated.
CAFs, isolated from HNSCC biopsies from 7 patients, were found to
stimulate HNSCC tumor cell proliferation. Interestingly, CAFs also
reduced the sensitivity of 5 tested tumor cell lines to the growth-
inhibitory effect of cetuximab. The effects were particularly
prominent in the UT-SCC-9 cell line. In this cell line cetuximab
caused a 40% reduction in cell number in the absence of CAFs.
However, in co-culture with fibroblasts cetuximab instead stimulated
tumor cell proliferation. Fibroblast conditioned media gave similar
results, indicating that the CAF-derived protective effect is mediated
by soluble factors.
The mechanism by which CAF-derived soluble factors reduce
cetuximab-induced growth inhibition will be further characterized.
According to preliminary data, fibroblast conditioned media pre-
vented the cetuximab-induced reduction in EGFR phosphorylation.
Thus, fibroblast-derived factors appear to interfere with the proximal
effectsof cetuximab on receptor activity. These results thus identify a
previously unrecognized CAF-dependent modulation of cetuximab-
s e n s i t i v i t y ,a n da l s op r e s e n tp r e l i m i n a r yd a t ao nt h eu n d e r l y i n g
mechanism. In a longer perspective these results should aid in
selection of HNSCC patients for cetuximab treatment. Finally, they
suggest targeting of CAF-derived factors, yet to be identified, as a
novel strategy to improve the effects of cetuximab.
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Introduction:
It has been established that tumor microenvironment inhibits the
infiltration and activity of T lymphocytes and creates the local
immunosuppression. However, it still remains unknown which
component of tumor microenvironment is really responsible for tumor
immunopathgenity. RCAS1 (receptor cancer binding antigen
expressed on SiSo cells) is a protein expressed by various cancer cells
responsible for the inhibition of activated immune cells such as T, B
lymphocytes and NK cells and induction of their apoptosis, participat-
ing in the tumor escape from host immunological surveillance and the
creation of immune tolerance for tumor cells. Tumor-associated
macrophages might promote tumor growth and metastases.
Materials and Methods:
RCAS1 and CD68 antigens immunoreactivity was determined in
50 tissue samples of salivary gland adenocarcinomas and in 50
tissue samples of their stroma and 30 tissue samples of healthy
control (palatine tonsils) by immunohistochemistry method in the
Department of Pathology.
S62Results:
RCAS1 immunoreactivity was identified in both adenocarcinoma
and healthy stromal samples. Significantly higher RCAS1 immu-
noreactivity was shown in the cancer samples than in stromal
samples. RCAS1 immunoreactivity in stromal samples was
significantly higher in patients with the presence of lymph node
metastases in comparison to patients without metastases. We also
observed significantly higher number of CD68 positive cells
(macrophages) in adenocarcinoma samples and in stromal samples
than in the control group. Moreover, the number of CD68 positive
cells in adenocarcinoma and stroma were higher in patients with
lymph node metastases in comparison to patients without
metastases. Additionally, in our study macrophages were identi-
fied to possess the immunoreactivity of RCAS1, RCAS1 express-
ing macrophages were observed in the mucous.
Conclusion:
In the present study we have demonstrated that RCAS1 expression
by the tumor cells, tumor microenvironment and tumor associated
macrophages participate in creating the immunosuppressive
microenvironment in salivary adenocarcinomas.
O71
Tumor Microenvironment Induced Drug and Radio Resistance
in Invasive Breast Cancer Cells
Sumanta Goswami
1,2
1Anatomy and Structural Biology, Albert Einstein College of
Medicine of Yeshiva University, Bronx, NY, USA,
2Department of
Biology, Yeshiva University, New York, NY, USA
Metastasis, drug and radio resistance continue to cause significant
morbidity and patient mortality. This is in spite of recent
introduction of a number of different chemotherapy agents and
newer radiotherapy protocols. Using unique animal models and
cell separation techniques coupled with sensitive assays we have
recently discovered that the invasive breast cancer cells are
hypoproliferative and antiapoptotic. Since the invasive cells have
shut down their cell cycle and have become dormant they continue
to resist cytotoxic drugs and ionizing radiation. We have used cells
isolated from the primary tumor, invasive cells, circulating tumor
cells and lung metastasis to identify the underlying molecular
mechanism for drug and radio resistance. We used a combination
of cytotoxic and cytostatic drugs along with molecular pathway
directed drugs to target the invasive, drug and radio resistant
breast cancer cells. Secondly using both classical gene expression
studies as well as by the identification of different invasion and
resistance specific splice variants we have identified a genetic
signature which will predict potentially invasive, chemo and radio
resistant cancers. Third we have evaluated the in vitro and in vivo
efficacy of a protein phosphatase inhibitor that pushes the dormant
cells into the cell cycle at both G0/G1 and G2/M stages, thereby
converting the resistant cells to chemo and radio sensitive. There
are two very important clinical advantages of this research
program; first we can predict which patient will respond to which
drug depending on the genetic signature of their cancer, second we
are able to target the dormant cells by reverting them to become
chemo and radiosensitive. In summary we conclude that the tumor
microenvironment renders the invasive cells chemo and radio
resistant and thereby protecting them from the initial chemo and
radio therapy. This probably causes a relapse of the disease after a
period of apparent remission.
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Melanoma is known for its poor response to current immuno-
therapies due to immunosuppressive cells and factors in the tumor
microenvironment, which inhibit antitumor immune responses.
We use a recently developed ret transgenic mouse skin melanoma
model, which closely resemble human melanoma with respect to
genetics, histopathology and clinical features. After a short latency
(20–70 days), around 25% of mice spontaneously develop
melanoma metastasizing to lymph nodes, liver and lungs.
We demonstrated a tumor infiltration with immature dendritic cells
(DCs) that secreted more interleukin (IL)-10 and less IL-12p70
and showed a decreased capacity to activate T cells compared to
DCs from normal animals. Observed dysfunction was linked to
p38 MAPK activation. Inhibition of its activity led to normaliza-
tion of cytokine secretion pattern and T-cell stimulation capacity
of DCs from tumor bearing mice. TCR zeta-chain expression in
lymphoid organs and tumors was down-regulated, which was
associated with an increase in Gr1+CD11b+ myeloid derived
suppressor cells (MDSC) in these mice. Co-culture of normal T
cells with MDSCs from tumor bearing mice led to the down-
regulation of zeta-expression. Oral application of an inhibitor of
phosphodiesterase-5 sildenafil (Viagra) resulted in a retardation of
melanoma progression associated with an increase in tumor-
infiltrating CD8
+ and CD4
+ T cells and in their zeta-chain
expression. Higher numbers of regulatory T cells (Treg) were
found at early stages of melanoma progression compared to more
advanced tumors. These data inversely correlated with Treg
amounts in the bone marrow suggesting a possible Treg
recruitment to primary tumors. Although anti-CD25 antibody
injections resulted in the efficient Treg depletion from lymphoid
organs, melanoma development was not delayed indicating that in
the autochthonous melanoma genesis, other immunosuppressive
cells could play replace tumor promoting Treg functions. We
suggest that effective melanoma immunotherapy should include
the neutralization of tolerogenic DCs, MDCS and Treg in the
tumor microenvironment.
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Human solid tumors have evolved numerous strategies for escape
from the host immune system. Recently, it has been shown that
regulatory T cells (Treg) accumulate in blood and tissues of patients
with cancer influencing prognosis. One mechanism for Treg-
mediated suppression of anti-tumor immunity involves ectonucleo-
tidases CD39 and CD73 overexpressed on CD4
+CD25
highFOXP3
+
cells. These enzymes sequentially convert ATP into AMP and
adenosine, which binds to A2a receptors (A2aR) on effector
cells, suppressing their functions. Treg express low levels of
adenosine deaminase (ADA) responsible for adenosine break-
down and of CD26, a surface-bound glycoprotein associated
with ADA. Inhibitors of ectonucleotidases or antagonists of the
A2aR block Treg-mediated suppression. The increased frequency
and suppressor activity of Treg in patients with cancer are in part
regulated by the presence in body fluids of tumor-derived
microvesicles (TMV) also referred to as exosomes. When
isolated and purified from tumor cell supernatants or sera of
patients with cancer, TMV induced conversion of CD4
+CD25
neg
into CD4
+CD25
highFOXP3
+ Treg and enhanced Treg prolifera-
tion (p<0.001) as well as suppressor functions (p<0.01). These
changes in Treg were associated with increased expression of
phosphorylated STAT3 and resistance of Treg to TMV-mediated
apoptosis. TMV were positive for TGF-β1 and IL-10 and their
suppressor functions were in part abrogated by neutralizing
antibodies to these cytokines. In addition to producing adenosine
and releasing TMV, human tumors were found to express TLR4.
Triggering of this receptor by its ligands, LPS or paclitaxel
(PTX), promoted tumor cell proliferation, activated the P13K
pathway up-regulated Akt phosphorylation and NF-κBt r a n s l o -
cation to the nucleus, increased resistance of the tumor to
apoptosis and protected the tumor from NK-cell mediated lysis.
Further, TLR4 triggering on tumors was associated with the up-
regulation of IRAK-4 expression, and increased production of
IL-6, IL-8, GM-CSF and VEGF. IL-4 ligation on tumor cells also
protected them from effects of chemotherapy. In aggregate, our
data suggest that the elimination of tumor immune escape will
require combination strategies designed to target several distinct
molecular mechanisms.
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Radiotherapy is successfully used to treat human cancer.
Emerging evidence suggests that radiation-induced modifica-
tions of the tumor microenvironment may contribute to the
therapeutic effects of radiotherapy. Recurrence after radiothera-
py, however, is associated with increased local invasion,
metastatic spreading and poor prognosis. We are investigating
whether radiation-modified tumor microenvironment may pos-
sibly contribute to the increased aggressiveness of relapsing
tumors. Irradiation of the prospective tumor bed results in a
sustained impairment of growth factor-driven and tumor angio-
genesis without disrupting the preexistent vasculature, through
sustained inhibition of proliferation, induction of senescence and
inhibition of migration and sprouting of endothelial cells. Using
xenografts tumor models and an orthotopic model of murine
breast cancer, we observed that tumors growing within a
preirradiated stroma have reduced growth while they display
increased hypoxia, necrosis, local invasion and lung metastasis.
Mechanisms of progression involve adaptation of tumor cells to
local hypoxic conditions as well as the selection of escape
variantsretaining an invasive and metastatic phenotype upon
returning to normoxia. Though gene expression analysis experi-
ments, we have identified the matricellular protein CYR61 and
αVβ5 integrin as molecules that cooperate to mediate lung
metastasis, as well as a gene expression signature associated
with tumor hypoxia and predictive for a shorter relapse-free
survival after adjuvant radiochemotherapy in human breast
cancer. The αV integrin small molecular inhibitor Cilengitide
prevented lung metastasis formation without impinging on
primary tumor growth. Radiotherapy also modify the recruit-
ment of bone marrow derived / immune cells known to
contribute to tumor angiogenesis and metastasis. Taken together
these results demonstrate the impact of radiotherapy-induced
modifications of the tumor microenvironment in determining
tumor evolution and identify candidate therapeutic targets. We
are currently investigating additional cellular and molecular
determinants of tumor escape and progression after radiotherapy,
and at this conference we will present the latest results.
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We have developed a linear model of prostate tissue that describes
gene expression changes as a sum of contributions of four major cell
types in tumor enriched samples including tumor cells, stroma cells,
epithelial cells of BPH, and dilated cystic glands. When combined
with knowledge of the cell type distribution as estimated by
pathologists, the model provides estimates of gene expression for
eachcelltype(1).Bycomparingtheexpressionofstromacellsinlow
(<15%) tumor samples with normal volunteer biopsy samples, we
derived 417 significant gene expression differences which were
further filtered to remove genes with significant expression in tumor
cells.Theresulting17genes,whichappearedtohavehighexpression
in stroma only when in the presence of tumor, were applied to a
training set of 18 PCa cases and 17 noncancer tissues of the same
cases all measured on U133plus2 Affymetrix arrays. The program
PAM yielded 97% accuracy for discriminating tumor cases vs. non
tumor cases. The classifier was then tested on multiple independent
prostate samples including 65 tumor cases and a separate 79 case set
both measured on U133A arrays and both publically available, and
55 independent cases measured on U133plus2 arrays in house which
yielded an accuracy of 96–100% for the three sets. To exclude
performance that may be based on recognition of tumor cells, we
tested the classifier on 9 additional independent normal volunteer
biopsy cases and 7 normal rapid autopsy cases that were histolog-
ically confirmed to be tumor free which yielded 100% accuracy as
nontumor cases for both series. Thus a classifier based on tumor-
adjacent stroma is highly accurate for discrimination of tumor and
nontumor.Asignificantnumberofthemillionprostatebiopsiesinthe
U.S. per year have equivocal pathological readings, therefore,
methods for augmenting diagnostic accuracy based on stroma may
be helpful.
1.Stuart et al. PNAS 2004;101:615–20.
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Circulating bone marrow derived endothelial progenitor cells (BM-
EPC) have been observed to contribute to neo-vascularization of
breast cancers and the identification of its systemic mediators will
impact clinical care. We discovered a crucial role for BM-EPCs in
breast cancer progression with estradiol (E2) as a major modulator.
We utilized TEK2/GFP-Balb/c ± ovariectomized ± estrogen supple-
mentation as our experimental mouse model. These mice were
transplanted with bone marrow (BMT) derived from TEK 2/GFP
micethatwereusedasdonors.Tumorswereinducedinthesemiceby
surgical implantation of TG1 or 4T1 murine mammary adenocarci-
noma cells (derived from syngeneic BALB/c mice; 2×10
6 cells/
0.3 ml PBS) into the fourth inguinal mammary gland after clearing
the fat pad region of BMT mice. BM-EPC mobilization at the tumor
site was measured and correlated with capillary density. We
observed the concomitant mobilization of GFP and CD133 (marker
of EPC) double-positive cells at the tumor site with high levels in
the blood prior to migration at the tumor site. Comparison of
estrogen supplemented and non-supplemented group, revealed that
estradiol supplementation enhances both mobilization of GFP-
CD133+ EPCs in the tumors as well facilitate EPCs to physically
integrate into neo-vasculature resulting in significantly higher
capillary density. The contribution of estrogen in angiogenesis and
tissue remodeling, which are two processes indispensable for tumor
growth, was also examined by Q-RT-PCR experiments on excised
tumor-inoculated mammary tissues, in which the transcripts of
various angiogenic cytokines were significantly increased. E2
stimulated EPCs were also observed to secrete paracrine factors
which increased the proliferation and migration of 4T1 tumor cells.
These in vivo studies were recapitulated in an in vitro model of
tubulogenesis. Our studies define BM-EPCs as possible prognostic
sensors and key determinants in vasculogenic remodeling necessary
for breast cancer progression.
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Breast cancer development is accompanied by progressive loss of
epithelial cell polarity and growth control, infiltration of macro-
phages and activation of angiogenesis. Understanding how epithe-
lial and stromal cell behavior and/or phenotype is coordinately
dysregulated in breast cancer, enables identification of molecules
that coordinately control not only normal cellular interactions in the
breast, but also tumor-associated interactions that promote breast
cancer progression. To this end we have been investigating a role
for the Homeobox (Hox) family of master morphoregulatory genes.
S65HoxD10 and HoxA5 are highly expressed in normal breast
epithelial cells and in quiescent vascular endothelium and fibro-
blasts and contribute to establishment of functional differentiated
breast tissue. However, invasive breast tumors progressively lose
HoxD10 and HoxA5 expression in both the epithelial and
endothelial cells. Significantly, restoration of HoxD10 in meta-
static breast epithelial cells induces a phenoytpic reversion and
restores polarity, reduces invasion and redcues tumor growth in
vivo and restoring HoxA5 leads to growth arrest and apoptosis
of tumor epithelial cells. Restoring epithelial HoxD10 also
reduces VEGF expression and restoring either HoxA5 or HoxD10
in epithelial cells also suppresses expression of several chemo-
kines including CCL-2 and CxCL12 that in turn decrease
recruitment of immune cells to tumors. In addition directly
restoring expression of either HoxD10 or HoxA5 in angiogenic
endothelial cells directly attenuates angiogenesis by reducing
endothelial cell invasion and stabilization of vascular structures.
Thus, both HoxD10 and HoxA5 are potent breast tumor
suppressors that coordinately stabilize the breast tumor microen-
vironment by inhibiting epithelial cell growth and invasion,
directly impairing angiogenesis and suppressing leukocyte infil-
tration (inflammation). We are currently developing targeted
approaches to restore expression of HoxD10 and/or HoxA5 to
cells within mammary tumor tissues in vivo.
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Multiple myeloma is a B-cell malignancy characterized by
proliferation of plasma cells in the bone marrow. It is the
second most common hematological malignancy and is still
largely incurable. One of the major problems is that myeloma
cells develop drug resistance upon interaction with bone marrow
stromal cells. To understand the importance of different stromal
cell components in the bone marrow microenvironment, we
examined the effects of macrophages on myeloma cell survival
and response to chemotherapy. We report here that macrophages,
in particular tumor-associated macrophages obtained by cultur-
ing macrophages with myeloma cell culture supernatants, are a
protector of myeloma cells. Macrophages protected both
myeloma cell lines and primary myeloma cells, isolated from
patients from spontaneous and chemotherapy drug-induced
apoptosis via attenuating the activation and cleavage of
caspase-dependent apoptotic signaling. The protective effect
was dependent on direct contact between macrophages and
myeloma cells. However, the reduced numbers of apoptotic
tumor cells in the cocultures were not the result of macrophage-
uptake of apoptotic cells, because macrophages with or without
the capacity to phagocytose apoptotic cells provide similar
protection to myeloma cells against chemotherapy-induced
apoptosis. Although tumor-associated macrophages secreted
large amounts of IL-6, which is the most important survival
factor for myeloma cells, our results show that IL-6 neutralizing
antibodies failed to significantly affect the protective effects of
tumor-associated macrophages, suggesting that other cytokines
may be involved. These findings are clinically relevant, because
we examined bone marrow biopsies of patients by immuno-
chemistry analysis and found that CD68
+ macrophages are
heavily infiltrated in the bone marrow of patients with myeloma
but not control patients. Thus, our results indicate that macro-
phages are an important component of the bone marrow stromal
cells and may contribute to myeloma cell survival and resistance
to chemotherapeutic treatment in vivo.
O79
Blockade of TNFα Signaling in Tumor-associated Macrophages:
a New Radiosensitizing Strategy
Yuru Meng
1, Michael A. Beckett
1, Hua Liang
1,N i c ov a nR o o i j e n
2,
Helena J. Mauceri
1, Kenneth Cohen
3, Ralph R. Weichselbaum
1
1Department of Radiation and Cellular Oncology, The University
of Chicago Medical Center, Chicago, IL, USA,
2Department of
Molecular Cell Biology, Vrije Universiteit, VUMC, Amsterdam,
Netherlands,
3Department of Medicine, Section of Hematology/
Oncology, The University of Chicago Medical Center, Chicago,
IL, USA
Radiotherapy is an important anti-cancer treatment and approx-
imately 60% of all cancer patients receive radiotherapy during
the course of their disease. However, improvements in the
therapeutic index of radiation therapy have been mostly based
on physical improvements in radiation delivery. Radiosensitizer
development targeting tumor cells has not yielded effective
agents. Recent investigations in several laboratories have
focused on the tumor stroma as a potential target for radio-
sensitization. Here we report that depletion of tumor associated
macrophages prior to radiotherapy increases the anti-tumor
effects of ionizing radiation (IR) following both systemic and
local injection of macrophage depleting Liposomal Clodronate
(Lip-Clod). These anti-tumor effects were noted following large
single dose (20 Gy) and low dose (2 Gy) fractionated radiation.
Co-implantation of tumor cells with BM-derived macrophages
(BMDMφ) resulted in increased tumor resistance to IR.
Experiments using animals with germ line deletions of TNF
receptors 1,2 (TNFR1,2-/-) or TNFα (TNF-/-) demonstrated
that the radioprotective effect of BMDMφ required intact
TNFα signaling. The radioprotective effect of TNFα was
mediated by the upregulation of VEGF production in tumor
associated macrophages (TAMφ). Treatment of experimental
tumors with a neutralizing antibody to TNFα (Enbrel
R)
improved tumor regression with IR compared to IR alone
without an increase in host toxicity. These data provide a
mechanistic basis for targeting macrophage populations general-
ly and TNFα induced macrophage VEGF specifically to improve
radiotherapy outcomes.
Y.M., M.A.B., and R.R.W. contributed equally to this work.
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Depending on the differentiation of EBV-carrying cells, the virally
encoded proteins are expressed in various combinations. These
determine the fate of the viral genome harbouring cells. Virus
transformed B lymphocytes - lymphoblastoid cell lines- LCL-
express six virally encoded nuclear and three surface localised
proteins. This phenotype is encountered only in B lymphocytes
and induces their proliferation. It is usually referred to as Type III
EBVexpression or growth transformation program. Such cells are
readily recognized by the immune response.
The presence of the EBV genome in lymphocytes with a restricted
viral protein expression, as it occurs in Hodgkin’s and nasal NK
lymphomas, that lacks the nuclear protein EBNA-2, does not
induce proliferation. However it modifies the behaviour of the
cell. Such cells can avoid apoptosis, and induce an enrichment of
inflammatory cells in the microenvironment environment. Inter-
cellular contacts and /or cytokines induce their proliferation.
We studied the details of IL21 imposed modification of EBV gene
expression: We found that in Type III cells IL-21, enhanced the
LMP-1 promoter and silenced the C promoter with the consequence
that 5 of the 6 EBNAs disappeared. EBNA-1 that can be transcribed
from its own specific promoter, Qp, was maintained. Thus the cells
switched to the Type IIa (EBNA-1 and LMP-1) pattern with
elevated expression of the LMP-1 protein. Exposure of Type I (only
EBNA-1 expressed) BL cells to IL-21, activatied the LMP-1p and
thus resultsd also in a Type IIa pattern because the cells maintained
the Qp deriven EBNA-1 expression. We could show that IL21 has a
direct effect on the LMP-1p. We postulate that silencing of the Cp
occurs through the activation of a suppressor protein
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The genetic profiling of B-cell malignancies is rapidly expanding,
providing important information on the tumorigenic potential,
response to treatment, and clinical outcome of these diseases.
However, the relative contributions of inherent gene expression vs.
microenvironmental effects are poorly understood. The regulation of
gene expression programs by means of adhesive interactions was
s tu d ie di nA R H - 7 7h u m a nma l ig n a n tB - c e llv a r i a n t s ,d e r i v e df r o mt h e
same cell line by selective adhesion to a fibronectin matrix. The
populations included cells that adhere to fibronectin and are highly
tumorigenic (designated “Type-A” cells), and cells that fail to adhere
to fibronectin, and fail to develop tumors in vivo (“Type-F” cells). To
identify genes directly affected by cell adhesion to fibronectin, Type-
A cells deprived of an adhesive substrate (designated “AF cells”)
were also examined. Bioinformatic analyses revealed a remarkable
correlation between cell adhesion, and both B-cell differentiation
state and the expression of multiple myeloma-associated genes. The
highly adherent Type-A cells expressed higher levels of NFkB-
regulated genes, many of them known to be associated with multiple
myeloma. Moreover, we found that the transcription of several
multiple myeloma-related proto-oncogenes is stimulated by adhe-
sion to fibronectin (i.e., expressed in “A-cells, but not in “AF”). In
contrast, Type-F cells, which display poor adhesive and tumorigenic
properties, expressed genes associated with higher levels of B-cell
differentiation. Our findings indicate that B-cell differentiation, as
manifested by gene expression profiles, is attenuated by cell
adhesion to fibronectin, leading to up-regulation of specific genes
known to be associated with the pathogenesis of multiple myeloma.
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Background:
Interaction of tumour cells and tumour stroma has a high impact on
tumour growth and progression due to different mechanisms in which
they are involved, e.g. cell proliferation and invasion. These processes
are normally regulated but in case of tumour growth several cell
regulation mechanisms are defective. DNA methylation of CpG sites
in promoter region of genes is known to be involved in regulation of
tumour suppressor genes. Furthermore microRNAs (miRNA) are
known to be crucial for negative regulation of translational gene
expression. Purposes of this work are isolation and epigenetic
characterisation of TAF from primary urinary bladder carcinoma.
Material and Methods:
TAFwereisolatedfromculturedurinarybladdertumourspecimenby
treatment with EDTA and differential trypsinisation. Non-tumour
fibroblasts were isolated from foreskin and normal urinary bladder
tissue. Furthermore total RNA was isolated from TAF and non-
tumour fibroblasts to analyse the miRNA expression profile by
miRNA array. DNA isolation was performed to determine the
methylation pattern of CpG sites in promoter region of selected
oncogenes in TAF and non-tumour fibroblasts.
Results:
We developed a cell culture routine to isolate and subsequently
cultivate TAF from primary material of urinary bladder carcinoma.
S67Microarray analyses indicated a significant down regulation of
expression levels of several miRNAs in TAF in comparison to non-
tumourfibroblasts.DeterminingthemethylationlevelofCpGsitesof
selected oncogene promoter regions revealed a specific methylation
pattern of TAF and non-tumour fibroblasts.
Conclusion:
The ability to obtain TAF from primary tumour material leads us
to analyse epigenetic characteristics of TAF. Thereby a specific
miRNA expression profile was observed in comparison to non-
tumour fibroblasts. Furthermore a specific methylation pattern of
CpG sites of several selected oncogenes was determined in TAF.
These results facilitate to understand the specific regulation of
gene expression in TAF.
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High matrix metalloproteinase 11/stromelysin-3 (MMP11/ST3)
expression in primary tumors is associated with cancer aggressive-
ness as well as with poor patient clinical outcome (Basset et al.,
Nature 1990, 348:699). Mouse tumor models show that MMP11 acts
very early subsequent to cancer cell invasion. The invasive processes
leadtothe proximity ofcancercellsandcellsof mesenchymal origin.
In this context, most studies focusing on cancer cell-connective cell
interactions have emphasized the role of fibroblasts, endothelial and
inflammatory cells in fully-constituted tumor stroma that contains
very few, if any, adipocytes. We have demonstrated the MMP11
involvement in cancer cell-adipocyte cross-talk. We showed that
cancer cells induce MMP11 expression by adjacent adipocytes/pre-
adipocytes at the human breast tumor invasive front.
These data point to the essential role of adipocytes in invasive steps
and highlights the MMP11 participation. The origin of peritumoral
fibroblasts, known to favor tumor progression, remains debated. Our
results support the concept that pioneer invading cancer cells that
induce the MMP11 production by proximal adipocytes/preadipo-
cytes, initiate a vicious cycle leading to a default of adipocyte
differentiation and the accumulation/maintenance of peritumoral
fibroblast-like cells. Accordingly, recombinant MMP11 reverts
chemically-induced adipocyte differentiation of MMP11-deficient
mouse embryonic fibroblasts (MEF) (Andarawewaet al.,CancerRes
2005, 65:19862) (Motrescu and Rio, Biol Chem 2008, 389:1037).
Finally, MMP11 exhibits collagenolytic activity against the native
alpha 3 chain of collagen VI, a collagen required for correct fat tissue
cohesion and adipocyte function (Motrescu et al. Oncogene 2008,
27:6347). Interestingly, collagen VI has been reported to be involved
in breast cancers (Iyengar et al., J Clin Invest 2005, 115:1163).
Collectively, our data constitute the first evidence implicating an
MMP in cancer cell-adipocyte cross-talk, and are of particular
interest since epidemiological studies identify obesity as a major
risk and/or a poor prognosis factor for cancer.
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We have introduced the proof of concept that by introducing sst2,
whose expression is lost in 90% of pancreatic cancers, into human
pancreatic cancer cells, in vitro and in vivo cell proliferation, tumor
progression and metastasis are decreased. Sst2 tumor suppressor
activity relies on an autocrine loop whereby its natural ligand
somatostatin is secreted by sst2-expressing cells resulting in
constitutive sst2 activation. However, molecular mechanisms respon-
sible for sst2-dependent inhibition of invasiveness are unknown.
The a6b4 integrin plays a critical role in epithelia integrity: its
presence in hemidesmosal structures (HDs) at the basal cell surface
links the intracellular intermediate filament network to the extracel-
lular laminins of the basement membrane. Interestingly, HDs are
frequently absent in cancer cells, whereas the a6b4 integrin (mostly
its β4 subunit) is overexpressed in several cancers, including
pancreatic, and contributes to carcinoma invasiveness by stimulating
cell migration. This is partly achieved through a6b4 integrin
delocalization into lamellipodia and filopodia.
We have demonstrated that somatostatin, by acting through sst2, can
revert a6b4 integrin delocalization to migration structures, an
hallmark of epithelial cancer cells, by forcing its relocalization to
HDs, thereby stabilizing epithelial cell anchorage to basement
membrane and inhibiting cell migration. Underlying molecular
mechanisms are here shown to rely on a sst2-dependent up-
regulation of HDs protein expression, including BP180.
Strikingly, knocking-down BP180 expression (siRNA) impairs
somatostatin-induced HDs assembly in sst2-expressing cells. Inter-
estingly, BP180 siRNA partially reverts sst2 inhibitory role on in
vitro and in vivo cell migration and invasion, as demonstrated using
the chick chorioallatoic membrane model whereby tumor progres-
sion of pancreatic cancer cell xenografts is monitored.
We have identified an original mechanism for sst2 to revert cancer
cell pro-migratory phenotype by relocalizing the a6b4 integrin to
HDs thereby facilitating hemidesmosome assembly and cancer
cell anchorage to basement membrane.
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S68The Junctional Adhesion Molecule-C (JAM-C) has been identified as
an adhesion molecule highly expressed by lymphatic sinuses of lymph
nodes, mesenchymal and endothelial cells
1. Functionally, antibodies
directed against JAM-C decrease tumor growth and modulate the
adaptative immune response
23 . The aim of the present study is to
better characterize the cellular compartment, which is targeted by anti-
JAM-C in vivo: lymphatic, mesenchymal or endothelial. We have
generated a new monoclonal antibody against a mouse lymphatic cell
line (JAM-C
high), which does not recognize a brain endothelial cell
line (JAM-C
low). This antibody is directed against thrombomodulin,
initially described as a vascular specific protein. We show here that
thrombomodulin is co-expressed with JAM-C on lymphatic sinuses
and fibroblastic reticular cells of lymph nodes and on tumoral vessels,
whereas it is not expressed on specialized vascular beds such as high
endothelial venules. This suggests that the role of thrombomodulin
largely exceed its reported function of a vascular specific protein
involved in coagulation and inflammation. We further demonstrate that
anti-JAM-C treatment specifically decreases the lymph node fibro-
blastic reticular compartment expressing PDGRFa and thrombomo-
dulin. Similarly, thrombomodulin expression associated with
tumoral vessels is reduced in anti-JAM-C treated mice, indicating
that inhibition of tumor growth by anti-JAM-C treatment may rely
on the killing of a stromal compartment present in tumor and lymph
nodes. Whether this cellular compartment is mandatory for tumor
growth and plays a role in tumor metastasis to lymph nodes is
currently addressed.
References:
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Little is known about the molecules that contribute to tumor
growth of epithelial ovarian cancer (EOC) that remains the
most lethal gynecological neoplasm in women.
Glucocorticoid-Induced Leucine Zipper (GILZ) is frequently
detected in epithelial tissues and controls key signaling
pathways. We investigated its expression by immunohisto-
chemistry in tumor specimens from 50 patients surgically
treated for diagnosis of epithelial ovarian cancer. GILZ was
detected in the cytoplasm of tumor cells of all the well-
defined histological types. GILZ immunostaining scores were
positively correlated to the proliferation marker Ki-67 (P<
0.00001). They were also higher in tumor cells containing high
amount of phosphorylated protein kinase B (p-AKT) (P < 0.01).
To further investigate the apparent dependency of proliferation
and AKT activation upon GILZ expression, we used BG-1 cell
line derived from tumor cells as a cellular model, either
overexpressing GILZ by stable transfection or bringing down
GILZ by the use of small interfering (si) RNA targeting GILZ.
Modulation of GILZ expression directly controlled cell prolif-
eration, phospho-AKT cellular content and AKT kinase activity.
It also changed the expression level of p21 and cyclin D1, two
proteins known to control cell cycle progression. Our findings
demonstrate the emerging role of GILZ, an intracellular factor
not identified before in EOC, in the control of cell proliferation
and AKT activity in ovarian epithelial tumor cells.
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Inflammatory mediators, such as prostaglandin E2 (PGE2), and
responsive angiogenic factors, mainly vascular endothelial growth
factor A (VEGFA), have emerged as pathways driving neo-
angiogenesis and supporting the progression and metastasis of
solid tumors.
To understand the relation in human solid tumors between COX
and LOX-derived eicosanoids and expression of VEGF family
members (VEGF
F) (VEGFA, -B, -C, -D and PlGF), we performed
a RT-qPCR comparative expression analysis of colon carcinoma
samples.
Up to now, tumor samples and matched normal colon tissues
from 52 patients were analyzed. The results showed a complex
and diversified expression phenotype. 88% of the tumor
samples showed increased expression of at least one VEGF
family member. In a considerable proportion of samples
multiple VEGF family members were overexpressed with a
predominance of VEGFA and especially PlGF. Correlating the
VEGF
F and eicosanoid enzymes gene expression profiles not
only revealed a clear linkage between both signaling pathways
but also a clear association of 5-LOX with VEGFB and COX2
with PlGF.
A similar analysis was performed on 23 colon polyps and 30 liver
metastases. Strikingly, already in polyps a pronounced inflamma-
tory expression profile with increased expression of COX
S69enzymes was apparent. This was accompanied by an increased
expression of mainly VEGFA and PlGF. Also in liver metastases,
an inflammatory signature accompanied by VEGF
F expression
was apparent. Yet, the profiles observed in liver metastases
diverged from those in colon polyps and carcinomas. This
divergence may be due to the different tumor microenvironment.
The results from this correlated expression analysis of VEGF
family members and genes involved in eicosanoid biosynthesis are
promising for the diagnosis and prediction of treatment outcome
of colon cancer patients. In addition, our results clearly indicate
that the perception of a COX2/PGE2-driven VEGFA expression,
sustaining neo-angiogenesis, is an oversimplification.
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The extracellular matrix molecule tenascin-C (TNC) is highly
expressed in most cancers which correlates with a bad survival
prognosis and tamoxifen resistance. TNC plays a role in
promoting tumor cell proliferation, angiogenesis, invasion and
metastasis but the molecular mechanisms are poorly understood
(1). We showed that TNC induces cell rounding by two
mechanisms: it counteracts cell adhesion to fibronectin by block-
ing the syndecan-4 / integrin alpha 5 beta 1 complex (2). This
stimulates tumor cell proliferation (3) by activation of oncogenic
Wnt (through repression of DKK1) and MAPkinase signaling (4).
TNC also stimulates endothelin receptor type A (EDNRA)
expression which maintains cell rounding (5). FAK, paxillin,
RhoA and Tropomyosin-1 are critical targets of TNC downstream
of syndecan-4 and EDNRA (5, 6). TNC also triggers cell migration
in combination with LPA/PDGF (6).
Results on the tumorigenesis-promoting effects of TNC in our
newly established transgenic mice that ectopically express TNC in
the pancreatic islets of insulinoma-prone SV40 Tag-expressing
RipTag2 mice (RT2/TNC) will be presented.
(Supported by INSERM, INCa, Bourse Region Alsace, Onco-
suisse, SNF, ARC, AICR, Krebsliga Beider Basel)
References:
(1) Orend & Chiquet-Ehrismann, 2006, Cancer Lett. 244, 143
(2) Orend et al., 2003, Oncogene 22, 3917
(3) Huang et al., 2001, Cancer Res. 61, 8586
(4) Ruiz et al., 2004, Cancer Res. 64, 7377
(5) Lange et al., 2007, Cancer Res. 67, 6163
(6) Lange et al., 2008, Cancer Res. 68, 6942
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The WW domain containing oxidoreductase (WWOX) spans one
of the most active common fragile sites, FRA16D, involved in
cancer. WWOX encodes a 46-kDa protein that contains two N-
terminal WW domains and a central short-chain dehydrogenase/
reductase (SDR) domain. Through its WW domain, the Wwox
protein interacts with its partners and modulates their functions.
Wwox suppresses the transactivation functions of several
transcription factors implied in cancer by sequestering them in
the cytoplasm. Targeted deletion of the Wwox gene in mice
causes increased spontaneous tumor incidence confirming that
WWOX is a bona fide tumor suppressor. Wwox expression is
absent or reduced in most cancer cell lines and its ectopic over-
expression induces apoptosis in vitro and suppresses tumor-
igenecity in vivo. Furthermore, Wwox attenuates the migration
and invasion ability of MDA-MB-231 breast carcinoma meta-
static cells. Additionally, its restoration results in reduced
attachment and migration on fibronectin. By contrast, knocking
down endogenous Wwox increases adhesion to fibronectin.
Therefore, Wwox acts as a tumor suppressor not only by
inducing apoptosis mediated by caspase activation but also
through modulating the interaction between tumor cells and the
extracellular matrix.
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Data on the biological effects of some overexpressed oncogenes
and their cooperation with cellular factors are, at least partially,
contradictory. A strong G1 arrest or high rate of apoptosis was
reported in transformed cells overexpressing temperature-sensitive
(ts) p53
135val when maintained at permissive temperature. Com-
parison of the experimental protocols reveals that cells used for
transfection strongly differ. Therefore, we decided to explore the
S70impact of primary cells used for generation of cell clones on the
biological effects evoked by p53 and c-Ha-Ras.
We used primary rat cells (RECs) isolated from rat embryos of
different age: at 13.5 gd (y) and 15.5 gd (o). We immortalized rat
cells using ts p53
135val mutant and additionally generated trans-
formed cells after co-transfection with oncogenic c-Ha-Ras[1].
The ts p53
135Val mutant, switching between wild-type and mutant
conformation, offers the possibility to study the escape from p53-
mediated cell cycle control in a model of malignant transformation
in cells with the same genetic background. Surprisingly, the
kinetics of cell proliferation at non-permissive temperature and
that of cell cycle arrested at 32°C strongly differed between cell
clones established from yRECs and oRECs[2]. Furthermore, the
kinetics of the re-enter of G1-arrested cells in the active cell cycle
largely differed between distinct cell clones. Finally, the suscep-
tibility of immortalized and transformed cells to growth-inhibitory
and apoptosis-promoting drugs was evaluated. Inhibition of
cellular CDKs by purine analogues revealed that y and o
transformed cells differentially respond to the pharmacological
CDK inhibitors thereby indicating that overexpression of genes
such as p53
135Val mutant and oncogenic-Ha-Ras is not able to fully
override the intrinsic cellular programme.
[1] Wesierska-Gadek J, Schmid G. (2000) J Cell Biochem 80:85–
103.
[2] Schmid G, Kramer MP, Wesierska-Gadek J. (2009) J Cell
Physiol 259:459–469.
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Multiple myeloma is a still incurable plasma cell tumor and
considerable efforts are undertaken to establish new immunother-
apeutic strategies to target this B- cell neoplasm. Chemokines are
major players in shaping the tumor microenvironment and can
contribute to immune escape of the malignant cells. In the search
for important actors of the chemokine network in multiple
myeloma we found CCL27, which has so far only been correlated
with skin diseases such as atopic dermatitis, consistently upregu-
lated in all cell lines investigated. In bone marrow supernatants of
tumor patients CCL27 expression correlated with the severity of
disease. Myeloma cells were found to express CCR10, the
respective receptor, and to be able to utilize the ligand-receptor
interaction as an autocrine proliferation loop. Additionally, trans-
endothelial migration of myeloma cells in response to CCL27 was
enhanced whereas migration over fibronectin was not affected. We
further investigated the impact of CCL27 on immune cells such as
T cells and dendritic cells. Dendritic cells differentiated and
matured in the presence of CCL27 exhibited a reduced capacity to
activate T cells in allogeneic mixed leukocyte reactions. T cell
proliferation as well as cytokine production was impaired. Treated
dendritic cells showed normal expression of costimulatory
molecules but impaired spontaneous migration as well as cytokine
production which might explain the impaired T cell function. In
coculture experiments with myeloma cell lines, however, these
dendritic cells induced enhanced growth of the malignant plasma
cells.
In summary, we found that CCL27 can modify migration of
malignant plasma cells and immune cells. In addition, this
chemokine modulates dendritic cells by impairing their potential
to activate T cells but, at the same setting, enhances their
potential to induce tumor cell growth. Targeting CCL27 therefore
could constitute an essential additional component in myeloma
therapy.
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Stromal cells represent a central component of the lymphoid
microenvironment and are involved in B cell lymphopoiesis and
leukemogenesis. Chronic lymphocytic leukemia (CLL) is charac-
terized by the accumulation of clonal B cells due to inhibition of
apoptosis and expansion of the malignant clone in the lymphoid
organs. However, CLL cells die rapidly by spontaneous apoptosis
in vitro. The aim of this study is to elucidate the role of lymphoid
microenvironment in the activation of the anti-apoptotic PI3-K/
Akt pathway and prolonging survival of CLL cells. Early passages
of primary human non-transformed bone marrow stromal cells
(BMSC) served as an in vitro model for lymphoid microenviron-
ment. Co-cultures of CLL cells with BMSC inhibited spontaneous
apoptosis of the leukemic cells. PI3-K inhibitors (wortmannin or
LY294002) or siRNAs against PI3-K-p110 and Akt1 prevented
the pro-survival effect of BMSC and led to apoptosis of the
leukemic cells. Apoptosis was associated with a decrease in the
PIP3, PDK1 and Akt1 and de-phosphorylation of the tumour
suppressor PTEN. Western blotting demonstrated a high expres-
sion of phosphorylated PTEN and casein kinase 2 (CK2) in CLL
S71cells. Since CK2 is involved in the phosphorylation of PTEN,
CLL cells were treated with CK2 inhibitors (apigenin, TBB, DRB
and DMAT) and cell viability was assessed by MTT assays and
FACS analysis. CK2 inhibitors decreased the phosphorylation of
PTEN and Akt1, induced apoptosis and overcame the pro-survival
effect of BMSC. Combination of inhibitors of CK2 and PI3-K
demonstrated an additive effect and significantly increased the rate
of apoptosis in CLL cells. In conclusion, the interaction between
CLL cells and the lymphoid microenvironment leads to the
activation of the anti-apoptotic PI3-K/Akt pathway, inactivation
of PTEN and prolongation of the survival of CLL cells. The
inhibition of PI3-K/Akt and recovery of PTEN activity by CK2
inhibitors may represent a promising therapeutic concept for CLL.
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The interaction with carcinoma (Ca) of lymphocytes (Ly) and
intercellular matrix (Ma) were investigated comparatively in 22
gastric, 26 pulmonary and 28 breast Ca. Ly are constant
companions of tumor cells which they may infiltrate and/or
destroy.Their amounts vary with the types of tumors.In the lung
B-and T-cell Ly are abundant in non-small cell Ca and plasma
cells in squamous cell Ca but are almost absent in carcinoids and
small cell Ca.In the breast Ly are more abundant in e-cadherin +
duct Ca than in the e-cadherin- lobular Ca.In the stomach B-and
T-cells are numerous in intestinal type and rare in diffuse type. In
all these Ca,well differentiated tumors are accompanied by more
Ly than poorly differentiated The Ma appears normally loose in
the former and collagenized, desmoplastic in the latter.The kinds,
a m o u n t sa n dd i s t r i b u t i o no fL ya l s ov a r yw i t ht h es t a g eo fC a
being more abundant in early stages and rare, replaced by
desmoplasia in late stages.In the breast,aggregates of Ly are next
to the precancerous lesions and Ca in situ far more than in late
stages of infiltrating Ca.FAS receptor was >than FAS-L ligand in
mammary tumors and in their infiltrating Ly while their ratios
were reversed in their lymph node metastases. In bronchi,Ly
accumulate next to dysplastic changes. In the stomach, B-cells
form barrier bands and reactive follicles in the mucosa around.
atypical cells while T-cells,mainly CD8+ infiltrate the Ca cells.
These observations indicate that the Ly and Ma reactions to Ca are
not uniform but correlated with the tumor type, grade and stage.
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Carcinoma-associated fibroblasts (CAFs) play important roles in
the genesis and thrive of various types of epithelial cancers,
including breast carcinomas. Indeed, various genetic and epige-
netic variations have been identified in stromal fibroblasts, and we
have recently shown that CAFs as well as their corresponding
counterparts (TCF) display neoplastic-specific changes (Hawsawi
et al., 2008). In the present study we have shown that the level of
p16 protein is lower in 80% of CAFs as compared to their
corresponding TCFs. This decrease resulted from lower stability of
the p16 mRNA owing to an increase in the level of the mRNA
binding and destabilizing protein AUF1 in CAF cells. Furthermore,
using specific p16-siRNA we have shown that p16 negatively
controls the expression of various proteins involved in the stromal-
epithelial interactions. These include the stromal cell-derived factor 1
(SDF1), the vascular endothelial growth factor (VEGF) and the
matrix metalloproteinase-2 (MMP2). In addition, ELISA and
immunoblotting assays were used to show that the level of these
proteinswashigherintheconditionedmediafromstromalfibroblasts
expressing specific p16siRNA as compared to control cells.
Importantly, conditioned media from p16-defective cells stimulated
the invasion and the migration of cultured human epithelial cells.
Theseresultsclearlyshowtheroleofthebreaststromalfibroblastp16
proteininsuppressing tumoregenesis.Moreover, wehaveshownthat
curcumin can normalize p16 expression and therefore reduces the
expression and the secretion of these cancer promoting factors. This
indicates that curcumin has potential use as stromal fibroblast
normalizing factor that can be utilized for the inhibition of both
cancer initiation and recurrence.
Hawsawi, N. M., Ghebeh, H., Hendrayani, S. F., Tulbah, A., Al-
Eid, M., Al-Tweigeri, T., Ajarim, D., Alaiya, A., Dermime, S., and
Aboussekhra, A. (2008). Cancer Res 68, 2717–2725.
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Ulcerative colitis (UC) is a chronic inflammatory bowel disease
that is closely associated with colon cancer. Here we report that
heparanase enzyme acts as an important mediator of colitis-
associated tumorigenesis. Heparanase is an only known mamma-
lian enzyme that cleaves heparan sulfate, the major polysaccharide
of the extracellular matrix, and plays multiple roles in inflamma-
tion and cancer progression. Applying histological specimens
from UC patients and a mouse model of dextran sulfate sodium
(DSS)-induced colitis, we found that heparanase is constantly
overexpressed and activated during the course of the disease, both
in the active and inactive phases of inflammation. Employing
heparanase-overexpressing transgenic mice in the model of colitis-
associated cancer, induced by carcinogen azoxymethane followed
S72by repeated DSS administration, we demonstrated that heparanase
overexpression markedly increased the incidence and severity of
colitis-associated colonic tumors, enabling faster tumor take,
angiogenic switch and enhanced tumor progression. Notably,
DSS-induced colitis alone (without azoxymethane pretreatment)
lead to formation of colonic tumors in heparanase-transgenic, but
not wild type mice, positioning heparanase as important physio-
logical determinant in inflammation-driven colon carcinoma,
replacing the need for carcinogen. Investigating molecular
mechanisms underlying heparanase induction in colitis, we found
that TNFalfa is responsible for continuous overexpression of
heparanase by chronically-inflamed colonic epithelium. Moreover,
our results suggest the occurrence of heparanase-driven vicious
cycle that powers colitis and associated tumorigenesis: heparanase
activity in inflamed colon, acting synergistically with the local
cytokine milieu, stimulates macrophage activation, and the
activated macrophages secrete TNFalfa which stimulate further
production of heparanase by colonic epithelium. In addition,
activated macrophages secrete cathepsin L – a cysteine protease
responsible for proteolytic activation of latent heparanase enzyme.
Altogether, our results identify heparanase as a key factor in
pathogenesis of colitis-associated cancer and attest the inhibition
of heparanase as a promising mean to disrupt the vicious cycle that
fuels chronic colitis and the associated tumorigenesis.
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Heparanase is a matrix-degrading enzyme whose increased expression
is significantly associated with malignant progression in many human
cancers. We have previously shown that heparanase expression
increases during tumorigenesis in the RIP1-Tag2 (RT2) transgenic
mouse model of pancreatic islet carcinogenesis. Moreover, we have
found that heparanase is expressed in human pancreatic neuroendo-
crine tumors and its increased expression is correlated with metastases.
However, the exact molecular and cellular mechanisms by which this
enzyme functions in pancreatic tumorigenesis remain to be elucidated.
To study the role of heparanase in RT2 tumorigenesis, we crossed
transgenic mice that constitutively overexpress heparanase (hpa-
Tg) to RT2 mice to generate the hpa-Tg RT2 line. Hpa-Tg RT2
mice exhibit increased tumor invasion, angiogenesis and lym-
phangiogenesis. To further investigate heparanase function in RT2
tumorigenesis, heparanase knockout mice have been crossed to
RT2 mice. These mice are currently being analyzed for multiple
parameters of tumorigenesis.
Additionally, a heparanase-overexpressing β-tumor cell line (Hpa-
βTC) was derived from a hpa-Tg RT2 tumor and utilized in in
vitro approaches to dissect the mechanisms by which heparanase
promotes tumor progression. The Hpa-βTC line was found to be
highly invasive in Matrigel invasion assays when compared to a
wildtype βTC line (WT-βTC). Furthermore increased heparanase
expression renders the Hpa-βTC line highly motile when tested in
cell migration assays. Interestingly, the WT βTC line has a very
low intrinsic migration ability that can be significantly enhanced
by factors secreted by the Hpa-βTC line in co-culture assays.
Efforts are currently underway to identify the precise factors that
are secreted by heparanase overexpressing cells in the tumor
microenvironment to promote malignant tumor progression.
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Maspin belongs to the serine protease inhibitor (SERPIN)
superfamily. Several molecular partners of maspin have been
identified to date, including the pro-form of urokinase-type
plasminogen activator (pro-uPA) and collagen I (Col I), the most
abundant protein in the bone matrix. Maspin is a tumor supressor
gene, since its expression inversely correlates with malignancy in
human breast and prostate cancer (PC) progression. Both tumors
metastasize to bone. In a murine model, maspin inhibited PC bone
growth, osteolysis and angiogenesis, and in so doing, increased
fibrosis and produced hollow lumen acini.
We investigated herein the effect of maspin in PC cell growth and
morphologyontopofa layerofpolymerizedColI(2D)orembedded
in the collagen matrix (3D). To this end, three different clones of
DU145 cells stable transfected with maspin (M3, M7 and M10) and
cells transfected with empty vector (Neo) were used. In 2D, the
maspintransfectants spread uniformly on Col I whereasthe Neocells
form disconnected patches. Reaction with overlaid fluorescein
labeled Col I (DQ-collagen) revealed that the Neo cells exhibit more
collagenolytic activity per cell than the maspin transfectants. In 3D,
however, the Neo cells spread whereas the M7 cells, which were
shown to express the most maspin, formed spheroid structures of
compact polarized cells in a cobblestone-like formation. Cell
polarization was ascertained by functional visualization of
collagenolytic activity and by b1-integrin immunostaining using
aZeissLSM510confocalmicroscope.DQ-collagencleavage was
detected in the periphery of the spheroids, whereas the core was
devoid of collagenolytic activity. The b1-integrin was also found
predominantlylocalizedatthebasalcell-matrixinterface. Hoechst
nuclear staining revealed hollow lumens. The M3 and M10 cells,
which express lower levels of maspin, formed less compact
spheroids. This maspin-induced cell redifferentiation appears to
be specific for fibrillar Col I, since in the basement membrane-like
Matrigel, containing nonfibrillar collagen IV, acinus formation
was not detected. In sum, this investigation shows that maspin can
restore the redifferentiation of PC cells in the bone microenviron-
S73ment, thus recapitulating the in vivo observations, with important
consequences for therapeutic intervention in PC metastatic
progression to bone.
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Retinoic acid (RA) is a potent agent that coordinates inhibition of
proliferation with differentiation of many cell types. Although the
striking success of epigenetic reversion of genetic malignant-
phenotype, as exemplified by RA-induced differentiation of acute
promyelocytic leukemia cells, has directed attention to bone-lining
osteoblasts that form the specialized microenvironment required
for development of human hematopoietic stem cells (HSC), there
is remarkably little data on the role of these epigenetic processes
mediated by RA signaling in coordinating osteoblastic differenti-
ation with hematopoietic development. We reported here that
either RA-induced lose of retinoic acid receptor alpha (RARa)
phosphorylation or mimicked RARa hypophosphorylation by
expression of RARa phosphorylation-defective mutant RAR-
aS77A mediates human osteosarcoma U2OS cell differentiation.
Gene expression analysis showed that either RA or RARaS77A
induces many same differentiation response molecules/pathways
mediating osteoblastic differentiation and hematopoietic develop-
ment. Importantly, overexpression of FGF8f in U2OS cells, a
secreted growth factor and one of the targets of both RA and
RARaS77A, not only induced expression of osteoblastic differenti-
ation response genes, but also inhibited proliferation of both human
lymphocytic and myeloid leukemia cells treated with U2OS
conditional medium or co-cultured with differentiating U2OS cells.
In addition, granulocytic differentiation of normal primitive human
CD34+ cells and myeloid leukemia cells was induced by co-culture
orconditionalmedium.Moreover,overexpressionofFGF8finU2OS
cells and human mesenchymal stem cells (hMSC) mimicked RA-
modulatedinductionofosteoblasticdifferentiation,whileU2OScells
expressing RARaS77A inhibited osteosarcoma formation in nude
mice. These findings strongly suggest a novel bi-directional RARa-
FGF8f signaling pathway that within the bone marrow hematopoietic
niche,coordinatesosteoblasticmaturationwithdifferentiationofboth
normal and malignant hematopoietic precursors through RARa-
modulated osteoblastic cell secretion of FGF8f.
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Expression of the Philadelphia chromosome (Ph+) translocation is
clinically important in acute lymphoblastic leukemia (ALL) and is
correlated with high risk of relapse and poor prognosis.
1 Our
laboratory has identified a subpopulation of Ph+ leukemic cells
which constitutively express VE-cadherin, interact with bone
marrow stromal cells (BMSC), express stem cell markers, and
are resistant to chemotherapy.
2 Tumor cell expression of VE-
cadherin has been associated with aggressive phenotype and poor
prognosis in other tumor models, but has not been investigated in
hematopoietic malignancies.
3 Therefore, we investigated the
regulation of VE-cadherin by BMSC and its contribution to Ph+
ALL therapeutic response. We determined that Ph+ ALL cell
lines, as well as primary patient cells, express VE-cadherin.
Exposure of Ph+ cells to Imatinib diminished VE-cadherin
mRNA, which is blunted by Ph+ ALL contact with BMSC.
Knockdown of VE-cadherin expression by siRNA rendered Ph+
ALL cells more susceptible to chemotherapy, even in the presence
of BMSC. Additionally, pre-treatment of Ph+ ALL cells with
ADH100191, a VE-cadherin antagonist, resulted in elevated Ser/
Thr phosphorylation of beta-catenin and increased apoptosis
during treatment. In contrast, lentiviral mediated expression of
VE-cadherin in Ph- ALL cells resulted in increased resistance to
treatment-induced apoptosis. These observations suggest a
therapeutic role for VE-cadherin in modulation of chemoresis-
tance in Ph+ ALL and demonstrate the importance of cues from
the microenvironment in regulating tumor cell response to
treatment.
1) Radich JP. Philadelphia chromosome-positive acute lympho-
cytic leukemia. Hematol Oncol Clin North Am 2001 Feb;15
(1):21–36.
2) Wang L, O’Leary H, Fortney J, Gibson LF. Ph+/VE-cadherin+
identifies a stem cell like population of acute lymphoblastic
leukemia sustained by bone marrow niche cells. Blood 2007 Nov
1;110(9):3334–44.
3) Hendrix MJ, et al. Expression and functional significance of
VE-cadherin in aggressive human melanoma cells: role in
vasculogenic mimicry. Proc Natl Acad Sci U S A 2001 Jul 3;98
(14):8018–23.
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There is recent evidence that mesenchymal cells derived from the
bone marrow play an important role in bone metastasis in several
cancers, including myeloma and neuroblastoma. We previously
reported that contact-independent interaction between neuroblas-
toma cells and bone marrow stromal cells (BMSC) stimulates the
production of interleukin-6 (IL-6) by BMSC which promotes the
growth and the survival of tumor cells (Ara et al., Cancer
Research 2009). Here, we have identified Galectin-3 binding
protein (Gal-3BP) as a soluble factor produced by neuroblastoma
cells that upregulates IL-6. We observed that several neuroblastoma
cell lines express and secrete Gal-3BP, and that expression correlates
with the ability of these cells to induce the production of IL-6 by
BMSC. Expression of IL-6 by Gal-3BP seems to be mediated by
Gal-3, a multifunctional glycoprotein that binds Gal-3BP and is
present in BMSC. Signaling involves activation of the Raf-1/MEK/
ERK1/2 pathway and can be blocked in the presence of the MEK
inhibitor PD 98059 or in the presence of an anti Gal-3 antibody. We
also observed that Gal-3BP can upregulate IL-6 in peripheral blood
monocytes suggesting that it may contribute to tumor-associated
inflammation. In primary neuroblastoma tumors, Gal-3BP is present
in tumor cells and in the surrounding extracellular matrix, whereas
IL-6 ispresent instromal and inflammatory cells. Preliminary studies
also suggest that higher levels of Gal-3BP are present in neuroblas-
toma tumors with an unfavorable histology and more severe clinical
outcome. Thus the data provide a novel function for Gal-3BP in the
tumor microenvironment and cancer progression.
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While macrophages are a fundamental component of the host
innate immune system, their presence within the tumor
microenvironment has been found to facilitate tumor initiation
and progression. Previously, we have shown that cysteine
cathepsin proteases are upregulated as tumors develop in the
RIP1-Tag2 (RT2) mouse model of pancreatic islet carcinogen-
esis and that tumor-associated macrophages (TAMs) are the
major source of cathepsin activity in tumors. Using pharmaco-
logical inhibition andgeneticablation,wehavefurther shownthat
specific cathepsins are critical in several steps of tumor progres-
sion, including tumor cell proliferation, angiogenesis and tumor
invasion. Therefore, we set out to investigate the mechanisms
whereby cathepsin activity is upregulated in TAMs.
Using an activity-based probe for cathepsin proteases and a
novel cell-based system, we have shown that tumor cell-
conditioned media (TCM) upregulates cathepsin activity in bone
marrow-derived macrophages. Cytokine protein expression
arrays revealed enrichment of several candidate cytokines and
growth factors in TCM. Through experiments using recombinant
proteins and neutralizing antibodies, we have identified interleu-
kin (IL)-4, a Th2 cytokine, as the tumor cell-secreted factor that
is responsible for the upregulation of cathepsin activity in TAMs.
To validate our in vitro findings, we have generated Il4 null RT2
mice, and shown that the cathepsin activity in TAMs was
significantly reduced in Il4 knockout animals. Taken together,
our results indicate that tumor cell-derived IL-4 is a principal
activator of TAM phenotype through upregulation of cathepsin
a c t i v i t yi nT A M s .
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A substantial body of evidence supports the notion that chronic
inflammation and cancer are associated. This association is
apparent under two circumstances: 1) Chronic inflammation can
predispose an individual to cancer and 2) Developing tumors
induce a micro and/or macro chronic inflammatory environment
associated with enhanced tumor development and metastasis.
Under both circumstances the generation of an immunosuppres-
sive environment is evident, enabling escape of the tumor from
immune surveillance. Based on our studies on mouse model
systems that mimic the immunosuppressive conditions generated
in tumor-bearing hosts, we proved chronic inflammation and
associated myeloid derived suppressor cells (MDSCs) as the
causative link for the induced immunosuppressive environment.
This leads to T and NK cells immune dysfunction associated with
zeta chain downregulation, as described in a large number of
various tumors. Moreover, we demonstrate that such a harmful
environment suppresses not only the host’s immune system but
S75also inhibits newly administered T lymphocytes, which is most
likely the limiting factor for the success of currently used cancer
immunotherapies based on vaccination and T cell transfer. Our
current studies focus on an in depth characterization of the chronic
inflammation induced immunosuppressive environment and its
impact on tumor development and spreading aiming at the
discovery of blockers neutralizing the immunosuppressive envi-
ronment. In parallel, we are in a process of establishing a high-
fidelity detection system for monitoring the existence of an
immunosuppressive environment. This novel approach will enable
a better understanding of tumor-associated immunosuppression
and facilitate the design of innovative strategies for cancer
immunotherapy that will be combined with monitoring the
patient’s immune status prior to a given immunotherapy. If
immunosuppression is detected, specific inhibitors for the immu-
nosuppressive environment will be applied prior to a given
immunotherapy, thus enabling the establishment of a successful
personalized cancer therapy.
O103
Functional Studies on Toll-Like Receptor Expression on Cell
Lines of Laryngeal Carcinoma
Jan Żeromski
1, Jan Sikora
1, Magdalena Frydrychowicz
1,
Bartosz Brzezicha
1, Grzegorz Dworacki
1, Mirosław Szczepański
1
1Poznan University, of Medical Sciences, Poznan, Poland
Toll-like receptors (TLRs) have been shown to play crucial role in
the recognition of unicellular pathogens and mount protective
immune response. They create link between innate and adaptive
immunity. TLRs are abundant on cells of the immune system but
have been also demonstrated on cells of other origin such as
various epithelia. We were able to show the expression of three
TLRs (TLR2, 3 and 4) on tumor cells of human laryngeal
carcinoma by means of immunohistochemistry. This study was
followed by the demonstration of most TLRs on cell lines of this
cancer both, on protein and molecular level. On the current study
we wished to see the impact of respective TLR ligands on TLR
expression in the cells mentioned.
Six larynx carcinoma cell lines obtained from Pittsburgh Cancer
Institute, USA, (courtesy of prof. Theresa Whiteside), have been
used. They were cultured for 24 hrs in the presence of respective
TLR ligands. Following culture cells were harvested and subjected
to flow cytometry both on intact and permeabilized cells, using
fluorochrome labelled anti TLR1-10 monoclonal Moabs. The cells
were evaluated in FacsCanto (BD) flow cytometer for mean
fluorescence intensity (MFI) of membrane and cytoplasmic cell
staining, using FacsDiva software.
Results: Each cell line exhibited distinct pattern of expression of
individual TLRs following interaction with respective ligand.
Unexpectedly, cell culture with ligand resulted in the decrease of
TLR expression in some cell lines. Cytoplasmic TLR staining had
usually higher MFI value than membrane one. TLRs 5, 7 and 9
showed the highest expression in the majority of tumor cells
tested. In general, cytoplasmic TLR protein product formation
seems to exceed cell membrane expression. In conclusion, culture
of TLR expressing tumor cells with respective ligand has
ambiguous effect on TLR expression but points out for potential
reactivity of tumor cells with TLR agonists.
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Interactions between cancer cells and normal, healthy cells present
cells are one of the most abundant cell types recruited to the
microenvironment of many tumors. The role of the immune
system during tumorigenesis is rather controversial; both tumor-
protective and tumor-promoting properties of the immune system
have been described. It is currently unclear which tumor types and
which tumor stages are either positively or negatively regulated by
specific components of the immune system. The overall goal of
our research is to address the role and underlying pathways of the
adaptive and innate immune system during spontaneous breast
cancer progression and metastasis formation. We utilize a mouse
tumor model that faithfully recapitulates human invasive and
metastatic lobular carcinoma, e.g. a conditional mouse breast
cancer model based on mammary epithelium-specific deletion of
p53 and E-cadherin. Like human breast cancers, mammary
carcinomas arising in this mouse model are characterized by
abundant presence of innate immune cells, including degranulat-
ing mast cells and macrophages, T and B lymphocytes, antibody
depositions and increased levels of pro-inflammatory mediators.
Suppression of chronic inflammation attenuates premalignant
progression and tumor formation. Preliminary data suggest a
critical role of adaptive immune cells in outgrowth of metastases.
By genetic elimination and pharmacological inhibition of specific
subsets of the adaptive and innate immune system, we are
currently investigating their functional significance in a tumor-
stage specific manner. Ultimately, the outcome of these studies
may shift therapeutic focus from a cancer cell intrinsic point of
view towards a more combined cancer cell intrinsic and extrinsic
point of view (Research supported by the Dutch Cancer Society,
NKB 2006–3715 and NWO/VIDI 91796307).
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Chronic inflammation is associated with the promotion and
enhancement of malignancy and tumor growth. Many tumors
enhance the accumulation of myeloid derived suppressor cells
(MDSC), which contribute to tumor progression and escape
from the immune system, by inducing tolerance of suppres-
sion. Previously, we have shown that tumor-derived IL-1β
secreted into the tumor microenvironment can induce a
massive accumulation of MDSC in the spleen of tumor
bearing mice and induce T cell suppression. In this work,
we describe a novel polymorphonuclear MDSC subpopulation
characterized by the phenotype: Gr1
+CD11b
+IL-4Ra
+CD115-
high-Ly6C
low/- SSC
high which we termed– Inflammatory MDSC
(Inf-MDSC). This population accumulates in the BM and spleen
of mice bearing 4T1 breast cancer tumors of cells which over-
expressing IL-1β (4T1/IL-1β)i nI L - 1 β dependent manner. We
showed the involvement of other inflammatory mediators such
as IL-6 and PGE2, in Inf-MDSC accumulation and differentia-
tion. Unlike to the MDSC from 4T1 tumor bearing mice, the
expression of Tcell mediates suppression; INOS2 and Arginase1
by Inf-MDSC are not dependent on IFNg. Inf-MDSC are able to
suppress NK cell activity in vivo via reduction of the NK
activating receptor NKG2D. In vitro this suppressive activity is
dependent on cell-to-cell contact. The inflammatory signal (IL-
1b) up-regulates IL-4Ra expression of MDSC, which correlates
with enhanced tumor growth and suppression of cytotoxic
activity of NK cell. Our data suggest that tumor derived
inflammation enhances the development of a specific MDSC
subset that has the ability to suppress T and NK cells, and
therefore, can serve as a new target for chemotherapy.
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Lung tumor prognosis is very bad, with a survival rate being
20 to 30% five years after surgery. In general, patients relapse
into three years because they develop metastasis. It is thus
crucial to identify novel therapies or combinatory therapies to
improve the prognosis of the disease. To date, the proposed
therapies for NSCLC patients consists in surgery associated
with neo-adjuvant or adjuvant polychemotherapy. Novel cancer
immunotherapies using TLR7 or 8 agonists are being devel-
oped, which are based on the amplification of immune
responses. However, recent studies implicate some TLRs in
t u m o rd e v e l o p m e n tb a s e do nt h e i ra b i l i t yt of a c i l i t a t et u m o r
growth, but TLR7 and 8 have not yet been implicated. We
hypothesized that TLR7 and 8 are expressed by lung tumor
cells, and their signaling could interfere with chemotherapy-
induced cell death.
We demonstrate for the first time that TLR7 and TLR8 are highly
expressed by primary human lung tumor cells in NSCLC. We
show TLR7 ligation with Loxoribine or TLR8 ligation with Poly
U results in activation of NF-kB and upregulation of Bcl-2
expression. This is associated with increased tumor cell survival
and a strong resistance to apoptosis induced by chemotherapeutic
agents that are currently used to treat patients. Finally,
transcriptional analysis revealed a gene expression signature
that suggests chronic stimulation of tumor cells by TLR7 and
8 ligands in situ.
TLR7 or 8 expression by lung tumor cells in patients could
predict bad responders to standard chemotherapies and could
allow to adapt the new therapeutic protocols. We propose that
anticancer immunotherapies using TLR7 or 8 adjuvants should
take into account the expression of these TLRs on tumor cells.
Indeed, such adjuvants could be a double edge sword by acting
on cells of the immune system or on tumor cells or both, with
opposite effects.
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Despite the demonstration that high Tcell infiltration of Colorectal
tumors (CRC) is of good prognosis, few is known about the tumor
reactivity of CRC infiltrating lymphocytes (TIL). The presence in
CRC, and phenotype of tumor reactive TIL was addressed. We
obtained ex-vivo TIL and TIL lines, by enzymatic digestion or
culture respectively, from primary, and metastatic CRC samples
(n=4), and tumor cell lines from four of these. TIL reactivity to
tumor cells was analyzed by intracellular cytokine secretion. In
two patients tumor-reactive T cells were detected among a subset
of TCRab CD8ab+CD4+ double positive (DP) TIL. Using a DP
TIL clone tumor reactivity was shown to be HLA-A2 restricted
and directed against a large panel of carcinoma but not EBV-B or
normal-cell lines. We then documented the presence of DP T cells
in human CRC and healthy colon mucosa, and showed that these
cells produced higher levels of IL-4 and IL-13 than CD4+ or CD8
+ SP T cells. These findings demonstrate the presence of DP T
cells in human normal colon mucosa and colonic tumor samples,
and show a major contribution of this subset to CRC TIL
reactivity. Their high capacity to secrete IL-4 and Il-13 suggests
that colon DP T cells are likely involved in colonic mucosa
homeostasis and in the immunity to human CRC.
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The cellular and molecular pathways that regulate platelet
activation, blood coagulation, and inflammation are emerging as
critical players in cancer progression and metastasis. We previ-
ously demonstrated that the pro-inflammatory Protease-Activated
Receptor a (PAR1, thrombin receptor) is overexpressed in
metastatic melanoma, where it modulates the expression of IL-8,
MMP-2, VEGF, PDGF, and integrins. Most recently, we demon-
strated that antagonists of the pro-inflammatory Platelet-
Activating Factor receptor (PAFR) abrogate experimental human
melanoma lung metastasis. We found that PAF activates p38
MAPK/CREB-mediated expression of MMP2 and MT1-MMP.
Here, we demonstrate that in metastatic melanoma cells, PAR1
and PAFR are constitutively active, linked together and regulate
gene expression. Indeed, in A375SM and C8161-c9 metastatic
melanoma cells, silencing of PAR1 with small hairpin RNA
resulted in downregulation of expression of PAFR and decrease in
production of PAF. Silencing of either PAR1 or PAFR expression
abrogated expression of MUC18, a critical marker of homo- and
heterotypic adhesion in melanoma. Overexpression of PAFR led to
restoration of MUC18 expression in PAR1shRNA cells, suggest-
ing that PAFR acts downstream of PAR1. We found that PAR1-
PAFR-MUC18 signaling mechanism mediates melanoma cells’
adhesion to microvascular endothelial cells, transendothelial
migration, and metastatic retention in the lungs. Rescuing PAFR
expression in PAR1-silenced cells restores metastatic phenotype of
melanoma, indicating that PAFR plays critical role in the molecular
mechanism of PAR1 action. Correlating with our previous findings
on PAR1, tissue microarray analysis revealed elevated PAFR
expressioninprimaryhumanmelanomaswithsubsequentmetastasis.
Finally, we demonstrate that PAFR knockout mice have delayed
B16F10 mouse melanoma tumor growth and lower B16F10 tumor
incidence as compared to wild-type C57Bl/6 counterparts. Together,
our results link the two pro-inflammatory G-protein coupled
receptors, PAR1 and PAFR, with the metastatic dissemination of
melanoma and suggest that functional PAFR is essential for pro-
tumorigenic influence of the tumor microenvironment. Our findings
suggest that PAR1, PAFR and MUC18 are attractive therapeutic
targets for preventing melanoma metastasis.
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In patients with gastric cancer, as well as other epithelial cancers,
there is an over-expression of proinflammatory cytokines. This is
accompanied by increased activation of NF-κB, which is believed
to contribute to tumor growth through inhibition of apoptosis of
malignant and premalignant cells.
To make a comprehensive investigation of the expression and
regulation of cytokines and other immune mediators in Helicobacter
pylori-induced gastric cancer, we performed a cDNA microarray
analysis of biopsies from tumour and tumour non-affected tissue of
gastric cancer patients as well as from antrum and corpus tissues of
cancer-free patients with or without H. pylori infection.
The analysis showed that around 10000 genes were expressed
at significant levels in the stomach mucosa, and a large number
of proinflammatory cytokines were upregulated in gastric
cancer patients. The expression of several of these molecules
was also verified by RT-PCR analysis. The upregulated genes
S78include both previously reported ones such as IL-1, IL-6, IL-8,
IL-11, WNT5A, COX-2 and MMP3, but there were also novel
findings such as increased expression of the cytokines IL-24
and LIF and the metalloproteinases ADAMTS4 and ADAMTS5
in gastric cancer tissue. Several of the upregulated cytokines were
also increased in H. pylori-infected cancer-free subjects, but in
gastric cancer patients the inflammation was uncoupled to infection
since bacteria were not detectable in their stomach tissue.
In conclusion, we demonstrate an extensive upregulation of
proinflammatory cytokines in the stomach mucosa of gastric
cancer patients, and we believe that this cytokine imbalance may
contribute to development and progression of gastric cancer.
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Although numerous cancer types express the matricellular protein,
osteopontin (OPN), and its levels in the plasma of cancer patients
are elevated implicating cancer cell-derived OPN in facilitating
tumor progression, the role of OPN expressed by other cells in
tumor progression is unclear, due to the lack of appropriate study
model. To assess the impact of host-derived OPN on tumor
progression and its contribution to levels in the serum, we
established a murine cutaneous OPN-null squamous cell carcino-
ma (SCC) cell line (ONSC) consisting of H-Ras and p53
mutations and which has the ability to develop SCC in immune-
competent mice. Subcutaneous injection of ONSC cells led to the
development of SCC, with a dramatic decreased incidence in wild-
type compared with OPN-null mice by 8–10 wk. Histopatholog-
ical, biochemical and hematological analyses of the tumor
microenvironment and/or serum from tumor-bearing mice during
the first few weeks indicated that 1) ONSC survival, proliferation
and differentiation in a weak acute inflammatory microenviron-
ment of OPN null mice is independent of OPN, and 2) host-
derived OPN is necessary for maintaining an acute inflammatory
response leading to lower incidence of SCCs in wild-type mice. Its
effect is not through increasing circulating inflammatory cells or
chemotaxis, instead we postulate that the response is likely
accomplished by enhancing the effect of and/or extending the life
of inflammatory cells in the tumor microenvironment. Further, the
elevated serum levels of OPN in mice harboring ONSC tumors
contributed by host cells, including activated, circulating inflam-
matory cells, indicates that the actual role of blood OPN in cancer
patients requires further investigation.
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Multi-layered epithelia, such as the epidermis, comprise a basal
layer of dividing cells, including stem cells, and suprabasal layers
of nondividing cells that are undergoing terminal differentiation.
Since a hallmark of cancer is uncontrolled proliferation, it is
widely assumed that tumours only start from dividing cells. Here I
show that nondividing epidermal cells in which mitogen-activated
protein kinase kinase 1 (MEK1) is constitutively active can initiate
tumour formation by recruiting basal cells that lack oncogenic
changes to the tumour mass. Tumour formation occurs when the
skin is wounded, and is dependent on an inflammatory infiltrate
including T-cells and macrophages. Tumours fail to form when the
infiltrating bone marrow-derived cells lack MyD88, a scaffolding
protein that acts downstream of both the IL1 receptor and Toll-like
receptors. These results show that nondividing, differentiated cells
can initiate tumor formation without re-acquiring the ability to
divide.
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Tumors depend on a permissive and supportive microenvironment
for their growth and spread. Emerging evidence suggests that both
resident and recruited bone marrow-derived cells play a critical
and supportive role in creating a pro-tumorigenic host immune
response. Indeed, an increased prevalence of recruited leukocytes
in tumors is correlated with a poor prognosis for the affected
patient. By contrast, therapies that eradicate certain immune cells
from the tumor microenvironment lead to longer remission periods
for the treated patient. Along with other recruited cells, multi-
potent mesenchymal stromal cells (MSCs) formerly known as
mesenchymal stem cells are also known to proceed from the bone
marrow to tumors, and once there to reside within tumor stromal
microenvironments. Previous studies have shown that LL-37
(leucine, leucine-37), the C-terminal peptide of human cationic
S79antimicrobial protein 18, stimulates the migration of various
immune cell types and is overexpressed in ovarian, breast, and
lung cancers. Although there is evidence to support a pro-
tumorigenic role for LL-37, the function of the peptide in tumors
remains unclear. Here, we demonstrate that neutralization of LL-
37 in vivo significantly reduces the engraftment of MSCs into
ovarian tumor xenografts, resulting in inhibition of tumor growth
as well as in the disruption of the fibrovascular network. These
tumor-associated MSCs secrete pro-inflammatory and pro-
angiogenic factors that further influence the immunosuppressive
tumor microenvironment. The data indicate that LL-37 facilitates
ovarian tumor progression through the recruitment of progenitor
cell populations that further help establish a favorable ovarian
tumor microenvironment.
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Due to the increasing incidence of breast cancer brain
metastasis (BCBM), the identification of mechanisms responsi-
ble for brain metastasis formation is imperative to develop
novel therapies. Specifically, mechanistic links between Her-2
and BCBM determinants are needed to elucidate the known
correlation between Her-2 overexpression and BCBM onset.
Heparanase (HPSE) is the only functional mammalian endo-
glycosidase degrading heparan sulfate (HS), the main polysac-
charide of basement membranes and tumor-surrounding
extracellular matrix. HPSE relevance in cancer progression
has been established: HPSE overexpression correlates with
metastasis, tumor vascularity, and with shorter post-operative
patient survival, making it an active target for anti-cancer
therapeutics.
We hypothesized that Her-2 augments BCBM by inducing
HPSE via Her-2/epidermal growth factor receptor (EGFR)
signaling. We examined HPSE levels, intracellular trafficking,
and activity in two human Her-2 - expressing BCBM cell
systems (MDA231Br3/2/1 and MDA231Br/Her-2/neo) and
BCBM clinical specimens. We demonstrate that: 1) HPSE is
present and functional according to their brain metastatic
propensities (231Br3 > 231Br2 > 231Br1 > 231Parental) and
Her-2 content; 2) EGF induces HPSE expression and nucleolar
localization in a dose/time-dependent manner; 3) DNA Top-
oisomerase I is a HPSE target in nucleoli of BCBM cells.
Equally relevant, to determine whether microRNAs play roles
in HPSE regulation, we used microRNA bioinformatic pro-
grams and identified miR-1258 as a bona fide microRNA
targeting hpse 3’-UTR region. Second, to determine miR-1258
contributions modulating HPSE expression and activity in
BCBM, we performed gain-/loss-of-function studies using miR-
1258 mimics and inhibitors, and discovered that miR-1258
affects HPSE abilities to promote in vitro cell invasion and
BCBM in xenografts.
These investigations provide first-time evidence showing that: 1)
HPSE is relevant in BCBM via Her-2 – dependent modalities; 2)
hpse is a gene target of microRNA regulation; 3) MiR-1258 is a
primary hpse microRNA candidate; 4) MiR-1258 regulates HPSE
affecting BCBM in vitro and in vivo.
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Genetic data indicate an acute wave of ceramide-mediated
endothelial apoptosis, initiated by acid sphingomyelinase
(ASMase), regulates tumor stem cell response to single high-
dose radiotherapy, obligatory for tumor cure. Here we show
that bFGF or VEGF pre-treatment of cultured endothelium
prevent ASMase activation, ceramide generation and endothe-
lial apoptosis, events reversible with exogenous C16-ceramide.
Anti-VEGFR2 acts conversely, enhancing ceramide generation
and apoptosis. In vivo, intravenous anti-VEGFR2 DC101 or anti-
VEGF G6-31, if delivered immediately prior to radiation,
synergistically increase ASMase-mediated endothelial apoptosis,
and radiation cure of MCA/129 fibrosarcomas and B16 melano-
mas implanted in wild-type mice. However both agents fail to
radiosensitize tumors in asmase
−/− mice, which provide
apoptosis-resistant vasculature, or in wild-type littermates pre-
treated with anti-ceramide antibody. Hence, VEGF/bFGF fail to
suppress apoptosis if ceramide levels remain elevated while anti-
angiogenic therapies fail without ceramide elevation, defining a
ceramide rheostat that determines outcome of single-dose
radiotherapy.
Significance: Anti-angiogenic therapy is currently conceived to
act by two differing mechanisms. One postulates anti-
angiogenesis prevents recruitment of endothelium into nascent
or damaged vasculature, effectively starving tumor, while the
other proposes anti-angiogenic therapies “normalize” dysfunc-
tional tumor vasculature thereby improving perfusion and
drug delivery. The “ceramide rheostat” model provides a
pharmacologically-tractable alternative paradigm for combining
anti-angiogenesis with anti-cancer treatments that target tumor
S80stem cell clonogens directly. Understanding the ordering of
biochemical events of radiation-induced, ceramide-mediated
endothelial cell death and its consequence for tumor response
enables design of temporal sequencing of anti-angiogenic
drugs preceding irradiation that optimizes radiosensitization,
enhancing tumor cure.
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Background:
Numerous studies have shown that metastases formation depends
on the ability of tumor cells to invade basement membranes and
tissue barriers in a process involving enzymes capable of
degrading extracellular matrix (ECM) components. One of these
enzymes is heparanase, an endoglycosidae which degrades
heparan sulfate.
Purpose:
Examine the expression of heparanase in oral carcinomas and
establish whether its extent, intensity and cellular localization can
be of prognostic value in predicting the outcome of oral cancer
patients and explore its role during cellular differentiation.
Methods:
Biopsy specimens from 50 oral carcinoma patients were immu-
nohistochemically analyzed for the expression and cellular
localization of heparanase, PC12 (pheochrocmocytoma) cultures
were used as an in-vitro model of cellular differentiation induced
by NGF.
Results:
Nuclear localization of heparanase was observed in all oral
verrucous carcinomas, a very well differentiated tumor that rarely
metastasize, as opposed to only 28% of nuclear localization
detected in oral squamous cell carcinomas. Heparanase expression
level also significantly correlated with the degree of tumor
differentiation. Moreover, while cytoplasmic localization of
heparanase was associated with high grade carcinomas, nuclear
localization of the enzyme was found primarily in low grade, well
differentiated tumors. Heparanase was suggested to be involved in
the differentiation of PC12 cell and was up regulated 6.5 fold
during NGF induced cellular differentiation. Furthermore, NGF
receptor TrkA seems to be involved in heparanase up regulation in
PC12.
Conclusion:
In rarely metastasizing verrucous carcinomas, heparanase was
expressed in the cell nucleus, as opposed to metastasizing oral
squamous cell carcinomas which exhibited mostly cytoplasmic
localization of the enzyme. Expression level and cellular localiza-
tion of heparanase could serve as reliable predictive indicators of
oral carcinoma development, metastatic potential and patient
prognosis.
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Primary central nervous system lymphomas (PCNSL) are
aggressive malignancies confined to the CNS, mostly of
diffuse large B cell histotype. Despite improved understanding
of the malignant B cell phenotype, little is known on the
tumour microenvironment and the response of the adaptive
immunity against PCNSL. We investigated the phenotype of
tumour infiltrating lymphocytes (TILs) and the expression of
chemokines in 22 cases of PCNSL from immunocompetent
patients. CD8+ T cells are selectively recruited to the tumour
mass and represent the majority of TILs. They tend to
accumulate in perivascular areas, are Granzyme B+, and
vigorously proliferate in situ. Their localization and density
correlates with the expression of the inflammatory chemokine
CXCL9 in the perivascular microenvironment. In addition to
CXCL9, CXCL12 is coexpressed on the tumour vasculature and
forms heterocomplexes with CXCL9, which enhance migration
of CXCR4+ malignant B cells. These findings indicate the
presence of a strong chemoattractant stimulus in the perivascular
microenvironment which serves as an important regulator for the
recruitment of adaptive immune effectors and for the angiocen-
tric positioning of malignant B cells in the perivascular cuff.
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Brain metastasis confers upon melanoma patients an extremely
bad prognosis. The mechanisms underlying homing to and
survival of metastatic melanoma cells in the brain are unknown.
Our working hypothesis is that interactions of melanoma cells
with microenvironmental factors of the brain regulate site specific
metastasis to this organ.
Our main objective is to identify key molecules associated with
melanoma brain metastasis that could serve as therapeutic targets.
We developed three systems of human melanoma variants that
form either local cutaneous tumors or variants from the same
human melanoma that form brain metastasis in xenografted nude
mice. As these variants have an identical genetic background, any
molecular differences between these variants reflect alterations
associated with the ability to form brain metastasis. We are
currently using these variants to establish a melanoma brain
metastasis specific genetic signature.
Gelatin zymography was used to determine MMP-2 activity in the
melanoma variants. Brain metastatic variants displayed a relatively
higher activity level of MMP-2 than local variants, indicating a
greater ability of the metastatic variants to invade through
basement membrane.
To identify chemokine receptors that might be involved in
melanoma homing to the brain, we analyzed the expression of
chemokine receptors and the membrane-bound chemokine
CX3CL1 in the local and metastatic variants. Five chemokine
receptors (CCR3, CCR4, CXCR3, CXCR7 and CX3CR1) and
CX3CL1 were expressed on the melanoma variants.
Other surface molecules associated with tumor progression were
found to be differentially expressed on local and metastatic variants.
Utilizing microarrays, we generated gene expression profiles of
the melanoma variants. This analysis revealed a set of genes
differentially expressed in local and metastatic variants.
Ongoing work focuses on differential interactions of local and
brain metastasizing variants with brain endothelia.
This study was supported by the Dr. Miriam and Sheldon G.
Adelson Medical Research Foundation (Needham, MA, USA)
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Interleukin-8 (IL-8) is a proinflammatory CXC chemokine which
activates intracellular signalling downstream of two cell surface
receptors CXCR1 and CXCR2. We have demonstrated increased
expression of IL-8, CXCR1 and CXCR2 in malignant epithelium
in human prostate cancer, with expression greatest in androgen-
independent metastatic prostate cancer tissue. However, since
CXCR1 and CXCR2 receptors are also expressed on endothelial
cells, infiltrating neutrophils and tumour associated macrophages,
the release of IL-8 from cancer cells is likely to make a significant
contribution in regulating the constitution and activity of the
tumour microenvironment. In addition, the detection of CXCR1
and CXCR2 expression on bone marrow stromal cells indicates
that infiltrating metastatic cells with elevated IL-8 expression may
have enhanced capacity to regulate the microenvironment of the
bone marrow cavity. Our studies are focused on characterizing the
effects of tumour-derived IL-8 signalling in modulating the function of
prostate cancer and bone marrow stromal cell function in order to
orchestrate the remodelling and colonisation of the bone by metastatic
prostate cancer cells. Administrati o no fI L - 8t ot h r e ep r o s t a t ec a n c e r
cell lines (LNCaP, PC3 and/or 22RV1 cells) and two bone marrow
stromal cell lines (HS5 and HS27A) increases AP-1 and NF-κB-
directed gene transcription, leading to increased expression of
cathepsin K and the potent, cell-tethered collagenase, MT1-MMP,
enzymes known to be implicit in promoting bone turnover. Further-
more, our studies demonstrate that IL-8 signalling promotes nuclear
translocation of the transcriptional co-activator, β-catenin, underpin-
ning increases in the expression of a downstream gene target of TCF/
LEF transcripiton complex, the serine protease uPA. RNAi-mediated
attenuation of β-catenin expression attenuated this IL-8 induced
increase in uPA expression. Current studies are characterizing the
importance of IL-8-induced protease activity within the bone micro-
environment, initiating bone remodelling and promoting activation of
matrix-associated growth factors to underpin the osteoclastogenic and
osteoblastic phases of bone metastasis in prostate cancer.
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Endoglin is a TGFβ coreceptor and is highly expressed on
angiogenic endothelial cells with a crucial role in angiogenesis. A
soluble form of endoglin is present in the circulation, which might
possess anti-angiogenic properties. Increased soluble endoglin
levels are reported in pregnant women suffering from pre-
eclampsia, but reports on soluble endoglin in cancer patients are
contradictory. We examined soluble endoglin levels in colorectal
cancer in association with the endoglin shedding mechanism.
Immunohistochemical analysis of colorectal cancer specimens
revealed high endoglin expression in angiogenic endothelial cells.
Interestingly, low endoglin expression on the tumour vessels was
accompanied by high MMP14 expression, the most abundantly
expressed membrane-type MMP. In the circulation of 23 patients
soluble endoglin levels were slightly decreased compared to
healthy controls. The mechanism of endoglin shedding was
evaluated in vitro using HUVEC endothelial cells, which secrete
high levels of endoglin. The release of endoglin was inhibited by
addition of broad-spectrum MMP inhibitors, but not by adding
specific serine- or cystein-protease inhibitors. Specific inhibitors
of the gelatinase or stromelysin MMP subclasses had no effect,
indicating that MT-MMPs are the primary protease candidates.
Therefore, we co-transfected endoglin and MMP14 in COS cells.
Co-expression of endoglin and membrane-bound MMP14 led to
strongly increased soluble endoglin levels, which required direct
interaction between endoglin and MMP14. Cells co-transfected
with a MMP14 mutant, lacking the trans-membrane domain, did
not generate soluble endoglin. Knockdown of MMP14 by shRNA
in HUVECs established that endoglin shedding was decreased
upon reduction of MMP14 expression. Finally, we confirmed that
soluble endoglin was capable of reducing angiogenic potential of
endothelial cells using endothelial sprouting assays.
In conclusion, this study shows that MMP14 mediates
endoglin shedding from endothelial cells, thereby regulating
the angiogenic potential of endothelial cells in the colorectal
tumour-microenvironment.
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Neuroblastoma (NB) is the most common extracranial solid tumor
in children. Survival rates of patients with metastatic disease are
poor despite extensive efforts.
We developed an orthotopic mouse model for human NB
metastasis comprising local and metastatic variants originating
from single tumors. The inoculation of the metastatic variants
into the orthotopic site (adrenal gland) generated lung macro-
metastasis within 12–16 weeks, however, the inoculation of
the local variants did not. Immunohistochemical examination
did not reveal NB cells in the lungs or bone marrow (BM) of
the mice inoculated with the local variant. In an attempt to
possibly rescue micrometastatic cells from these organs, we
cultured lungs and BM from mice orthotopically inoculated
with local NB variants. After 6–12 weeks an outgrowth of NB
cells was observed. Immuno-phenotypying of these cells
indicated that the lungs and BM of the mice contained
dormant human NB cells.
We hypothesize that the lungs and BM of NB-inoculated mice
contain proliferation-restraining components against which the
cells that form macro-metastasis developed resistance.
We tested this hypothesis and found that:
1. BM endothelial cells contain factors that inhibit the proliferation
of micro BM metastases.
2. Spent medium of normal lung tissue contains factors that inhibit
the proliferation of micro and macro lung metastases.
3. Spent medium of lung tissue from tumor-bearer mice contains
factors that inhibit the proliferation of micro lung metastases but
enhance the proliferation of macro lung metastases.
4. Micro BM metastases contain factors that enhance the
proliferation of BM endothelial cells, in an organ specific manner.
The working hypothesis for future studies is that micrometastases
remain dormant for long periods of time because they are inhibited
by factors in their microenvironment.
This study was supported by a grant from Bonnie and Steven
Stern, New York, NY, USA
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Background: Invasion and metastases of cancer cells and the
development of resistance to anticancer therapies are the main
causes of morbidity and mortality from cancer. The objective of
this study was to correlate the expression of urokinase plasmin-
ogen activator (uPA) and CD44 with MDR1 and MRP2 in
epithelial ovarian cancer (EOC) cell lines, primary tumours and
metastatic lesions during EOC progression.
Methods: The expression and co-localization of uPA, CD44,
MDR1 and MRP2 were examined on primary and metastatic EOC
cell lines and paraffin-embedded tissue sections from primary
EOC (n=120), the matched metastatic lesions (n=40) and normal
ovarian tissues (n=20) using confocal microscope by different
monoclonal antibodies.
Results: The co-expression of uPA, CD44, MDR1 and MRP2 was
found in primary (OVCAR-3 and A2780) and metastatic (SKOV-3
and OV-90) cell lines. The expression of uPA, CD44 and
MDR1was found in 88%, 83% and 88% of primary EOC and
90%, 85% and 90% of the matched metastatic lesions respectively
and but not in normal ovarian tissues. Most of tumours showed
moderate to strong intensity staining. The over-expression of uPA,
CD44 and MDR1 was significantly associated with various
progression parameters such as tumour stage, grade, residual disease
status relapse and presence of ascites (P <0.05) but not with
histology type (P>0.05). Co-localization of uPA, MDR1 and CD44
in primary tumours and metastatic lesions was observed.
Conclusions: Over-expression of uPA, CD44 and MRD1 is
correlated with EOC progression; both uPA and CD44 are related
with drug resistance during EOC metastasis and could be useful
therapeutic targets to prevent the development of incurable,
recurrent and drug resistance EOC.
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Ectopic cytokines released by cancer or stromal cells in the
microenvironment of malignant tumors contribute to the cancer
pathogenesis. IL-10 and TGF-β abnormally produced by some
tumors may display an immunosuppressive effect; VEGF ectop-
ically secreted by some cancer stromal cells participates in the
neoangiogenesis; TNFα overproduction contributes to the cachex-
ia occurring at terminal stages of cancer (1).
To counteract the effects of pathogenic cytokines in various
chronic diseases, anticytokine Abs have been used either passively
administered or induced by an active immunization. In some
cancers, anti-VEGF mAbs used in association with chemotherapy
have proved to be therapeutically beneficial (2).
Our group have prepared a VEGF immunogen, constituted by a
KLH-VEGF heterocomplexe, termed VEGF kinoid. Active im-
munization of mice with the VEGF derivative immunogen,
appropriately adjuvanted, proved to be fully innocuous and
mounted a high anti-VEGF neutralizing Ab titer but not a cellular
response. Purified IgG from immune sera decreased by ≥50%
tumor growth of human A673 rhabdomyosarcoma cells and HT29
colon carcinoma xenografted in Swiss nude and Nod/SCID mice
respectively. Following active mVEGF kinoid immunization,
Balb/c mice challenged with syngeneic CT26 colorectal tumor
cells showed a reduced growth of metastases and a reduced tumor
vascularization but had no effect on the primary tumor cell growth
(3).
In cancer treatments besides VEGF kinoid other kinoids targeting
pathogenic cytokines could represent future medications as TNFα
kinoid (4) which is currently used in Crohn’s disease clinical trials.
(1) Zagury D, et al. Cytokine Growth Factor Rev. 2003 14:123–37.
(2) Escudier B, et al. Expert Rev Anticancer Ther. 2008 8:1545–
57.
(3) Rad FH, et al. PNAS. 2007 104:2837–42.
(4) Le Buanec H, et al. PNAS. 2006 103:19442–7.
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As yet, it is assumed that tumors defy experimental therapeutic
access from inside in a comprehensive and reconstructive way
(systems view) but only comply an observation-guided, contra-
intuitive knowledge about biochemical pathways. Based on this
familiar assumption the rational for new therapeutic strategies is
commonly derived from theme-dependent context knowledge.
Comparative analyses of anti-inflammatory activities and clinical
response induced by continuously administeredbiomodulatory
treatment modules (module M: metronomic low-dose chemother-
apy, module A: pioglitazone plus etoricoxib, module A+M, and
module A+M/+: plus second transcriptional modulator (interferon-
alpha or dexamethasone) in metastatic stage of different metastatic
tumors (266 patients; 54% systemically pre-treated; metastatic
S84melanoma, sarcoma, renal clear cell carcinoma, hormone-
refractory prostate cancer, gastric cancer, and Langerhans’ cell
histiocytosis) were performed to uncover and reconstruct tumors’
systems structures mediating tumor-associated inflammation (eight
phase II trials, thereof two randomized). Tumor- and stage-specific
therapeutic accessibility of inflammation-related processes to
induce response in all tumor types indicates a constitutive
spin-off of new systems functions during the metastatic process
and differential integration of inflammation into the tumor
compartments’ context-dependent ‘living world’,w h i c hi s
featured by tumor- and subtype-specific rationalization process-
es: Inflammation-related activities are communicatively pro-
moted and differentially adapted during tumor evolution.
Empirically, differences may be detected in modalities of
evolutionary systems development (heterogeneity in tumor-
associated inflammation-related systems), and in the acquired
functional impact of inflammation-related systems (tumor-
specific mechanisms of action induced by metronomic low-
dose chemotherapy). Availability of markers for ‘late-stage’
response to systems-directed anti-inflammatory therapies supports
the tumors’ modular features. Biomodulatory therapies,administered
as fixed modules may contribute to discover and understand novel
regulatory systems in tumor biology. The study highlights the claim
for validity of therapeutic inflammation control as an important
prerequisite for tumor control, which is shown to be the basis for
action-relevant yes/no statements generating facts on-site in the
tumor via biomodulatory therapy modules.
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We previously demonstrated that the switch from non to highly
tumorigenic phenotype of human melanoma cells is directly
related to procathepsin L secretion, which modified tumor
microenvironment. Indeed, we demonstrated that secreted proca-
thepsin L cleaves human C3, the third component of complement
and consequently increases cell resistance to complement-
mediated cell lysis. In addition, secreted procathepsin L cleaves
other extracellular components. We clearly demonstrated the
involvement of procathepsin L secretion in tumor progression by
developing three different assays: 1) the inhibition of secreted
procathepsin L activity by preincubating human melanoma cells
with polyclonal anti-cathepsin L antibodies; 2) the increase of
procathepsin L secretion by transfecting non-tumorigenic cells
with cathepsin L cDNA to overexpress procathepsin L and to
increase its secretion; 3) the inhibition of procathepsin L secretion.
This latter was triggered by intracellular expression of an anti-
human cathepsin L single chain variable fragment (ScFv),
prepared in our laboratory from a monoclonal anti-cathepsin L
antibody. In all these previous experiments, melanoma cells were
processed before their injection into nude mice. Recently, we
designed a new lentiviral vector in which this anti-cathepsin L-
ScFv was cloned. This anti-cathepsin L ScFv lentiviral construct
was optimized to transduce human melanoma cells with the
highest intracellular expression of anti-cathepsin L-ScFv. In these
transduced cells, procathepsin L secretion was strongly inhibited.
In addition, injection of this anti-cathepsin L-ScFv lentiviral
vector into tumors already induced in nude mice, inhibits tumor
progression and associated angiogenesis. This is the first report to
demonstrate that targeting procathepsin L secretion with anti-
cathepsin L-ScFv lentiviral construct constitutes a new gene
therapy to inhibit the progression of tumors induced by human
melanoma cells.
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The chemokine receptor CXCR4 is critically involved in the
migration of hematopoietic cells to the stroma-derived-factor-1α
(SDF-1a)-producing bone marrow microenvironment. We and
others have previously demonstrated that stroma/leukemia inter-
actions mediate protection of leukemic cells from chemotherapy-
induced apoptosis (Konopleva, Leukemia 16:1713, 2002). Inhibition
of CXCR4 with a specific peptide abrogated this effect and
sensitized leukemic cells to chemotherapy (Zeng et al. MCT 5,
3113, 2006). Importantly, CXCR4 is upregulated by physiological
hypoxia in the bone marrow (Fiegl et al. BLOOD, 113:1504, 2009)
and contributes to pro-survival signaling in hematopoietic cells,
through PI3K/AKT, MAPK and STAT3 signaling. AMD3465, a
second generation small-molecule CXCR4 inhibitor with greater
potency than AMD3100 (Plerixafor) was used to test the hypothesis
that CXCR4 inhibition disrupts stromal/leukemia cell interactions
and overcomes stroma-mediated resistance. Results show that
AMD3465 inhibits surface expression of CXCR4 on AML cells
and SDF-1a and stroma (MS-5)-induced migration of leukemia
cells. In vitro, stromal cells protect leukemic cell lines and primary
AML cells from spontaneous, chemotherapy, and tyrosine kinase
(TKI) inhibitor-induced apoptosis. CXCR4 inhibition enhanced
Ara-C-, Busulfan- and Sorafenib- (FLT3-ITD inhibitor) induced
apoptosis and, importantly, downregulated AKT and MAPK
signaling. In vivo xenografts into (NOD/SCID/IL-2Rα-1-) mice
and syngeneic (Ba/F3-ITD) leukemia models showed even more
pronounced effects, resulting in mobilization of leukemia stem cells
and much enhanced efficacy of Ara-C and Sorafenib (Zeng et al.
BLOOD, e-pub Oct 2008). In patients with AML in CR, treatment
with AMD3100+G-CSF mobilized up to 80% leukemic cells into
circulation. Conclusion: Data suggest that SDF-1a/CXCR4 inter-
S85actions contribute to the resistance of leukemic cells to chemother-
apy and TKI-induced apoptosis. Disruption of these interactions by
CXCR4 inhibitors represents a first strategy for targeting the
complex leukemia cell/microenvironment interactions. Several
clinical trials to test this concept in leukemia patients are in
progress.
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Emerged evidence suggests endothelial nitric oxide synthase
(eNOS)-derived NO is particularly important in tumour angiogen-
esis and hence a novel target for cancer treatment. eNOS
activation requires tetrahydrobiopterin (BH4) as a cofactor for
NO production. However, the role of BH4 in eNOS regulation,
potentially involving phosphatidylinositol 3-kinase (PI-3K) sig-
nalling pathway, remains to be established. The effects of BH4 in
tumour angiogenesis are not known. To investigate this pathway,
we augmented BH4 levels in vascular endothelial cells by
supplementing cultures with sepiaterin, a BH4 precursor for the
pterin salvage pathway synthesis. We also made a genetically
modified murine fibroblast cell line over-expressing GTP cyclo-
hydrolase I (GTPCH, the rate-limiting enzyme for the de novo
BH4 synthesis) under doxycycline (Dox) control and analysed the
effects in a mouse xenograft. In cell cultures, sepiapterin increased
Akt/eNOS phosphorylation in a dose dependent manner in COS-7
cells (no endogenous eNOS) transfected with human eNOS
cDNA. This augmentation was abrogated by wortmannin or
Ly294002, PI3K inhibitors. eNOS/Akt phosphorylation by sepiap-
terin in both HUVEC and bovine aortic endothelial cells (BAEC)
was also significantly enhanced, in association with increases in
NO production, cell proliferation and migration, and capillarity-
like tube formation. Furthermore, sepiapterin greatly increased
GTP-bound wild-type Ras protein. But this effect was diminished
by L-NAME, an eNOS inhibitor. In mouse xenografts, GTPCH
over-expression increased the expression of Ki67 and CD34 in
tumour tissue. Conversely, switch off of GTPCH expression by
Dox in drinking water or inhibition of its enzymatic activity by
intraperitoneal injection of DAHP (GTPCH inhibitor) signifi-
cantly decreased CD34 positive endothelial cells in mouse
xenografts. This study demonstrates a critical role for BH4 in
tumour angiogenesis, which is at least partially mediated by
activating the pathway of PI3K/Akt/eNOS/wild-type Ras protein
in vascular endothelial cells. Our findings suggest that BH4
synthesis may be a rational target for inhibiting tumour
angiogenesis.
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Angiotensin-(1–7) [A7] is an endogenous seven amino-acid
peptide hormone of the renin-angiotensin system that exhibits
antiproliferative properties. We showed that A7 significantly
inhibited the growth of non-small cell lung adenocarcinoma in a
xenograft mouse model. In this study, human BT474 HER2-
amplified estrogen receptor positive breast cancer cells were
injected into the mammary fat pad of athymic mice; tumors grew
to approximately 200 mm
3 prior to infusion with saline or 24µg/
kg/h A7 for 18 days. A marked reduction in tumor volume (5209±
419 mm
3 to 1656±124 mm
3; n=5, p<0.05) and weight (3.6±
0.2 g to 2.2±0.1 g; n=5, p<0.05) was observed in mice
administered A7 as compared to saline control animals. Vessel
density was decreased approximately 50% by the heptapeptide,
demonstating that A7 has antiangiogenic properties. Picrosirius
red histochemistry showed that interstitial fibrosis (4.91±0.96
percent/field versus 1.22±0.19; n=17–20, p<0.0005) and peri-
vascular fibrosis (49.32±3.20 percent/vessel versus 13.35±2.23;
n=20–21, p<0.0001) were significantly reduced with A7
administration. This decrease in fibrosis was associated with a
reduction in collagen I deposition, suggesting that A7 has an
antifibrotic effect in breast cancer. Treatment with the heptapep-
tide significantly decreased (31% reduction, n=4, p<0.05) the in
vitro growth of cancer-associated fibroblasts (CAFs) isolated
from orthotopic breast tumors which could lead to a decrease in
mitogenic factors and metalloproteinases produced by CAFs. A
2.3-fold increase in the mitogen-activated protein (MAP) kinase
phosphataseDUSP1wasalsoobserved,suggestingthatthereduction
in fibroblast proliferation may be due in part to inhibition of MAP
kinase activity. Taken together, these data suggest that A7 may serve
as a first-in-class chemotherapeutic agent for breast cancer targeting
the tumor microenvironment through a reduction inangiogenesis and
a decrease in CAF proliferation.
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S86Triple negative breast tumors are aggressive, highly metastatic
cancers that lack estrogen and progesterone receptors and have
basal expression of the human epidermal growth factor receptor
HER2. Angiotensin-(1–7) [A7], an endogenous heptapeptide
hormone that activates the mas receptor, significantly reduced
the in vivo proliferation of human triple negative breast tumor
growth in an orthotopic model. Athymic mice with tumors
produced by injection of MDA-MB-231 cells into the mammary
fat pad were treated for 28 days with saline or 1000 μg/kg A7,
delivered by daily subcutaneous injection. A7 markedly reduced
tumor volume (170.8±21.4 mm
3 versus 546.7±87.9 mm
3;n = 5 ,
p<0.05) and tumor wet weight (0.5±0.1 g versus 1.0±0.2 g; n=5,
p<0.05) compared to the tumors from control animals. A7
decreased ERK1/ERK2 MAP kinase activities and increased
MAP kinase phosphatase DUSP1 in both parent cells and
orthotopic tumors, while an siRNA to DUSP1 prevented the
attenuation of ERK activities by the heptapeptide. These results
suggest that A7 upregulates a MAP kinase phosphatase to reduce
MAP kinase activities and decrease tumor growth. The inhibition
in tumor growth by A7 was associated with a reduction in vessel
density (32.0±7.0 vessels/field to 87.8±6.4, p<0.05), a 59%
decrease in placental growth factor (PlGF) and a 72% reduction in
vascular endothelial growth factor (VEGF), indicating an inhibi-
tion of angiogenesis. Incubation of the parent cells with A7
reduced PlGF and VEGF by more than 60% in a receptor-
mediated process. Transfection of siRNAs to DUSP1 into breast
cancer cells reversed the decrease in PlGF and VEGF with A7
treatment, suggesting that reduction of angiogenic cytokines was
mediated by an increase in DUSP1. Based on the antiproliferative
and antiangiogenic properties of the heptapeptide, A7 may serve
as an effective, first-in-class compound for the treatment of triple
negative breast tumors targeting the specific receptor mas.
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Phytoestrogens have been shown to be potential compounds in
breast cancer prevention and treatment by poorly understood
mechanisms. One of the most abundant phytoestrogen in Western
diet is the mammalian lignan enterolactone (ENL). We have
previously reported a pro-angiogenic action of estradiol counter-
acted by the anti-estrogen tamoxifen in breast cancer. The
proinflammatory cytokines IL-1alpha and IL-1beta have been
shown to be major pro-angiogenic whereas the IL-1 receptor
antagonist (IL-1Ra) seems to inhibit tumor angiogenesis. Here we
show that estradiol decreased secreted IL-Ra of breast cancer cell
in vitro and that the addition of tamoxifen or ENL to the cells
reversed this decrease. Moreover, tamoxifen exposure alone
increased IL-1Ra levels significantly compared to control cells.
Mice bearing estrogen dependent breast cancers were treated with
subcutaneous injections of tamoxifen, fed with ENL, or continued
exposure of estradiol only. In these solid breast cancer tumors
extracellular IL-1Ra was sampled in situ using microdialysis after
2–3 weeks of treatment. Tumors of mice treated with tamoxifen or
fed with ENL had significantly increased extracellular IL-Ra
levels compared with control tumors exposed to estradiol only in a
similar fashion as shown in vitro and these tumors also exhibited
decreased vessel area. Moreover, treatment with subcutaneous
injections of recombinant IL-Ra protein resulted in tumor
regression in vivo despite continued estradiol exposure. We
conclude that estradiol down-regulate IL-1Ra in breast cancer
cells. In addition, we show that an anti-estrogenic effect of ENL in
breast cancer include restoration of IL-1Ra levels and that one of
the anti-tumorigenic effects of tamoxifen may be mediated via
potent increase of IL-1Ra levels in estrogen dependent breast
cancer. Taken together our results suggest that increasing IL-1Ra
may be a possible anti-estrogen therapeutic option for breast
cancer treatment and prevention.
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Tumor angiogenesis is a critical event in tumor growth and
progression. Anti-angiogenic drug such as Avastin, Sutent,
Nexavar and Torisel, have been approved for the treatment of
advanced human cancers, opening the way to anti-angiogenic
therapy in clinical oncology. However, the improved use of
current approved drugs, or the development of novel ones, is
limited by the lack of reliable surrogate markers that may allow a
non-invasive and cost-effective monitoring of angiogenesis and
identification of responding patients.Several studies performed
using mouse models showed that bone marrow-derived (BMD)
myeloid cells and several cell subpopulations, are important
modulators of tumor angiogenesis. Once those cells are attracted
at the tumor site by tumor-released factors, they promote
angiogenesis, tumor growth, invasion and metastasis. Moreover,
it appears that the tumor could educate these cells before they
enter the tumor microenvironment. Previous studies suggested the
possibility that circulating BMD myeloid cells may be imprinted
by tumor-derived signals even before they reached the tumor. If
induced changes can be detected by non-invasive procedures,
these cells, and associated molecular events, could be used to
identify surrogate markers of tumor angiogenesis. Following the
screening of different human and murine tumor models, we
observed a myeloid cell population mobilized in mice bearing
4 T1-breast cancer cells-derived tumors. Particularly, we detected
S87a striking accumulation of a subpopulation of F4/80+ cells
(monocytic lineage) and neutrophils in the peripheral blood of
orthotopically-injected 4 T1 mice. Microarray-based gene expres-
sion analysis of F4/80+ cells isolated from the peripheral blood of
control, 4 T1-bearing and anti-angiogenic drug treated 4 T1-
bearing mice is ongoing with the purpose to identify relevant
genes associated with tumor growth or angiogenesis. These results
will be validated in human peripheral blood cells collected from
healthy volunteers, and cancer patients before, during and after
anti-angiogenic therapies.
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Viral nanoparticles offer an attractive multivalent platform for
diagnostic in vivo imaging of prostate and other cancers. We have
developed a nanoparticle platform based on the cowpea mosaic
virus (CPMV) that offers discrete control over the conjugation of
detection moieties, solubilization polymers and targeting ligands
to the viral capsid. We report here the specific targeting and
imaging of human PC-3 prostate cancer cells in vitro and in vivo
with PEGylated fluorescent viral nanoparticles conjugated to a
pan-bombesin peptide. The amphibian tetradecapeptide, bomb-
esin, selectively interacts with the gastrin-releasing peptide (GRP)
receptor family that is over-expressed on human prostate cancer
cells. Bombesin peptide was conjugated to CPMV particles
functionalized with a near-infrared (NIR) dye (Alexa Fluor 647)
and polyethylene glycol (PEG) using the copper(I)-catalyzed
azide-alkyne cycloaddition reaction. Absorbance measurements
indicated that each nanoparticle contained 90 NIR dyes and
80–95 PEG or bombesin-PEG units. The integrity of CPMV
particles was verified by FPLC, SDS PAGE and transmission
electron microscopy. The bombesin-targeted CPMV particles
showed a marked increase in uptake by PC-3 cells compared to
a non-targeted control as measured by flow cytometry, and
specificity was confirmed by successful blocking with an
excess of soluble bombesin peptide. Targeting of PC-3 cells
in vitro was confirmed by confocal microscopy. Bombesin
conjugated CPMV showed impressive targeting and uptake in
human prostate tumors in vivo, using a shell-less avian embryo
tumor model. Taken together, we have shown here that
bombesin-targeted viral nanoparticles offer a highly selective
imaging tool for human prostate tumors, using a platform with
future potential for clinical non-invasive imaging strategies and
drug delivery.
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The microenvironment of tumor cells in the bone marrow may be
actively involved in the progression of malignant diseases. In
multiple myeloma (MM), interactions of bone marrow stromal
cells with the malignant plasma cells have gained significant
importance as targets for novel therapeutic agents. Based upon
these observations, we aimed at analyzing in detail the secretory
capacity of bone marrow fibroblasts obtained from patients with
MM in order to better understand their contribution to disease
progression. We therefore analyzed the secretome of primary bone
marrow fibroblasts of MM patients by proteome profiling based
on highly sensitive mass spectrometry. Normal skin and bone
marrow fibroblasts were found to secrete various extracellular
matrix (ECM) proteins including fibronectin, collagens and
laminins, in addition to some chemokines and cytokines including
CXCL12, follistatin-like 1, insulin-like growth factor binding
proteins 4, 5 and 7; and SPARC. In contrast, bone-marrow-derived
fibroblasts from MM patients secreted increased amounts of ECM
proteins and alpha-fetoprotein in addition to insulin-like growth
factor II, stem cell growth factor and matrix metalloproteinase-2.
Co-culture of primary MM cells with these fibroblasts further
stimulated the secretion of ECM proteins, of cytokines such as
inhibin beta A chain and growth factors such as connective tissue
growth factor, which might be relevant to support the malignant
clone. Analyses of the secretion capacity of bone marrow fibroblasts
from patients with MGUS show that their secretome profile is also
different compared to that of normal bone marrow fibroblasts.
Proteome profiling of secreted proteins may thus help to identify
relevant tumor-associated proteins, to increase our understanding of
cell cooperativity and thereby increase our understanding of
progression events in monoclonal gammopathies.
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S88Endothelial cells (EC) substantially shape the tissue microenvi-
ronment which plays a critical role in tumor progression. We
established protein maps of the secretome of human umbilical vein
endothelial cells (HUVEC), human liver endothelial cells (HLEC)
and human tumor derived endothelial cells (HTEC) from ovarian
carcinoma. HLEC and HTEC were isolated using magnetic beads
(anti CD31). Phenotype and function was confirmed by FACS
analysis (positive for CD31, CD34, CD54 and CD62e after
stimulation with TNF-α, podoplanin expression <10%, CD91
negative). Cells from passages 3–5 were cultured in proteinfree
medium. After 24 hrs, supernatants were subjected to 1D gel
electrophoresis followed by nanoflow liquid chromatography and
MS/MS fragmentation analysis. Data were organized by the CPL/
MUW proteomics database. We identified more than 250 proteins
encompassing extracellular matrix proteins (collagens, fibrillin-1,
fibulin-3, endothelial cell-selective adhesion molecule, dystrogly-
can, laminins, multimerin-1, proteoglycan-I, perlecan), proteases
(MMPs, ADAMs, legumain, serine proteases 23 and HTRA1),
peptidases (aminopeptidases, angiotensinase C, carboxypeptidase
C and E, dipeptidyl-peptidase 2 and gamma-glu-X carboxypep-
tidase), protease inhibitors (TIMPs, PAI-1, serpin I2), growth
factors (CTGF, PDGFs, SDF) and cytokines (interleukin-6, -8).
By comparison with various other cell types (fibroblasts, VEGF
and Il-1β activated HUVEC) we could establish protein profiles
typical for various functional states. HLEC generated a proin-
flammatory microenvironment (secretion of IL-6, IL-8, several
other inflammation associated proteins). The microenvironment
generated by HTEC was characterized by growth factors (PDGF-
A, CTGF) and other proteins associated with angiogenic activa-
tion, promotion of cell survival and cell growth. These results
provide the up to now most comprehensive protein maps of the
secretome of endothelial cells and demonstrate the value of
proteomics to investigate the tissue microenvironment.
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Background: Tumour development and progression are strongly
affected by interaction of tumour cells and tumour stroma. For
different tumour models (e.g. breast cancer) a supportive effect of
TAF on the tumour genesis was demonstrated. Aims of the present
work are the isolation and proteomic characterisation of TAF from
primary urinary bladder tumour specimen. A further part of this
study will deal with the influence of urinary bladder carcinoma
cell lines on protein expression of TAF.
Material and Methods: TAF were isolated from cultured urinary
bladder tumour specimen. Therefore, primary tumour material was
treated with EDTA followed by differential trypsinisation. Non-
tumour fibroblasts were isolated from foreskin and normal urinary
bladder tissue. Analyses of protein patterns were carried out on
cultivated fibroblasts by SELDI-TOF-MS. TAF and foreskin
fibroblasts were co-cultivated with several urinary bladder cancer
cell lines in separated cell culture compartments followed by
SELDI-TOF-MS analyses.
Results: By optimizing cell culture routines it was possible to
isolate and subsequently cultivate TAF from primary tumour
material of the urinary bladder. SELDI-TOF-MS measurements
reveal differences in the proteomic patterns of TAF and non-
tumour fibroblasts. Co-cultivation of urinary bladder carcinoma
cells and TAF or non-tumour fibroblasts induces modified protein
patterns in the different cell types.
Conclusion: TAF can be isolated and cultivated separately from
primary tumour material. They are characterised by the expression
of a specific protein pattern in comparison to non-tumour
fibroblasts. Co-cultivation with tumour cells revealed the induc-
tion of a modified expression profile in fibroblasts and vice versa.
The present results will provide a more detailed knowledge of the
role of TAF in tumour development of urinary bladder carcinoma.
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One of the possible main route by which tumor cells modulate the
response of the immune system within the tumor microenviron-
ment is by secretion of soluble human leukocytes antigens (sHLA)
carrying their peptide cargo. The HLA molecules are normally
considered only to be transporters that carry peptides from the
cytoplasm to the cell surface for surveillance by circulating T
lymphocytes. However, many types of cancer cells are known to
release into the serum large amounts of soluble HLA molecules
still bound with their authentic peptides repertoires (the sHLA-
peptidomes). Since the sHLA peptidomes are largely derived from
the diseased cells, these monomeric sHLA-peptide complexes
bind to circulating T cells and can modulate their anti-cancer
cytotoxic activities. Furthermore, the identified serum sHLA
peptidome provide a rich source of information about the tumor
cells and the analysis of these peptidomes can be used as a
sensitive serum-based cancer diagnostic. In this study we show
that a few milliliters of fresh human plasma are sufficient for
detailed analyses of sHLA-peptidomes, composed of thousands of
peptides. The methodology comprises of a single-step immunoaf-
finity purification of the sHLA molecules from fresh human
plasma, followed by analysis of the bound peptides by capillary
chromatography and tandem mass spectrometry. This sHLA-
S89peptidomics approach was validated with plasma of a few patients
with multiple-myeloma and leukemia, resulting in identification of
numerous cancer related sHLA peptides, potentially useful as
disease biomarkers, which were absent from the sHLA-
peptidomes of the healthy controls. The repertoires of sHLA
peptides recovered from the plasma of the cancer patients or from
the bone marrow plasma were mostly identical. Therefore, the
analysis of the blood sHLA peptidome provides an exciting
glimpse onto the tumor microenvironment and may facilitate
intervening in its immune suppressive properties.
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Hypoxia, characteristic of fast growing solid tumors, recruits and
immobilizes macrophages and enhances angiogenesis. Mono-
cytes extravasation from the circulation across the basement
membrane and extracellular matrix, which is mediated by matrix
metalloproteinases (MMPs), is accompanied by their maturation
into macrophages. However, the mechanisms evoked by hypoxia
that regulate monocyte/macrophage behavior are largely un-
known. We show that hypoxia reduces TIMP-2 secretion from
primary monocytes or from U937 and THP-1 monocytic cell
lines by 3–4 folds (p<0.01), by inhibiting its transcription.
PMA-induced maturation of these cells, irrespective of hypoxia,
also causes a 2–3- fold reduction of TIMP-2 (p<0.05), not by
enhancing its intracellular or extracellular degradation, but by
inhibiting its translation. We demonstrate involvement of SP-1 in
transcriptional inhibition of TIMP-2 in monocytes, and suggest
that hypoxia-induced enhancement of SP-1 phosphorylation
dissociates it from TIMP-2 promoter, and disrupts coordinative
recruitment of other transcription factors, such as NFY. Hypoxia
reduces TIMP-2 secretion from endothelial cells by 2-folds (p<
0.05), and increases endothelial cell migration/proliferation in a
TIMP-2-dependent manner, whereas the reduced TIMP-2 secretion
from monocytes and macrophages do not affect their migration.
Thus, we suggest that various mechanisms control TIMPs synthesis
and expression in different cell types and processes, and that overall
reduced TIMP-2 secretion in the hypoxic tumoral microenvironment
contributes to enhance angiogenesis.
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Hypoxia is a common feature of tumors that contributes to
malignancy and treatment resistance. The basis for these effects
derives in part from a transcriptional response mediated by the
HIF family of transcription factors. Hypoxia also has been shown
to activate the unfolded protein response (UPR) which induces a
protective response against hypoxia induced cell death both in
vitro and in xenografts in vivo. Here we show that the protective
effect of the UPR during hypoxia is mediated through regulation
of autophagy. We discovered that the UPR induces the
transcription of the essential autophagy genes LC3B and
ATG5 during hypoxia through its ability to regulate the
transcription factors ATF4 and CHOP respectively. LC3B and
ATG5 are not required for the initiation of autophagy, but
instead mediate phagophore expansion and formation of the
autophagosome. Transcriptional induction of LC3B during
hypoxia functions to replenish LC3B protein levels which are
normally turned over during the process of autophagy, and thus
allow autophagy to continue during extended hypoxic expo-
sures. We show that cells engineered with various defects in
PERK/UPR signalling fail to transcriptionally induce LC3B and
thus become rapidly depleted of LC3B protein during hypoxia.
Activation of autophagy and induction of LC3B was also
observed in hypoxic areas of tumor xenografts derived from
cell lines and in a series of 12 human head and neck xenografts
established directly from tumors. Importantly, pharmacological
inhibition of autophagy sensitized cells to hypoxic exposure,
reduced the viable fraction of hypoxia in xenografts, and
sensitized tumors to irradiation. These data suggest that
regulation of autophagy via the UPR facilitates cell survival
during hypoxia and that this pathway is an interesting
therapeutic target in combination with radiotherapy.
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Brain edema is a hallmark of human malignant brain tumors and
contributes to the clinical course and outcome of brain tumor
patients. The so-called peritumoral edema or brain swelling
imposes in T2-weighted MR scans as high intensity areas
surrounding the bulk tumor mass. The mechanisms of this
increased fluid attraction and the cellular composition of the
microenvironment are only partially understood. Here, we focus
on the molecular and cellular characterization of this particular
zone. We identified that areas of perifocal edema not only include
the tumor invasion zone but also are associated with the occurance
of neuronal cell death and increased astrocytic distribution
surrounding the bulk tumor mass. Moreover, a high number of
activated microglial cells accumulate at the tumor border. Thus,
the area of perifocal edema is mainly dominated by reactive
changes of vital brain tissue. We further analyzed the peritumoral
zone by biochemical means and identified augmented levels of the
neurotransmitter glutamate. RNA interference or pharmacological
approaches towards glutamate modulations attenuated neuronal
cell death and brain swelling. We will present further data which
corroborate the concept that brain swelling may in part be a
consequence of the neurotoxic tumor microenvironment.
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We have shown that expression of the proinflammatory CXC
chemokine, interleukin-8 (IL-8) and its receptors CXCR1 and
CXCR2 is elevated in malignant prostate cancer (CaP) epithelium.
Published studies confirm that hypoxia and/or chemotherapy-
induced stresses underpin AP-1, HIF-1 and NFκB-mediated
transcription-driven increases in IL-8, CXCR1 and CXCR2 expres-
sion in CaP cells. The current study determines the relevance of
PTEN, a commonly mutated or deleted tumour suppressor gene in
CaP,inregulatingtheinductionofCXC-chemokinesignalingandthe
cellular response of stressed CaP cells. Time-dependent increases in
CXCL8, CXCR1 and CXCR2 mRNA were observed in PTEN-
deficient LNCaP and PC3 cells. ELISA confirmed increased IL-
8 secretion following hypoxia, while immunoblotting confirmed
elevated CXCR1 and CXCR2 expression in both cells. In contrast,
CXCL8, CXCR1 and CXCR2 expression was only marginally up-
regulated inPTEN wild-type DU145 and 22Rv1 cells under hypoxia.
Subsequently, PTEN status was shown to regulate the magnitude and
duration of CXC-chemokine-promoted signaling and altered gene
expression profiles. For example, CXCL8 administration increased
expression of HIF-1α and increased the activity of this transcription
factor in PTEN-deficient LNCaP and PC3 cells but not in PTEN
wild-type cells. Furthermore, expression of HIF-1 target genes
(VEGF, TGFα) was also induced following CXCL8 stimulation in
PTEN deficient but not PTEN wild-type cells. Attenuation of PTEN
in the DU145 and 22Rv1 cells using siRNA revealed the CXCL8-
induced responses including the increase in HIF-1 expression and
activation. Functionally, the transcription-mediated elevation in IL-
8 signalling underpins an increased survival of hypoxic prostate
cancer cells to DNA-damage-based chemotherapy. In summary, our
studies suggest that the magnitude of CXC-chemokine signaling and
it subsequent effects is functionally important in PTEN-deficient
prostate tumours, promoting proliferation, survival, chemoresistance
and an androgen-independent transition in the cancer cells, while
simultaneous effects on the tumour stroma will potentiate angiogen-
esis and recruitment of a disease-progressing immune cell infiltrate.
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Inflammatory conditions in selected organs increase the risk of
cancer. An inflammatory component is present also in the
microenvironment of tumours that are not epidemiologically
related to inflammation. Recent studies have begun to unravel
molecular pathways linking inflammation and cancer. Sche-
matically, an intrinsic (driven by genetic events that cause
neoplasia) and an extrinsic (driven by inflammatory condi-
tions which predispose to cancer) pathway link inflammation
and cancer. Smouldering inflammation in the tumour micro-
environment contributes to proliferation and survival of
malignant cells, angiogenesis, metastasis, subversion of adap-
tive immunity, response to hormones and chemotherapeutic
agents. As such, cancer-related inflammation (CRI) represents
a target for innovative diagnostic and therapeutic strategies.
We surmise that CRI represents the seventh hallmark of
cancer.
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Conventional therapies of cancer rely upon radiotherapy and
chemotherapy. Such treatments supposedly mediate their effects
via the direct elimination of tumor cells. However, anticancer
such therapies can also modulate the host immune system in
S91several ways. Drugs can inhibit immunosuppressive pathways,
or activate distinct immune effectors, or sensitize tumor target
cells to CTL attack or generate an immunogenic cell death
modality, all culminating in eliciting or enhancing anticancer
immune responses contributing to the tumoricidal activity of
the drug. Indeed, we reported that anthracycline-mediated cell
death is immunogenic in tumor bearing hosts through a
molecular pathway involving membrane exposure of calreticu-
line (CRT) by tumor cells
1,2,3. CRT is mandatory for the uptake
by dendritic cells of dying tumor cells. More generally,
anthracyclines, X-Rays and platinum based-therapies mediate a
tumoricidal activity relying on CD8+ T cells, CD11c+DC, IFNg/
IFNgR signalling pathway but not IL-12. We addressed which
biochemical or metabolic components expressed or released by
dying tumor cells could trigger the immune system and
participate to the immunogenicity of cell death. While
HMGB1/TLR4 are mandatory for the processing of dying bodies
by DC and the activity of chemotherapy, other components
recently unravelled will be presented at the meeting. These
results delineate a clinically relevant immunoadjuvant pathway
triggered by tumor cells.
1. Obeid M, et al. Calreticuline exposure dictates the immunoge-
nicity of anthracyclines. Nat. Med. 2007, Jan 13 (1): 54–61.Epub,
ahead offprint Dec 24, 2006
2. Zitvogel L, et al. Cancer in spite of immunosurveillance.
Immunosubversion and immunosuppression Nat. Rev. Immunol.
2006 Oct 6, 715–27.
3. Casares N, et al. Caspase-dependent immunogenicity of
doxorubicin-induced tumor cell death. J Exp Med. 2005 Dec
19;202(12):1691–701.
4. Apetoh L, et al. TLR4 -dependent contribution of the immune
system to the antitumor effects of chemotherapy and radiotherapy.
Nat. Med. Aug; 2007.
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The concept that leukocytes are components of malignant tumors
is not new; however, their functional involvement as promoting
forces for tumor progression has only recently been appreciated.
We are interested in understanding the molecular mechanisms that
regulate leukocyte recruitment into neoplastic tissue and subse-
quent regulation those leukocytes exert on evolving cancer cells.
By studying transgenic mouse models of skin, lung and breast
cancer development, we have recently appreciated that adaptive
leukocytes differentially regulate myeloid cell recruitment, activa-
tion, and behavior, by organ-dependent mechanisms. Thus,
whereas chronic inflammation of premalignant skin neoplasms is
B cell–dependent, during mammary carcinogenesis, T cells appear
to play more of a dominant role in regulating pro-tumor and pro-
metastatic properties of myeloid cells. To be presented will be
recent insights into organ and tissue-specific regulation of
epithelial cancer development by adaptive and innate immune
cells, and thoughts on how these properties can be harnessed for
effective anticancer therapeutics.
Funding from the National Institutes of Health and a Department
of Defense Era of Hope Scholar Award.
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Intratumoral Immune Reaction: A Novel Paradigm
for Cancer
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To date the anatomic extent of tumor (TNM classifications) has
been by far the most important factors to predict the prognosis of
colorectal cancer patients. However, the impact of immune
responses and tumor escape on patient prognosis in human cancer
is poorly understood.
We showed that tumors from human colorectal cancer with a high
density of infiltrating memory and effector memory T-cells (TEM)
are less likely to disseminate to lymphovascular and perineural
structures and to regional lymph-nodes. We showed that the
combination of immune parameters associating the nature, the
density, the functional orientation and the location of immune cells
within the tumor was essential to accurately define the impact of
the local host immune reaction on patients prognosis. We
proposed to define these immune criteria as “immune contexture”.
Investigation of the CRC primary tumor microenvironment
allowed us to uncover the association of favorable outcomes with
efficient coordination of the intratumoral immune response. We
described four major immune coordination profiles within CRC
primary tumors depending on the balance between tumor escape
and immune coordination.
In conclusion, the density and the immune-cell location within the
tumor have a prognostic value that are superior of those of the
TNM classifications. Tumor invasion is statistically dependent on
the host immune reaction.
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Tumor-associated macrophages (TAMs) are abundant in virtually
all types of malignant tumour. These highly versatile cells respond
to the presence of stimuli in different tumour regions with the
release of a distinct repertoire of growth factors, cytokines,
chemokines, and enzymes that regulate tumor progression. The
S92distinct tumour microenvironments where TAMs are found
include areas of invasion where TAMs promote tumour cell
motility; stromal and peri-vascular areas where TAMs may
promote metastasis; and avascular and peri-necrotic areas where
they are thought to stimulate angiogenesis. In fact, TAMs
accumulate in hypoxic areas of tumours in large numbers and
our most recent data show that hypoxia, necrotic debris and/or
hypoxia-induced cytokines like angiopoietin-2 stimulate expres-
sion of important tumour-promoting genes like VEGF, EGF and
IL-6 by TAMs. This may explain why high TAM density in these
areas correlates with increased tumour angiogenesis and metasta-
sis. Large areas of hypoxia and necrosis form in tumors after
administration of chemotherapeutic agents, radiotherapy or drugs
that disrupt the tumor vasculature. This is often accompanied by a
marked influx of macrophages into the tumor residue where they
are activated to stimulate its revascularisation and re-growth. In
this way, macrophages act as a powerful ally in tumor resistance
and recovery. We are currently exploiting the natural ability of
macrophages to migrate into to such poorly vascularised tumor
areas to deliver therapeutic virus. To do this, we have developed a
novel technology to genetically manipulate macrophages to
synthesise and release therapeutic virus under the control of
hypoxia-responsive promoter elements. This restricts viral pro-
duction (and thus therapeutic gene expression in the virus) to cells
in hypoxic/necrotic tumor areas. In this way, the responses of
macrophages to tumor hypoxia can be exploited to deliver gene
therapy to tumors.
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The progression of ductal carcinoma in situ (DCIS) to invasive
ductal carcinoma is a key yet poorly understood event in breast
tumor progression. Comparative molecular analyses of tumor
epithelial cells from in situ and invasive tumors have failed to
identify consistent tumor stage-specific differences. However, the
myoepithelial cell layer and basement membrane, present only in
DCIS, are key distinguishing and diagnostic features. To deter-
mine the contribution of non-epithelial cells to tumor progression,
we analyzed the role of myoepithelial cells and fibroblasts in the
progression of DCIS using a xenograft model of human DCIS.
Progression to invasion was promoted by fibroblasts, but was
inhibited by normal myoepithelial cells. The progression-
promoting effects of fibroblasts could be eliminated by COX-2
inhibitors. Invasive tumor epithelial cells from these progressed
lesions formed DCIS rather than invasive cancers when re-injected
into naïve mice. Molecular profiles of myoepithelial and luminal
epithelial cells isolated from primary normal and cancerous human
breast tissue samples corroborated findings obtained in the
xenograft model. These results provide the proof of principle that
breast tumor progression could occur in the absence of additional
genetic alterations in tumor epithelial cells. Furthermore, our data
suggest that a key event of tumor progression is the disappearance
of the normal myoepithelial cell layer and basement membrane
due to defective myoepithelial cell differentiation provoked by
microenvironmental signals. Thus, myoepithelial cells could be
considered gatekeepers of the in situ to invasive breast carcinoma
transition and understanding the pathways that regulate their
differentiation may open new venues for breast cancer therapy and
prevention.
O146
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Breast cancer a common malignancy and a leading cause of
cancer-related mortality. Currently, it is clear that a significant
percentage of patients respond well to first line therapy and will
not relapse or evolve to metastatic disease. However, discrimina-
tion of these patients from those that will progress is poor. To
avoid over-treatment and to administer a tailored therapies we still
need to further improve diagnostic and prognostic tools. We must
look beyond the tumor cells themselves, and into the tumor
microenvironment, to have additional clues to predict probability
of progression and metastatic dissemination. Gene expression
profiling could be a useful approach to characterize not only tumor
cells but also the surrounding microenvironment. We used a gene
expression dataset of 159 breast cancer cases with follow-up
information of at least 8 years to discriminate the tumors that will
eventually give rise to recurrence or metastases from those that
will progress. We performed a hierarchical clustering by consid-
ering genes involved in cell-cell and cell-matrix interactions and
signaling that were or were not associated with tumor relapse. We
found two main clusters, one is enriched in cases with metastases
and the other containing only a few metastatic cancer samples. We
then compiled a list of genes that are significantly differently
expressed between correctly classified cases with metastases and
the most frequently misclassified cases using a permutation test.
The tumor-microenvironment signature set used here gave
prediction of progression rates that were essentially super-
imposable on larger previously published gene signature sets.
Interestingly, we found that there was a cluster of frequently
misclassified cancers using the diverse gene signature sets. Gene
expression profiles of the tumor microenvironment may permit
additional levels of selection that could identify the outlying
samples that cluster with non-progression profiles but are
malignant.
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Migration: Implications to HER2-positive Breast Cancer
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Growth factors and their transmembrane receptors contribute to all
steps of tumor progression, from the initial phase of clonal
expansion, through angiogenesis to metastasis. An important
example comprises the epidermal growth factor (EGF) and the
respective receptor tyrosine kinase, namely ErbB-1/EGFR, which
belongs to a prototype signaling module that implicated in
carcinoma development. The extended module includes two
autonomous receptors, EGFR and ErbB-4, and two non-
autonomous receptors, namely: a ligand-less oncogenic receptor,
HER2/ErbB-2, and a kinase-dead receptor (ErbB-3). This
signaling module is richly involved in human cancer and
already serves as a target for several cancer drugs. Along with
regulation of cell proliferation, EGFR family members control
cellular motility through a process requiring newly synthsized
RNA molecules. Using DNA arrays and immortalized mam-
mary cells we study mechanisms underlying enhanced cell
motility upon EGFR activation. These studies will be
described and their relations to clinical observations will be
discussed.
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Steven Paget’s ‘seed and soil’ hypothesis introduced the concept
that a receptive microenvironment in distant organs is required for
the colonization, survival and outgrowth of metastatic tumor cells.
Meanwhile, the early molecular and cellular events taking place
within distant tissues that “prime the soil” for tumor cell
colonization are only beginning to be discovered. Previously, we
showed that tumor-specific growth factors promote the mobiliza-
tion of vascular endothelial growth factor 1 (VEGFR1)
+ hemato-
poietic progenitor cells (HPCs) and VEGFR2
+ endothelial
progenitor cells (EPCs) to the developing tumor vasculature.
However, the role of BM-derived cells in tumor metastasis was
largely unidentified. We have demonstrated that BM-derived
HPCs promote a conducive microenvironment for tumor growth
termed the “pre-metastatic niche”. Here, secretory factors of the
primary tumor induce modifications within pre-metastatic tissues
prior to the arrival of tumor cells and stromal cells. Blocking
VEGFR1 function was seen to abrogate HPC recruitment and
consequent metastasis, whereas inhibiting VEGFR2 function
prevented micrometastatic to macrometastatic transitioning. The
HPCs at the pre-metastatic sites maintained their progenitor cell
status, expressing markers such as CD34, CXCR4, CD11b, c-Kit
and Sca-1. Prior to the arrival of HPCs at the pre-metastatic niche,
focal upregulation of fibronectin isoforms occurred. BM-derived
cells expressing VLA-4 integrin preferentially bound to regions
with enriched fibronectin expression, contributing to site-
specificity for tumor metastasis. Despite these findings, the precise
function of VEGFR1 expression within these hematopoietic cell
types is not understood. By lentiviral gene transfer targeting the
haematopoietic compartment, we found that downregulation of
VEGFR1 expression in the BM drastically reduced the occurrence
of metastatic tumor burden, whereas overexpression of VEGFR1
enhanced progression of macrometastasis in the lung. Studies to
determine the functional role of VEGFR1 expression within BM-
derived cells in promoting metastatic progression are ongoing and
will likely enhance our understanding of the factors that enable
metastatic progression.
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Heparanase activity is strongly implicated in cell invasion
associated with tumor metastasis, angiogenesis and inflammation,
a consequence of structural remodeling of the extracellular matrix
(ECM). Heparanase upregulation correlates with increased tumor
vascularity and poor postoperative survival of cancer patients.
Moreover, heparanase levels in the urine and plasma of cancer
patients often correlate with the severity of the disease and
response to anti-cancer treatments, indicating that the enzyme is a
valid target for anti-cancer drug development and a promising
tumor marker. Given the potential tissue damage that could result
from inappropriate cleavage of heparan sulfate (HS), tight
regulation of heparanase expression and function are essential.
Apart of stimulatory elements along the heparanase promoter, we
identified AU-rich element in the 3’ untranslated region that
suppresses heparanase gene expression. Regulation at the protein
level includes modulation of its cell surface expression, cathepsin
L-mediated processing, cellular uptake, secretion, and cytoplasmic
vs. nuclear localization. Heparanase also augments cell adhesion
and signaling cascades leading to enhanced phosphorylation of
selected protein kinases and increased transcription of genes
associated with aggressive tumor progression. This function of
heparanase appears independent of its enzymatic activity and HS
S94substrate and is mediated by a protein domain localized at the C-
terminus (C-domain) of the protein. The C-domain is critical for
heparanase secretion and signaling functions and for maintaining
the 3D structure of the active enzyme. The functional repertoire of
heparanase is further expanded by its regulation of syndecan
clustering and shedding. Studies applying heparanase over-
expressing and knock-out mice emphasize its role in tissue
morphogenesis and as a master regulator of other ECM degrading
enzymes. Heparanase is causally involved in inflammation and
accelerates colon tumorigenesis associated with inflammatory
bowel disease. Inhibitors directed against the C-domain, combined
with inhibitors of heparanase enzymatic activity are being
developed to halt tumor growth, metastasis, angiogenesis and
inflammation. A lead compound (non-anticoagulant glycol-split
heparin), highly effective against myeloma tumors, was selected
toward a clinical trial in cancer patients.
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One of the main stumbling blocks in establishing personalized
cancer therapy has been the paucity of pre-clinical experimen-
tal models in which the actual cancer cells from a patient can
be successfully grown in a manner which mimics growth in the
human body for testing of anti-cancer treatments tailored to the
individual patient. We have demonstrated that human embry-
onic stem cells (hESC) - derived microenvironment provide a
niche which enables the growth of important subsets of ovarian
cancer stem cells, which evade growth in conventional
systems. Six different subpopulations of ovarian cancer cells
from one patient have been generated and characterized.
Remarkably – in the embryonic stem cell based model – the
ovarian cancer cells from a single patient – recapitulated the
broad repertoire of properties that can be seen in tumors
observed across the entire spectrum of many different patients.
Moreover, the embryonic stem cell platform, exposed the key
subpopulations of ovarian cancer stem cells – which are
believed to be the most important target for a sustained
response with anti-cancer therapy. These subpopulations show
the capacity for both self-renewal and tumorigenic differenti-
ation in a niche-dependent manner, and are characterized by
the expression of specific markers for cancer stem cells. This
study underscore the potential experimental utility of the
hESC-derived cellular microenvironment to expose certain
cancer cell sub-populations that do not grow into a tumor in
the conventional direct tumor xenograft platform and therefore
are most probably not readily accessible to characterization and
testing of anticancer therapies.
O151
Hepatomimetic Properties of Colon Cancer Cells:
Microenvironmental Regulation and Clinical Implications
Fernando Vidal-Vanaclocha
1, Javier Beaskoetxea
2, Naiara Telleria
2,
Amaia Del Villar
2, Andrés Valdivieso
3,J o r g eO r t i zd eU r b i n a
3
1Department of Cell Biology and Histology, Basque Country
University School of Medicine, Leioa, Bizkaia, Spain,
2Pharma-
kine SL, Derio, Bizkaia, Spain,
3Hepatobiliar Tumor Surgery
Sevice, Cruces Hospital, Cruces-Baracaldo, Bizkaia, Spain
Organ-specific colonization of cancer cells is an important feature of
metastasis and it has been reported that distinct alterations in gene
expression underlie metastasis to defined organs. However, the
regulation and clinical projection of this tropism are unknown. DNA
microarrays and RT-PCR were used todeterminethe geneexpression
profile of hepatic colorectal carcinoma metastases and tumor-
unaffected liver tissue from same patients. HT-29 human colon
carcinoma and primary cultured human hepatocytes and liver
myofibroblasts were used to determine if both tumor and liver cells
are mutually influencing their expression of metastasis-associated
genes. Three microenvironment-related gene expression catego-
ries were detected: 1) Hepatic metastases genes not expressed
by tumor-unaffected liver tissue. Some of them were already
expressed at primary tumors of patients having hepatic colon
carcinoma metastases in less than five years, and were
expressed by both HT-29 cells given cultured liver cell-
conditioned media (CM) and liver cells given HT-29 cell-CM.
2) Genes co-expressed by hepatic metastases and tumor-
unaffected liver tissue. These were not expressed by primary
tumors. This category also included both liver-specific genes
expressed by HT-29 cells given liver cell-CM, and colon
cancer-specific genes expressed by liver cells receiving HT-29-
CM. 3) Genes of tumor-unaffected liver tissue not expressed at
hepatic metastases. These were expressed by liver cells, but not
by colon cancer cells, and represented the genetic background
of the hepatic metastasis microenvironment. In addition, gene
expression profiles of hepatic metastases demonstrated a
resemblance to tumor-unaffected hepatic tissue, suggesting
hepatomimetic properties of metastatic colon cancer. Hepatic
tissue also adopted colon cancer-specific genes induced by
tumor-derived factors. Mutual gene expression mimic phenom-
ena stem from exposure of metastatic cells to the hepatic
microenvironment, and of liver cells to tumor factors. The
distinct clinical features of microenvironment-related hepatic
metastasis gene categories suggest their implications in the
hepatotropism and metastatic development of colon carcinoma.
S95O152
Disabled-2 a Potential Integrator of TGF-β Signaling
and Trafficking in Epithelial to Mesenchymal Transition
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Dedifferentiation of epithelial carcinomas and epithelial to
mesenchymal transition (EMT) involve complex and coordinated
changes to the trafficking and signaling apparatuses of the cell.
Two of the main signaling pathways which induce and react to
these phenotypic-morphological changes are the TGF-β and Ras
signaling pathways. Thus, proteins which interact with compo-
nents of both pathways have the potential to integrate the different
signaling stimuli. Furthermore, alterations to signal compartmen-
talization, by modifications to the intracellular localization of
signaling molecules through trafficking, are a potential mode of
regulation of their signaling output. In this context, Disabled-2
(Dab2), a multidomain endocytic adaptor that interacts with the
TGF-β receptors, SMAD proteins, Dab2IP (a Ras-GAP), Grb2,
Src and integrins is a candidate regulator of dedifferentiation and
EMT. Here, we report that in contrast to epithelial-like tumor cells,
Dab2 is expressed in undifferentiated carcinomas and in mouse
mammary tumor cells which undergo EMT. These cells also
present enhanced activation of Ras and its downstream effectors
and differences in the expression of proteins related to TGF-β
signaling. Furthermore, Dab2 enhances the internalization of TGF-
β receptors and alters their signaling output. In addition, elevation
of the expression levels of Dab2 leads to an enhancement of cell
spreading on fibronectin, a characteristic of the EMT-like cells.
Moreover, manipulations to the levels of activation of Ras or ERK
entail an abrogation of this enhanced spreading capacity. We
propose that TGF-β and Ras signaling regulate EMT and that
Dab2 is involved in the determination of the phenotype-specific
signaling output.
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Cancer progression and metastasis are linked to epithelial-
mesenchymal transition (EMT) and the invasive potential of
tumor cells. In tumor microenvironment, transforming growth
factor β (TGF-β) cytokines are prominent inducers of EMT and
tumor invasion. The EMT process is implicated in the acquisition
of the metastatic potential, the generation of cancer-initiating stem
cells and resistance to chemotherapy. The development of anti-
TGF-β therapy is a challenging task because TGF-β is a potent
tumor-suppressor in early-stage cancers, inhibiting cell growth and
promoting cell death. For the past several years, our research has
been focused on the identification of key molecules responsible
for oncogenic activities of TGF-β.
Our study of TGF-β-induced EMT in the context of carcinoma and
normal epithelial cells has uncovered major elements of the Ras and
TGF-β pathways controlling cellinvasion and the EMT process. The
studyrevealedthatoncogenicRasdoesnotinduceEMTbutaltersthe
EMTresponsetoTGF-β.Innormalcells,TGF-βup-regulatesTPM1
expression thereby inducing actin fibers and stable cell-matrix
adhesions that reduce cell motility and invasion. In malignant cells,
oncogenic Ras and epigenetic pathways silence TPM1 expression,
enhancing cell-invasive capacity. This discovery explains the switch
in the TGF-β function in cancer as well as reveals risk factors of
metastasis and molecular targets for anti-cancer therapy.
To further dissect the role of matrix-adhesion components we used
siRNA approach. The functional studies assessed EMT markers,
integrins, cell adhesion, migration and invasion in vitro, as well as
the tumorigenic potential in an orthotopic xenograft model in vivo.
Our data indicate changes in the expression of specific integrins in
advanced-stage cancers. These molecules may represent novel
biomarkers and targets for anti-cancer drug discovery research.
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One source of a tumour blood supply is of course the native host
vessels also termed vascular co-option. We have examined brain
metastases for the use of host vessels in both experimental brain
metastasis models and in clinical specimens. Indeed, over 95% of
early micrometastases examined demonstrated vascular cooption
with little evidence for isolated neurotropic growth. This vessel
interaction was adhesive in nature implicating the vascular
basement membrane (VBM) as the active substrate for tumor cell
growth in the brain. Accordingly, VBM promoted adhesion and
invasion of malignant cells and was sufficient for tumor growth
prior to any evidence of angiogenesis. Blockade or loss of the b1
integrin subunit in tumor cells prevented adhesion to VBM and
attenuated metastasis establishment and growth in vivo.
The engagement of the tumour cells with the host vasculature also
had the effect of inducing expression of the endothelial activation
protein VCAM-1. VCAM-1 can be detected by magnetic
resonance imaging using a new targeted contrast agent, in which
VCAM-1 antibodies have been coupled to microparticles of iron
oxide (MPIOs). Using this imaging method we have been able to
detect microscopic brain metastases in experimental models.
Our data establishes a new understanding of CNS metastasis
formation and identifies the neurovasculature as the primary
functional compartment for such growth. It also provides a
detection strategy for microscopic brain metastases.
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The Aging Host Microenvironment May Reduce Tumor
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Numerous cancers display a lower aggressiveness in aged as
compared to young patients. The mechanisms underlying this
phenomenon are not yet elucidated. Several mechanisms have
nevertheless been demonstrated: reduced tumor cell proliferation
in the old, increased apoptosis, decreased angiogenesis and
immune response modification. We have found another mecha-
nism of the age- dependent reduced tumor progression: a
decreased DNA ploidy in B16 melanoma grown in old (near
diploidy) as compared to those developing in young mice (near
tetraploidy) (Exp. Gerontol., 43: 164, 2008).
Morphologically,tumorcellsfromagedmicewereofsmallercelland
nuclear size than those of young animals. Flow cytometry forward
scatter data also showed a smaller cell size of melanoma cells from
old mice. According to DNA flow cytometry profile, while B16
melanoma cells from young animals contained a high tetraploid cell
percentage, those derived from oldanimalswere mostlynear diploid.
Tetraploidy is considered to precede aneuploidy which, in turn, is
at the origin of neoplasia genetic instability. The tetraploidy to
near euploidy transit in melanoma cells of aged mice might
therefore constitute a mechanism by which the genetic instability
inherent to tumor progression is attenuated.
Our findings indicate that the aging microenvironment can actually
affect the tumor cell genome. In tissues of aged organisms, tumor
progression might possibly be prevented via normalization of a
tetraploid checkpoint. We propose that the previously described
mechanisms of the reduced tumor progression in the aged might lead
toareducedgeneticinstability.Theaging microenvironment,withits
reduced availability of growth factors and hormones which reduces
tumor cell proliferation, withits higher content of apoptosis-inducing
agents(cortisone, TNF) and withits reduced angiogenesis– which in
turn reduces tumor cell proliferation - , this aging microenvironment
constitutes a non-permissive surrounding for genomic instability, a
prerequisite for tumor progression.
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Cancer-associated fibroblasts (CAFs) promote tumor growth and
progression. Significant progress has been made in the last years
concerning identification of novel CAF-derived factors. However,
the mechanisms underlying the conversion of fibroblast to CAF
phenotype remain largely unknown. Epigenetic and genetic
mechanisms have been suggested, although the latter remains
controversial. In this study we hypothesized that CAF phenotype
can be induced by activation of developmentally important
mesenchymal transcription factors. To test this hypothesis, we
focused on the role of FoxF1 in lung cancer since this factor is
critically involved in mesenchymal-epithelial interactions during
lung development. Ectopic FoxF1 expression in murine fibroblasts
induced upregulation of ASMA, HGF, FGF-2 and integrin beta3.
Moreover, ectopic FoxF1 enhanced fibroblast collagen gel
contraction. Consistent with these findings, knockdown of
endogenous FoxF1 in lung fibroblasts resulted in downregula-
tion of HGF, FGF-2 and integrin beta3. Upregulation of FoxF1
in fibroblasts increased their ability to stimulate migration of
A549 lung cancer cells and, conversely, downregulation of
FoxF1 in lung fibroblasts reduced this ability. Most interest-
ingly, co-injection experiments demonstrated that fibroblasts
with high FoxF1 expression were more potent than control
fibroblasts in supporting subcutaneous tumor growth following
co-injection of A549 cells and either of the two types of
fibroblasts. Tumors with FoxF1 expressing fibroblasts also
displayed higher vessel density. Clinical relevance of these
findings was supported by the demonstration of significant
association between short survival and high FoxF1 CAF
expression in lung cancer. Ongoing experiments include
analyses of clinical samples to identify upstream regulators of
CAF FoxF1 expression.
Taken together, our observations suggest that FoxF1 confers
tumor-promoting properties on lung fibroblasts, and thus provide
experimental support for the concept that CAF phenotypes can be
induced by activation of developmentally important transcription
factors.
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Significantly increased immature myeloid cells are found in
peripheral blood and tumor tissues of cancer patients. The number
of these cells correlates with staging of tumor progression.
However, their impacts on tumor progression and underlying
mechanisms remain to be elucidated. In mouse models, these cells
are identified as Gr-1+CD11b+ cells. They are well known for
their immune suppression function thus are called myeloid
immune suppressor cells or myeloid derived suppressor cells in
tumor immunology field. Recent years, we found these cells
infiltrate into tumor microenvironment, produce high levels of
multiple matrix metalloproteinases (MMPs) such as MMP13,
S97MMP14, MMP2 and MMP9, as well as TGFß1. They signifi-
cantly contribute to vasculature remodeling and tumor cell
invasion. In addition, these cells are recruited to breast carcinomas
lack of TGFß signaling through SDF-1/CXCR4 and CXCL5/
CXCR2 chemokine axes. They mediate the switch of TGFß
signaling from a tumor suppressor to a tumor promoter. Further-
more, Gr-1+CD11b+ cells are also significantly increased in lungs
of mice bearing mammary adenocarcinomas prior to tumor cell
arrival. These immature myeloid cells decrease INF-γ production
and increase pro-inflammatory cytokines in the premetastatic lung.
Interestingly, MMP9 produced by these cells disrupt VE-cadherin
junction of endothelial cells. Deletion of MMP9 normalizes
aberrant vasculature in the premetastatic lung, and diminishes
lung metastasis. The production and activity of MMP9 is
selectively restricted to lungs and organs with large number of
Gr-1+CD11b+ cells. Our data suggest that Gr-1+CD11b+ cells
alter premetastatic lung into an inflammatory and proliferative
environment, diminish immune protection and promote metastasis.
Our studies demonstrate that Gr-1+CD11b+ cells exert pro-tumor
activities in tumor microenvironment and distant premetastatic
lung. Thus inhibition of Gr-1+CD11b+ cells could normalize host
environment, improve host immunosurveillance and inhibit tumor
metastasis.
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The Ets family of transcription factors have been shown to play a
key role in promoting the growth of breast cancer cells. Work from
our laboratory has shown that Ets2 is involved in regulating
growth and metastasis through a tumor-independent mechanism in
the MMTV-PyMT model. Therefore, the goal of this work is to
understand the role of Ets2 signaling in the tumor microenviron-
ment at both the primary and metastatic site.
Our hypothesis is that Ets2 activation in the lung stroma promotes
the growth of breast cancer lung metastases. In order to test this
hypothesis in vivo, we used a genetic approach to conditionally
delete Ets2 from only fibroblasts. A fibroblast-specific (Fsp)
promoter was used to drive expression of cre recombinase to
functionally delete a floxed Ets2 allele. We then injected highly
metastatic murine breast cancer cells derived from MMTV-PyMT
tumors (Met-1) into the lateral tail vein of both wild-type and Fsp-
cre; Ets2
−/− mice in order to assess metastatic incidence and tumor
burden in the lung (N=15). Metastases were tracked using in vivo
bioluminescence imaging (BLI) and final tumor burden was
assessed by quantitative histomorphometry.
In conclusion, we determined that the deletion of Ets2 in lung
fibroblasts delayed the incidence of breast cancer lung metastases
~4 weeks. Furthermore, metastatic tumor burden was significantly
reduced in the lung (p<0.02). We further demonstrated that this
decrease in tumor burden was not related to a decrease in
endothelial cell recruitment (angiogenesis) or local macrophage
infiltration (inflammation). This therefore suggests that Ets2 action
in the tumor microenvironment may have a novel role in
promoting lung metastases and we are currently investigating
other potential mechanisms. Our overall understanding of the
genetic contributions of the tumor microenvironment at the
metastatic site will be essential to delay or inhibit metastasis.
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It is well recognized that multiple myeloma (MM), a hematologic
cancer that is still incurable, is protected by the bone marrow
microenvironment consisting of stromal cells, matrix, and cyto-
kines such as IL-6 and IGF-1. However, our studies have also
suggested that myeloma cells induce systemic changes in patients
that promote myeloma cell growth and protect myeloma cell
apoptosis. One of the changes is the presence of high levels of
circulating C-reactive protein (CRP) in myeloma patients. Elevat-
ed levels of CRP are present in patients with infections,
inflammatory diseases, necrosis, or malignancies including MM.
Recently we made a striking discovery that CRP enhances
myeloma cell proliferation under stressed conditions and protects
myeloma cells in vitro from apoptosis induced by chemotherapy
drugs, IL-6 withdrawal, or serum deprivation. In vivo injections of
human CRP around subcutaneous tumors protected tumor cells
and significantly undermined the therapeutic effects of dexameth-
asone or melphalan in xenografted myeloma-SCID and SCID-hu
mouse models. CRP protected tumor cells from apoptosis via
binding Fcg receptors (FcgRs), preferentially the activating
FcgRIIA/C, but not the inhibitory FcgRIIB, leading to PI3K/Akt,
ERK, and NF-kB pathway signaling and inhibited activation of
caspase cascades induced by chemotherapy drugs. CRP also
enhanced myeloma cell secretion of IL-6 and synergized with IL-6
to protect myeloma cells from chemotherapy drug-induced
apoptosis. These findings are clinically relevant, since we found
CRP accumulating on myeloma cells from all myeloma-patient
bone marrow biopsies examined; no CRP was found on marrow
cells from healthy individuals (Yang et al., Cancer Cell, 2007;
12:252–265). To confirm the results, we recently generated two
stable human myeloma cell lines, ARP-1 and MM1-144, which
secrete CRP after infection with lentiviral vectors containing the
human crp gene. These two cell lines became significantly less
S98sensitive to dexamethasone-induced apoptosis, which could be
reversed by CRP-neutralizing antibodies. Thus, our results
provide strong evidence for a novel effect of CRP on myeloma
cells.
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The role of host cells in tumor progression and metastasis is now
well recognized. We show that bone marrow-derived hematopoi-
etic progenitor cells (HPCs) help to initiate the metastatic cascade
by creating a supportive microenvironment in distant tissue sites.
In addition to detection of these cells in pre-metastatic and
metastatic tissues, we can now monitor HPCs in the circulation in
mouse models as well as for patients in the clinical setting.
Patients with advanced carcinoma show elevated levels of
circulating HPCs by flow cytometry compared to low levels in
healthy controls. We identify a defined circulating cell population
that correlates with the presence of tissue-specific HPCs at the pre-
metastatic niche. These circulating cells express CD34 and
VEGFR1 as well as cKit, CD133, and CXCR4, with a subset
expressing CD11b. Moreover, the degree of elevation of these
cells correlates with clinical stage with significant increase in
mobilized HPCs in patients with metastatic disease as compared to
localized disease at presentation and in ongoing studies is being
correlated with metastatic progression. We also show that patients
with high circulating HPCs have greater colony forming assay
capacity than healthy controls, suggesting these cells functionally
maintain their progenitor status. Beyond the HPC elevation
observed in newly diagnosed patients, these cells appear to be
mobilized in the setting of tumor surgical resection and may
explain the finding shown previously of enhanced metastasis
observed after surgical removal of the primary tumor in mouse
models. This process can potentially be inhibited and thereby
derail the early systemic changes occurring even in those patients
with so-called localized cancers. Targeting these cells at different
clinical time points may significantly impact the outcome of
metastatic spread, and monitoring patients for HPC mobilization
may help define a population of cancer patients at higher risk for
metastatic disease, enabling more tailored therapies.
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Preneoplastic hepatocytes isolated from liver nodules are unable to
grow or progress to cancer when orthotopically transplanted into
normal syngenic recipients. However, we have reported that these
cells can selectively expand upon transplantation into the liver of
animals pre-exposed to retrorsine (RS), a compound that blocks
endogenous hepatocyte cell cycle. Furthermore, such expanding
clusters form new hepatic nodules that rapidly progress to
hepatocellular carcinoma. Thus, it would appear that if the original
nodular architecture is disrupted, the resulting isolated cells
display no evidence of growth autonomy when seeded in a normal
orthotopic environment and can only progress to cancer via
formation of new nodular lesions in the host liver.
To further extend these observations, in present study we re-isolated
nodular hepatocytes from the first RS-treated and transplanted host
and performed a second serial orthotopic transplantation in the liver
of either normal or RS-treated recipients. Animals were treated
according to our original protocol and 100 thousands nodular
hepatocytes were infused via a mesenteric vein. Results were
striking: while transplanted cells grew very rapidly in the liver of
animals pre-treated with RS (several macroscopically visible
nodules, up to 2 mm in diameter, were already apparent at 2 weeks
after cell infusion), no evident growth was seen in the
corresponding untreated recipients. However, the growth rate of
second-passage nodular cells was higher compared to that observed
following the first transplant in the RS-treated host.
We interpret these results to suggest that (i) isolated nodular
hepatocytes do not display any significant degree of growth
autonomy after multiple in-vivo passages; (ii) an appropriate tissue
microenvironment is essential for their selective expansion; (iii) once
a nodular lesion is re-formed in the host, this sets the stage for tumor
progression to occur within such a unique microenvironment.
(Supported in part by AIRC, Italy and MIUR-PRIN, Italy)
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Previously, we have shown the importance of IL-1, mainly IL-1b
in tumor-mediated angiogenesis. Here, we describe some of the
S99mechanisms by which host-derived IL-1 participates in angiogen-
esis. We assessed invasiveness, inflammatory and angiogenesis
patterns of B16 melanoma cells in Matrigel plugs in mice deficient
in IL-1 expression (IL-1β and IL-1α KO mice) and in mice
deficient in IL-1Ra, as compared to control mice. Reduced tumor
invasiveness and angiogenesis was observed in Matrigel plugs in
mice deficient in IL-1 expression, as compared to control mice. In
contrast, mice deficient in IL-1Ra, where there is overexpression
of IL-1, show the most intensive angiogenic response. CD34-
positive hemopoietic stem cells were the earliest and most
abundant infiltrating population; in control mice, their levels in
Matrigel plugs were higher than in mice deficient in IL-1
expression. CD34-positive cells are probably key players in
tumor-mediated angiogenesis in this model. Reconstitution of the
bone marrow of IL-1 deficient mice by cells from control mice
leads to an increased number of CD34-positive cells, as well as
increased tumor invasiveness and angiogenesis, comparable to
control mice. We found that several populations of CD34-positive
cells invaded the Matrigel after injection of melanoma cells to
different KO mice. Both IL-1α and IL-1β are probably involved
in the induction of CD11b
+,C D 3 4
+ and VEGFR1
+ cells,
designated as hematopoietic precursor cells, whereas IL-1β is
mostly involved in CD34
+, VEGFR2
+, CD31
- cells, known as
endothelial precursor cells. It was found that both cell types can
produce VEGF and thus promote tumor induced angiogenesis. At
the same time, only inhibition of IL-1β reduces the angiogenic
response induced by injection of B16 melanoma cells in control
mice. Thus, inhibition of IL-1β at early stages of tumor
development may prove to be effective for use in anti-tumor
therapy.
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Cooperation through the sharing of diffusible factors of tumor
microenvinoment and the redirection of some specific guardian
pathways raises new questions about tumorigenesis and has
implication on designing new therapeutic approaches.Tissue
microenvironment strongly influences tumorigenesis and neo-
vascularization, redirecting some pathways versus a persisting
pro-survival state. Recent studies suggest a potential role of IL-6-
sIL6R in the pathogenesis of colon cancer, although data on the
possible relationship between IL-6 production and tumour
progression are still conflicting. Increased formation of IL-6-sIL-
6R complexes that interact with gp130 on the cell membrane leads
to increased expression and nuclear translocation of STAT3, which
can cause the induction of anti-apoptotic genes, such Bcl-xL.
Moreover, as it has been observed in critical conditions (hypoxia,
oxidative stress), STAT 3 activation influences the preferential
expression of VEGF-A165a, leading to the inhibition of
programmed cell death inducing Bcl-2.In colon cancer progression
we observed that the cooperative production of IL-6 released as by
the tumour itself as by tumour associated macrophages and the IL-
6 induced VEGF-A, could influence tumour cell proliferation,
favour apoptotic escaping and cell migration.The IL-6 and
VEGFA165 treatment of a colon cancer cell line, Caco-2,
modulated the expression of genes involved in tumor invasion
and apoptosis, as observed by microarrays. In particular, IL-6
downmodulated Bax expression at mRNA level. Concomitantly,
IL-6 exposure influenced Bax also at protein level acting on the
Bax-Ku70-sCLU physical interactions in the cytoplasm, by
affecting the Ku70 acetylation and phosphorylation state. More-
over, we demonstrate that IL-6 together with VEGF are able to
inhibit Bax-dependent cell death also by increasing the production
of the pro-survival form of Clusterin, shifting death into survival.
Strikingly we observed that the cooperation between IL-6 and
VEGFA165 influenced the expression of tumor suppressing
miRNAs affecting the epigenetic HDAC-1 activity and the
epithelial to mesenchymal transition, turning the neoplastic cell
from epithelial to mesenchimal, strongly correlated to the
malignization of many types of cancers. These still obscure
molecular interactions, underlie the relevant role of these micro-
environmental factors in the complicated cross talk among
molecules that could effectively turn the cell fate.
O164
Receptor “Hijacking” by Malignant Glioma Cells: A Tactic
for Tumor Progression
Ji Ming Wang
1, Keqiang Chen
1, Wanghua Gong
1, Jian Huang
1
1Cancer and Inflammation Program, National Cancer Institute at
Frederick, Frederick, MD, USA
Gliomas are the most common and deadly tumors in the central
nervous system (CNS). In the course of studying the role of
chemoattractant receptors in tumor growth and metastasis, we
discovered that highly malignant human glioblastoma and ana-
plastic astrocytoma specimens were stained positively for the
formylpeptide receptor (FPR), which is normally expressed in
myeloid cells and accounts for their chemotaxis and activation
induced by bacterial peptides. Screening of human glioma cell
lines revealed that FPR was expressed selectively in glioma cell
lines with a more highly malignant phenotype. FPR expressed in
glioblastoma cell lines mediates cell chemotaxis, proliferation and
production of angiogenic factors, vascular endothelial growth
factor (VEGF) and CXCL8 (IL-8), in response to agonists released
by necrotic tumor cells.Furthermore, FPR in glioblastoma cells
activates the receptor for epidermal growth factor (EGFR) by
increasing the phosphorylation of a selected tyrosine residue in the
S100intracellular tail of EGFR. Thus, FPR hijacked by human
glioblastoma cells senses agonists in the tumor microenvironment
and exploits the function of EGFR to promote rapid tumor
progression.
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Recent results suggest that bone marrow derived hematopoietic
cells regulate angiogenesis in tumor microenvironment. Leukotri-
ene B4 (LTB4), a 5-lipoxygenase (5-LOX) metabolite of arach-
idonic acid has been well-documented to be a potent chemotactic
factor for granulocytes. LTB4 exerts its biological activities
through two distinct LTB receptors: BLT1, a high affinity receptor,
and BLT2, a low affinity receptor. Although other 5-LOX
metabolites, LTC4 and LTD4 were reported to be proangiogenic
in chick chorioallantoic membrane system, roles of LTB4 in
enhancement of tumor-associated angiogenesis have not been
clarified. We developed BLT1 knockout mice (BLT1-KO), and
tested whether or not LTB4-BLT1 signaling enhanced the
recruitment of hematopoietic cells to the tumor microenvironment
and tumor-associated angiogenesis. When Lewis lung carcinoma
(LLC) cells were implanted to the subcutaneous tissues of mice,
tumor growth in BLT1-KO mice was significantly less than that
in wild type counter parts (WT). This reduction was accompa-
nied with the reduced angiogenesis estimated by CD31 expres-
sion and mean vascular density in the stoma tissues. LLC growth
and tumor-associated angiogenesis in this model were dependent
on the vascular endothelial growth factor (VEGF). The expres-
sion of VEGF in the stromal tissues in BLT1-KO mice was
reduced in the stromal tissues compared with that in WT mice.
Myeroperoxidase mRNA levels in the stromal tissues in BLT1-
KO mice were not reduced compared with those in WT,
however, the accumulation of mast cell in the stromal tissues
were significantly less in BLT1-KO than in WT. The same was
true in WT treated with a 5-LOX inhibitor, AA861. Mast cells
from WT mice expressed BLT1, and LTB4 enhanced the
chemotaxis of mast cells. Disodiumcromoglycate sodium that
suppresses the mast cell function blunted the growth rate of LLC
tumors together with reduction in angiogenesis. These results
suggested that recruitment of mast cells to the tumor microenvi-
ronment via BLT1 signaling enhances tumor-associated angiogen-
esis, and that blockade of BLT1 signaling may be promising to
treat solid tumors.
O166
Invasion of Human Breast Cancer Cells In Vivo Requires
both Paracrine and Autocrine Loops Involving the Colony
Stimulating Factor-1 Receptor
Antonia Patsialou
1, Jeffrey Wyckoff
1,2, Yarong Wang
1,
Sumanta Goswami
1,4, E. Richard Stanley
3, John Condeelis
1,2
1Department of Anatomy and Structural Biology, Albert Einstein
College of Medicine, Bronx, NY, USA,
2Gruss Lipper Biophotonics
Center, Albert Einstein College of Medicine, Bronx, NY, USA,
3Department of Developmental and Molecular Biology, Albert
Einstein College of Medicine, Bronx, NY, USA,
4Department of
Biology, Yeshiva University, New York, NY, USA
Metastasis of adenocarcinomas involves the dissemination of
tumor cells from the primary tumor, and their transport to, arrest
and growth in the target organ. We have used intravital imaging to
observe tumor cell invasion and intravasation directly in living
mouse and rat primary mammary tumors and have shown that
dissemination of tumor cells involves active motility and trans-
endothelial migration into blood vessels. Infiltrating macrophages
promote these behaviors of carcinoma cells via a colony-
stimulating factor-1/epidermal growth factor (CSF-1/EGF) para-
crine loop. In this macrophage-dependent invasion, tumor cells
secrete CSF-1 and sense EGF, while the macrophages secrete EGF
and sense CSF-1.
In patients, CSF-1 and its receptor (CSF-1R) have been implicated
in the progression of breast cancer. This is based on high levels of
circulating CSF-1 in patient sera with aggressive disease and
increased CSF-1R staining in tumor tissues. However, there have
been no direct in vivo studies to determine whether a CSF-1
autocrine signaling loop functions in human breast cancer cells in
vivo and whether it contributes to invasion in a mechanism similar
to the rodent models.
We have tested this hypothesis directly in vivo using MDA-MB-
231 cell-derived mammary tumors in SCID mice. We show for the
first time that in vivo invasion in a human mammary tumor
model is dependent on both the EGF/CSF-1 paracrine signaling
with host macrophages, as well as autocrine signaling in the
tumor cells that express both CSF-1 and CSF-1R. In particular,
we show that the autocrine-mediated invasion is a tumor
microenvironment specific event, as it is evident only in the
mouse xenograft in vivo and not in the cultured cell line.
Furthermore, we show that this amplification of the autocrine
invasion in the xenograft is due to an upregulation of the CSF-
1R inside the primary tumor that is dependent on transforming
growth factor-beta1 signaling in vivo.
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To attain their biological active forms, a variety of protein
precursors are processed by proteases named proprotein conver-
tases (PCs). These include PC1, PC2, Furin, PC4, PACE4, PC5
and PC7. Our previous studies were the first to demonstrate the
importance of the maturation of protein precursors such as matrix
metalloproteases, adhesion molecules, growth factors, and growth
factors receptors by these enzymes in carcinogenesis and
angiogenesis. We found that inhibition of the PCs in various
tumor cells inhibited their malignant phenotypes and their ability
to mediate tumor growth and angiogenesis. We also identified
PDGF-A, PDGF-B, VEGF-C as new PCs substrates. Inhibition of
PDGFA and VEGF-C processing by directed mutagenesis
inhibited tumor growth and the formation of tumor vascular and
lymphatic vessels, respectively. Similarly, over-expression of the
general PC inhibitor alpha1-PDX and knockdown of the
convertases expression in tumor cells using siRNA strategy
inhibited processing of IGF-1 receptor and its subsequent
activation by IGF-1 to induce IRS-1 and Akt phosphorylation.
These tumor cells when injected into the liver circulation of
mice prevented tumor cells interaction with liver endothelial
cells and adhesion and showed a significantly reduced ability to
form liver metastases. Based on these and other findings we
postulate that PCs play a key role in the growth, survival and
metastatic potential of tumor cells by regulating the activity of
their cognate substrates and downstream effectors. Regulation
of PCs activities may provide a powerful adjunct approach in
cancer therapy.
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We applied confocal microscopy to the study of thick section of
follicular lymphoma (FL) biopsies. We investigated the expres-
sion of different phenotypic markers characterizing the immu-
nological microenvironment (CD3, CD8, CD20, CD4, CD56),
together with activation markers such as granzyme B, perforin,
g-interferon and phosphotyrosines. We observed, in most cases,
a rich infiltrate of lytic granules-bearing cytotoxic cells,
representing about 25% to 40% of the immunological FL
microenvironment, that was not observed in control reactive
lymph nodes. Cytotoxic cells were not localized in follicular
areas but rather in the peri-follicular areas. Only a part of lytic
granules-bearing cytotoxic cells were CD8
+, indicating that the
immunological infiltrate in FL contains CTL and other not yet
identified subsets of killer cells. The enrichment of cytotoxic
cells in the peri-follicular areas of FL affected lymph nodes
could have an impact in the control of the disease progression.
As an initial approach to test this hypothesis we investigated
whether FL derived B cells might be susceptible to lysis
mediated by CTL cells in vitro. Our results show that primary
polyclonal CD8
+ Tcells from healthy donors or from FL patients
efficiently annihilate super FL derived cells (KARPAS 422)
loaded with a cocktail of bacterial super-antigens.
Taken together our results indicate that CTL and other killer cells
are selectively recruited in FL affected lymph nodes and might be
involved in the immune surveillance against malignant B cells.
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Metastasis is a late event in cancer development, and is
responsible for 90% of deaths from solid tumors. The proteolytic
cascade can play an important role in metastasis as proteolytic
activity can be channeled down specific pathways, and several
proteases have been implicated in various stages in metastasis. In
order to better understand the role of the proteolytic cascade in
metastasis, we have utilized a novel microarray that has the ability
to distinguish human and mouse protease and protease inhibitor
expression in the tumor microenvironment. With this microarray,
we have profiled the protease and inhibitor expression patterns of
a xenograft model system in which metastatic breast cancer cells
that home specifically to the bone, brain, or lung are used to
generate tumors of shared parental origin in distinct locations.
Several different proteases and their endogenous inhibitors,
including multiple cysteine cathepsins, exhibit temporal, cell
type-, and location-specific patterns of expression. In vitro
invasion and co-culture experiments reveal that monocytes and
astrocytes, two significant stromal components of the metastatic
tumor microenvironment, are able to modulate the invasiveness of
bone- and brain-homing metastatic derivatives, respectively.
Additionally, tumor cells in turn can regulate the expression
of proteases and endogenous inhibitors in stromal cells. Finally,
shRNA knockdown of cathepsin B in tumor cells significantly
impairs the invasion of brain-homing metastatic cells in culture,
and knockdown of cathepsins B or L has contrasting effects on
the development of metastatic brain tumors in vivo. These
results indicate that many different proteases and their
endogenous inhibitors play a significant role in the develop-
ment of metastatic tumors, and that their selective, and likely
combinatorial, inhibition may have significant therapeutic
benefit.
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Tumor growth depends on establishment of new blood vessels
through de novo angiogenesis, which in turn provide a route for
metastasis. It has been shown that EGFL7 is highly up-
regulated in endothelial cells during angiogenesis, and that it
accumulates on the basal side of endothelial cells in nascent
sprouts. While a number of reports have suggested a role in the
remodeling of the extracellular matrix, the precise function of
EGFL7 in angiogenesis is yet to be elucidated. We have
recently discovered that some metastatic human tumor cell
lines, including the human fibrosarcoma HT1080, express
elevated levels of EGFL7 protein. We hypothesized that EGFL7
influences the metastatic progression of HT1080 by modulating
tumor angiogenesis. For this reason, we investigated the role of
EGFL7 expression in the metastatic progression of the HT1080
cell line in vitro and in vivo. We found that over-expression of
EGFL7 in HT1080 cells does not affect their proliferation in
vitro.I na nin vivo chorioallantoic membrane angiogenesis
assay, over-expression of EGFL7 significantly reduced angio-
genesis compared to controls. When tumors were grown in an
avian xenograft model, those expressing high levels of EGFL7
grew more slowly and showed significantly delayed vascular-
ization. Analysis of the vascular ultrastructure suggested that
the vasculature in EGFL7 over-expressing tumors was less
tortuous and leaky compared to controls. Metastasis of HT1080
cells to the brain and liver was reduced by more than 80% in
EGFL7 over-expressing tumors. Taken together, these results
indicate that expression of EGFL7 by tumors influences the
stability of the neovasculature and therefore, it may be a novel
therapeutic target for anti-cancer strategies.
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Bone marrow is an accommodating microenvironment for
prostate cancer cell localization and growth; however, host
countermeasures likely exist to constrain tumor occupation of
the skeleton. Megakaryocytes develop adjacent to bone and
migrate to the vascular sinusoids before releasing platelets to
the circulation. Hence, they have the potential to encounter
tumor cells early in their progression into the bone. The
purpose of this study was to determine the impact of
megakaryocytes (MKs) on prostate cancer (PCa) cells using
in vitro and in vivo approaches. K562 (human megakaryocyte
precursors) and primary MKs induced from mouse bone marrow
hematopoietic precursor cells were used in co-culture experi-
ments with PCa cells (PC-3, VCaP, C4-2B). K562 potently
suppressed PC-3, VCaP, and C4-2B cell numbers in co-
culture; whereas they increased osteoblastic SaOS2 cells. The
MK/PCa restrictive effect was more potent when cells were
cultured in direct contact, and also when less differentiated MKs
were used. The inhibitory effect of MKs was pro-apoptotic as
determined by propidium iodide (PI) and annexin V flow
cytometric analysis in addition to a restrictive proliferative
effect seen via reduced levels of cyclin D1 mRNA. A PCR
pathway analysis followed by quantitative RT-PCR revealed
increased PC-3 mRNA levels for the pro-apoptotic genes
apoptosis-associated speck-like protein containing a CARD
(aka ASC/TMS1/PYCARD) and death-associated protein kinase
1 (DAPK1) after co-culture with K562 cells. In vivo, athymic
mice were administered thrombopoietin (TPO) to expand their
megakaryocyte populations prior to intracardiac PC-3 lucif-
erase tagged (PC-3
luc) cell inoculation. TPO significantly
increased MKs in the bone marrow and reduced numbers of
luciferase positive prostate tumors in the long bones. These
data show a novel role for megakaryocytes as potential gate-
keepers in the bone marrow microenvironment of the prostate
skeletal metastatic lesion.
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The microenvironment is being increasingly recognized as critical
component in tumor progression and invasion. During cell
migration, there is a continuous interaction between cell surface
receptors and ECM proteins. In the present communication we
studied the effect of Fibronectin-integrin interaction in human
laryngeal carcinoma cell line, Hep-2 and the downstream
effectors. The study indicates that culture of Hep-2 cells in SFCM
in presence of FN enhances MMP-9 expression. FN induces the
activity and expression of MMP-9 by binding to its receptor a5b1
in Hep-2 cells. This induction occurs through the possible
involvement of multiple signaling pathways. We propose that
there is a “cross-talk” between the signaling pathways. The
silencing of FAK with FAK siRNA and its subsequent effect on
FN-induced MMP-9 expression has confirmed the involvement of
S103FAK as an important modulator in the pathway. When FN binds to
its receptor, it causes the phosphorylation of FAK, which in
turn causes activation and nuclear translocation of PI-3 K and
subsequent activation of ERK finally leading to MMP-9
transactivation and stimulation. PI-3 K on the other hand,
upon integrin ligand interaction, could also independently
activate ILK. These signaling pathways work in concert with
each other and disruption of one could affect the function of
another. The signals from the signaling pathways finally leads
to the increased DNA binding activity of important transacting
factor on MMP-9 promoter and thus transcription of MMP-9
in turned on. Our study provides scopes for future clinical
interventions by targeting these signaling pathways in FN-
induced MMP-9 upregulation and invasion of laryngeal cancer
cells.
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Ovariancancerischaracterizedbymetastasistotheperitonealsurface
liningthe abdominalcavity.Itremainsunclear whichfactorspromote
this process. We have investigated the interaction between ovarian
cancer (OVCAR-5, OVCAR-3, and SKOV-3) and peritoneal cells
(LP-9) by co-culture and proteomic screening of conditioned media.
One of the molecules found to be differentially expressed was the
extracellular matrix adhesion protein, transforming growth factor-
beta-induced protein (TGFβI, also known as big-H3 or keratoepi-
thelin). Non-malignant ovarian surface epithelial cells and peritoneal
mesothelial cells expressed high TGFBI levels. In contrast primary
serous and matching metastatic tumour cells had very low levels of
TGFBI. In functional experiments recombinant TGFβI significantly
increased adhesion of the ovarian cancer cell lines to LP-9 peritoneal
cells by up to 25% (P<0.01) and increased motility of OVCAR-5
cells by 62% (P<0.001). Furthermore, addition of neutralising
TGFβIa n t i b o d yr e d u c e dO V C A R - 5a d h e s i o nt oL P - 9b y2 1 %
(P<0.001). TGFβI was found to be predominantly produced by
the peritoneal cells and to be processed to smaller forms in the
ovarian cancer-peritoneal cell co-culture. MALDI-TOF/TOF
mass spectrometry identified TGFβI processing at both the N
and C terminal domains. The addition of broad spectrum protease
inhibitors blocked the TGFβI processing and reduced OVCAR-5
adhesion to LP-9 cells by 40% (P<0.001). We conclude that
TGFβI produced by peritoneal cells can promote ovarian cancer
cell adhesion and motility.
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p-Stat3 Dependent Function of Myeloid Suppressor Cells
through the TLR2-MyD88 Pathway
Grégoire Mignot
1, Chalmin Fanny
1,2, Ladoire Sylvain
1,2,3,
Vincent Julie
1,2, Apetoh Lionel
4,R é b éC é d r i c
1,3, Ghiringhelli François
1,2,3
1INSERM U866, Dijon, France,
2Faculty of Medecine and
Pharmacy, Dijon, France,
3Anti-cancer center Georges François
Leclerc, Dijon, France,
4Brigham and Women’s Hospital, Harvard
Medical School, Boston, MA, USA
Myeloid suppressor cells (MDSCs) have been identified in
humans and mice as a population of immature myeloid cells with
ability to suppress T cell activation. MDSCs, which accumulate in
tumor bearing hosts, have been shown to contribute to cancer
development in mice and humans. Recent evidence suggests that
the transcriptional factor Stat3 is constitutively activated in many
mouse and human cancer cells. Indeed, tumors that constitutively
express phosphorylated-Stat3 (p-Stat3) released some tumor
derived factors that induced Stat3 activation in myeloid cells, a
phenomenon which leads to MDSCs accumulation and immune
suppressive activity. However, the exact nature of the tumor-
derived factors accounting for this immunosuppression has not
been investigated.
Here, we studied the factors released by 3 tumor cell lines that
constitutively expressed p-Stat3 and induced MDSCs suppressor
activity in a Stat3 dependent manner. Surprisingly, we showed that
tumor derived exosome (TDE) -and not a tumor derived soluble
factor- determines MDSCs Stat3-dependent suppressive activity.
Moreover, we could demonstrate that, in both mice and humans,
membrane Hsp72 from TDE triggers Stat3 activation in MDSCs in a
TLR2/MyD88 dependent manner through anautocrine production of
IL-6. Accordingly, targeting exosome production in vivo using
dimethylamiloride blunts the suppressive activity of MDSC and
enhanced the efficacy of cyclophosphamide treatment in three
different mouse tumor models. Finally, we also demonstrated that
this mechanism supporting suppressive MDSCs activity is relevant
in cancer patients. Collectively, our findings show for the first time
in both mice and human settings that membrane TDE associated
Hsp72 restrained tumor immune surveillance by supporting MDSCs
suppressive functions.
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S104Globally, human papillomavirus (HPV) causes more human malig-
nancies than any other virus. High grade cervical intraepithelial
neoplasia (CIN2/3) occurs only in the setting of persistent mucosal
infection with an oncogenic strain of HPV, and presents a compelling
opportunity to test immunotherapies because expression of two viral
proteins, E6 and E7, are functionally required to initiate and maintain
disease. We have a large prospective cohort of subjects with CIN2/3
who are followed for a brief, 15-week window prior to definitive
excision of the cervical squamocolumnar junction (cervical conization
or LEEP procedure). Not all dysplastic lesions progress to cancer; 25%
of HPV16+ CIN2/3 undergo complete regression in this timefrqme.
However, systemic HPV16 E6 and E7 Tcell responses are marginally
detectable, and do not correlate with lesion regression. However,
CIN2/3 does recruit inflammatory infiltrates. Memory T cells
accumulate in dysplastic mucosa, and spectratyping provides strong
evidence that these often contain clonally expanded populations. In our
cohort, intraepithelial CD8+ infiltration at t0 was predictive of
regression by twk15. In contrast, in lesions that failed to regress in
the study window, inflammatory infiltrates were restricted to the
cervical stroma, whilst intraepithelial CD8+ infiltrates were minimal.
Detectable IFNγ immune responses to E6 and E7 measured in
patient-matched peripheral blood obtained at the same visits did not
correlate with lesional CD8+ infiltrates. These observations suggest
that in the setting of natural infection, cellular immune responses to
HPV antigens measured in the peripheral blood do not accurately
reflect the composition or function of immune infiltrates in the
cervical mucosa. Our work is focused on determining the immuno-
logic signature of lesions which allow intraepithelial effector cell
access. The identification of homing mechanisms for genital immune
surveillance could suggest optimal routes of vaccination, and inform
monitoring of immune responses likely to traffic to the genital
mucosa.
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Microenvironment by Signalling Inhibition as a Strategy
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Tumour hypoxia is an important determinant of the efficacy of cancer
therapy since well-oxygenated cells are more sensitive to drugs and
radiation and less likely to be metastatic than hypoxic cells. Reducing
tumour hypoxia is thus a potential strategy for improving cancer
treatment. We previously showed that targeting Ras activity improves
oxygenation in tumours expressing oncogenic RAS and contributes to
the radiation response. Upstream inhibition of Ras at EGFR, and
downstream inhibition at PI3K and Akt also improve tumour
oxygenation.
We have used multi-modality imaging studies of tumour micro-
environmental changes induced by inhibitors of signalling
proteins. Two cell lines were studied one driven by overexpression
of EGFR and the other by mutation of N-ras. We have also made
studies in a spontaneous MMTV neu breast cancer mouse tumour
model. The EGFR kinase inhibitor Iressa, the prenyltransferase
inhibitor L-778,123, the PI3K inhibitor PI-103 and the HIV
protease inhibitor Nelfinavir were used to block signalling at
EGFR, at Ras, PI-3 K and at Akt respectively.
Bioluminescence imaging in vivo demonstrated that HIF-1
promoter activity is reduced with inhibition of downstream
signalling. Confirmation of tumour oxygenation was obtained
immunohistochemically using nitroimidazole (EF5) binding and
evaluating Carbonic Anhydrase-9 levels. Tumour vascular
function was improved as measured by contrast-enhanced ultra-
sound power doppler. Confocal/multiphoton imaging revealed
increased tumour vascularity and an increase in extravascular
perfusion.
These data suggest that it is possible by targeting signalling
intrinsic to the tumor cells themselves to manipulate the tumor
microenvironment in a manner that renders the tumor more
susceptible to cytotoxic therapy with drugs or radiation. We
will present data supportive of this hypothesis both from
Radiation growth delay assays and cytotoxic drug uptake and
metabolism.
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M-CSF Inhibition Selectively Targets Pathological
Angiogenesis and Lymphangiogenesis
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Anti-angiogenic therapy for the treatment of cancer and other
neovascular diseases is desired to be selective for pathological
angiogenesis and lymphangiogenesis. Macrophage-colony stimu-
lating factor (M-CSF), a cytokine required for the differentiation
of monocyte-lineage cells, promotes the formation of high-density
vessel networks in tumors (Lin et al. 2001; 2006) and therefore
possesses therapeutic potential as a M-CSF inhibitor (Aharinejad
et al. 2004; Paulus et al. 2006). However, the physiological role of
M-CSF in vascular and lymphatic development, as well as the
precise mechanisms underlying the anti-angiogenic effects of M-
CSF inhibition, remains unclear. Moreover, therapeutic potential
of M-CSF inhibition in other neovascular diseases has not yet
been evaluated. In this study, we used osteopetrotic (op/op) mice
to demonstrate that M-CSF deficiency reduces the abundance of
LYVE-1
+ and LYVE1
- macrophages, resulting in defects in
vascular and lymphatic development. In ischemic retinopathy,
M-CSF was required for pathological neovascularization, but was
not required for the recovery of normal vasculature. In mouse
osteosarcoma (established from c-Myc–overexpressing, Ink4a/
ARF
−/−, bone marrow-derived stromal cells), M-CSF inhibition
effectively suppressed tumor angiogenesis and lymphangiogene-
sis, and disorganized extracellular matrices. In contrast to VEGF
blockade, interruption of M-CSF inhibition did not promote rapid
S105vascular regrowth. Continuous M-CSF inhibition did not affect
healthy vascular and lymphatic systems outside tumors. These
results suggest M-CSF-targeted therapy is an ideal strategy for
treating ocular neovascular diseases and cancer (Kubota et al. J.
Exp. Med. 2009).
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Emerging evidence demonstrates that SDF-1 (or CXCL12) and
CXCR4, a chemokine and chemokine receptor pair, play impor-
tant roles in multiple stages of tumorigenesis. We have recently
developed a series of potent and selective CXCR4 peptide
antagonists, and one of which is currently in Phase 1 clinical
trials for cancer. This peptide antagonist specifically blocks SDF-1
binding to human and monkey CXCR4 with IC50 values of 0.079
and 0.097 nM, respectively. It inhibits SDF-1-induced GTP
binding with Kb value of 0.38 nM. In human lymphoma U937
cells expressing endogenous CXCR4, the peptide inhibits SDF-1-
induced cell migration with IC50 value of 0.26 nM. It also inhibits
SDF-1/CXCR4-mediated intracellular signaling, exhibiting a
dose-dependent inhibition of SDF-1-stimulated pERK and pAkt
in multiple tumor cell lines. Biochemical and cellular analysis
revealed that this peptide has no apparent agonist activity.
Pharmacokinetic analysis demonstrated that the terminal elimina-
tion half life of this peptide is 1.5, 3.3, and 3.3 hr, and the
subcutaneous bioavailability is 100, 68 and 100% in rat, dog and
monkey, respectively. In a mouse pharmacodynamic model,
this peptide induces a dose and time-dependent increase of
circulating white blood cells/neutrophils and hematopoietic
progenitor cells with an ED50 value of 0.74–0.85 mg/kg, and
this PD effects last 6–24 hr depending on dose. Similar
pharmacodynamic effects were observed in monkey based on
an increased level of circulating CD34+ cells, white blood
cells and neutrophils. Analysis of pharmacokinetic and
pharmacodynamic data from multiple species supports a once
daily subcutaneous injection dosing regimen in the clinic.
Additionally, the peptide has shown dose-dependent inhibition
of tumor growth in multiple human xenograft models utilizing
cell lines that express high levels of CXCR4, such as non-
Hodgkin’s lymphoma and lung tumor models. It also inhibits
tumor cell metastasis in an experimental breast tumor metastasis
model.
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Cysteine cathepsin proteases are deregulated in many human
tumors, and have been implicated in promoting angiogenesis,
invasion, and metastasis. Their genetic ablation or pharmacolog-
ical inhibition significantly impairs tumor progression in several
mouse models. Oncologists rely heavily on maximum tolerated
dose (MTD) chemotherapy to treat cancer, but this frequently
leads to chemoresistance and has limited efficacy against
metastasis, the primary cause of cancer deaths. Continuous low
dose (CLD) chemotherapy delivers lower doses at greater
frequency, and has been shown to be anti-angiogenic. We
hypothesized that combining cathepsin inhibition with agents
targeting cancer cells and vasculature could dramatically improve
anti-tumor efficacy and prevent metastatic progression.
Using a mouse model of breast cancer (MMTV-PyMT), we treated
mice with MTD paclitaxel (Tax
MTD), CLD cyclophosphamide
(Cyc
CLD), and a cathepsin inhibitor (JPM), alone and in
combinations. While JPM alone had no effect on mammary tumor
burden, it significantly impaired tumor growth when combined
with Tax
MTD (52% reduction vs. 37% for Tax
MTD alone). Adding
JPM to the Tax
MTD+Cyc
CLD combination accomplished a signif-
icant 83% reduction compared to 62% without JPM. Interestingly,
tumor lysates from Tax
MTD–treated mice contained higher levels
of cathepsin activity and mRNA. As infiltrating immune cells are
the primary source of cathepsins in these tumors, we reasoned that
tumors may mobilize cathepsin-positive cells from the bone
marrow after Tax
MTD treatment to promote recovery from the
cytotoxic assault, potentially explaining why cathepsin inhibition
in the context of Tax
MTD treatment is more effective than treating
with either drug alone. Indeed, increased cathepsin activity-
positive cells were found in the blood 48 hours after Tax
MTD
treatment. Our current data also suggests that cathepsin
inhibition specifically impairs the development of lung
metastases. These analyses clearly support a therapeutic
benefit from adding cathepsin inhibition to chemotherapeutics
in the treatment of breast cancer and the prevention of
metastases.
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Inhibition of cell death is a critical pathophysiological factor that
contributes to the initiation and progression of cancer. Recently, much
attention has focused on developing therapeutic agents aimed at cancer
cell survival pathways involving factors such as MEK kinase and
AKT. Unattenuated, tumour-associated expression of PAX2, a
transcriptional regulator implicated in oncogenesis and cancer devel-
opment, has been observed to play a direct role in these pathways.
PAX2 expression is aberrantly turned on in a number of cancers such
as Wilm’s Tumor, breast, ovarian, bladder and prostate. We have
discovered a novel mechanism by which PAX2 promotes cancer cell
survival through the suppression of the host defense peptide and
putative tumor suppressor Human Beta Defensin-1 (hBD-1). Our
current findings provide the first indication of the cellular factors
responsible for deregulated PAX2 expression in prostate cancer and
how targeting these factors promote cancer cell death. Collectively,
these data offers substantial evidence of the therapeutic potential of
inhibiting PAX2 for the treating prostate cancer.
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The recruitment of host vasculature and the infiltrative behaviour of
gliomas underscore the significance of tumor-stroma interactions in
braintumor pathogenesis. The aim of this project is to identify cancer-
related changes in the stroma during brain tumor progression that can
be targeted therapeutically. However, targeting tumor-activated
stromal cells require further insight into the mechanisms that regulate
the tumor-stroma interplay. Since, any tumor biopsy contains a
mixture of cancer cells and stromal cells, we are unable to determine
whether a given gene expression profile or protein signature isderived
from stromal or cancer cells. For the same reason, we are also unable
to specify the directions of cross-talk between compartments; whether
an influence is excerted upon the tumor by the surrounding stroma, or
vice versa. In this project, we have generated a green fluorescent
p r o t e i n( G F P )- e x p r e s s i n go nt h en u d er a tb yc r o s s i n gn u d er a tw i t ha
transgenicGFP-expressingline.Weimplanthumangliomabiopsiesin
green-fluorescent (GFP) immunodeficient rats. The resulting xeno-
graft tumors are dissociated into a cell suspension and FACS-sorted
intoGFP-positivestromalcellsandGFP-negativetumorcells.Wealso
obtained cell suspensions of stromal cells from normal brain. Human
specificnucleiantibodystaining hasconfirmedthatsufficientpurity of
the sorted cells. Using this tool, we intend to delineate the gene
expression profiles and protein signatures unique to the tumor-
activated stromal cells. This information will subsequently be used
to tailor drug regimens that target tumor-activated stroma and tumor-
stroma interactions.
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Introduction: Androgen-dependent prostate cancer is frequently
treated with androgen ablation therapy (AAT), however tumours
often recur in 1 – 3 years with an aggressive, androgen-independent
phenotype.Itisproposed thattreatment-inducedstressfactorsinthe
tumour microenvironment, may contribute to this failure.
Method: LNCaP tumours were grown on the backs of male SCID
mice. Tumour oxygenation was measured before and (a) 24 hours
after treatment with a panel of anti androgens (b) during 28 days of
daily dosing with bicalutamide (2 mg/kg). LNCaP tumour fragments
were implanted into a dorsal skin flap (DSF) onto the backs of SCID
mice. The animals were treated with bicalutamide (2 mg/kg) daily
and tumour vasculature was imaged weekly for 21 days.
Results: Flutamide (25 mg/kg) and bicalutamide(10 mg/kg) signifi-
cantly reduced tumour oxygenation after 24 hours. Bicalutamide
administered daily at a clinically relevant dose (2 mg/kg) over 28 days
resultedin profound decrease intumour oxygenationwithin 1–3d ay s
which persisted for a further 10 days until levels gradually began to
increase, reaching almost pre-treatment levels by day 28. In tandem,
tumour vasculature began to decrease until day 14 when only large
feeder vessels were present however by day 21 the re-emergence of
connecting vessels was apparent (imaged in DSF). Tumours excised
0 – 28 days) show altered genetic profiles and by day 28 excised
tumour cells were more invasive. This was confirmed in vivo when
metastatic deposits in the lungs were quantified in bicalutamide-
treated animals and compared to vehicle-treated animals.
Conclusion: ThisstudyshowsthatAATalterstumouroxygenationas
early as 24 hours after treatment initiation causing profound hypoxia
for 10 – 14 days. Within this time we propose that a selection pressure
is created, which favours a more aggressive androgen-independent
phenotype. This could explain why this treatment ultimately fails and
suggests that new therapeutic strategies should be developed.
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Most solid tumors consist of a mixture of neoplastic and non-
neoplastic cells together with ECM components. This cellular
microenvironment directly modulates tissue architecture, cell
morphology and cell fate and the ECM–stromal cell interaction
contribute to the neoplastic phenotype. The conversion of
fibroblasts into myofibroblasts, as mediated by TGFb is the most
prominent stromal reaction in many epithelial lesions thus emerges
as a viable target for pharmacological intervention.
Halofuginone is an inhibitor of Smad3 phosphorylation down-
stream of the TGFb signaling. Halofuginone inhibited myofibro-
blasts activation and their ability to synthesize ECM resulted in
inhibition of tumor progression in various cancer xenografts such
as Wilm’s tumor, pancreas and renal carcinoma. In prostate cancer
xenografts, halofuginone inhibition of tumor progression was
correlated with reduction of plasma PSA. The myofibroblasts are
essential for tumor establishment and progression. Pancreatic
tumor cells when implanted alone in mice produce few tumors
that progress at a low rate. Addition of myofibroblasts resulted in
more tumors that developed at much higher rate. Inhibition of
myofibroblasts activation by halofuginone prior to implantation
reduced tumor number. Moreover, in an orthotopic model, more
tumors were developed in the fibrotic pancreas compare to the
normal pancreas. Halofuginone treatment inhibited pancreas
fibrosis and reduced tumor number. Halofuginone is an ideal
candidate for combination therapy, because of its unique mode of
action and the dissimilarity of its targets from chemotherapy. In
various xenografts halofuginone synergizes with low dose of
chemotherapy resulting in a major reduction in tumor progression
comparable to that observed by high dose of chemotherapy.
We suggest that targeting fibroblast-to-myofibroblast transition
with halofuginone significantly slow tumor progression and when
combined with low doses of chemotherapy a major anti-tumoral
effect is achieved, avoiding the need of high dose of chemother-
apy without impairing treatment efficacy.
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Previously, we showed that caveolin-1 (Cav-1) expression is down-
regulated in human breast cancer-associated fibroblasts. Here, we
discuss recent evidence that an absence of stromal Cav-1 expression
inhuman breastcancersisa powerful single independent predictor of
earlydisease recurrence,metastasis and poor clinical outcome. These
findings have now been validated in two independent patient
populations. Importantly, the predictive value of stromal Cav-1 is
independent of epithelial marker status, making stromal Cav-1 a new
“universal” or “widely-applicable” breast cancer prognostic marker.
We propose based on the expression of stromal Cav-1, that breast
cancer patients could be stratified into high-risk and low-risk groups.
High-risk patients showing an absence of stromal Cav-1 should be
offered more aggressive therapies, such as anti-angiogenic
approaches, in addition to the standard therapy regimens.
Mechanistically, loss of stromal Cav-1 is a surrogate biomarker
for increased cell cycle progression, growth factor secretion,
“stemness”, and angiogenic potential in the tumor microenviron-
ment. Since almost all cancers develop within the context of a
stromal microenvironment, this new stromal classification system
may be broadly applicable to other epithelial and non-epithelial
cancer subtypes, as well as “pre-malignant” lesions (carcinoma in
situ). We conclude that Cav-1 functions as a tumor suppressor in
the stromal microenvironment.
An absence of stromal caveolin-1 expression predicts early tumor
recurrence and poor clinical outcome in human breast cancers.
Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG,
Sabel M, Kleer CG, Brody JR, Lisanti MP.Am J Pathol. 2009
Jun;174(6):2023–34.
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Tumor angiogenesis and Epithelial-mesenchymal transition (EMT)
are key step toward cancer metastasis. Inhibition of PARP has
been reported to have anti-neoplasic effect as monotherapy or in
combination with chemo or radiotherapy in different tumor
settings. In this study we present results that PARP inhibition,
as monotherapy, is able to countertact metastasis of melanoma
cells to lung and other organs by interfering with tumor
angiogenesis through alterations in vimentin and v-cadherin
expression levels and EMT, resulting in down regulation and
inactivation of Snail1. We also show that PARP-1 is a potent
regulator of SNAIL-1 activation through modification of
SNAIL-1 by poly(ADP-ribosylation) and direct protein-protein
S108interaction. These results suggest that inhibition of PARP
through its ability to interfere with key metastasis-promoting
processes, could suppress invasion and colonization of distant
organs by aggressive metastatic cells.
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Cancer-associated fibroblasts (CAFs) are important modula-
tors of tumor growth, invasion, and metastasis. Recently, we
demonstrated that the response to chemotherapy of an
individual tumor also depends on CAFs. Therefore, targeting
CAFs with small molecule inhibitors may be an attractive
strategy to enhance sensitivity of solid tumors to conventional
chemotherapy.
We isolated CAFs from 62 lung tumors. A subset was
analyzed for their sensitivity to a panel of 162 kinase
inhibitors and to Cisplatin. Sensitivity of CAFs from individ-
ual tumors to Cisplatin was highly variable (GI50 2.8–29.0
µM). CAF strains responding to Cisplatin in isolated culture
turned out to be significantly less sensitive when cocultivated
with the tumor cell line H1299 indicating a protective effect
of the tumor cells on CAFs. All CAF strains investigated were
sensitive to PDGFR inhibitors such as Dasatinib. In addition,
the Mdm2 antagonist Nutlin-3 turned out to be a promising
compound for targeting CAFs. Both PDGFR inhibitors and
Nutlin-3 blocked CAF proliferation without inducing cell
death. Nutlin-3 also protected CAFs from Cisplatin-induced
cell death.
Microarray analysis of CAFs cultivated in presence or absence of
Dasatinib identified 368 genes whose expression was changed
significantly at least twofold. 87 of these encoded cell cycle
related proteins with only 3 of them being upregulated by
Dasatinib. 265 genes were downregulated in the presence of
Dasatinib. Among these we found genes encoding repair
proteins like FANC family members and BRCA1. 103 genes
were upregulated such as genes encoding PDGFRB, ECM
components and adhesion proteins. Further analysis will reveal
whether this signature may have prognostic value and if CAFs can
be modulated by Dasatinib to be less supportive to tumor cells.
In conclusion, we identified several small molecule inhibitors with
significant effects on CAFs. Our study may guide the development
of novel treatment strategies combining these inhibitors with
conventional chemotherapy.
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Introduction: The RGD-binding integrins αvβ3 and αvβ5 play
key roles in tumour angiogenesis. We examined an [
18F] labeled
small peptide (AH111585) containing an RGD (Arg-Gly-Asp)
sequence. AH111585 binds with high affinity (nM) to αvβ3 and
αvβ5 integrins, which are highly expressed on tumour neo-
vasculature. In this study, [
18F]AH111585 was used to examine
the response of human glioblastoma (U87) xenografts to treatment
with the anti-angiogenic therapy Sunitinib.
Materials & methods: U87 tumour uptake of [
18F]AH111585
w a sd e t e r m i n e db ym i c r o P E Ti maging (% id/g) following
administration of the anti-angiogenic therapy, such as Sunitinib.
Tumour microvessel density (MVD) was also analysed post-
therapy.
Results: Dymanic mircoPET imaging of [
18F]AH111585 uptake
demonstrated that tumour uptake peaked ~30 mins post-injection
of the tracer (5% id/g). Whole body biodistribution studies
confirmed rapid clearance of [
18F]AH111585 from the blood with
predominantly urinary excretion. Following administration of the
clinically relevant anti-angiogenic therapy Sunitinib, a reduction in
[
18F]AH111585 tumour uptake was demonstrated compared to
vehicle controls. Skeletal muscle, used as a reference tissue,
demonstrated equivalent [
18F]AH111585 uptake pre- and post-
therapy. A reduction in MVD was also seen in anti-angiogenic
therapy treated tumours.
Conclusions: The data demonstrate that [
18F]AH111585 can
detect changes in tumour uptake following acute anti-angiogenic
therapy. The results suggest this imaging agent may provide
clinically important information to guide patient management and
monitor response to anti-angiogenic therapies.
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Mesenchymal Stromal Cells (MSC) in AML Bone Marrows
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Bone marrow-derived mesenchymal stromal cells (BM-MSC)
have the capacity to differentiate into various cell types to
support normal and malignant hematopoiesis. However, little
is known about the molecular genetics of these cells. We
therefore isolated MSC from normal donors and from patients
with acute myeloid leukemias (AML). Purity of MSC
preparations was >95%. Ten samples from AML patients with
normal (n=7) and abnormal leukemia karyotypes (n=3) were
analyzed by conventional cytogenetics, array-CGH and FISH.
Genomic DNA from MSC was extracted and array compara-
tive genomic hybridization (aCGH) was performed using the
PerkinElmer Constitutional Chip 4.0 that contains 5,200 BAC
clones with human inserts that detects and maps changes in
DNA copy number variations. DNA from AML MSC and a
normal reference genome were differentially labeled with
fluorescent dyes and hybridized to the array. Abnormalities
detected by aCGH require the presence of at least 20% of
cells carrying identical aberrations. For confirmation, individ-
ual BAC DNAs were labeled using the Invitrogen DNA
labeling kit for FISH. Results: Conventional cytogenetics (G-
banding analysis) showed normal diploid chromosomes in 9/
10 cases, except in one sample (47, XX, +5). The
corresponding AML karyotype was apparently unrelated 46,
XX, der(16)t(1;16) (q21; q12.1). This finding was confirmed
by FISH and aCGH. At variance to BM-MSC derived from
normal donors (n=4), AML-derived MSC showed abnormal-
ities (gains and losses) in different chromosomal regions in all
cases. The most frequently involved chromosomes were No.
3, 4, 6, 7, 8, 10, 15, 16, 19, and 22. All abnormalities were
confirmed by FISH using the identical BAC clones employed
on the array. Conclusion: Results suggest that stromal cells
from newly diagnosed leukemias carry clonal genomic
abnormalities at high frequency. Hence, AML bone marrows
contain two populations of clonally abnormal cells (AML and
MSC).
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Background:
Epithelial-mesenchymal transition (EMT) is frequently activated
during carcinogenesis resulting in metastatic spread. EMTactivation
downregulates E-cadherin expression leading to increased motility
and gain of a more mesenchymal phenotype. The c-Met receptor
and MACC1 (metastasis-associated in colon cancer-1) are upregu-
lated in CRC metastases and can be considered to be markers of
metastatic potential. Here we assessed the expression of genes
associated with EMT in CRCs and liver metastases (LMs).
Methods:
Human primary CRC (n=11) and LM (n=21) samples were obtained
under full ethical approval from Queen’s Medical Centre, Nottingham,
UK. Samples were stored in RNAlater prior to RNA extraction,
cDNA synthesis, and real-time quantitative PCR to determine
expression levels of EMT markers (Snail, Slug, Zeb1, E-cadherin),
mesenchymal markers (vimentin, s100a4), as well as the c-Met
receptor, MACC1, hepatocyte growth factor (HGF), and TGFβ1
relative to the housekeeping gene hypoxanthine-guanine phosphor-
ibosyltransferase. A student’s t-test was used for statistical analysis.
Results:
Snail (p<0.005), vimentin (p<0.0001), s100a4 (p<0.005), and
TGFβ1 (p<0.005) were significantly upregulated in LMs com-
pared to normal liver. MACC1 was significantly uregulated in
CRCs and LMs (p<0.01), and only weakly expressed in normal
liver. In CRCs, c-Met (p<0.005) expression was significantly
increased compared to normal colonic mucosa, whereas HGF (p<
0.05), Slug (p<0.01), Zeb1 (p=0.005), s100a4 (p<0.05), and
vimentin (p<0.001) expression were significantly downregulated.
E-cadherin expression was significantly decreased in CRCs (p<
0.01), and liver metastases (p<0.005) compared to normal colon.
Comparison of expression of EMT markers between CRCs and
LMs showed that HGF (p=0.001), Snail (p<0.001), Slug (p=0.026),
Zeb1 (p<0.001), vimentin (p<0.005), and TGFβ1 (p<0.005) were
all significantly upregulated in LM tissue.
S111Conclusion:
EMT markers were significantly increased in LMs compared to
CRCs. MACC1 was significantly increased in CRCs, and for the
first time shown to be significantly increased in LMs. Snail,
TGFβ1, and vimentin, provide the best markers for LM.
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Heparanase is an endo-β-D-glucuronidase, the predominant
enzyme that degrades heparan sulfate side chains of heparan
sulfate proteoglycans. Traditionally, heparanase activity was
correlated with the metastatic potential of tumor-derived cells,
attributed to enhanced cell dissemination as a consequence of
heparan sulfate cleavage and remodeling of the extracellular
matrix barrier. More recently, heparanase up-regulation was
documented in an increasing number of human carcinomas
and hematological malignancies. In many cases, heparanase
induction correlated with increased tumor metastasis, vascular
density, and shorter post operative survival of cancer patients,
thus providing a strong clinical support for the pro-metastatic
and pro-angiogenic functions of the enzyme and encouraging
the development of heparanase inhibitors as anti-cancer drugs.
Mechanisms responsible for heparanase induction are largely
unknown. We hypothesized that heparanase may be regulated
post-transcriptionally by regulatory sequences located at the
3′-untranslated region (3′-UTRs) of the gene. We provide
evidence that the 3′-UTR of heparanase contains an adeno-
sine/uridine (AU)-rich element [5′-(AUUU)n-3′] present within
the 3′-UTRs of many proto-oncogene and cytokine mRNAs.
This element confers post-transcriptional gene regulation by
decreasing mRNA stability and/or by inhibition of mRNA
translation. PCR amplification of heparanase 3′ UTR revealed
the existence of two products in all human cell lines
examined, in a similar ratio. Sequencing of the lower
molecular weight PCR product identified a deletion of 185
nucleotides, resulting in loss of the highly conserved AU-rich
element. Loss of this element was associated with increased
heparanase enzymatic activity and cell invasion. Moreover,
heparanase transcript lacking the AU-rich element was elevated
in renal carcinoma biopsies compared with the adjacent normal
looking tissue, indicating that this regulatory mechanism is
clinically relevant.
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S100P is a member of the S100 family of small regulatory
calcium-binding proteins
1, which has been shown to play a role in
the metastatic phase of cancer. Intracellular overexpression of
S100P under physiological conditions has been correlated to
metastasis and poor overall survival in breast cancer patients
2. The
mechanism of the Metastasis-Inducing Calcium-binding protein,
S100P in metastasis has not yet been fully elucidated.
To investigate the role of metastatic S100P on cell activity, several
analyses such as motility assays, gene expression using micro-
arrays and Real-Time PCR, changes in intracellular signalling
induced by addition of extracellular S100P have been performed.
These experiments were carried out using an expression system
developed in our laboratory consisting of a human S100P cDNA
inserted in a tetracycline inducible vector transfected into non-
metastatic benign rat mammary tumour-derived cells (Rama 37),
and human cervical carcinoma cells (HeLa).
Results observed after microarray hybridisation showed 8 upregu-
lated genes and 3 downregulated genes, after intracellular over-
expression of S100P in rat mammary tumour cells. Extracellular
addition of S100P has been shown to increase cell motility
suggesting alternative cell motility stimulation via a cell surface
receptor. Extracellular S100P has been shown to activate intracel-
lular phosphorylation of a member of Serine/Threonine-specific
protein kinase family: Akt and Extracellular signal-Regulated
Kinases: Erk 1/2 through the Receptor for Advanced Glycosyla-
tion End-Product (RAGE).
Results enabled the Metastasis-Inducing Calcium-binding protein
mechanisms to become clearer as S100P that could represent a
potential target for novel diagnostic and therapeutic applications.
1 Becker, T., et al., Eur. J. Biochem. 207, 541–547.
2 Wang G., et al., Cancer Res. 60,1199–1207.
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S112The p53 protein is responsible for control of the cell cycle,
apoptosis and DNA repair. The abundance of p53, sub-cellular
localization, and the interaction with cofactors play a central
role in the regulation of its different biochemical functions.
p53 in cytoplasm is functional and exhibits a spectrum of
different biological effective pathways. p53 in cytoplasm
exerts intrinsic 3¢®5¢ exonuclease activity with various
RNA and DNA substrates. p53 may act as an external
proofreader for errors introduced by exonuclease-deficient
DNA polymerases. p53 can remove 3′-terminal nucleotides
from RNA substrates containing an ARE element (localized to
the 3′ un-translated region of many proto-oncogene and
cytokine mRNAs). The sub-cellular localization of p53 and
its functions are influenced by various external stimuli.
Hence, the exonuclease activity in cytoplasm with activated
p53 induced by drug treatment or following g-irradiation was
elucidated. The treatment of HCT116(p53+/+) cells with
Doxorubicin (Doxo) or DL-a-difluoromethyl-ornithine
(DFMO) enhanced the cytoplasmic levels of p53. Interesting-
ly, the exonuclease activity with various ARE-RNA substrates
in cytoplasmic extracts of Doxo- or DFMO-treated cells was
lower than in controls. Conversely, there was no decrease in
exonuclease activity with DNA substrates. Apparently, the
observed reduction in exonuclease activity with RNA sub-
strates after Doxo- or DFMO-treatment is not a general
phenomenon. The cytoplasmic extracts of HCT116(p53+/+)
cells were further examined for exonuclease activity following
g-irradiation (IR) or treatment by low-molecular weight
immunoenhancer ammonium trichloro(dioxyethylene-O,O’-)
tellurate (AS101). The increase in the level of p53 is
concomitant with an increase in constitutive excision capacity
in IR-exposed or AS101-treated cytoplasmic extracts with
ARE-RNA and DNA substrates. Altogether, the data demon-
strate the difference in expression of exonuclease activity in
cytoplasmic fractions when p53 is stabilized under various
stress scenarios.
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Background:
Human Papilloma Virus (HPV) is an important etiologic factor in
the development of head and neck squamous cell carcinoma
(HNSCC). Although HPV + tumours typically present at a more
advanced stage, they are associated with a more favourable
prognosis. Tumour hypoxia has been associated with radioresist-
ance but direct measurement of tumour oxygenation has practical
limitations. Consequently, candidate endogenous markers of
hypoxia (EMH) (e.g. Glucose Transporter 1 (GLUT1) and
Carbonic Anhydrase IX (CAIX)) have been evaluated. No
previous studies have stratified EMH analysis by HPV status.
Moreover, there have been no previous studies quantifying EMH
expression within the stromal compartment of these tumours.
Methods:
Ninety-two patients diagnosed with locally advanced HNSCC and
treated with concurrent cisplatin and radiotherapy between 2000
and 2005 were identified. Fifty-five patients had pre-treatment
FFPE tumours available for analysis. Triplicate 0.6 mm cores were
assembled into TMAs. Semi-quantitative p16 immunohistochem-
istry (IHC) staining was used as a surrogate for HPV status.
Automated, quantitative IHC (AQUA HistoRx™) was used to
quantify staining for CAIX and GLUT1, as candidate EMH. We
analysed the tumour and stromal expression of each candidate
EMH, stratified by tumour p16 status. Overall survival was
estimated from Kaplan-Meier method and curves compared using
a log rank test.
Results:
53% of tumours were p16+ and 47% were p16-. For patients with
p16- tumours and high stromal CAIX expression, 2-year overall
survival was 33%, compared to 91% with low stromal CAIX
expression (p<0.05). At 5 years, this overall survival difference
remained significant (42% vs 22%, respectively, p<0.05). Epithelial
CAIX expression was not a statistically significant predictive factor.
Conclusion:
High stromal CAIX expression is a significant negative
predictive factor for survival in locally advanced HNSCC
patients with p16- tumours. This finding may impact therapeu-
tic targeting for this patient group, including use of hypoxic
radiosensitizers.
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S113Introduction: Multiple myeloma (MM) is an incurable malig-
nancy of plasma cells. Intensive interaction of the neoplastic
cells with their microenvironment undermines effective disease
treatment. MM cells secrete VEGF that promotes cytokine
production and proliferation of the tumor cells. The angiogenic
effect of VEGF in the bone marrow is established yet less is
known about VEGF signaling in MM cells. Here we evaluated
the anti-myeloma effect of VEGF inhibition by Avastin (human-
ized anti-VEGF monoclonal antibody). Moreover, we aimed to
identify VEGF dependent signaling cascades in MM cell lines
with specific emphasis on pathways that regulate protein
translation initiation.
Methods: MM cell lines (8226, U266, ARK, ARP1) were cultured
5 days with Avastin (0.01µg/ml - 4 mg/ml) and tested for:
viability (WST1), proliferation (cell count), cell death (Annexin/
7AAD, LC3II), cell cycle (flow cytometry), and VEGF targets
(mTOR, ERK, eIF4E, etc; immunoblot). Autophagy inhibitor
used: 3-methyladenine (3MA).
Results: Dose dependent reduced viability was demonstrated in all
Avastin treated MM cell lines. RPMI 8226 and ARK demonstrated a
G1 cell cycle arrest and decreased total cell number whereas U266 and
ARP1showedelevatedautophagy(LC3II).Co-administrationof3MA
and Avastin to U266 and ARP1 yielded a synergistic decrease in
viability and elevated apoptotic cell death suggesting that autophagy
rescued the VEGF- inhibited cells from death. Changes in VEGF
targets included decreased pmTOR, pERK and peIF4E. Reduced
eIF4E dependent translation was evidenced by decreased Cyclin D1 in
G1 arrested RPMI 8226 and ARK. Additional VEGF signaling
pathways will be assessed.
Significance: Our findings so far, establish that VEGF is critical to
MM cell lines’ viability and that Avastin has a significant deleterious
effect on MM cell lines that is independent of its anti-angiogenic
mechanism. Identification of VEGF dependent targets in MM cell
lines will promote the design of effective drug combinations.
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Childhood acute lymphoblastic leukaemia (ALL) relapse is
characterized by malignant cell infiltration of medullary and
extramedullary tissues. Thus it is important to better understand
the mechanisms governing migration and dissemination of
leukemic cells. We investigated the role of the small GTPase
Rac1 in the control of CXCL12-induced migration of leukemic
cells on fibronectin, which plays a key role in leukemic cell
invasion. Nalm-6 cells (a human B-ALL cell line), transformed to
overexpress either wild-type or a constitutively inactive form (N17
mutant) of Rac1, were seeded on fibronectin-coated wells.
Adherent cells were kept in an incubation chamber under a
phase-contrast microscope. Time-lapse video was numerized
before and after addition of 100 ng/ml CXCL12, and images
were used to quantitate cell migration speed. Spontaneous
migration was not significantly different between control and
transformed cells. After addition of CXCL12, the migration speed
of control, non-transformed cells increased to reach a maximum
within 2 hours, and returned to baseline values after 4 hours. In
cells tranformed with the N17 mutant, the stimulation of cell
migration by CXCL12 was more intense than in control cells (p<
0.001) and was still observable after 5 hours. Flow cytometry
analysis showed that modifications in Rac1 expression or activity
did not significantly affect cell surface expression of the integrins
VLA-4 and VLA-5, which are involved in Nalm-6 cells migratory
process on fibronectin. However, the SDF-1 receptor CXCR4 was
up-regulated (+93%) at the surface of cells overexpressing Rac1,
an effect that was prevented by a 24-hour treatment with the Rac
inhibitor NSC23766. Taken together, these results suggest that
Rac1 plays an important regulatory role in the response of B-ALL
cells to the chemoattractant cytokine CXCL12, and thus may
control mechanisms involved in leukemic cell dissemination.
Poster No. 9
Down-Expression of RB18A/MED1, a Co-Factor
of Transcription, Regulates Modifications of the Tumor
Microenvironment to Trigger Strong Tumorigenic
Phenotype of Human Melanoma Cells
Raymond Frade
1
1INSERM U.672 (former U.354), Immunochemistry of Cell
Regulations and Virus Interactions, Evry, Ile-de-France, France
The human gene RB18A/MED1, also named TRAP220 or
DRIP205, encodes for a single 205 kDa co-factor of transcription
that interacts with nuclear receptors and transcription factors
essential for cell growth. We originally identified this human gene
and demonstrated that RB18A/MED1 is antigenically and func-
tionally related to p53. In addition, RB18A/MED1 chromosome
localization on locus 17q12-q21.1 suggested its involvement in
human cancers. Since, others described over expression of
RB18A/MED1 in breast, colon and prostate cancers.
We herein analyzed RB18A/MED1 expression in human melano-
ma cells. We found that RB18A/MED1 is either highly or weakly
expressed in melanoma cells, depending on their respectively non
or highly-tumorigenic phenotype. Therefore, we analyzed whether
a relationship could exist between RB18A/MED1 expression and
melanoma cell phenotype. For this purpose, we down-regulated
RB18A/MED1 expression by transfecting melanoma cells with a
RB18A/MED1 siRNA specific for the 3′-untranslated region of
native RB18A/MED1 RNA, already demonstrated to inhibit
specifically RB18A/MED1 protein expression. A non-specific
(scramble) siRNA was used as control. The specificity of this
RB18A/MED1 siRNA was also supported as, in transfected cells,
lamin A/C expression or cathepsin L and MMP2 expression and
secretion were not modified. The use of microarray membrane
carrying 113 cancer-related genes, western blot and specific
S114activities demonstrated that RB18A/MED1 knockdown signifi-
cantly inhibits TIMP-3 expression and increases uPAR expression,
two genes well known to be involved in melanoma cell invasion
by modifying tumor microenvironment. Indeed, RB18A/MED1
knockdown in melanoma cells in vitro increased their invasive
properties, without modification of cell proliferation.
Furthermore, RB18A/MED1 knockdown in vivo switched mela-
noma phenotype from non- to strongly-tumorigenic in nude mice.
Thus, our data demonstrated for the first time that down-
expression of RB18A/MED1 in human melanoma cells strongly
increases tumor progression by modifications of the tumor
microenvironment.
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SNAIL1 (SNAI1), ZEB1, E-cadherin (CDH1) and vitamin D
receptor (VDR) genes regulate the epithelial-mesenchymal transi-
tion (EMT) that initiates the invasion process of many tumor cells.
We hypothesized that this process could also affect the behavior of
normal cells adjacent to the tumor. To verify this hypothesis, the
expression level of these genes was determined by quantitative
RT-PCR in tumor, normal adjacent and normal distant tissues from
32 colorectal cancer patients. In addition, we extended the study to
human SW480-ADH colon cancer cells co-cultured with deriva-
tive cells over-expressing the mouse Snai1 gene. Of 18 CC cases
with SNAI1 expression in tumor tissue, 5 also had SNAI1 in
normal adjacent tissue. Expression of SNAI1, but not of ZEB1,i n
tumor tissue correlated with downregulation of CDH1 and VDR
genes in both tumor (p=0.047 and p=0.014, respectively) and
normal adjacent tissue lacking SNAI1 expression (p = 0.054 and
p=0.003). ZEB1 expression was directly related to VDR expres-
sion in tumor tissue (r=0.39; p=0.027) and inversely to CDH1 in
normal adjacent tissue (r=−0.46; p=0.010). CDH1 was also
downregulated in SW480-ADH cells co-cultured with Snai1-
expressing cells. Furthermore, proteomic analysis showed differ-
ences in the conditioned media obtained from the two cell types.
These results indicate that histologically normal tissue adjacent to
tumor tissue expressing the EMT-inducing gene SNAI1 shows
alterations in the expression of epithelial differentiation genes such
as CDH1 and VDR.
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PEDF is a potent angiogenesis inhibitor (Dawson et al., 1999). We
have earlier shown decreased PEDF levels in metastatic prostate
tumors in rats and humans, compared with non-metastatic disease
implying that the loss of PEDF contributes to the progression to a
metastatic phenotype (Halin et al., 2004).
To study the effects of PEDF over-expression on prostate tumor
growth and metastasis, MatLyLu rat prostate tumor cells were
transfected with a plasmid expressing human PEDF. PEDF over-
expression slowed orthotopic rat prostate tumor growth and
decreased the number and size of lymph node metastasis. Vascular
growth was affected both in the tumor and in the surrounding
normal tissue.
Recently, ATGL was described as a receptor/binding protein
for PEDF (Notari et al., 2006). In addition, we therefore
examined if PEDF and ATGL expressions were regulated by
the prostate tumor microenvironment. Both PEDF and ATGL
mRNA and protein levels were markedly down-regulated in
AT-1 tumors growing in the prostate compared to the tumor
cells in vitro suggesting that some factor in the prostate
microenvironment suppresses the intratumoral PEDF system.
ATGL mRNA levels were also significantly suppressed in the
normal prostate tissue surrounding the tumor compared to
normal prostate tissue from naive rats. In previous studies we
have shown that orthotopic AT-1 tumors accumulate macro-
phages in the tumor and in the surrounding normal tissue
(Halin et al., 2009). Here we show that these macrophages
express TNFα and that TNFα down-regulate the expression of
both PEDF and ATGL in vitro. This suggests that tumor
associated macrophages could downregulate the PEDF system
in prostate tumors by secreting TNFα and thereby facilitate
tumor angiogenesis.
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S115Sonic Hedgehog (Shh) signaling pathway regulates the epithelial
stem cell proliferation and development of organs, and activation
of this pathway is observed in a variety of cancers. However, the
precise role of Shh signaling pathway in the development of colon
cancer cells is poorly understood. Herein, we investigated the role
of Shh signaling pathway in tumorigenesis of colon cancer cells
and the molecular mechanisms underlying these effects. We
showed that colon cancer cell lines express all the components
of Shh signaling, albeit to different extents. Moreover, blockade of
the Shh pathway by KAAD-Cyclopamine (a Shh signaling
inhibitor) or Gli3 siRNA led to decreased proliferation of various
colon cancer cells. Importantly, inhibition of Gli3 by treatment
with its siRNA resulted in the enhanced expression of p53 proteins
compared to treatment with control siRNA. On the contrary,
treatment of colon cancer cells with KAAD-Cyclopamine, Gli1
siRNA, or Gli2 siRNA, did not show the increase in the levels of
p53 expression, but not transcription. Treatment with cyclo-
hexamide showed that the stability of the p53 protein in the colon
cancer cells transfected with Gli3 siRNA was higher than in the
cells transfected with control siRNA. Furthermore, treatment with
MG132, a specific inhibitor of proteasomes, led to accumulation
of p53 in Gli3 siRNA-overexpressing cells. To identify the
mechanism by which Gli3 siRNA induces p53 stabilization, co-
immunoprecipitationan and in vivo ubiquitination assay was
performed. Importantly, we found that Gli3 siRNA results in the
stabilization and activation of p53, via the prevention of MDM2-
mediated p53 ubiquitination and degradation. These results, taken
together, suggest that Gli3 regulates the proliferation of colon
cancer cells by inducing turnover of p53.
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Purpose
Tumor microenvironment possesses extreamly important role for
tumor progression and metastasis. Cytokines have autocrine and
paracrine functions, and they are also secreted by normal and
cancerous cells. Herewith we investigated an indicator for the
efficacy of radiotherapy in cervical cancers (CC) using microarray
analysis and immunohistochemical analysis.
Patients and methods
One hundred and four patients with CC were recruited and divided
into two groups (research set: n=35, and validation set: n=69).
Microarray analysis was performed in research set and further
immunohistochemical analysis (IHA) was performed for all
patients to detect candidate radioresponsive markers using pre-
radiotherapy and mid-radiotherapy biopsy samples, which were
taken one week after initiation of radiotherapy.
Results
FGF2 in tumor cells (FGF2–T) significantly increased in midtreat-
ment samples compared with pretreatment samples in research set
of patients, and the ratio change of FGF2-T was significantly
related with better prognosis. This evidence was confirmed in
validation set. Next using all 104 patimets we found IHA positive
FGF2 in stromal cells (FGF2-S) in 85 patients, and the
radiotherapy-induced increase of FGF-S in 23 patients. Though
positive FGF2-S in pretreatment samples was significantly related
with increased expression change of VEGF, it was not related with
poor prognosis.
Conclusion
Radiation causes severing the normal or cancerous associations
with adjacent cells and changes the extracellular matrix environ-
ment. Therefore, we need to investigate not only pretreatment
status of tumors, but also modified tumor structures during
fractionated radiotherapy. In this study, we found FGF2-T
expression change as a monitoring marker for the effectiveness
of radiotherapy, and found the relationship between FGF2-S in
pretreatment status and VEGF expression change in a subgroup of
patients.
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Rationale:
Pancreatic cancer is one of the most deadly cancers in the world
with a very low (5%) survival rate at 5 years. Identification of
new therapeutic targets and new biomarkers remains mandatory
and will allow a better understanding of molecular mechanisms
responsible for pancreatic tumor progression. The MUC4
membrane mucin is one marker candidate as it is not expressed
in normal pancreas whereas it is neo-expressed as early as
precursor stage of pancreatic intraepithelial neoplasia (PanIN)
and constanttly increases during the carcinogenetic sequence.
Moreover, as an ErbB2 partner and target of TGF-b pathway,
MUC4 actively participates in signalling pathways associated
with tumor progression.
Aim:
To define the roles of both MUC4 and ErbB2 in pancreatic
carcinogenesis in vitro and in vivo.
Material and Methods:
The human pancreatic adenocarcinomatous cell line CAPAN-2
was used to establish stable knocked-down (KD) cellular clones
by a shRNA approach.
S116Results:
CAPAN-2 MUC4-KD clones have a proliferation defect compared
to CAPAN-2 Mock clones expressing MUC4. Decrease of
proliferation is correlated to a decrease in cyclin D1 expression
whereas cell cycle inhibitor p27kip1 is not affected. CAPAN-2
MUC4-KD migration properties were reduced. Invasive properties
were not altered. CAPAN-2 ErbB2-KD cellular clones have
reduced proliferative and invasion properties. Moreover, we show
that CAPAN-2 lacking MUC4 are more sensitive to chemother-
apeutic drug gemcitabine. Transcriptomic analysis on 44 K
Agilent microarrays allowed us to establish a molecular signature
of pancreatic cancer related to MUC4 expression. Finally,
subcutaneous xenografts of MUC4-KD cellular clones in nude
mice lead to decreased tumor formation and size.
Conclusion:
These results indicate that MUC4 and ErbB2 play major roles in
biological properties of pancreatic tumor cells suggesting their
important function in tumor progression and confirm potential of
MUC4 as a therapeutic target.
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RUNX3 that belongs to the RUNX family of transcription factors
acts as a tumor suppressor in gastric cancer. RUNX3 is also a
functionally important component in transforming growth factor-β
(TGF-β) mediated signaling pathway. Our previous studies
demonstrated that TGF-β was implicated in Sonic hedgehog
(Shh)-induced cellular signaling in gastric cancer. Herein, we
investigated the involvement of RUNX3 in the modulation of Shh-
mediated tumorigenic process in gastric cancer cell. To elucidate
the role of TGF-β signaling in Shh-mediated proliferation of
gastric cancer cells, we transfected gastric cancer cells with the
Shh expression plasmid pcDNA3.1/Shh or with the vector
pcDNA3.1 as a control. We found that higher concentrations of
TGF-β significantly decreased cell proliferation in control gastric
cancer cells, whereas no inhibition was observed in Shh trans-
fectants that were treated with TGF-β. As TGF-β signaling can be
affected by either stability or the subcellular localization of the
RUNX3, we attempted to determine whether Shh increases
RUNX3 expression. RT-PCR analysis showed that in the Shh
transfectants, the RUNX3 expression was enhanced, but not
transcription. In addition, treatment with MG132, a specific
inhibitor of proteasomes, led to reduction of RUNX3 proteins in
AGS cells transfected with Shh. The expression of RUNX3 is
frequently inactivated by DNA methylation or its protein
mislocalized in many cancer types, including gastric and breast
cancer. Importantly, we found that overexpression of Shh
facilitated nuclear export of RUNX3. Moreover, RUNX3 seques-
tered in the cytoplasm is rapidly degraded through a proteasome-
mediated pathway. On the contrary, blockade of the Shh pathway
by KAAD-Cyclopamine (a Shh signaling inhibitor) or Shh
blocking antibody led to decreased nuclear export and degradation
of RUNX3. In summary, these results indicate that the cytoplasmic
localization and subsequent degradation of RUNX3 mediated by
Shh signaling, which are correlated with the development of TGF-
β resistance in gastric cancer.
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It is very important to distinguish between tumor and normal tissue
for accurate pathology diagnosis and effective cancer treatments.
Particularly after surgical removal of cancer, residual tumor tissue
often causes high recurrence and mortality rate as well as poor
prognosis.For thisreason,the demand for defining cleartumor tissue
margin at a molecular level has been raising. We therefore suggest
that molecular tumor margin must be considered in tumor microen-
vironment (TME), especially in the aspect of extracellular matrix
(ECM) which is a main component of TME, as well as tumor cells.
Defining the portraits of tumor margin facing normal tissue can be a
prerequisite step for further application of molecular margin to
eliminate the chance of tumor recurrence.
Breast cancer is the best model for TME remodeling study
because of frequent accompanied desmoplasia and clinical
requirement for minimized operation. In our study, we made a
tissue classification as follows, rear tumor burden, tumor margin
predominantly facing the normal tissue, and normal tissue remote
from the tumor burden. Differential ECM expression in each tissue
was compared by using ECM array based on real-time RT-PCR,
and further validated by western blot.
On analysis of ECM transcript gene array, LAMA3, which is a
subunit of laminin332, was significantly overexpressed in tumor
margin in comparison with adjacent tumor burden or normal tissue
in 6 breast cancer samples. Fibronectin 1 and SPARC (osteonec-
tin) were shown to be downregulated in tumor margin. E-cadherin
was downregulated in the tumor margin in contrast to upregulated
N-cadherin.
In conclusion, tumor margin could be independently unique zone
differentiated from rear tumor burden and remote normal tissue,
which appears dynamic and functionally most active zone during
TME remodeling.
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L3MBTL4 gene, a human homolog of Drosophila lethal(3)
malignant brain tumor(D-l(3)mbt), lies in a region of chromosome
arm 18p that is frequently deleted in breast cancer cells. The D-l
(3)mbt protein is required for the negative control of cell
proliferation; it is considered as a tumor suppressor. The loss of
function of D-l(3)mbt causes hyperplasia and transformation of the
neural cells resulting in brain tumors in Drososophila. L3MBTL1
the human paralog of L3MBTL4 has been proposed as a target
gene in the myeloid malignancies associated with 20q deletions.
The four human L3MBTL proteins shares MBT repeats involved
in transcriptional repression and chromatin remodeling. The MBT
repeat is capable of methyl-lysine histone recognition. The
presence of MBT repeats in L3MBTL4 suggest that it could also
interact with chromatin.
We hypothesizedthatL3MBTL4loss-of-function couldplay a rolein
cellular transformation. We established genomic profiles by array
comparative genomic hybridization and search for mutations by
sequencinganalysisonlarge set ofprimarybreasttumors.Our results
demonstrate that L3MBTL4 is targeted by losses and mutations
suggesting that it could be a tumor suppressor gene.
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The novel protein PTPIP51 (protein tyrosine phosphatase interact-
ing protein 51) shows a tissue-specific expression pattern and is
associated with cellular differentiation and apoptosis in several
mammalian tissues. Overexpression of the full-length protein
enhances apoptosis. PTPIP51 is a positive regulator of the MAPK
on Raf level. Various carcinoma express PTPIP51. Here we
demonstrate the expression profile of PTPIP51 in human
keratinocyte carcinoma (KC), prostate carcinoma (PCa) and in
glioblastoma multiforme (GBM).
Paraffin embedded sections of KC, PCa and GBM were analyzed
by immunohistochemistry and in situ hybridization. RT-PCR was
performed on cryo samples. For PCa, and benign prostate
hyperplasia (BPH) as reference, bisulfite DNA treatment, followed
by sequencing of PCR products was performed in order to analyze
CpG methylation within the promoter region on the ptpip51 gene.
PTPIP51 mRNA and protein was detected in all investigated
tumor tissues.
Basal cell carcinoma (BCC), squamous cell carcinoma (SCC),
Bowen’s disease (BD) and keratoacanthoma (KA) displayed a
specific localization pattern of PTPIP51 in malignant keratino-
cytes. For SCC, BD and KA a mainly membranous localization
was investigated, whereas BCC showed an either cytoplasmic or
predominantly membranous expression.
Tumor cells of the PCa express PTPIP51, however a stronger
expressionofPTPIP51ispresentinnervefibres,immunecellsandin
smooth muscle and endothelial cells of vessels. Methylation experi-
ments revealed that at least 70% of methylated CpGs in the CpG
islands of the ptpip51 gene promoter region was identified in BPH
samples. A loss of methylation has been found in the PCa group.
Glioblastoma cells showed a mainly nuclear but also cytoplasmic
expression of PTPIP51. These cells displayed a co-expression
of PTPIP51 with its in-vitro interaction partners, PTP1B and
14-3-3β.
For all tumor tissues, PTPIP51 could also be traced in the
surrounding stromal microenvironment. Infiltrating immune cells
of both the innate and the adaptive immune system and endothelial
cells lining arterial and venous vessels strongly expressed
PTPIP51.
We suggest PTPIP51 to play a role as a cellular signaling partner
for processes mandatory for tumor development and progression.
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The IGF axis has been associated with risk of developing various
types of human cancer. However, the role of circulating IGF-1 and
IGFBP-3 in lung cancer is still elusive, probably due to the nature
of IGFBP-3 that could either suppress or enhance the IGF action.
In this study, we determined the role of IGFBP-3 in the IGF action
S118and lung cancer development by analyzing a mouse model that
convey lung-specific human IGF-1 transgene (IGF
Tg), germline-
null mutations of IGFBP-3, or both (BP3
+/−, BP3
−/−, IGF
Tg ;
BP3
+/+, IGF
Tg ; BP3
+/−, IGF
Tg ; BP3
−/−). Serum IGFBP3 levels
of BP3
+/− and BP3
−/− mice were 50% of the wild-type (WT)
(BP3
+/+) mice and undetectable, respectively, leading to 20% and
50% decrease in serum murine IGF-1. Compared to WT mice, the
mice with genetic changes in IGF-1 and/or IGFBP-3 showed
significantly increased spontaneous lung tumor formation and
progression to adenocarcinomas (AC) with the greatest pathogenesis
in IGF
Tg;BP3
+/− mice. The severity of this phenotype correlated
with activation of IGF-1R. The IGF
Tg; BP3
+/− mice exhibited the
greatest incidence and number of ACs following exposure to the
tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
while the overall tumor incidence was similar among the lines.
These findings suggest the importance tissue-derived IGF-1 in lung
cancer and the dual impact of IGFBP-3 in locally available IGF-1,
activation of IGF-1R, and lung cancer development.
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Background:
CD26, also known as dipeptidyl peptidase IV (DPPIV), is present
at the cell surface of a variety of tissues, including the epithelial
lining of the normal human colon. CD26 expression is decreased
in a number of malignancies and in the instance of colon cancer
this decrease in level is believed to facilitate the process of
metastasis to distant organs including lymph nodes and liver.
CD26 itself is a multifunctional anchor protein that serves as the
major cellular binding protein for the ecto-enzyme adenosine
deaminase (ADA) and also interacts with proteins of the
extracellular matrix, principally collagen and fibronectin. CD26
also possesses an intrinsic dipeptidyl peptidase enzymatic activity,
allowing it to cleave and inactivate peptides like CXCL12, the
ligand for the chemokine receptor CXCR4. To further explore the
potential anticancer properties of the bioflavonoid compound
apigenin, we investigated its effects on the cellular expression of
CD26 on human colorectal carcinoma cells.
Methods:
Cell-surface expression of functional CD26 protein on HT-29
colorectal carcinoma was quantified using a cell-based radio-
immunoassay. The multiple functions of the CD26 molecule were
explored through measurements of DPPIV enzymatic activity,
binding of exogenous ADA and adhesion to cellular fibronectin.
Cell viability was assessed through MTT assay and by trypan blue
exclusion.
Results:
Apigenin significantly up-regulated CD26 cell-surface expression
and functions. This would be predicted to act to oppose the
metastatic process. When apigenin was combined with chemo-
therapeutic agents utilized in the treatment of colorectal cancer, the
increase in CD26 expression was further enhanced.
Conclusion:
By increasing the expression of CD26 and its functions to normal
levels, apigenin could be of benefit in restraining the tendency of
colon cancer cells to metastasize, and enhancing the action of
chemotherapeutic agents.
Supported by NSERC of Canada and by studentship award from
Dalhousie CRTP.
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Thymidine phosphorylase (TP), also known as platelet-derived
endothelial cell growth factor (PD-ECGF), catalyzes the conversion
ofthymidinetothymineand2-deoxy-D-ribose-1-phosphate.Inmany
tumors, elevated levels of TP are associated with increased
angiogenesis, metastasis and poor prognosis. In particular, TP was
found to increase the expression and secretion of angiogenic factors,
such as vascular endothelial growth factor (VEGF), matrix metal-
loproteinases (MMP)andinterleukins (IL). The enzymatic activity of
TP was found to be crucial for its angiogenic properties.
In human glioblastomas, which are highly vascularized tumors, TP
expression was found to correlate with angiogenesis. In order to
identifyangiogenesismediatorsofTPinglioblastomas,wetransfected
U87 human glioblastoma cells with TP cDNA (U87/TP) or with an
empty vector (U87/EV). Three clones of U87/TP with a different
expression level of TP were obtained. Using a human angiogenesis
antibody array the secretion of 42 (anti-)angiogenic proteins was
compared in TP- and mock-transfected cells. Angiopoietin-2 (Ang-2)
secretion was found to be significantly (10-fold) reduced in U87/TP
cells, compared to mock-transfected cells. Further analysis showed
that also the intracellular Ang-2 protein level was significantly lower
in U87/TP cells than in U87/EV cells, although Ang-2 transcription
was not affected by TP. In contrast, Ang-1 mRNA and Ang-1
secretion were significantly (4-fold) increased in TP-expressing U87
cells.Addition of thymidine (substratefor the TPenzymatic reaction)
or an inhibitor of TP did not affect the changes in Ang-1/2 secretion,
indicating that the enzymatic activity of TP is not important for the
observed effects. Our findings indicate that increased TP expression
inthe tumormicroenvironmentmaysignificantlyincreasetheAng-1/
Ang-2 ratio, leading to increased Tie-2 receptor activation. The latter
is currently under investigation.
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Background:
Vitamin D (VD) effects on stromal-epithelium interactions may
interfere with breast cancer (BC) development. We have previ-
ously identified some regulated genes in a BC organ culture
model, which preserves epithelial mesenchymal interactions. Our
present aim was to specifically evaluate the epithelial component
behavior and determine whether candidate genes were directly
modulated by VD in breast cell lines or indirectly regulated
through stromal interactions in MCF7 xenograft.
Methods:
Human BC samples were sliced, cultivated and VD treated (24 h).
Affymetrix gene expression profile was obtained. Mammary epithe-
lialmodelof celltransformationHME,HME
LT,H M E
LT+Ras and also
MCF7 cells (in vitro or xenograft) were used to follow-up VD
regulated genes by qPCR, western blotting, confocal microscopy
and ELISA assays.
Results:
Seven up-regulated genes were confirmed modulated (RT-qPCR
analysis) in the cell transformation model after VD treatment
(24 h), including BMP6 and DPP4. Among them, CD14, IL1RL1
and SHE were also modulated in MCF7 cells. Despite constant
levels of CD14 protein in all cells, a significant increase in sCD14
was seen. Conversely, detectable CA2 protein levels were present
only in HME and HME
LT VD treated cells. Conclusion: Novel
VD regulated genes were identified in this model, some of them
probably influenced by the stromal compartment. Supported by
FAPESP 2007/04799-2, CAPES, NIH CA69700.
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Inestrogenreceptorpositivebreastcancer,oneofthemostsignificantly
upregulated genes is the ubiquitin ligase Siah2. Knocking out Siah2
significantly delays the onset of breast cancer in the PyMTAg-derived
breast cancer mouse model. Mammary epithelial cells from Siah2
knockout mice produce and secrete elevated levels of cytokines,
including CXCL10 and GM-CSF. On a molecular level, this is caused
by constant nuclear NFkB localisation and a higher sensitivity to
TNFalpha-mediated activation, identifying Siah2 as a novel negative
regulator of this tumor progression pathway. The elevated cytokine
secretion in turn results in increased immune cell infiltrate in the
mammary glands, suggesting increased immune surveillance. Siah2
knockout tumor cells from mice with tumors at advanced stage have
strongly reduced stroma. This is caused by the inability of the Siah2
knockout host stromal cells to respond to attraction signals derived
from the tumor epithelium. Further evidence for this is supported by
data from in vitro work and in transplanted tumor models showing
that Siah2 knockout tumor cells can recruit stroma to the tumour in
wildtype mice, whereas wildtype tumor cells growing in Siah2
knockout mice are not associated with stromal infiltration.
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Periostin(POSTN)isanextracellularmatrixN-glycoproteinof93kDa.
Six different splice isoforms were reported, but only four of them
sequenced. Their functional significance is unknown. The protein is
expressed in normal tissues like the periosteum and overexpressed in
many cancerous tissues, including lung and kidney cancer. In cancer,
its role is tumor promoting, whereby conferring increased invasion,
survival and angiogenesis in the context of epithelial-to-mesenchymal
transition via integrin-activated Akt signaling. We previously
reported that high protein expression correlates with decreased
survival in non-small cell lung cancer (NSCLC). This study aims at
further analysis of expression and localization of periostin isoforms
in lung and renal cell carcinoma (RCC) and at their functional
characterization. We performed isoform-specific RT-PCR, immuno-
histochemistry and immunoblot analysis on frozen tissues of 30
patients each with NSCLC and kidney carcinoma and their matched
non-neoplastic controls. Furthermore we cloned and sequenced the
region of periostin mRNA that undergoes alternative splicing (exons
17–21), giving rise to different isoforms. We identified four
periostin isoforms in the lung and three in the kidney; each co-
expressed in both tumor and matched non-neoplastic control.
Cloning analysis of one patient with clear cell RCC revealed a
new isoform of periostin. High expression of periostin was found in
both the stroma as well as in the tumor cell cytoplasm of NSCLC
and RCC and correlated with higher pT. On immunohistochemistry,
protein expression was regularly accentuated at the tumor-stroma
interface. These results suggest potential novel tissue-specific
functions of periostin isoforms in RCC and NSCLC and open up
the possibility of organ-specific targeted therapy against the desmo-
plastic stroma of the tumor microenvironment.
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The p53 tumor suppressor acts as a major barrier against cancer.
To a large extent, this is due to its ability to maintain genome
stability and to eliminate cancer cells from the replicative pool
through cell-autonomous mechanisms. However, in addition to its
well-documented functions within the malignant cancer cell, p53
can also exert non-cell-autonomous effects that contribute to
tumor suppression. We now report that p53 can repress the
production of the chemokine SDF-1 by cultured human and
mouse fibroblasts, due to transcriptional repression of the SDF-1
gene. Interestingly, mutant p53 exerts a gain-of-function effect on
SDF-1 transcription, showing an opposite effect to the WT p53.
We found that this effect of p53 on stromal SDF-1 production
might impact on different aspects of tumor development.
Specifically, using conditioned media (CM) of the fibroblasts,
we show that p53-mediated repression of SDF-1 expression can
attenuate tumor cell migration and invasion triggered by such CM.
In addition, CM of p53-deificent fibroblasts is more capable of
stimulating the proliferation of tumor cells. The extent of
suppression of SDF-1 expression increases with p53 activity, as
shown by Nutlin treatment, suggesting that the biological effect of
this phenomenon may become more pronounced under physio-
logic and pathologic conditions that entail extended triggering of
the p53 pathway. Finally, we show that repression of SDF-1 by
p53 in stromal cells attenuates tumor growth in mice.
In recent years, several publications have suggested that
stromal p53 has an inhibitory effect on tumor development,
thereby creating a selective pressure on the tumor cells to
down-regulate its activity. However, no specific molecular
mechanism has been proposed so far. Our findings suggest
that stromal p53 can exert at least some of its inhibitory effects
on tumor growth via repression of SDF-1 expression within the
stromal compartment.
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The histhological organization of the mammary gland reflects a
spatial interaction of epithelial and myoepithelial cells with the
specialized basement membrane (BM) composed by the extra-
cellular matrix (ECM) proteins, which is disrupted during the
tumorigenic process. In a previous study we identified the pro-
apoptotic genes PAWR (PKC apoptosis WT1 regulator; also
named PAR-4, prostate apoptosis response-4) and PHLDA1
(pleckstrin homology-like domain, family A, member 1; also
named TDAG51) as differentially expressed in breast tumors.
Next, using IHC on TMA containing a large series of primary
breast tumors we provide evidence that PAWR and PHLDA1
reduced expression are frequent events associated with a more
aggressive phenotype. Three-dimensional (3D) cell culture of
the spontaneously immortalized cell line MCF10A is a well-
established model system to study breast epithelial cell biology
and morphogenesis. MCF10A cells grown in 3D form sphe-
roids, acquire apicobasal polarization and lumen formation that
resemble acini structures, process that involves cell death. Here,
using this system with growth factor reduced matrigel, we
evaluated the expression pattern of PAWR and PHLDA1 and
activated caspase 3 by immunofluorescence on day 3, 5, 7 and
10 of morphogenesis of MCF10A cells. We provide preliminary
results showing that the PHLDA1 was reduced during
MCF10A morphogenesis and was highly expresssed in the
cells in contact with the matrigel, suggesting its role on acinar
polarity and cell-extracellular matrix contact. On the other
hand, PAWR was highly expressed in the MCF10A cells inside
the acini structure, suggesting that PAWR might have a role for
the lumen acini formation. During the morphogenesis of
MCF10A cells in 3D cell culture, the cells within the lumen
show apoptotic activity evidenced by caspase-3 activation.
PAWR expression on this cells was only partially co-
expressed with activated caspase-3. Although preliminary our
results suggest that PHLDA1 and PAWR may have a role in the
process of the mammary gland morphogenesis.
Supported by FAPESP and CNPq.
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Our realisation is that the stem-cell niche or microenvironment
plays more than just a supporting role in tumour progression
represented a radical shift in the study of stem-cell biology.
To introduce briefly, in the bone marrow, osteoblasts and
endothelial cells constitutes the major cellular components
contributing to the endosteal and vascular niches that serve as
the microenvironment for maintaining haematopoietic stem cells
(HSCs). The niche is also likely comprised of osteoclasts and
endothelial cells, fibroblasts and cancer-associated fibroblasts
(CAFs), as well as adipocytes and macrophages.
S121Although the profound influence of the stroma on tumorogenesis
is now widely accepted, a full understanding of the cross talk
between stem cells and the niche (which translates into changes
in transcriptional networks and chromatin modifications), mi-
croenvironment role on heterogeneity of embryonic and adult
stem cells as well as role in development of leukaemia (LSCs)
and cancer stem-cells (CSCs), remains a nascent field. In this
scenario, there is an urgency to map transcriptional factors and
cell signalling networks from different niches in one place, in
order to exploit stem-cell niche for potential therapeutic
benefits.
To accomplish this goal, we are trying to apply an multidisciplin-
ary approach to address and document molecular networks that
involves in normal and in disease conditions, which is including
the role of tumor initiating genes in tumor microenvironment
during metastasis, small nonprotein-coding RNAs (such as micro-
RNA pathway that differentiate LSCs from CSCs, for an
example), signalling by morphogens and growth-factors (IGF1R
is expressed exclusively in the hESCs, for an example) as well as
functional assays (to distinguish normal HSCs from cells that have
undergone some degree of neoplastic progression) and novel
imaging methodologies.
Hope our advanced ‘connectome- review’ initiative will eventually
help us to increase quality of life for survivors of various cancers.
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The progression of metastasis is a complex event thought to
incorporate the reversible developmental process of epithelial-
mesenchymal transition (EMT). We are interested in the role of
microRNAs in EMT and are focused on expression of the miR-
200 family in in vitro and in vivo examples of this process. Madin-
Darby Canine Kidney (MDCK) cells induced to undergo EMT
with either TGF-β or the protein tyrosine phosphatase Pez,
exhibited a strong downregulation of miR-200.
1,2 We have shown
miR-200 is essential for the maintenance of the epithelial
phenotype and sustains E-cadherin expression by post-
transcriptionally inhibiting ZEB1 and ZEB2, which are E-
cadherin transcriptional repressors that contain multiple miR-200
binding sites in their 3′UTRs.
2 In vivo, qPCR analysis of miR-
200 expression in human ductal (epithelial) and metaplastic
(mesenchymal) breast cancers showed ductal tumours had high
levels of E-cadherin and miR-200, whereas invasive metaplas-
tic tumours lacked both, indicating loss of miR-200 may
increase tumour aggressiveness.
2 We developed a method for in
situ hybridisation of miRNAs to screen formalin-fixed paraffin-
embedded tumours. We are using this technique, along with
immunofluorescence and immunohistochemistry, to assess ex-
pression of miR-200 and EMT markers in human colon
adenocarcinomas. We hypothesise miR-200 will be downregu-
lated in budding cells, which have detached from the primary
tumour and display typical features of EMT including translo-
cation of β-catenin to the nucleus and loss of E-cadherin.
3 We
are also conducting laser capture microdissection to quantitate
and compare levels of miR-200 in normal epithelium, tumour
core and the invasive front.
1. Wyatt L. et al. (2007) J Cell Biol. 178(7):1223–35.
2. Gregory, P.A. et al. (2008) Nature Cell Biology 10(5): 593–601.
3. Brabletz, T. et al. (2001) PNAS 98(18): 10356–10361.
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Alterations in the tissue microenvironment collaborate with cell
autonomous genetic changes to contribute to neoplastic progres-
sion. Senescent fibroblasts, similar to cancer-associated fibroblasts
(CAFs), have a unique expression profile and promote preneo-
plastic cell growth in vitro and in vivo. Because senescent cells
accumulate with age, their presence is hypothesized to facilitate
preneoplastic cell growth and tumor formation in older individu-
als. We have previously identified osteopontin (OPN) as one of the
differentially secreted proteins in senescent fibroblasts. Further-
more, we demonstrated that targeting OPN by RNAi, had no
impact on senescence induction; however, it dramatically reduced
the growth-promoting activities of senescent fibroblasts in vitro
and in vivo. OPN’s role as a paracrine stimulator of preneoplastic
growth was further corroborated by its early expression in
senescent stroma present in preneoplastic lesions that arise
following DMBA/TPA treatment of murine skin. To further
understand the importance of OPN and the associated senescence
S122secretome, we are investiating its regulation in senescence. We
confirmed that senescence triggers a robust DNA damage
response (DDR) represented by activation of ATM. Inhibition of
ATM, but not p53, leads to a significant decline in OPN levels. In
addition, analysis of human OPN promoter luciferase constructs
revealed a distinct pattern of upregulation in response to
senescence induction, suggesting binding of putative transcription
factors. Together, our results demonstrate that OPN is a critical
senescent stromal-derived factor and that specific mechanisms
control its regulation in senescence.
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ADAMTS1 (a disintegrin and metalloprotease with thrombo-
spondin motifs) is an extracellular metalloproteinase known to
participate in a variety of biological processes including
inflammation, angiogenesis and development. Its role in cancer
has also been highlighted although the specific mechanisms
have not been fully disclosed. Using distinct methods we have
identified various factors on the extracellular milieu as targets
of the action of this protease, including the inhibitor TFPI-2,
the proteoglycan syndecan-4, and the basement membrane
glycoproteins nidogens. Our studies in cellular and xenograft
models showed the relevance of these substrate-protease
partners for the development of vasculogenic-like networks,
rich in matrix components. This phenomenon, first character-
ized for aggressive melanoma cells and named vasculogenic
mimicry, illustrates a paradigm of tumor cell plasticity.
Accordingly, our main objective was to study the implication
of ADAMTS1 in the formation of pseudo-vascular channels in
both melanoma and sarcoma settings. We demonstrated its
mRNA and protein expression in aggressive Ewing sarcoma
and melanoma cell lines that formed vascular-like structures in
3D-cultures. We also studied the presence of specific substrates of
ADAMTS1 in these cell lines. In addition we approached
xenograft assays using HT1080 fibrosarcoma cells, negative for
ADAMTS1, which were properly modified to study the functional
role of this protease. After the subcutaneous injection of these
cells in Nu/Nu Balb/c mice, we observed that ADAMTS1
overexpression altered tumor growth rate and induced the
appearance of vascular-like structures together with the over-
expression of endothelial-specific genes, such as VE-Cadherin.
Currently we are characterizing the phenotypic properties of both
sarcoma and melanoma cells and its alteration by the protease
ADAMTS1.
Our work appears in accordance with recent reports that suggest
the essential role of extracellular matrix remodeling for tumor
plasticity and it provides new insights behind the concept of
cancer stem cells.
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The microenvironment on which tumors grow is complex
consisting mainly of tumor epithelial cells and associated
fibroblasts as well as non transformed epithelial cells, normal
fibroblasts and also endothelial and immune cells. The exact
role of these cell types, interacting with each other, in the
progression of breast cancer has yet to be fully understood.
One approach to study this interaction is to determine changes
in gene expression profiles between fibroblasts and non-
malignant or malignant breast epithelial cells, evaluated
separately. Previously, we have demonstrated changes in
differential expression profiles of mammary epithelial cells
and fibroblasts in a co-culture model; herein we attempt to
show these interactions by removing each cell type directly
from the respective tissue. For this purpose, we have
compared gene expression profiles between tumoral and
matched normal epithelial and also stromal versus tumoral
breast epithelial tissues from patients diagnosed with clinical
stage II, luminal subtype, invasive ductal carcinoma, all
obtained through Laser Capture Microdissection (LCM). After
each tissue type removal, i.e., tumoral and normal epithelium
and stromal tissue (avoiding capturing endothelial and immune
cells), total RNA was extracted, amplified and hybridized onto
Affymetrix GeneChip U133 X3P arrays. Genes differentially
S123expressed between groups were identified using Limma
algorithm (p<0.01) of the Bioconductor software suite and
further assessed using gene ontology analysis, performed using
the GO Tree Machine tool. When compared to epithelial
tumoral cells, stromal cells presented enriched categories
related to “T cell receptor signaling pathway” (p=0.004);
“protein folding” (p=0.008); and “chemotaxis” (p=0.006).
The most prominently enriched category in tumoral versus
normal breast epithelium were “inflammatory response” (p=
0.002) and “response to stress” (p=0.009). The evaluation of
components separately resulted in distinct signatures that
should help to better understand some of the molecular
mechanisms involved in the complex heterotypic signaling
between epithelial cells and fibroblasts.
Supported by FAPESP/CNPq.
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Hypoxia inducible transcription factors (HIF) are key regulators of
cellular adaptation to hypoxia in normal but also in pathologic
conditions such as cancer development. They are involved in
melanocyte transformation, tumour progression and metastasis of
melanoma cells. HIF is a heterodimeric protein composed of an
alpha subunit regulated by oxygen pressure and a beta subunit
constitutively expressed. In melanoma, HIF1a and HIF2a subunits
are recovered. Although both HIFa subunits are structurally
homologous, they exhibit different roles sometimes antagonist in
the tumoral development. In order to understand these different
behaviours, stable human melanoma cell lines overexpressing
HIF2a protein were constructed. Surprisingly, in these cells, a
decrease in HIF1a protein expression was monitored under
hypoxia. HIF1a protein underexpression was inversely correlated
with HIF2a protein amount. To explain this observation, transcript
concentrations of HIF1a and aHIF were measured using a qRT-
PCR assay. aHIF is a natural antisense of HIF1a transcript
complementary to HIF1a mRNA 3′untranslated region, suspected
to negatively regulate HIF1a mRNA amounts. Under hypoxia,
aHIF RNA quantity was strongly increased in control transfected
melanoma cells (empty vector) whereas aHIF induction was
totally lost in stable cell lines overexpressing HIF2a. To confirm
that the loss of aHIF induction was correlated with HIFa subunit
pattern, we selected renal carcinoma cell lines naturally exhibiting
high levels of both HIF-a proteins or high amounts of HIF2a
protein and low quantities of HIF1a protein. Disappearance of
aHIF induction under hypoxia was only confirmed in the cell lines
expressing high levels of HIF2a protein and low amounts of
HIF1a protein. In conclusion, we have observed that, in the cell
lines studied, a high HIF2a protein expression could be correlated
with a decrease of HIF1a expression and a loss of aHIF induction
under hypoxia. Experiments are currently in progress to elucidate
molecular mechanisms explaining these observations.
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Breast cancer is the most commonly diagnosed cancer affecting
Canadian women and is the second leading cause of cancer
deaths in these patients. The acquisition of metastatic abilities by
breast cancer cells is the most deadly aspect of disease
progression. Upon dissemination from the primary tumor, breast
cancer cells display preferences for specific metastatic sites. The
liver represents the third most frequent site for breast cancer
metastasis, following the bone and lung. Despite the evidence
that hepatic metastases are associated with poor clinical outcome
in breast cancer patients, little is known about the molecular
mechanisms governing the spread and growth of breast cancer
cells in the liver.
We have utilized 4 T1 breast cancer cells to identify genes that
confer the ability of breast cancer cells to metastasize to the liver.
In vivo selection of parental cells resulted in the isolation of
independent, aggressively liver metastatic breast cancer popula-
tions. The expression of genes encoding tight-junctional proteins
were elevated (Claudin-2) or lost (Claudin-3, -4, -5 and -7) in
highly liver aggressive in vivo selected cell populations. We
demonstrate that loss of claudin expression, in conjunction with
high levels of Claudin-2, is associated with migratory and invasive
phenotypes of breast cancer cells. Furthermore, overexpression of
Claudin-2 is sufficient to promote the ability of breast cancer cells
to colonize and grow out in the liver. Finally, examination of
clinical samples revealed that Claudin-2 expression is evident in
liver metastases from patients with breast cancer.
S124The identification and functional validation of candidate genes
important for the ability of breast cancer cells will provide basic
insights into the pathways required for breast cancer cells to
metastasize to the liver. Our results suggest that claudin-2 may
play an important role in enabling breast cancer cells to
metastasize to the liver.
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Cholangiocarcinoma is the carcinoma generated from bile duct
epithelium. The prevalence of cholangiocarcinoma is low among
worldwide, however it was raised each year. In Thailand
cholangiocarcinoma is endemic especially in northeastern part
and associated with a liver fluke Opisthorchis viverrini infection.
The prognosis of cholangiocarcinoma is quite poor because it has
high metastasis rate. Previous study showed that cholangiocarci-
noma had impairment of estrogen metabolizing enzyme that could
leading to the accumulation of estrogen in plasma as we found in
our preliminary study. Estrogen itself could induce tumor
progression include tumor growth and invasion. TFF1 trefoil
protein, an estrogen responsive protein, is a secreted protein that
has motogenic effect and can promote cell migration and invasion.
In this study we tested the effects of 17b-estradiol, the most potent
natural estrogenic substance, on invasion and metastasis genes
expression of cholangiocarcinoma cell lines in vitro. To test the
role of TFF1 trefoil protein in estrogen-stimulated invasion, the
permanent knockdown cholangiocarcinoma cell line and mock
cell were generated and treated with 17b-estradiol. The results
showed that 17b-estradiol could stimulate the invasion of
cholangiocarcinoma cell but not in TFF1 knockdown cell
compared to both negative control and mock control. Eighty-four
tumor metastasis genes expression of estrogen treated cholangio-
carcinoma cells (normal control, mock and TFF1 knockdown cell)
w a sm e a s u r e db yR T
2 Prolifiler
TM PCR array system. By
compared between 3 cell groups, the result indicated 14 genes
(CHD4, COL4A2, CST7, CTBP1, KISS1R, IL18, MET, MMP10,
NF2, NME1, PTEN, TIMP2, TIMP4 and TRPM1) associated with
invasive property induced by estrogen and TFF1 trefoil protein.
The pathway of estrogen induced metastasis genes should be
analyzed and the results should indicate the mechanism and
control of cholangiocarcinoma metastasis for development of new
therapeutic method.
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Matrix metalloproteinases (MMPs) are a family of zinc-dependent
endopeptidases that play a role in extracellular matrix (ECM)
remodeling. While MMP activity is normally tightly regulated,
both at the expression level and by endogenous tissue inhibitors of
metalloproteinases (TIMPs), dysregulation of MMP activity has
been linked to many pathological conditions, including cancer
progression and metastasis. The expression of MMPs in colorectal
carcinoma (CRC), including MMPs-1,2,7,9 and 13, has been
correlated with disease prognosis.
We have previously shown that tumour microenvironmental
factors regulate the cell-surface levels of CD26 and CXCR4, two
proteins involved in the migration and invasion of CRC cells.
While there is evidence linking the expression of MMPs to cell
regulation through CXCR4, no information is available to address
whether MMPs are important in the overall response of CXCR4
and CD26 to the cellular microenvironment, or whether there is a
link to CD26 regulatory pathways. In this work we examined
whether different factors, or stressors, found in the tumour
microenvironment were able to regulate MMP-7,9,13 and TIMP-
1-3 mRNA expression and protein secretion.
We show that such tumour microenvironmental stressors,
including adenosine and its metabolites, are able to enhance
mRNA expression of MMP-7,9 and 13 as determined by
quantitative RT-PCR. Additionally, Western blot analysis indi-
cated that these microenvironment stressors are not only able to
increase gene expression, but also enhance MMP protein
secretion.
Together, these data suggest that factors in the tumour microen-
vironment are able to regulate changes in protein expression,
possibly playing a role in the migratory phenotype of the CRC
cells in a local context. These changes may work alongside with,
and possibly be mechanistically linked to, the down-regulation of
CD26 and up-regulation of CXCR4 that occurs under the same
conditions.
Supported by an NSERC award to J.B. and studentship award to
K.T. from CRTP.
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In many cancers, the inflammatory response has been shown play a
role in tumor formation, progression and metastasis. Although the
immune microenvironment has been characterized during the preneo-
plastic and invasive stages in a mouse model of pancreatic ductal
adenocarcinoma(PDA) (Clark et al 2007),the inflammatory response
involved in initiation of preneoplastic lesions called pancreatic
intraepithelial neoplasias (PanINs) is unknown. Additionally, the
functional involvement of immune cells in tumor development and
the progression of PDA isunclear. In thisstudy we usemouse models
of pancreatitisand PDAtoexplore to the contributions of the immune
response to tumor initiation and progression. We use flow cytometry
tocarefullymonitortheinflammatoryresponseduringtheinitiationof
PanIN formation. Additionally, we show that components of the
immune system are significantly involved in acinar cell damage that
occursduringamousemodelofpancreatitis.Thisdamage,alongwith
a genetic activation ofKras,leadstothe developmentof preneoplastic
lesions and promotes tumor development (Carriere et al 2009, Morris
et al, in revision). Our study also indicates an important role for the
inflammatoryresponseinpromotingprogressionofneoplasticlesions
to invasive disease.
Clark, CE, Hingorani, SR, Mick, R, Combs, C, Tuveson, DA and
Vonderheide, RH. Dynamics of the immune reaction to pancreatic
cancer from inception to invasion. Cancer Res. 2007 Oct 1;67
(19):9518–27.
Morris, JM, Cano, DA, Sekine, S, Wang, SC and Hebrok, M. Beta-
catenin serves as a molecular switch between acinar regeneration
and Kras induced acinar to ductal metaplasia. In revision.
Carriere, C, Young, AL, Gunn, JR, Longnecker, DS and Korc M.
Acute pancreatitis markedly accelerates pancreatic cancer progres-
sion in mice expressing oncogenic Kras. Biochem. Biophys. Res.
Commun, 2009 May 8;382(3):561–5.
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Traditional Chinese Medicine (TCM) has long been practiced in
China over thousands of years. Currently, TCM medications are
gaining much attention from modern pharmaceutical institutes and
have been studied systematically. Recent studies illustrated that
Scutellaria barbata (SB) is one of the potential herbs exhibiting
anti-tumor efficacy on several tumors, such as head and neck
carcinoma, lung cancer and ovarian cancer. Human telomerase
reverse transcriptase (hTERT), a human catalytic subunit of
telomerase, which highly expressed in over 80% human cancers,
is an indicative marker for treatment efficacy and therapeutic
monitoring. In Hong Kong, colorectal cancer ranks the second of
the leading cause of cancer death.
This study aimed to comparatively study the modulation of hTERT
mRNA expression by Scutellaria barbata (SB) at transcriptional
level in colorectal cancer cell (HT-29) and the HT-29 immunized
BALB/c nude mice models. The efficacy of SB on HT-29 cancer
cells was determined by MTT assay; whereas the size of the colon
cancer in xenografts was monitored by magnetic resonance
interference (MRI) at pre- and post-SB treatment. The modulation
of hTERT mRNA expression in HT-29 cells and the excised
tumors were determined by real-time PCR using TaqMan probe at
pre- and post-SB treatment with untreated control cells/tumors and
the internal control of GAPDH.
The efficacy of SB on HT-29 cells was in a dose- and time-
dependent manner with the LD50 achieved at 550µg/mL and
72-hour incubation. A 50% reduction in size of the excised tumors
was determined in SB-treated xenografts (10 mg/kg/day) for
21 days when compared with that of the untreated control tumors.
For the hTERT mRNA expression, a 1.3-fold down-regulation was
quantitated in HT-29 cells at LD50; whereas a 0.6-fold reduction
was quantitated in SB-treated excised tumors at Day 21.
In summary, SB was effective not only to inhibit HT-29 colon
cells, but also reduce the tumor size of the colon cancer
xenografts. The hTERT mRNA expression was down-regulated
by SB in both in vitro and in vivo models. Thus, hTERT could be
an effective marker for monitoring SB treatment for colon cancer.
This study is supported by the Central Research Grant of The
Hong Kong Polytechnic University (G-YG88).
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Colorectal cancer (CRC) is the second most common type of
malignancy in the Western world. COX-2 derived PGE2 promotes
CRC progression. However, increased cardiovascular risks of
selective COX-2 inhibitors limit their use in chemoprevention. We
have observed that Celebrex induces a scaffolding protein MAGI1
(Membrane Associated Guanylate Kinase with Inverted domain
structure -1) in COX-2 positive colon carcinoma-derived cell lines
(e.g. SW480, HCT116, HT29). MAGI1 appears to function as
scaffold that assemble multimolecular complexes at functionally
relevant subcellular sites in polarized epithelial cells. When overex-
pressed, this inner membrane associated protein completely inhibited
both migration and invasion of colon carcinoma cells in vitro.
S126Moreover, MAGI1 enabled colon cancer cells to re-establish cell-to-
cell contacts leading to epithelial-like phenotype and increased
adhesion on different extracellular matrix proteins. Conversely,
stable MAGI1 knock-down though an shRNA approach, favored
anchorage independent cell growth. One of the reported MAGI1
binding partners in cell junction complexes is beta-catenin. MAGI1
overexpression induced increased beta-catenin membrane localiza-
tion while its activity as transcription factor was decreased. The
opposite effects were observed in cells in which MAGI1 was knock-
down.We are currently testing the effect of of MAGI1 modulation in
tumour growth, local invasion and distant metastasis formation. The
screening for MAGI1 expression in colon carcinoma tissue is also in
progress.Thisworkdemonstratesthatmolecularscaffoldsarecritical
in organizing signaling complexes that control cell adhesion/
migration and that a deeper understanding of the effector systems
regulating junctional complexes and cell scattering may open new
avenues for development of specific therapies targeting invasion and
dissemination of CRC cells.
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Retinoic acid-inducible gene I (RIG-I), as a sensor of viral RNA,
plays important roles in the induction of virus-mediated type I IFN
production and antiviral responses. Recently, identification of
negative regulator of RIG-I in the regulation of antiviral innate
immune response has attracted much attention and many negative
regulatorsofRIG-Ihavebeendiscovered.However,theroleofRIG-I
in tumor development or treatment remain unclear. With tissue array,
we find that the expression of RIG-I is reduced significantly in
hepatocellular carcinoma (HCC) and some other tumors, such as
bladder cancer, renal clear cell carcinoma, endometrial carcinoma
and esophagus cancer. Basis FGF, a member of the FGF family, is
expressed in many kinds of cancer cells and can stimulate the
proliferation of cancer cells of mesodermal, neuroectodermal,
ectodermal and endodermal origin. As a mitogenic factor, basic
FGF has a close relation with cancer development. Interestingly, we
demonstrate that basic FGF can inhibit the mRNA expression of
RIG-I in a time-dependent manner in SMMC-7721 HCC cells which
highly expressFGFR1 andFGFR3. PD173034, the specificinhibitor
of basic FGF, can reverse the inhibition of RIG-I expression by basic
FGF. Furthermore, inhibitors of PI3K/Akt and ERK pathways
(LY294002 or U0126) can also reverse the inhibition of RIG-I
expression by basic FGF. Importantly, overexpression of RIG-I
enhancesthe suppression ofSMMC-7721cellgrowthby interferon a
(IFNa), which is attributed to more cell arrest at G2/M phase and the
promotion of apoptosis of SMMC-7721 cells. These results
demonstrate that FGF-mediated suppression of RIG-I in HCC cells
contributes to the low responsiveness of HCC to IFNa treatment.
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Invasion and metastasis of tumor cells from primary site into
stroma and the metastatic organ is a key step in cancer
progression with poor prognosis. The 5-year survival rate of
head and neck cancer patients, the sixth most common cancer in
the developed world, is approximately 50%, despite the recent
advances in treatment modalities. Even favorable prognosis in
patients that respond to available treatments is often confounded
by recurrences and secondary neoplasm, which are generally less
sensitive to therapy. Indeed, understanding the biology of the
metastatic and invasive cell motility in the tumor microenviron-
ment is critical for developing novel strategies for treatment and
prevention in oral cancer patients. Recently, we have established
human head and neck primary cell lines panel composed of cells
acquired the tumorigenicity and metastasis in tongue tumor
xenograft model in immunodeficiency mice. High throughput
gene array analysis in these cells against the normal human oral
keratinocytes demonstrates the differential expression of a
number of molecules involved membrane trafficking process.
Among them, RAB25, member of RAB11 small GTPases
family essential for membrane protein recycling and translo-
cation of proteins from trans-Golgi network to plasma
membrane. Loss of RAB25 expression in metastatic cells has
been confirmed by RT-PCR and Western blot analysis
compared to both non-metastatic and normal cells. Indeed,
expression of RAB25 in the metastatic cells displayed
significant arrest of cell invasion and metastatic both in vitro
a n di nv i v om o d e lc o m p a r e dt op a r e n t a lc e l l s .F u r t h e r m o r e ,
intravital imaging technique in tongue tumor xenograft with
the genetically modified both to express a fluorescent marker
and to either express (or ablate) RAB25 in metastatic and
non-metastatic cells, respectively, allow us to investigate the
interaction of the tumor and the tumor microenvironment that
contribute to the metastatic invasion of this cancer in the
physiologic condition.
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S127Carbonic anhydrase IX (CAIX), like other members of the
carbonic anhydrase family, catalyzes the reversible hydration of
CO2. CAIX is normally expressed only in the epithelial cells of
the gut, but is frequently upregulated in cancer cells. CAIX has
now been shown to be a marker for hypoxic regions of breast
tumors, is associated with poor prognosis, and is linked to
acidification of the tumor microenvironment which favors cancer
cells survival and resistance to chemotherapeutic agents. CAIX
expression has also been linked to the basal B, triple-negative
phenotype, an aggressive breast cancer for which there are few
treatment options. It has been proposed that CAIX reduces
extracellullar pH (pHe) and increases intracellular pH (pHi)
through functional interactions with one or more of the bicarbon-
ate transporters and CAII, one of the cytosolic CAs. We have
utilized a novel technique to provide evidence that these relation-
ships exist. We have shown previously that MDA-MB-231 breast
cancer cells express only one membrane-associated form of the
CA....i.e., CAIX. Thus, cell surface activity measurements reflect
the activity of only this isoform. This form is induced by hypoxia,
and we show here using the
18O-exchange technique that
membranes isolated from hypoxic cells have a substantial increase
in CA activity. We then utilized this technique in whole cells.
These data demonstrated that the activity of CAIX can be
distinguished from that of CAII and infers a role for the
bicarbonate transporter in their individual catalytic activities.
Application of an impermeant sulfonamide, which selectively
blocks CAIX activity, confirmed its specific contribution to cell-
surface CA activity. Further, inhibition of bicarbonate transport
demonstrated the requirement of this component in the cross-talk
between the two CAs. A model predicted by these studies will be
presented.
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The protease cathepsin-D (cath-D) is secreted at high levels by
breast cancer cells and triggers fibroblast outgrowth via a
paracrine loop (Laurent-Matha et al., 2005). Here, we evidence
that cath-D interacts with the extracellular domain of the beta
chain of the LDL receptor-related protein-1, LRP1, in fibroblasts.
LRP1 is composed of a 515 kDa extracellular alpha chain and an
85 kDa beta chain. The beta chain contains an extracellular
domain, a trans-membrane region and a cytoplasmic tail. LRP1
originally identified as an endocytosis receptor, is also involved in
signal transduction by tyrosine phosphorylation of its cytoplasmic
NPXY motifs. LRP1 was then shown to participate in cell
signalling by regulated intramembrane proteolysis (RIP). In the
RIP process, LRP1betae chain undergoes ectodomain shedding,
generating the membrane-associated LRP1 fragment, that becomes
a substrate for constitutive intramembrane cleavage by gamma-
secretases, producing the LRP1 cytoplasmic intracellular domain
that acts as a transcriptional modulator. In this study, we show that
cath-D binds to residues 349–394 of LRP1beta and this binding is
not competed by the chaperone protein RAP. Interaction occurs in
lipid rafts, as well as in vesicular-like structures and secreted cath-
D is partially endocytosed by LRP1 in human breast fibroblasts.
We demonstrate that the ability of secreted cath-D to promote
fibroblast invasive growth depends on the presence of LRP1.
Interestingly, the gamma-secretase inhibitor, DAPT, that inhibits
the release of LRP1beta intracellular domain, also triggers
fibroblast outgrowth, suggesting involvement of LRP1 RIP. We
further show that both LRP1beta intracellular domain and
membrane-associated LRP1beta fragment production are de-
creased in presence of wild-type or catalytically-inactive cath-D,
suggesting a cath-D-mediated inactivation of RIP signalling
by competition with the first cleavage event. In summary, our
results indicate that cath-D hypersecreted by cancer cells triggers
the fibroblastic outgrowth in the breast tumor micro-environment
in an LRP1-dependent paracrine manner by inhibiting LRP1
RIP.
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Breast cancer, a complex and multifactorial disease, is the most
commonly diagnosed malignancy affecting women; its aetiology
may include diet and xenobiotic compounds that influence breast
microenvironment (1). Currently available methods of breast
cancer detection have well-described limitations (2); in this
respect, the biological intraductal approaches directly assess the
microenvironment of the breast (3). Breast nipple aspirate fluids
(NAF) can be non-invasively obtained from the breast in almost
all women (4), thus representing a promising biological tool to
assess metabolic and molecular changes occurring in cells lining
the ducts from which breast cancer arises. The analyses of NAF
collected from healthy and breast cancer patients allows to identify
S128biomolecular characteristics (1) assessing morphological (5,6),
protein (7) and hormonal (8) changes in the breast ductal
microenvironment. The NAF studies set the basis for biomarker
discovery useful for the early detection and prevention of breast
cancer, improving the identification of women with increased
breast cancer risk analyzing directly the breast intraductal
microenvironment.
References: 1. Mannello et al. Genes Nutr 3,2008,77–85. 2.
Fabian et al. Endocr.Relat Cancer 2005, 12:185–213. 3. Dua RS et
al. J.Clin.Oncol. 2006, 24:1209–1216. 4. Petrakis NL. Epidemiol.
Rev. 1993, 15:188–195. 5. Mannello F et al. J.Clin.Lab Anal.
2000, 14:330–335. 6. Mannello F et al. Breast Cancer Res.Treat.
2007, 102:125–127. 7. Mannello et al. Expert Rev Proteomics
6,2009,43–60. 8. Mannello F et al. Expert Rev Endocrinol Metab
2009 (in press).
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The phosphoinositide 3-kinase related kinases (PIKKs) family
mainly comprised the ATR ATM and DNA-PK proteins. These
large proteins initiate cellular stress responses when genome
integrity is compromised. Emerging evidence suggest that hypoxia
led to activation of these stress kinases in severe hypoxic
conditions. For example, stalled replication forks contribute to
ATR activation. ATM is also activated in severe hypoxia (less than
0.1% O2) through alternate mechanisms that do not involve DNA
breaks. However, the role of this DDR –like response on hypoxia
tolerance remains unknown. We first demonstrated here that the
third member of the PI3KK family, DNA-PK (that comprises a
DNA binding sub-unit Ku and a catalytic sub-unit DNA-PKcs) is
activated by mild hypoxia conditions (0.1 to 1% O2). This was
shown by Ku/DNA-PK mobilization from a soluble nucleoplasmic
compartment to a less extractable nuclear fraction and its
autophosphorylation on serine 2056. This activation was inde-
pendent of DNA double strand breaks (DSBs) and probably
relies on the chromatin modification observed in hypoxic cells
according to our preliminary results. Importantly, DNA-PK
nuclear activation positively regulates HIF-1α accumulation and
its subsequent target gene expression as shown using DNA-PK
deficient cells. This effect is dependent of the kinase activity of
the whole DNA-PK complex since a strong decrease in HIF-1α
expression was observed in cells deficient in its regulatory sub-
unit Ku and in presence of a selective inhibitor of the kinase
activity of DNA-PK, Nu7026. Finally, the reduced half-life of
HIF-1α in DNA-PK deficient cells upon hypoxia provided a
mechanistic explanation for the observed effects. In conclusion,
our results demonstrate that a new nuclear and DNA dependent
stress response pathway contributes to the adaptative response of
hypoxic tumours cells and shed a new light on the interest of
DNA-PK inhibitors to down-regulate HIF-1α expression in
human tumours.
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We screened thirty-four methanolic plant extracts for inhibition of
constitutive nuclear factor kB (NF-kB) activity by a NF-kB-
luciferase reporter gene assay. Strong inhibition of NF-kB activity
was found in extracts of leaf and rhizome from Nuphar lutea L.
SM. (Nuphar). The inhibitory action was narrowed down to a
mixture of thionupharidines and/or thionuphlutidines that were
identified in chromatography fractions by one- and two-
dimensional NMR analysis. Dimeric sesquiterpene thioalkaloids
were identified as the major components of the mixture. The
Nuphar alkaloids mixture (NUP) showed a dose dependent
inhibition of NF-kB activity in a luciferase reporter gene assay
as well as reduction of nuclear NF-kB subunits expression as
tested by western blots and immunohistochemistry. Decreased
DNA binding was demonstrated in Electro Mobility Shift Assays
(EMSA). NUP inhibited both inducible and constitutive NF-kB
activation and affected the canonical and alternative pathways.
Suppression of NF-kB was not cell type specific. Induction of
apoptosis by the alkaloid mixture was demonstrated by time-
dependent and dose-dependent cleavage of procaspase-9 and
PARP. Synergistic cytotoxicity of the active mixture with cisplatin
and etoposide was demonstrated. In addition, NUP partially
protected mice from LPS- induced septic shock and from
experimental B16 melanoma lung metastasis.
Overall, our results show that NUP inhibits the NF-kB pathway
and acts as a sensitizer to conventional chemotherapy, enabling the
search for its specific target and its application against cancer and
inflammation.
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To understand the molecular mechanisms that underlie the metastatic
process is of pivotal importance in cancer research. In an unbiased
genetic screen for genes that are involved in metastasis formation we
identified ASAP1 (Arf-GAP with SH3-domains, Ankyrin-repeats
and PH-domains), and subsequently showed that it promotes tumor
cell motility and invasiveness.Loss and gain of function experiments
in a pancreatic carcinoma model demonstrate a functional role for
ASAP1 in regulating metastasis. In human colorectal cancer patients
we found that ASAP1 expression strongly correlates with short
metastasis-free survival and poor prognosis. At the molecular level,
preliminary co-immunoprecipitation experiments have shown that
ASAP1 binds to both h-prune and nm23-H1 (Non-Metastatic protein
23-H1), proteins that are also involved in the metastatic process.
Using the highly metastatic breast cell line MDA-MB-231 that
endogenously expresses ASAP1, nm-23H1 and h-prune as well as
their interaction partners c-src and GSK3-_, we have begun to
characterizetheputativeternarycomplexbyaddressingthefollowing
issues: a) the influence of the complex’s components on each other’s
activities; b) further possible interaction partners that may modulate
the complex’s activity; c) effects of the complex in terms of cellular
motility and metastasis formation both in vivo and in vitro.
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Background: Castration therapy is the standard treatment for
advanced prostate cancer, but for reasons largely unknown the
effect is only moderate and temporary in comparison with that
in non-malignant prostate tissue. In non-malignant prostate
tissue castration-induced epithelial cell death is, in part,
initiated by vascular regression and tissue hypoxia. Prostate
tumours are however hypoxic already prior to treatment and it
is unknown whether castration results in an additional drop in
tissue oxygen, and if so whether it is of importance for the
therapeutic response. In this study we therefore started to
explore the effects of castration therapy in relation to tumour
hypoxia.
Methods: For this purpose we used the androgen sensitive rat
Dunning H prostate tumour model that transiently responds to
castration treatment followed by a subsequent relapse, much like
the scenario in human patients. Tumour tissues from three
different groups; intact, one day, and seven days post castration
therapy, were analysed using stereological methods.
Results: We found that hypoxia was transiently up-regulated
following castration therapy and correlated with the induction of
tumour cell apoptosis. When castration therapy was combined
with tirapazamine (TPZ), a drug that targets hypoxic cells and the
vasculature, the effects on tumour cell apoptosis and tumour
volume were enhanced compared to either castration or TPZ
alone.
Conclusions: This study suggests that castration - induced tumour
hypoxia could be a novel target for therapy.
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Cells acquire different phenotypes and responses depending on
their growth environment and signals derived from it. When
mesenchymal cells are grown as multicellular spheroids, a massive
proinflammatory, proteolytic and growth factor response promot-
ing tumor invasiveness is induced. Genome-wide microarray
analysis revealed three major phenotypic changes in fibroblast
spheroids compared to standard 2-dimensional culture; arrest in
cell cycle, downregulation of cytoskeleton and induction of
secreted proteins (chemokines, proinflammatory cytokines and
growth factors). In addition to downregulation of cell cycle
proteins, the list of upregulated genes resembled remarkably those
reported to be induced during cellular senescence. Furthermore,
fibroblast spheroids stained positively to senescence associated ß-
galactosidase. Interestingly, classical senescence pathways, p53-
p21 and retinoblastoma, were downregulated. Furthermore, the
cell cycle arrest was reversible, indicating a mechanism different
from that in cellular senescence. A mechanism to leading to this
activation (now named as nemosis) and cell cycle arrest is still
largely uncharacterized, but one of the first processes seen in
nemosis is autophagy. Keeping in mind the important role of
autophagy in cellular senescence, it might be that autophagy has a
major role in regulation this kind of fibroblast activation.
Since senescent fibroblasts have been shown to stimulate growth
of non-invasive cells in vivo and convert them to invasive, we
tested whether fibroblast spheroids are able to modulate growth
of metastatic keratinocytes in xenograft model. Interestingly,
fibroblast spheroids were able to inhibit growth of tumor cells in
vivo.
S130Our results show an important and interesting function of fibroblasts.
Furthermore, targeting mechanisms leading to nemotic activation
may function as a new therapeutic approach in cancer treatment.
This work was supported by the Helsinki Graduate School in
Biotechnology and Molecular Biology, Finnish Cancer Societies,
and Academy of Finland.
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Tumor cells develop multiple mechanisms including a dysregu-
lated metabolism to escape T-cell mediated immune recognition.
Tumor-derived metabolites are known to modulate cellular
components of stromal cells, like immune effector cells and
antigen-presenting cells. Studies on malignant tumors, such as
malignant melanoma, have revealed loss of methylthioadenosine
phosphorylase (MTAP) expression in vitro and in vivo. In this
context it has also been shown that MTAP deficient tumor cells
secrete 5′-deoxy-5′-methylthioadenosine (MTA). Recent in vitro
data have revealed that MTA by modulating melanoma cells as
well as tumor infiltrating fibroblasts leads to tumor progression.
In our studies we have demonstrated that MTAP deficiency plays an
important role also in renal cell carcinoma (RCC). We have analysed
240 tissue microarraysof RCC including different subtypes (clear cell,
papillary, chromophobic and oncocytoma). We have found that 55%
of all tumors are deficient in MTAP expression while corresponding
normal tissues exhibit significantly higher expression of MTAP.
Additionally, RCC cell lines showing loss of MTAP expression on
mRNA and protein levels displayed an accumulation of MTA in the
cell culture medium as measured by mass spectrometry.
Furthermore we have analysed the effects of MTA on human
CD4+ and CD8+ T cells in vitro. Here we show that MTA
suppresses proliferation of T lymphocytes in a reversible manner.
We further demonstrate that in vitro induction of Ag-specific
immune responses is completely abrogated by small amounts of
MTA. Also effector functions of highly activated cytotoxic CD8+
T cells, like secretion of IFN-gamma and cytotoxicity against
antigen presenting target cells, are diminished greatly in the
presence of MTA.
In summary, loss of MTAP expression in malignant tumors results
in the secretion of MTA causing direct inhibition of the functional
activity of human T cells. Inhibition of specific metabolic
pathways in malignant tumors may provide a promising approach
to improve the immunotherapy of cancer.
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Tumour cells exist in a hostile environment in which they are
exposed to many stresses including hypoxia. One consequence of
the hypoxic conditions is an increase in extracellular levels of the
purine nucleoside adenosine, which has many effects on tumour
cells including enhanced migration. This is achieved through an
increase in the levels of the chemokine receptor CXCR4 which,
along with its ligand CXCL12, is a key player in breast cancer
metastasis.
The cellular response to stress is mediated by a family of
proteins alternatively known as heat-shock proteins (HSPs),
molecular chaperones, or stress proteins. One such chaperone,
the small heat shock protein HSP27, has been implicated in
changes in cancer cell migration. We have therefore studied the
regulation of HSP27 in human breast cancer cells by conditions
that normally exist in the stressful environment of a tumour.
We aim ultimately to establish whether changes in HSP27 may
be linked to hypoxia, adenosine levels and alterations in the
CXCL12-CXCR4 migratory pathway.
As revealed by western immunoblotting and immunofluorescence
staining, the abundance of HSP27 protein in breast cancer cells
increased beginning 3–6 h after initiation of exposure either to
hypoxia or to the purine nucleoside adenosine, with a maximal
effect after 24–48 h. Further studies detail the signaling pathways
and important features of the HSP27 response. These data
represent the first stage in our exploration of the link between
physiological stress and the capacity for migration in breast cancer
cells.
Funded by the Natural Sciences and Engineering Research
Council of Canada.
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S131Obesity is associated with increased risk and mortality in colon
cancer, and epidemiological and clinical evidence point to insulin
resistance as playing a central role in the underlying molecular
pathways. Inflammatory cytokines and growth factors elevated by
insulin resistance are potential drivers of tumour blood vessel
formation (angiogenesis). Therefore, the purpose of this study was
to investigate correlations between markers of obesity, insulin
resistance, angiogenesis, tumour pathology and patient survival in
colon cancer patients.
Immunoassays were used to measure levels of adiponectin, C-
reactive protein (CRP), insulin, insulin-like growth factor-1 (IGF-
1), C-peptide, vascular endothelial growth factor-A (VEGF-A) and
angiopoietin-2 (Ang-2) in colon cancer patient serum samples (n=
400). Levels of these markers were analysed together with
clinicopathological parameters including patient age, gender and
tumour characteristics (from Cancer Society Tissue Bank, Christ-
church), and Body Mass Index (BMI) and survival data obtained
from medical records.
In serum, levels of adiponectin were inversely correlated with
patient BMI and IGF-1 protein levels (p<0.0001). CRP levels
were positively correlated with the levels of VEGF-A and Ang-
2, tumour stage, size, depth, and necrosis (all p<0.001). Levels
of both VEGF-A and Ang-2 were also positively correlated
with tumour size, depth and lymph/vascular invasion. In
addition, VEGF-A levels were positively correlated with
tumour stage, and Ang-2 protein levels with tumour necrosis
(all p<0.05). Preliminary analysis of survival data show better
outcome for patients with serum adiponectin levels in the
highest quartile, and worse outcome for patients with serum
VEGF-A, Ang-2 (p<0.05) and CRP (p<0.05) levels in the top
quartile.
Our clinical data show colon cancer patients with high BMI
and low serum adiponectin have high circulating levels of
pro-angiogenic and inflammatory factors that are correlated
with adverse tumour characteristics and reduced patient
survival.
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Resistance of chemotherapy and the rapid formation of metastasis
are the main problems in the treatment of highly invasive cancers.
Growing evidence suggests that V-ATPase, which is highly
overexpressed in metastatic cancer cells, contributes to an acidic
tumor environment, promoting cancer progression and metastasis.
Archazolid B is a V-ATPase-inhibitor, isolated originally from the
myxobacterium Archangium gephyra.
We therefore hypothesize that Archazolid B could be a potent
compound to inhibit the metastatic process in highly invasive
cancer cells and to overcome chemoresistance by directly
regulating the pH gradient within the tumor microenvironment.
We could show that Archazolid B changes the intra-and extracel-
lular pH of tumor cells and potently inhibits the proliferation of
highly metastatic cancer cells (L3.6pl: IC50 ~8 0p M ;S K - B R - 3 :
IC50 ~ 500 pM). Interestingly, Archazolid B has only a moderate
apoptotic effect (about 20 % apoptosis at 1 nM, 48 h) accompanied
by the activation of Caspase 8 and 9 and the downregulation of anti-
apoptotic proteins. Along with a strong inhibition of the clonogenic
tumor cell growth, our most recent data shows that Archazolid B
potently inhibits the migration of highly metastatic cancer cells.
Taken together, Archazolid B inhibits the growth and survival of
highly proliferating cancer cells as well as their migration.
Ongoing experiments will investigate molecular mechanisms and
targets involved other than V-ATPase. Since V-ATPase, targeted
by Archazolid B, controls the cancer microenvironment this
experimental drug opens up the opportunity to increase the
efficiency of different chemotherapeutics and therefore to over-
come drug resistance of highly invasive cancer cells.
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In the progression of cancer, malignant cells evolve strategies to avoid
an immune response probably through induction of immune tolerance.
It is proposed that dendritic cells (DC) have a dramatic impact on
tumor immune tolerance and that the tumor microenvironment
determine differentiation of DC into a tolerogenic phenotype. Indole-
amine 2,3 dioxygenase catalyzes the rate limiting step in the
breakdown of L-tryptophan and has been shown to be involved in
immune tolerance and cancer progression. However, nothing is known
about metabolites of the tryptophan catabolism on DC function.
CD14
+ cells were isolated from periperal blood and activated to
fully mature DC in vitro. In parallel cultures, DCs were generated
in the presence of different concentrations of kynurenine and
quinolinic acid. These mature DC were used to analyse expression
of differentiation markers by FACS, to stimmulate naïve T-cells to
proliferation, and to induce Th-1 T-cell response.
Kynurenine, but not quinolinic acid, had a dramatic effect on the
expression of the DC maturation marker CD83, suggesting that
kynurenine has an impact on DC maturation. The expression of
MHC-class I molecules, the co-stimulatory receptors CD80/CD86
S132and CCR7 on DC was not affected by kynurenine or quinolinic
acid. In further analysis we found that kynurenine treated DC
dramatically decrease the ability of T-cells to produce INF-gamma
a key cytokine indicating a Th-1 immune response. Subsequently
T-cell subpopulations were analysed and found that the portion of
CD4
+CD25
+ T-cells was significantly increased in the T-cell
population generated by kynurenine treated DC, which indicate an
increase in a suppressor T-cell population.
In summary, these data suggest that kynurenine “primed” mDC
induce generation of suppressor T-cells. Based on the data
presented above we hypothesize that metabolites of the kynur-
enine pathway are important determinants in turning the immune
system especially DC to a tolerogenic phenotype.
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Recent studies indicate that tumoral invasion and metastasis,
triggered by the hypoxic microenvironment, involves strategic
relocalization of convertases, adhesion molecules, and metal-
loproteases. We used the highly invasive human fibrosarcoma cells
HT-1080, stably transfected with eGFP-tagged-furin in order to
study the impact of hypoxia on the cellular localization of the
convertase furin. Our results indicate that in hypoxic cells, furin is
relocalized at the plasma membrane and is internalized via both
clathrin- and caveolin/raft dependent endocytosis. Using furin
trafficking mutants, we demonstrate that filamin-A, a cytoskeletal
tethering protein, is essential for the membrane localization of furin
under hypoxia. We further demonstrate that in hypoxic cells, furin
and its substrate MT1-MMP relocalize to specific pericellular
compartments and this relocalisation is associated with an increased
cell ability to convert pro-MT1-MMP into its active form. Because
MT1-MMP is known to be involved in ECM degradation at site of
invadopodia, we further looked at the implication of cell-surface
furin in the formation and functions of these structures. Using a
matrix degradation assay, we found that furin colocalize at
invadopodia sites with its substrate MT1-MMP under hypoxic
conditions. This is associated with an increase in both formation
and functions of invadopodia. To better characterize the impact of
hypoxia on the invadopodia formation, we next demonstrate that
overexpression of furin increases the number of invadopodia and
their capacity to degrade ECM. Furthermore, the inhibition of furin
with PDX or the MT1-MMP inhibitor GM6001 decreases invado-
podia numbers and functions. This is correlated with a decrease in
cell invasion in a 3D assay. Our results suggest that hypoxia
promotes the formation of a peripheral processing compartment in
which furin is concentrated for enhanced processing of substrate
involved in the formation of invadopodia leading to cell invasion.
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The loss of growth control is one important characteristic of tumor
progression. This can be a consequence of a reduced dependence
of the tumor cells on growth-stimulatory factors and/or of a
decreased sensitivity to growth-inhibitory factors and can be
caused by an aberrant expression of growth factors and their
receptors.
A progression model for human skin squamous cell carcinoma
(SCC) based on the keratinocyte cell line HaCaT was used to
elucidate the molecular basis of this increasing environment-
independent tumor growth. This model system includes ras-
transfected and in vivo passaged cells forming tumors of all stages
of tumor progression, ranging from benign to late stage malignant
and metastasizing tumors. Using a cDNA array comparing the
transcriptome of the benign HaCaT-ras A-5 and the high-grade
malignant HaCaT-ras A-5RT3 cells, 67 differentially regulated
cytokines, growth factors and receptors were identified. Among
these differentially expressed genes, Insulin-like Growth Factor II
(IGF-II) was shown to be up-regulated associated with increasing
tumor malignancy. Stimulation of the benign HaCaT-ras A-5 cells
with recombinant IGF-II resulted in increased proliferation and
migration/invasion in cell monolayer and in 3-D skin organotypic
culture (OTC). The stable IGF-II over-expressing HaCaT-ras A-5
transfectant E2 (A-5E2) demonstrated a proliferation stimulating
phenotype leading to a highly increased epithelial growth and
differentiation in comparison to the control transfected HaCaT-ras
A-5 clone SV3 (A-5SV3) in skin OTCs in vitro as well as in
transplantation assays in vivo. Additionally, IGF-II over-
expressing A-5E2 cells induced an earlier and stronger recruitment
of neutrophils but not macrophages and an enhanced angiogenesis
in in vivo transplantation assays compared to the control A-5SV3
cells. In summary, the strong proliferation stimulating function and
the additional pro-angiogenic, pro-migratory and stroma-inducing
characteristics of IGF-II have an important effect on tumor
progression and tumor-stroma interaction.
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S133TGF-beta and their receptors are key regulators of many
aspects of cell growth, differentiation, and function. Regulation
of TGF-beta expression and activation is crucial for normal
development and growth control. The loss of responsiveness of
different tumor cells to the antiproliferative effects and a novel
nexus between TGF-beta expression and increased tumorige-
nicity, invasion and drug resistance is a common feature in
carcinogenesis. Here we show, by in silico meta-analysis of
breast cancer microarray data that TRAF Family-Associated
NF-KappaB Activator (TANK), a signaling adaptor protein
reported to be involved in regulating NF-κB activity, is
upregulated in metastatic breast cancer and grade 3 tumors.
Further, upregulation of TANK was seen in 67% of invasive
breast cancers (n=148) by immunohistochemistry based tissue
microarray analysis and by western blotting in a number of
human breast cancer cells lines. In BT474, breast cancer cells
that are refractory to TGF-beta, targeted down regulation of
TANK using either siRNA or shRNA lead to increased
sensitization to TGF-beta and chemotherapeutic agents. Further,
d i s r u p t i o no fS M A D 2a n dN F - κB transcriptional activity was
monitored by promoter assay, western blotting and functional
ELISAs in TANK siRNA transfected cells when compared to
non silencing siRNA or vector control. Taken together, these
results suggest a link between NF-κBa n dT G F β signaling and
that loss of responsiveness to TGF-beta may be mediated by
the over-expression of TANK.
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To characterize the prognostic significance of stromal PDGFR-
alpha expression in colorectal cancer (CRC), we evaluated the
expression of PDGFR-alpha using a tissue micro array (TMA) of a
population-based CFRC cohort of having undergone standardized
treatment.
The TMA was composed of more than 300 primary tumors, more
than 60 lymph node metastases and 114 samples from normal
colon. Samples from lymph nodes and normal mucosa were
derived from patients whose primary tumors were also part of the
TMA. PDGFR-alpha expression was analyzed by immunohisto-
chemistry, and expression was scored separately for epithelial
cells, stroma fibroblasts and perivascular cells.
In general, PDGFR-alpha expression was frequently seen in
perivascular cells and fibroblasts, but not in epithelial cells.
Fibroblast expression was up-regulated in tumors as compared to
normal tissue. PDGFR-alpha expression was higher in colon
cancer fibroblasts than in rectal cancer fibroblasts. PDGFR-alpha
expression in primary tumor CAFs was correlated with more
advanced N stage.
Several associations were observed between PDGFR-alpha ex-
pression in lymph node metastases and survival. Increased
expression of PDGFR-alpha in lymph node fibroblasts was
associated with worse survival in the whole patient cohort. High
PDGFR-alpha expression in fibroblasts or pericytes in lymph
nodes was associated with increased recurrence risk in curatively
treated patients. The associations between survival and stromal
PDGFR-alpha lymph node expression were also significant in a
multivariate analysis. Interestingly, also high expression of
PDGFR-alpha in fibroblasts of normal mucosa was associated
with worse over-all survival.
These findings thus highlight the prognostic potential of tumor
stroma and specifically demonstrate novel prognostic significance
of stromal PDGFR-alpha in CRC. The associations between
PDGFR-alpha status of normal mucosa and survival also points
to the importance of “host factors” in tumor progression.
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Early detection and prognostic profiling of cancers has the
potential to increase lifespan and quality of life. The “field effect”
hypothesis that motivated this investigation suggests that there are
cellular changes that occur both within and around tumor cells that
could be detectable in serum. These changes may be detectable
before the disease is histologically identifiable using the current
testing methods. This valuable information could potentially come
from serum where early stages of tumorigenesis lead to changes in
the serum peptidome. An experiment testing this idea was carried
out using a rat model of mammary carcinoma. Samples were
collected at different stages of progression and abundant proteins
depleted to determine if MALDI-TOF mass spectrometry could
provide a proteomic profile that could identify disease. MALDI-
TOF spectra were obtained on an Applied Biosystems Voyager-
DE PRO Biospectrometer and analyzed using peak picking
computer algorithms and logistic regression models. MALDI-
TOF analysis was performed on sera taken from control and
carcinogen-treated at each necropsy time point. The peak 4253 m/
z revealed a monotone change in the intensity difference that was
statistically significant between the treated and untreated rats over
weeks 2, 3, 4, and 5. The corresponding band was excised from a
gel and possible identifications were determined via electrospray
ionization (ESI). One biologically plausible candidate for this
band was Dermcidin, a protein previously linked to breast cancer.
S134We have found Dermcidin levels to increase in serum during
disease progression, gaining significance as tumor size increases.
We are currently characterizing the role that Dermcidin plays in rat
mammary carcinogenesis and investigating a potential correlation
with human breast carcinogenesis.
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CD24 is a mucin-like, highly O- and N-glycosylated, glycosyl-
phosphatidylinositol (GPI-) anchored membrane protein. It is
expressed in maturing B-cells, neutrophils, epithelial cells and
neuronal tissue. CD24 is also overexpressed in various types of
human cancers such as lung, stomach, colorectal, prostate, breast
and ovarian. In tumors, CD24 has been shown to affect cell
proliferation and migration, tumor growth and invasion. However,
the cellular downstream events of CD24 remain completely
unclear.
Here, we investigated CD24-dependent gene regulation in RNAi
and overexpression systems in vitro. RNA-microarray based chip-
analysis verified by quantitative real-time PCR, identified a small
number of genes that were regulated by CD24 expression. One
of the most promising target genes is tissue factor pathway
inhibitor-2 (TFPI-2). This member of the Kunitz-type serin
proteinase inhibitor family functions in the maintenance and the
stability of the tumor microenvironment. TFPI-2 is secreted
into the extracellular matrix (ECM) and acts as an inhibitor of
matrix metalloproteases (MMP) or plasmin-mediated ECM
proteolysis. Downregulation of TFPI-2 protein enhances cancer
cell ability to degrade ECM due to the lack of this potent
inhibitor function. Using ovarian carcinoma cells and CD24-
transfected cell lines, we provide evidence that CD24 promoted
effects on tumor cell invasion and MMP-activity could be
mediated by TFPI-2 levels.
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Bone marrow (BM) is not only the organ where hematopoiesis
takes place, but also a target for metastasis from different solid and
hematologic cancers.The extracelular matrix (ECM) meshwork
envolving BM cells, creates well defined niches where cells must
receive appropriate signs for hematopoiesis to take place. We
believe thatHere we attempt to identify a role for ECM niche
interactions with invading cancer cells are important for the
success of the metastatic process. Therefore we started to
characterize the ECM and integrin receptor expression patterns
in murine BM, using RQ-PCR, FACS and immunofluorescence.
We observed that fibronectin is widely distributed within BM,
while laminins and collagen IVare predominantly associated with
basement membranes. Megakaryocytes and endothelial cells
express important amounts of these ECM molecules, megakar-
yocytes being the major fibronectin producers. Integrin receptors
are expressed, generally, by hematopoietic and endothelial cells.
Our in vitro data indicate that hematopoietic progenitor cells prefer
fibronectin matrices in terms of adhesion and survival, so we want
to scrutinize possible cell-ECM interactions in vivo. For that we
developed a new immunostainning technique where whole BM
are isolated, extensivly permealised, stainned for different cell
types and molecular markers and analysed by confocal microsco-
py. Our protocol overcame frequent immunostainning-related
problems like bone decalcification, section damage, antigen
masking and loss of the three-dimensional structure. We found
that mature BM cells are distributed close or within fibronectin-
rich areas and this association increases during BM remodeling
following irradiation. Hematopoietic progenitor cells reside in
close association with fibronectin, becoming clustered within
fibronectin niches; such interactions are impeded in the presence
of integrin neutralizing antibodies. Our ongoing work concerns the
putative role of BM microenvironment in creating favorable
conditions for circulating tumor cells spreding and survival within
BM. Using our in vivo 3-dimensional model we are currently
analysing the behaviour of metastatic tumor cells in an altered
fibronectin BM environment.
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The ADAMs (a disintegrin and metalloprotease domain) are
membrane-anchored glycoproteins characterized by a multi-domain
structure, which includes a metalloprotease and a disintegrin domain.
Because of their proteolytic and cell-adhesion activity, the ADAMs are
involved in various biological process, including fertilization, neuro-
genesis, angiogenesis and inflammation. ADAM23 exhibits the typical
structure of ADAM family members, although its metalloprotease
domain is inactive (1). Loss of ADAM23 expression is observed in
different types of tumors and, in breast tumors, silencing by promoter
hypermethylation is associated with the development of distant
metastasis and a worse disease outcome (2–3). Analysis of ADAM23
binding to integrins revealed a specific interaction with avb3 integrin
mediatedbythedisintegrindomain(4).Recently,wedemonstratedthat
ADAM23 negatively modulates avb3 integrin activation during
metastasis (3). Ablation of ADAM23 expression using shRNA
S135enhanced integrin activation by 2–4 fold and ADAM23 knock-down
cells showed enhanced migration and adhesion to classical avb3
integrin ligands. Three ADAM23 splicing isoforms have been
describedsofar,twoofthem(alphaand beta)containatransmembrane
domain that differ in their aminoacid sequence, and the third one
(gama) does not encode a transmembrane domain, suggesting to be a
secreted protein (5). In the present work, we analyzed by Real-Time
PCR the expression pattern of ADAM23 splicing isoforms and found
that they are differentially expressed in tumor cell lines. Moreover,
using siRNA to specifically knock-down the expression of each
splicing isoform, we found that they play different roles on the
modulationofavb3activity,affectingmigrationandadhesiontoclassic
avb3 ligands.
1 – Sagane et al (1998). Biochem J 334:93–8
2 – Costa FF et al (2004). Oncogene 23:1481–8
3 – Verbisck NV et al (2009). Cancer Research in press
4 – Call S et al (2000). Mol Biol Cell 11: 1457–69
5 – Sun YP et al (2004). Gene 325: 171–8
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Compelling evidence support a link between inflammation, cell
survival, and cancer, with a central role played by NF-κB, a master
switch of inflammation. Recent studies implicate some TLRs in
tumor development or regression, and immune escape. However,
mechanisms leading to tumor growth or apoptosis induced by TLR
stimulation are not fully understood. Several studies strongly
suggest that chronic inflammation in lungs induced by chronic
bronchitis, chronic obstructive diseases or tobacco smoke, increases
the risk of carcinogenesis. We hypothesized that TLRs can
contribute to lung inflammation and tumor development.
TLR expression in lung cancer was assayed by immunohisto-
chemistry or flow cytometry. NFκB activation was determined by
western blot and nuclear translocation assay. Clonogenicity of
stimulated cells was analyzed by colony assay. Transcriptomic
analysis were performed by Taqman LDA technology. Tumor
growth in vivo was analyzed in NOD/SCID mice.
We have observed that primary human lung tumors express TLR3,
TLR4, TLR7 and TLR8 and that stimulation of these receptors in
lung tumor cell lines by Poly I:C, LPS, Loxoribine or Poly U
induces NFκB activation through atypical signaling pathway, with
phosphorylation of IκBα without its degradation and nuclear
translocation of p50 and p65 NFκB subunits. Interestingly, we
observed that TLR3 stimulation induces apoptosis. On the
contrary TLR4, TLR7 and TLR8 stimulation induces cell survival
and increases clonogenicity. Moreover, despite a common atypical
activation of NFκB, our transcriptomic analysis revealed major
differences in gene modulation after triggering of TLR3, TLR4,
TLR7 and TLR8. Finally, in vivo TLR7 stimulation of human
lung tumor cells dramatically increases tumor growth.
Altogether, these data emphasize that TLR4, TLR7 or TLR8
triggering can directly favor tumor development whereas TLR3
signaling can induce tumor cell death. These data suggest that
anticancer immunotherapy using TLR adjuvants should take into
account the expression of these TLRs in lung tumor cells.
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In the most common primary brain tumors, malignant glioma cells
invade the extra-cellular matrix (ECM) and proliferate rapidly in the
cerebral tissue which is mainly composed of hyaluronan (HA) along
with the elastin present in the basement membrane of blood vessels. To
determine the role of ECM components in the invasive capacity of
glioma cell lines, we developed a 3-D cell culture system, based on a
hydrogel in which HA can be co-reticulated with kappa-Elastin (HA-
kE). Using this system, the invasiveness of cells from four glioma cell
lines was dramatically increased by the presence of kE and a related,
specific peptide (VGVAPG)3 (see figure 1 A and B). In addition,
MMP-2 secretion increased and MMP-12 synthesis occurred.
Extracellular injections of kE or (VGVAPG)3 provoked a pro-
nounced, and dose-dependent increase in [Ca
2+]i. kE significantly
enhanced expression of the genes encoding elastin-receptor and
tropoelastin, the migration (see figure 2 A and B), the adhesion and
t h ep r o l i f e r a t i o no ft h eg l i o m ac e l l s .W ep r o p o s et h ee x i s t e n c eo fa
positive feedback loop in which degradation of elastin generates
fragments that stimulate synthesis of tropoelastin followed by further
degradation as well as migration and proliferation of the very cells
responsible for degradation. All steps in this ECM-based loop could
be blocked by addition of either of the EBP antagonists, lactose and
V-14 peptide, suggesting that the loop itself should be considered a
new therapeutic target. We are currently confirming our findings by
studying the correlation between the sensitivity of patients’
glioblastoma cells and the patient’ss u r v i v a l .
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Brain metastasis is a common cause of mortality in cancer
patients, and associated with poor prognosis. In order to better
understand the complex metastatic process and the interaction
between metastases and the microenvironment, we developed a
new animal model, where human brain metastases were xeno-
grafted into the brains of immunodeficient rats.
Tumor take was achieved in 7 out of 9 human brain
metastases implanted. By MR imaging, the animal brain
metastases showed similar radiological features as observed
clinically. Histological comparisons between the primary
tumors from the patients, the patient brain metastases and
the xenografted brain metastases showed similar growth
patterns. An immunohistochemical study showed similar
marker expressions between the patient tumors and the
corresponding animal brain tumors. A DNA copy number
analysis showed several chromosomal deletions and amplifi-
cations, but only one change, gain of 2q, was exclusively
found in the animal brain metastases. In conclusion, we have
developed a representative in vivo model for studying meta-
static brain cancer, which will be used to assess responses to
treatment.
This model was refined by establishing a cell line (H1) from one
of the brain metastases (primary: melanoma). In order to follow
systemic spread of the cell line in vivo, we generated two new cell
lines by transfecting with either dsRed or H1 GFP-Luc reporter
genes. The transgene-positive cells were selected by fluorescence
activated cell sorting to obtain homogenously fluorescent cell
lines. A pilot study showed that the H1/dsRed cells were
tumorigenic when implanted intracranially and subcutaneously in
matrigel, in nod/SCID eGFP positive mice. A bioluminescence
assay using optical imaging on H1/GFP-Luc cells was done in
vitro, which showed a strong luciferase activity in the cells.
Currently the H1/GFP-Luc cells is injected intracardially, to study
the ability of systemic homing of these cells into the brain of nod/
SCID mice.
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Integrins are transmembrane receptors which mediate interactions
of cells with the extracellular matrix. Among integrin receptors,
several bind to laminins, major components of the basal lamina. In
particular, integrin alpha6 beta1 and alpha6 beta4 can bind to
laminins 111, 332 and 511. A specific feature of integrin alpha6
beta4 is its participation to hemidesmosomes, anchorage junctions
found in epithelia (skin, intestine), which are the devices by which
epithelial cells attach to the basal lamina. In the cells, molecular
interactions of alpha6 beta4 with plakins results ultimately with
the establishment of a connection with the keratin intermediate
filament network. Hemidesmosomes provide cells with resistance
against mechanical stress, and it has been largely documented that
molecular alterations of hemidesmosomal composition leads to
tissue integrity defects such as epidermolysis bullosa. In addition
to this structural role, hemidesmosomes are also signalling entities
since plakins or integrin cytoplasmic tails recruit signalling
molecules. By regulating cell fundamental behaviours (adhesion,
migration, proliferation, survival), integrin signalling pathways
contribute to the control of tissue integrity and homeostasis. To be
able to analyze the functions and signalling of integrin alpha6
beta4 in vivo in different tissues, we have generated a conditional
integrin alpha6-floxed mutant line. We are using this mouse model
to study the functional role of integrin alpha6 beta4 in intestinal
physiology and pathology.
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Despite improvement in earlier detection and treatment, prostate
cancer (PCa) still remains a leading cause of death in most Western
countries. CD151, a member of the tetraspanin superfamily is
involved in cell signaling, cell motility, cell adhesion, and tumour
metastasis by acting as a molecular facilitator recruiting groups of
specific cell-surface proteins and thus stabilizing functional
signaling complexes
1. CD151 was identified to be the first
tetraspanin member to be linked as a promoter of metastasis
2.
We have previously shown that CD151 has prognostic value in
PCa; patients with lower expression of CD151 protein have better
prognosis than patients with higher levels of expression
3. We are
now interested in CD151’s role in PCa as a motility and metastasis
promoter. Human PCa cell lines LNCaP and PC3 were used in cell
migration and invasion assays (Matrigel membrane; BD). The
motility and invasiveness of wild-type LNCaP (low endogenous
level of CD151) vs. CD151 transfected LNCaP cells and PC3
(high endogenous level of CD151) vs. CD151 knock-down PC3
cells (KD PC3) was analyzed. LNCaPs transfected with CD151
showed increased cell motility and invasion compared to control
LNCaPs (P<0.05), while KD PC3 cells demonstrated reduced cell
motility and invasion compared to control PC3s (P<0.05).
Currently, paired primary and secondary PCa tumors generated
using a SCID mouse model bearing implanted human PCa cell
lines are being examined for expression of CD151, and its
relationship to the density of blood and lymphatic vasculature
markers assessed using immunohistochemistry.
Although its mechanism in tumor progression is still unknown,
CD151 could be a valuable biological marker for the prognosis of
PCa.
1 Maecker HT et al. FASEB J. (1997) 11: 428–442
2 Testa JE et al. Cancer Research (1999) 59: 3812–3820
3 Ang J et al. Cancer Epidemiol Biomarkers & Prevention (2004)
13: 1717–21
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In B-cell chronic lymphocytic leukemia (B-CLL), malignant
cells are not susceptible to apoptosis in vivo, while they die
rapidly in vitro in the absence of specialized non-hematopoietic
feeder cells, such as mesenchymal stem cells (MSC). Recent
observations have suggested that there is a functional relation-
ship between B cell clone and the bone marrow (BM) stroma.
We have thus compared BM-MSC obtained from B-CLL patients
and healthy subjects.
We found that most BM-MSC cultures from B-CLL patients failed
under standard culture conditions, in contrast with normal BM. In
agreement, CD45
negCD14
negCD73
pos cells in unmanipulated BM
S138 S138samples (subset previously shown to contain CFU-F (Veyrat-
Masson et al., BJH, 2007)), were under the threshold of detection
in most of B-CLL BM samples. In productive cultures, we found
more CFU-F from B-CLL formed by large, polygonal MSC.
These cells proliferated poorly and in most cases could not be
further amplified. The use of soluble factors such as bFGF enabled
us to detect CFU-F in most malignant samples and to amplify
MSC but their frequency remained lower than in control BM. By
ELISA, we observed that CLL-MSC release higher amounts of IL-
6, IL-8, VEGF and MCP-1. Finally, among 384 genes tested by
RQ-PCR (TLDAs, Applied Biosystem) for 9 expanded BM-MSC
(5 untreated B-CLL ; 4 normal), we identified 16 statistically up-
regulated genes and 41 down-regulated genes. Up-regulated genes
included several growth and angiogenic factors as well as key
players of the stroma - tumor cell crosstalk. Most down-regulated
genes were involved in differentiation pathways.
These results show that CLL-MSC were quantitatively and
functionally altered and could be involved in the B-CLL specific
stromal cell alterations previously reported (dysregulation of
cytokine secretion, angiogenesis, host-tumor relationships). These
findings also suggest the possible permissive role of MSC on B-
cell clone progression.
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New well characterized models representing the heterogeneity of
human colorectal cancers (CRC) are needed to develop effective
therapeuticagents forthatindication; establishment ofsuchtoolswill
allow a better prediction of the clinical outcome, taking into account
the diversity of each patient tumor phenotype and genotype. For this
purpose and with the financial support of the French Ministry of
Industry, wehave associated effortsfrom hospitals, academic groups,
biotech and private pharmaceutical companies. From May 2007 to
October 2008, 63 surgical specimens [primary tumors (44) and /or
metastasis (19)] were collected from CRC patients after obtaining
informed consent and confirmation of negative HBV, HCV, and
HIVs serologies. Tumor samples were subcutaneously xeno-
grafted in Nude and SCID mice. Thirty-five transplantable
tumors were passed at least once in animals, indicating a high
take rate (55%). The established models are being evaluated forex
vivo and in vivo sensitivities to relevant anticancer drugs (5-FU,
oxaliplatin and irinotecan), histological and molecular character-
istics. Initial molecular characterization includes determination
of the MSI status, genetic annotation of APC, KRAS, BRAF,
TP53, CTNNB1, PI3KCA, FBXW7, and determination of gene
copy number using CGH technology. Preliminary molecular and
histological characterizations indicate a 35% KRAS mutation rate
on clinical samples, which is in accordance with the mutation
frequency described in the literature for CRC, and a high degree
of histological similarity between early passages of xenografts
and the original clinical tumor samples. All model characteristics
are being compiled in a web-based database for efficient features
search and interconnection. We will present the first character-
ized models and will discuss their usefulness and chance to bring
benefit to patients via novel therapeutic strategies.
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New blood vessel development is an important process in tumor
progression. In multiple myeloma (MM), the growth of neoplastic
plasma cells is directly regulated by neoangiogenesis. Evidence is
emerging that angiogenesis not only relies on the sprouting of resident
endothelial cells from preexisting vessels. Circulating endothelial
progenitors (CEP) derived from the bone marrow and blood
circulating endothelial cells detached from mature vessels (CEC)
may also contribute to postnatal angiogenesis. Upon cell activation,
procoagulant microparticles (MP) derived from platelets, leukocytes,
endothelial cells or erythrocytes are also found in circulating blood.
Besides their potential implication in cancer-associated thrombosis,
MPs are able to trigger an angiogenic program. Interestingly, MM is
characterized byan increased incidence of deep venous thrombosis. In
this context, we aimed to test the potential usefulness of studying
angiogenic markers (levels of CEP, CEC, VEGF, Endostatin) and MP
in circulation but also directly in the bone marrow, as potential
biomarkers for the prognostic and the follow-up of myeloma patients.
DNA+CD45- CD31+ CD146+ CD34+ circulating endothelial cells
were enumerated using a flow cytometer dedicated to the study of
rare events(Cyan
TM ADPAnalyser). Phenotypic specifications were
shown to be partly shared with plasma cells. Endothelial cell
phenotype was confirmed by immunocytochemistry using anti-von
Willebrand Factor staining and UEA-1 lectin binding. In parallel,
annexinV+CD41+ platelets-derived microparticles were quantitated.
Quantification and kinetics of occurrence of CEC, CEP and MP
should reflect vascular injury or malignancy and would be therefore
useful to optimize therapeutic options. This project aim to develop a
less invasive method to improve the patient management.
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We developed a human to mouse xenograft model of Neuroblas-
toma (NB) consisting of local and metastatic variants from each of
2 NB cell lines (MHH-NB11 and SH-SY5Y). The local and
metastatic variants derived from each of these tumors had the
same genetic background and could thus serve as an unlimited
source for the identification of specific NB metastasis biomarkers.
A NB-specific oligonucleotide-array detected 4 genes that were
differentially expressed both by stage 1 and stage 4 NB patients as
well as, correspondingly, by the local and metastatic MHH
variants.
These genes are: Damage Specific DNA Binding Protein 2
(DDB2) participating in DNA damage repair; Thymidine Kinase
1 (TK1) a cytosolic enzyme involved in DNAsynthesis; Hexoki-
nase 2 (HK2) an enzyme that participates in the glycolytic
pathway; Cingulin like 1 (CNGL1) a homologue of the tight
junction component Cingulin.
Protein level validation of the differentially expressed genes
revealed a similar pattern to that indicated by the microarray
analysis. Furthermore, HK2 and CGNL1 showed the same
expression pattern both in the SY5Y and MHH systems. We
hypothesize that a differential expression of these proteins by local
and metastatic NB variants is a general feature of NB metastasis.
In addition to an increased expression of HK2, the metastatic NB
variants exhibited also an increased activity of this enzyme.
Inhibition of HK’s activity by 3-bromopyruvic (3-BrPa), a specific
HK’s inhibitor, decreased the enzymatic HK activity in the local
variants, whereas the metastatic variants were resistant to the
effects of this compound. Furthermore, inhibitor-treated metastatic
variants manifested an increased enzymatic activity.
3-BrPa selectively killed the MHH and the SY5Y metastatic
variants compared to the local ones suggesting a dependence of
such cells on this enzyme.
This study was supported by grant from: Bonnie and Steven Stern,
New York, NY, USA.
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Ovarian cancer is the most common fatal gynaecological malig-
nancy in western country and is diagnosed at an advanced stage.
Epithelial ovarian cancer cells frequently metastasize by i)
formation of cell aggregates or spheroids in malignant ascite
which functions as a permissive microenvironment ii) implanta-
tion of these cell clusters onto the mesothelial surface of the
abdominal cavity (peritoneum) iii) invasion of the mesothelial
extracellular matrix (ECM) environment.
The aim of our study was to investigate adhesive and remodelling
events underlining these processes. Our previous studies
a,b,c incite
us to focus on vitronectin (Vn) and fibronectin (Fn), two ECM
proteins widely founded in ovarian cancer microenvironment,
especially in peritoneal mesothelium. We developed in vitro cell
culture method based on the inhibition of cell adhesion to a
substratum to generate multicellular suspension aggregates. In
these conditions IGROV1 ovarian cancer cells generate viable cell
clusters in suspension. Thus, we first studied the implication of Vn
and its main receptors (αv integrins) in the initiation of cancer cell
aggregates formation and second the Fn remodelling during
aggregates adhesion. In cells clusters, Vn and alpha-v integrins
are localized at cell-cell contacts. Addition of anti-Vn, anti-αv
integrins or cyclic peptide cRGDfV to cell culture inhibited initial
aggregates formation. Moreover, the remodelling of coated plasma
Vn and Fn was studied in the presence of IGROV1 cell
aggregates. Whereas Vn was weakly remodelled, Fn was
drastically dislocated. In this context, proteolytic activities are
investigated by Vn or Fn zymography.
These results suggest that Vn and its receptors contribute to the
formation of spheroids in ascite and that Fn dislocation could
facilitate ovarian adenocarcinoma cells dissemination through
peritoneal mesothelium.
a Leroy-Dudal et al., Int. J. Cancer, 114, 531–543, 2005
b Leroy-Dudal et al. Bull. Cancer, 95(9), 829–839, Review, 2008
c Heyman et al., Tumor Biology, 29, 231–244, 2008
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Background:
Heparanase is an endo-β-D-glucuronidase capable of cleaving
heparan sulfate, activity that is strongly implicated in cellular
invasion associated with tumor metastasis, angiogenesis, and
inflammation. Heparanase up-regulation was documented in an
increasing number of human carcinomas and hematological
malignancies, induction that was associated with increased tumor
metastasis, vascular density and shorter post operative survival
rate. These studies provide compelling evidence and a strong
clinical support for the pro-metastatic and pro-angiogenic func-
S140tions of the enzyme, positioning heparanase as an attractive target
for the development of anti-cancer drugs. In addition, heparanase
was noted to exert biological functions apparently independent of
its enzymatic activity, enhancing the phosphorylation of selected
protein kinases and inducing gene transcription. Protein domains
that mediate enzymatic activity-independent functions of hepar-
anase have not been so far elucidated.
Principle findings:
We utilized structure prediction server (http://www.robetta.org)t o
predict the three dimensional structure of active heparanase. The
structure obtained clearly delineates a TIM-barrel fold previously
anticipated for the enzyme. Interestingly, the model also revealed
the existence of a C-terminal domain (C-domain) apparently not
being an integral part of the TIM-barrel fold. We provide evidence
that the C-domain is critical for heparanase enzymatic activity and
secretion. Moreover, the C-domain was found to mediate non-
enzymatic functions of heparanase, facilitating Akt phosphoryla-
tion, cell proliferation, and tumor xenografts progression. Binding
experiments indicate the existence of high affinity, low abundant
cell surface receptor, and cross-linking experiments revealed the
existence of two major cell surface binding protein(s)/receptor(s)
complexes, exhibiting molecular weights of ~ 130 and ~ 170 kDa
that interact with heparanase C-domain.
Conclusions:
These findings support the notion that heparanase exert enzymatic
activity-independent function, and identifies, for the first time,
protein domains responsible for heparanase-mediated signaling.
Inhibitors directed against the C-domain, combined with inhibitors
of heparanase enzymatic activity, are expected to neutralize
heparanase function and to profoundly affect tumor progression
and metastasis.
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Tumor associated macrophages have been described in primary
tumors.Theypolarizetowards thealternatively activatedphenotype
(M2) with a distinct receptor and cytokine pattern and support
tumor growth. Less is known however about macrophage polari-
zation and the pro-tumoral macrophages in metastasis formation.
In a mouse model of experimental metastasis, we i.v. injected
B16F10 melanoma cells into C57BL/6 syngeneic mice and
monitored lung colony formation. In a time course of tumor cell
challenge, we analysed immune cell infiltration and cytokine
expression in order to characterize the metastatic lung environment.
Shortly after tumor cell injection (30 min), we found an inflamma-
tory response, involving Gr-1+, CD11b+, Ly6C+neutrophil and
monocyte infiltration that ceased within 24 h. After 24 h, we
observed CD68+, CD11b+monocyte/macrophage recruitment that
lasted no longer than up to 48 h of tumor cell challenge. The
recruited macrophages displayed a cytokine pattern resembling the
M1 macrophage subpopulation predominantly with IL-12 expres-
sion.Althoughwedidnotfindmacrophagerecruitment after48hof
tumor cell injection onwards, the cytokine pattern of the macro-
phages in the metastasis bearing lung shifted in favour of the M2
phenotype with typically higher IL-10 than IL-12 expression.
Co-culture of in vitro polarized bone marrow derived macrophages
and B16F10 cells helps reveal the mechanism driving the pro-
tumoral function of M2 macrophages in melanoma. In order to
investigate the involvement of macrophage receptors in the
establishment of a metastatic environment, we used macrophage
receptor deficient mice. Preliminary results show that scavenger and
mannose receptors might be involved in lung metastasis formation
in a tumor cell specific manner. The effect of macrophage receptor
deficiency on macrophage polarization will be discussed.
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Glioblastoma multiforme (GBM), the most aggressive type of
brain tumor, robustly infiltrates into normal brain parenchyma.
This diffuse infiltration precludes complete tumor removal, and
contributes to treatment failure and death. Therefore, approaches
that target cell migration would be expected to provide a
therapeutic benefit. The receptor tyrosine kinase EphA2 is highly
overexpressed in GBM tumor cells and its expression serves as a
negative prognostic factor. Functionally, EphA2 plays an essential
role in regulating GBM cell motility. We have found that GBM
cells secrete the intracellular chaperone protein heat shock protein
90 (Hsp90). Extracellular (eHsp90) possess distinct cellular
functions from the intracellular Hsp90 chaperone, and has been
implicated in promoting cell motility. Importantly, we now
identify a unique relationship between eHsp90-dependent signal-
ing and EphA2 activity. Interference with extracellular Hsp90
(eHsp90) suppresses EphA2 signaling and dramatically inhibits
GBM motility. eHsp90 has been proposed to signal via LRP1, a
multi-functional endocytic receptor. LRP1 is upregulated in GBM
cells and its expression correlates with cell migration and invasion.
Silencing of LRP1 also suppressed EphA2 signaling and dramat-
ically reduced cell motility, implicating an eHsp90-LRP1 signal-
ing axis in regulation of EphA2 activity. EphA2 is phosphorylated
by src and we show that perturbation of src signaling mimics the
effects of eHsp90 targeting or LRP1 silencing, thereby implicating
Src as a critical effector in EphA2 signaling. We propose that
eHsp90-LRP1 signaling crosstalks with EphA2 signaling via src.
Our results identify a novel mechanism by which GBM tumors
secrete Hsp90, which acts in a paracrine manner to induce
motility. We anticipate that interference with the eHsp90-LRP1
signaling axis will attenuate GBM infiltration in vivo. Experi-
ments are underway to elucidate whether other components of the
brain parenchyma may secrete eHsp90, thereby further contribut-
ing to GBM aggressiveness.
S141Poster No. 76
Maspin Inhibits the Invasion and Metastasis of Human
Tumor Cells
Brigitte Goulet
1, Wendy Kennette
1, Amber Ablack
1, Joe Mymryk
1,3,4,
Alan B. Tuck
1,2,4, Ann F. Chambers
1,2,4,J o h nD .L e w i s
1,3,4
1London Regional Cancer Program, LHSC, London, ON, Canada,
2Pathology, University of Western Ontario, London, ON,
Canada,
3Surgery, University of Western Ontario, London, ON,
Canada,
4Oncology, University of Western Ontario, London,
ON, Canada
Maspin (Serpin B5) is a tumor suppressor that promotes apoptosis
and inhibits angiogenesis, tumor formation and metastasis of
breast cancer. A number of early clinical studies found that
increased levels of Maspin were associated with a worse
prognosis, while others found decreased Maspin expression in
the primary tumor and undetectable levels in metastases. In
subsequent studies, it was found that nuclear localization
correlated with a well-differentiated phenotype, chemo-
responsiveness and improved survival. These clinical data suggest
that the anti-metastatic activity of Maspin resides in the nucleus.
However, the exact mechanism by which Maspin prevents
metastasis is unknown.
To investigate this, we assessed the effect of Maspin over-
expression in two human cancer cell lines that do not normally
express Maspin; MDA-MB-231-luc-D3H2LN, a lymph node-
tropic breast cancer cell line, compared to HEp3, a (head and
neck) squamous cell carcinoma. Over-expression of Maspin
inhibited invasion of both cell lines in the Boyden chamber assay,
but did not inhibit cell spreading of cells grown in Matrigel. In
vivo, it was observed that while Maspin expression did not affect
migration velocity, there was a 40% decrease in average
displacement compared to control cells. Over-expression of
Maspin in both cell lines resulted in diminished lung metastasis
using a spontaneous metastasis assay in chick embryos. However,
in an experimental metastasis model, the ability to seed secondary
sites and establish metastases was comparable to that of vector
control cells. These data indicate that Maspin expression inhibits
an early step in metastasis from a primary tumor.
Funded by a Post doctoral Fellowship Award from the Terry Fox
Foundation (to BG) and grant #016506 from the Canadian Breast
Cancer Research Alliance (to ABT, AFC, JDL).
Grant #018176 from NCIC/Terry Fox Foundation (to JDL).
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Tumor lymph vessels are a key component required for
tumor growth and metastatic progression. However, contro-
versy exists as to the origin of these vessels and the specific
cells that comprise them. In this study, the orthotopic B16
melanoma model was used to study the role of bone marrow-
derived cells (BMDCs) in lymphangiogenesis and lymph
node metastasis. In mice transplanted with bone marrow
from GFP transgenic mice, LYVE1
+/GFP
+ BMDCs were seen
at the invasive edge of growing tumors as early as seven days
post tumor implantation and were seen incorporating into
developing lymph vessels by day 10. Many of these cells were
also CD11b
+, suggesting a new role for myeloid cells in
lymphangiogenesis. CD45
+/CD11b
+/LYVE1
+ cells were also
detectable in the circulation by flow cytometry of peripheral
blood and this population increased with tumor progression.
The myeloid cell contribution in lymphangiogenesis was
further investigated by examining the function of vascular
endothelial growth factor receptor 1 (VEGFR1). VEGFR1 was
co-localized with LYVE1-expressing lymph vessels in the
primary tumor throughout the course of tumor progression.
Targeting VEGFR1 by neutralizing antibody resulted in
decreased LYVE1 expression at the primary tumor, decreased
lumen size and an overall delay in lymph vessel maturity at the
invasive edge of the primary tumor. A decrease in circulating
CD45
+/CD11b
+/LYVE1
+ cells was seen with VEGFR1 anti-
body treatment, as well as decreased lymph vessel diameter and
decreased metastases in local and draining lymph nodes.
Together these results demonstrate that VEGFR1-expressing
myeloid cells are important in the process of lymph vessel
development that is, in turn, necessary for local lymph node
metastasis and subsequent distant dissemination of tumor cells.
Early targeting of BMDCs via VEGFR1 blockade can hinder
lymph vessel maturation and thereby inhibit lymphatic metas-
tasis, thus serving as a novel therapeutic strategy in the
treatment of metastatic disease.
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In primary colorectal cancer (CRC) high densities of tumor
infiltrating lymphocytes (TIL) were shown to be correlated
with improved survival. TILs therefore represent a prognostic
tool in the treatment of CRC, a high density of immune cells
being associated with good outcome independently of other
established prognostic markers. We investigated the relation
between infiltrates of immune cells in liver metastases of CRC
and response to chemotherapy using immunohistochemical
staining. Liver samples from 33 patients with metastasized
CRC (samples from 22 patients were used as training set and
samples from 11 patients as validation set) were analyzed.
Patients underwent surgery after the initial workup appeared
to warrant complete surgical removal of the liver metastases.
In these patients, only partial resections were possible and
these patients received palliative chemotherapy afterwards.
Statistically significant differences within the training set
allowed prediction of response to chemotherapy by evaluation
of the invasive margin of the liver metastasis. Complete
sections were examined using an automated high-resolution
microscope.
The observed differences (see figure, CD3 positive cells stain
dark red, panel A shows a sample with high infiltrate density,
panel B shows a sample from another patient with low
density) in TIL densities also translated into differences in the
time to progression under chemotherapy, where higher
numbers of positively stained cells were associated with
longer intervals. The difference between the groups with
either response or no response to chemotherapy in time to
progression was statistically significant (Mann-Whitney-U,
p<0.001, two-tailed, z=−3,961, n=33). Our results suggest
that the immune system influences efficacy of chemotherapy.
We have first evidence that the impact of the local immune
response on the clinical course is a general phenomenon, not
limited to the primary tumor but also present in metastatic
lesions. This might have implications for the assessment of
therapy options.
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Therapy resistance is a major problem in the treatment of breast
and ovarian cancer. We observed in our expression profiling study
in breast cancer a gene cluster of ECM related genes, with a
similar expression pattern, that was associated with first-line
tamoxifen response in advanced breast cancer (Jansen et al. J Clin
Oncol 2005). We subsequently validated these ECM genes
(COL1A1, FN1, LOX, SPARC, TIMP3, TNC) in 1286 breast
carcinomas using qPCR.
High TIMP3, FN1, LOX and SPARC expression is associated
with a worse prognosis for 680 untreated lymph node negative
patients (p<0.03) that is independent of traditional prognostic
factors for FN1, LOX and SPARC. Interestingly, only high
TNC expression was associated with resistance to tamoxifen
treatment in the adjuvant (n=145, HR=1.42, p=0.004) as well
as the advanced setting (n=298, HR=1.20, p<0.001). This
association is independent of traditional prognostic and predic-
tive factors.
Moreover, in ovarian cancer we also identified a gene cluster of
ECM related genes with a similar expression pattern that was
S143associated with platin-based chemotherapy resistance (Helleman et
al. Int J Cancer2006). Pathway analysis of both ECM gene clusters
using Ingenuity Pathway Analysis (IPA) showed that both clusters
form one gene network with transforming growth factor beta
(TGFB) as the key gene. This suggests that TGFB is involved in
the regulation of these ECM genes.
We hypothesize that binding of cancer cells to different ECM
proteins could result in a similar growth stimulus via integrins
possibly together with growth factor receptors. This growth
stimulus could overrule the apoptotic signal generated by
chemotherapy or could make breast cancer cells independent
of the estrogen growth signalling. By analyzing publicly
available data we currently investigate whether the ECM,
TGFB and related miRNAs, play a general role in therapy
resistance (e.g. endocrine, chemo-, radiotherapy) in different
tumor types.
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Prostate cancer (PCa) progression after androgen deprivation
therapy resulting from up-regulation of lipogenesis pathways
and increased intra-tumoral production of androgen from
cholesterol has been previously reported by us. We are interested
in the role of cholesterol-trafficking triggering androgen synthe-
sis and the ability of xenobiotics to alter this. Presence of lipid
rafts (LR) in cholesterol-rich prostasomes are the communica-
tion entities that act within the tumoral microenvironment
(Fig1). We recently demonstrated presence of steroidogenesis
enzymes in circulating prostasomes. The current study was
designed to establish cell line models for use in evaluation of the
effects of xenobiotics on LR signalling involved in prostasome
formation and the role of prostasomes as steroidogenesis
enzyme transporters.
We evaluated a panel of human PCa cell lines to determine their
ability to undergo steroidogenesis as compared to that previously
determined in LNCaP cells in vitro. We used both a ‘snapshot’
approach using tandem LCMS/MS analysis to profile the presence
of steroids in PC3, DU145, LNCaP, VCaP and C4-2 cells in an
androgen-deficient environment, as well as treatment with a radio-
labelled androgen precursor to monitor downstream androgen
production using radiomatic HPLC in conjunction with LCMS.
Prostasomes isolated from PC-3 and VCaP cells were imaged
using transmission electron microscopy.
Cell lines known to express androgen receptor, including the
androgen-resistant C4-2 cells, are efficient at producing androgens
while PC-3 and DU145 cells do not produce androgens. The use
of these model systems is important for studying the effects of
xenobiotics on LR signalling involved in prostasome formation as
well as the potential role of prostasomes as steroidogenesis
enzyme transporters.
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Most animal models typically involve ectopically implanted
cancer cell lines. Since tumor-stroma interactions are organ
specific, and cancer cells undergo profound changes during in
vitro culture, the resulting tumors have a limited relevance to the
patient tumor. To address this issue, we inserted human colorectal
tumor biopsies onto the ceacal wall of scid mice, and used a mice
strain expressing the green fluorescent protein (GFP) to enable
separation of the tumor and host compartments.
Biopsy specimens from 8 histologically verified colorectal cancers
(CRC) were minced into pieces that were xenografted in 20 GFP-
scid mice. The animals were palpated for tumors, of which some
were subsequently monitored in vivo, using a small animal, 7
Tesla, Magnetic Resonance Imager. Tumor imaging parameters
such as tumor size, vascularity and presence of metastatic sites
were assessed. At this stage, 9 animals have been sacrificed due to
prominent disease, and tumor growth was histopathologically
confirmed in all cases. However, the remaining 11 animals have
considerable palpable tumour masses, suggesting a 100% tumor
take rate. Preliminary analysis suggests that the pathological
S144staging and TNM of the patient tumors does not impact survival
times, ranging from 42 to 448 days.
The tumors demonstrate a histoarchitecture similar to the parent
tumors. These studies will be extended to include immunohisto-
chemical staining for markers of stromal activation. Moreover,
tumors have been dissociated and FACS sorted into GFP cancer
and GFP
+ stromal cell populations of more than 95% purity,
providing a valuable tool for in vitro experiments.
We conclude that this model mimics the histopathological features
of human CRCs, and provide reproducible high take rates.
Furthermore, the fluorescent mouse phenotype is useful for
separation of tumor and host compartments, allowing further
studies of tumor-stroma interactions.
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Notch signaling plays critical roles in the progression of human
malignancies, however the precise role and mechanism of Notch1
in tumor invasion and metastasis remains unclear. In an earlier
report, our group demonstrated that Notch1 truncation occurs
frequently in retrovirus-induced thymomas in MMTV/c-myc
transgenic mice producing the overexpression of a distinct
secreted Notch1 mutant product. It was hypothesized that this
Notch1 mutant plays a role in neoplastic progression. In order to
assess this, transgenic mice were generated to overexpress the
mutated form of Notch1 in T cells and the myeloid lineage.
Recently, it was found that tumor progression is facilitated in
transgenic mice treated with chemical carcinogen. In addition,
increased pulmonary metastasis was observed when syngeneic
breast tumor cells were inoculated in these mice. Transplantation
studies reveal that the observed increase in metastasis in our
model is due to hematopoietic cells, and further inoculation
studies demonstrate that this is occurring through a paracrine
loop. Additionally, transgenic primary subcutaneous tumors have
increased microvascular density and are highly necrotic compared
to wild-type controls. Early findings from preliminary experi-
ments suggest increased tumor permeability within primary
tumors, as well as increased intravasation in tumor-bearing
transgenic mice.
A major barrier to successful long-term cancer treatment is
recurrence and metastatic spread. The outcome of these studies
will allow us to determine a clear functional role for Notch1
involvement in tumor microenvironment and metastasis, as well as
lead us to the identification of mechanisms involved in this novel
pathway of cancer spread. From this, we can form a basis from
which we can identify potential new molecular targets for the
development of rational cancer therapies in the future.
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Background: A NOD/Scid mouse expressing enhanced green
fluorescent protein (eGFP) has been developed and established
with different transfected dsRed cell lines (1). We wanted to
develop a mice mammary tumor model (4 T1) in these eGFP mice
and use this model to further explore our previous observations of
a significant decrease in tumor growth in DMBA induced
mammary tumors in rats after hyperbaric oxygen treatment (2–3).
Methods: We injected 3 million dsRed transfected cells into the
eGFP mice, subcutaneously in the groin-area. After the tumors had
become ~ 3 mm in diameter the mice were divided in two groups.
One group was exposed to 2,5 atm pure oxygen (3 exposures a
90 min), whereas another was housed under normal atmospheric
conditions and served as controls. Using light microscopy as well as
multiphoton confocal microscopy, we investigated the tumor-host
interaction in situ. The effect of the treatment on tumor volume was
determined by measuring the tumor size with a caliper day 1, 4 and 8.
Results: The experiments confirmed that we have established a
very aggressive dsRed mammary tumor in the eGFP mice, showing
the tumor cells invading the stromal cells as well as a number of
vascular elements in situ. Furthermore, tumor growth was signifi-
cantly reduced after HBO treatment compared to control animals
and a significant decrease in collagen density was also found.
Conclusion: We have established a dsRed mammary tumor in
eGFP expressing mice. This model will enable us to study tumor-
stroma interactions in a new and more specified way. The
reduction in tumor growth and collagen density found in the
HBO treated tumors will be further elucidated.
References:
1. Niclou SP et al. Faseb J; 22, 3120–3128, 2008.
2. Stuhr LEB et al. Cancer Letters, 210 (1), 35–40, 2004.
3. Raa A et al. BMC Cancer, 30 (7), 23, 2007.
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The communication between the tumor cells and the surrounding
cells helps to drive the process of tumor progression. Especially,
angiogenesis by endothelial sprouting from preexisting venules
facilitates solid tumor growth by providing oxygen and nutrients
to proliferating cells, and acts as a physical route for metastasis
transport. Therefore, detection of anti-angiogenic agents is one of
the most promising approaches to control tumor progression.
Vascular endothelial growth factor (VEGF), a major angiogenic
factor, is produced by many tumor as well as normal cells, and
induces the expression of various angiogenesis-related proteins
such as interleukin-8 (IL-8). Platycodin D, the major constituent in
the root of Platycodon grandiflorum, has been reported to have a
number of pharmacologic activities including anti-inflammatory
and anti-allergic activities. In this study, we examined the ability
of platycodin D to interfere with the various steps of angiogenesis.
Platycodin D treatment inhibited VEGF-induced adhesion, prolif-
eration, DNA synthesis, chemotactic motility and tube formation
in a dose-dependent manner in primary cultured human umbilical
vein endothelial cells (HUVECs). Platycodin D reduced VEGF-
induced phosphorylation of ERK1/2, p38 and JNK, closely
associated with tube formation of HUVECs, and also reduced
the IL-8-induced tube formation as well as VEGF-induced
IL-8 expression in HUVECs. Furthermore, the anti-angiogenic
activity of platycodin D was confirmed by performing the Matrigel
plug assay in mice. In a mouse tumor xenograft model, platycodin
D inhibited the growth of MDA-MB-231 breast carcinoma, and
reduced the expression of VEGF, CD34 and IL-8. Taken together,
our results indicate that platycodin D exerts anti-angiogenic action
by regulating MAPKs activation and IL-8 expression. Therefore,
platycodin D may beneficial for prevention and treatment of
angiogenesis-dependent human diseases such as tumor.
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Changes in the immunological equilibrium in the tumor microen-
vironment are critical for the progression of a developing tumor,
allowing tumor escape from immune surveillance and metastases.
We have identified that invasive B16 F10 melanomas naturally
secrete CCL21, a ligand for CCR7, which is used by dendritic
cells and naïve T cells to home to the T cell zone of the lymph
node to initiate an immune response. B16 F10 melanoma cells
were engineered to either knockdown, maintain or over-express
CCL21. Chemokine secreting tumors, but not knockdown var-
iants, attracted CCR7
+ lymphoid tissue inducer cells (LTis,
CD45
+CD3
−CD4
+IL-7Ra
+ROR-γt
+) into the tumor and drove
lymphoid-like changes in the tumor microenvironment including a
reticular fibroblast stromal network (CCL21
+gp38
+ ERTR7
+-
LYVE-1
−) surrounding the tumor, HEV-like vessels (ERTR7
+
PNAds
+LYVE-1
−) inside the tumor, and, importantly, an over-
expression of complement regulating receptors. This microenvi-
ronment, reminiscent of the T cell zone in the lymph node,
attracted naive T cells into the tumor where, we hypothesized, they
could be educated towards a tolerogenic phenotype only in a
regulatory microenvironment. Recent studies have suggested a role
of complement in tumor growth, and since complement can serve
both immune regulatoryand functionalrolesdepending its processed
form, weimplanted thesetumors intoC3-/-mice. We found that both
CCL21expressingandknockdowntumorsgrewpoorly,andCCL21-
secreting tumors could not drive a regulatory Tcell response as they
did in wild type mice. These findings suggest that invasive tumors
may utilize complement dependent strategies in the newly formed
quasi lymph node microenvironment, to further provide a regulatory
environment for in situ education of Tcells shifting the host immune
response from a functional to regulatory repertoire.
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Purpose: Pro-inflammatory processes of the early postoperative
states may induce peritoneal metastases in patients with advanced
diseases. To identify that wound healing response after an abdominal
incision leads to increased MMP-9 activity locally, therefore
providing a favorable environment for peritoneal metastasis. In-
creased MMP9 in a post-operative injury setting increases the number
and severity of peritoneal metastasis when compared to mice without
wounds.
Methods: Eighteen C57bl/6 J male mice were obtained at 8 weeks of
age. Metastatic tumors were initiated using a peritoneal injection
model with syngeneic MC38 murine colon cancer cells. Peritoneal
injections were performed into the intraperitoneum at right lower
quadrant area via 25G syringe. A 1.5 cm upper midline incision was
made in the abdominal wall to recapitulate the postoperative wound
model. The abdominal wall was closed by a continuous 4-0 prolene
suture with 5 stitches. Mice were sacrificed at various time points.
And we observed the rate of the peritoneal metastasis from each
group.
Results: By making incision into the abdominal wall, we induced
inflammation of the mouse and observed the incidence of the
peritoneal metastasis was increased(Fig.1). Early stage of wound
healing process increases pro-inflammatory cytokines and number
S146of inflammatory cells in the peritoneum, and this leads to increase
pro-MMP9 proteins. And the inflammatory process which
initiated by the wound, in turn, increased the proliferation of the
mesothelial cells and provoked expression of the inflammatory
cells and increased parietal peritoneal metastasis.
Conclusion: stage of wound healing process increases pro-
inflammatory cytokines and number of inflammatory cells in the
peritoneum, and this leads to increase pro-MMP9 proteins. So the
increased pro-MMP9 proteins play a key role on the growth and
progressions of cancer cells in peritoneal metastasis.
Figure 1.
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Inflammatory cells have been widely accepted to contribute to
tumor formation and progression. In a HaCaT model for human
squamous cell carcinoma (SCC) of the skin, we have observed
that infiltration of inflammatory cells does not only promote
tumorigenesis but is indispensable for persisten angiogenesis and
the development of malignant tumors. Analysis of the inflam-
matory infiltrate revealed that the majority of the inflammatory
infiltrate constitutes of CD11b
+/Gr-1
+ cells. Depletion of these
cells from tumor bearing nude mice resulted in a decrease in
tumor growth, reduced angiogenesis and an inhibiton of tumor
invasion. In order to characterize the tumor-supporting capacities
of inflammatory cells we analysed the contribution of neutro-
phils and macrophages to tumor invasion in vitro. We were able
to demonstrate that both cell types strongly enhance invasion of
SCC tumor cells in the presence of exogenously added
stimulating cytokines while they do not influence invasion
without additional cytokine stimulation. This implies that
inflammatory cells need stimulation by specific mediators to be
activated towards a tumor supporting phenotype. In this context
we are currently analysing selected stimulatory factors with
respect to their influence on both neutrophils and macrophages
and have identified a novel factor that activates these two cell
types.
Poster No. 88
Ovarian Cancer Cells Acquire Chemoresistance through
Intercellular Transfer of MSC-Derived PgP
Raphaël Lis
1,2, Pejman Mirshahi
2, Rowaida Ziad Taha
1, Mary
Poupot
3, Eliane Mery
4, Jean Jacques Fournié
3, Denis Querleu
4,
Massoud Mirshahi
2, Arash Rafii
1
1Stem Cells Research, Weill Cornell Medical College - Qatar,
Doha, Qatar,
2Tumor cells resistance, Centre de Recherche de
Cordeliers - INSERM U872, Paris, France,
3Oncology, Centre de
Physiopathologie Toulouse Purpan - INSERM U563, Toulouse,
France,
4LFR 44, IFR 31, Institut Claudius Regaud, Toulouse,
France
Background:
The microenvironment plays a major role in the onset and
progression of metastasis. Epithelial ovarian cancer (EOC) tends
to metastasize to the peritoneal cavity where interactions within
the microenvironment might lead to chemoresistance. Mesothelial
cells and particularly Mesenchymal Stem Cells (MSC) are
important actors of the peritoneal homeostasis; we determined
their role in the acquisition of chemoresistance of ovarian tumours.
Methodology/Principal Findings:
We isolated MSC from ascitis of patients with ovarian carcinosis
using limiting dilution. We studied their ability to confer chemo-
resistance through heterocellular interactions. These MSC derived
from ascitis diplayed positive immunostaining for CD9, CD10,
CD29, CD146, CD166 and Multi drug resistance protein, as
described in the litterature. They preferentially interacted with
epithelial ovarian cancer cells. This interaction induced chemo-
resistance to platin and taxans with the implication of multi-drug
resistance proteins. This contact enabled EOC cells to capture
patches of the MSC membrane through intercellular transfer of
S147membrane and proteins (also referenced as trogocytosis), therefore
acquiring their functional P-gp proteins and thus developing
chemoresistance. Presence of MSC in ovarian cancer tissue
micro-array from patients with neo-adjuvant chemotherapy was
also significantly associated to chemoresistance.
Conclusions/Significance:
This is the first report of intercellular transfer of protein
occurring between a cancer cell and a stromal cell (here MSC).
This interaction induced autonomous acquisition of chemo-
resistance. The presence of stromal cells within patient’s tumour
might be predictive of chemoresistance. The specific interaction
between cancer cells and stromal cells might be targeted during
chemotherapy.
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EGFR is an important regulator of breast cancer progression and is
capable of integrating multireceptor signaling pathways to
promote metastasis. Through these interactions, EGFR is subject
to extensive regulatory cues from the extracellular matrix (ECM),
of which the extracellular glycoprotein hyaluronan (HA) is a
major component. In mammary tumors, HA is deposited in the
stromal compartment surrounding tumor epithelium where it
functions in both biomechanical support and, through binding to
the adhesion receptor CD44, modulates intracellular signaling. We
have used a 3D collagen culture system in which HA is either
polymerized into a collagen matrix to mimic epithelial-stromal
interactions or provided soluble in the media (sHA). We have
found that collagen-embedded HA (eHA) inhibits EGFR activa-
tion and alters cell morphology by inhibiting filopodia formation
while soluble HA promotes these events. The ability of cells to
spread on a collagen matrix is also impaired on eHA, demonstrat-
ing a novel function for eHA in regulating cell morphology and
membrane dynamics. Inhibition of EGFR and alterations to cell
morphology are due to cell-matrix interactions, as collagen
polymerization is unaltered by eHA. EGFR interaction with the
HA receptor, CD44, is impaired on eHA suggesting that this is a
mechanism by which HA regulates EGFR activity. Furthermore,
given the ability of EGFR to alter cell morphology on a matrix, we
have examined the ability of erbB ligands to regulate cell
morphology on diverse matrix substrates and have found that
these ligands induce collagen-dependent changes indicative of
EMT. These findings highlight a novel role for eHA as a
protective molecule when encountered in the collagen matrix
during cancer progression, while reinforcing the tumor promoting
effects of sHA, and demonstrate the ability of the ECM to alter
erbB-dependent EMT.
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Most tumors are characterized by an acidic and hypoxic
microenvironment that promotes metastasis. The Na
+/H
+ exchang-
er (NHE-1) plays an important role in the regulation of pH
homeostasis. It has been demonstrated that NHE-1 is constitutive-
ly active in tumor cells, promoting cell invasion, but the
mechanisms are not defined. One of the ways that tumor cells
are able to promote invasion is by forming invadopodia.
Invadopodia are actin-rich structures that are responsible for focal
concentration of matrix-metalloproteases (MMP) that degrade the
extracellular matrix. Our lab has shown that hypoxia significantly
increases invadopodia formation in human fibrosarcoma cells (HT-
1080). Also, it has been demonstrated that MMP degrading
activity is dependent on extracellular acidic pH. Therefore, the aim
of our study is to identify the role of NHE-1 in hypoxia-induced
invadopodia production. We observed that hypoxic stimulation
increases NHE-1 mRNA and protein expression. Intracellular pH
monitoring by live-cell imaging revealed that NHE-1 activity is
also increased in hypoxic conditions. Using inhibitors and
shRNA-mediated depletion, we demonstrated that NHE-1 partic-
ipates in invadopodia formation in HT-1080 cells. Zymography
assays showed that inhibition of NHE-1 activity resulted in
the loss of MMP activation. Disruption of extracellular pH
abolished invadopodia-mediated matrix degradation. Moreover,
NHE-1 overexpression stimulated invadopodia formation and
invadopodia-associated matrix degradation. Alltogether, our
results indicate that NHE-1 is involved in hypoxia-dependent
matrix degradation by invadopodia and suggest a mechanism by
which the hypoxic and acidic tumor microenvironment promotes
metastasis.
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Multiple myeloma is the second most common haematopoietic
malignancy and remains incurable. The mechanism of survival
S148and proliferation of myeloma cells depends on the bone marrow
microenvironment, the specific location where myeloma expan-
sion occurs. Activation of growth factor pathways such as IGF-1
and IL-6 provide myeloma cell growth and drug-resistance.
Recently, myeloma cells were shown to respond to IGF-1 and
IL-6 via strong PKB/Akt activation. Although deregulation of Akt
during myeloma tumorigenesis has been confirmed by many
studies, it is currently unknown which Akt isoform is induced
most frequently by growth factors.
In order to assess growth factor-induced upregulation of
distinct isoforms we elucidated Akt isoform profile for the first
time in multiple myeloma. Both Akt1 and Akt3 were the
predominant active isoforms in myeloma cell lines. Interesting-
ly, activated Akt3 was induced by IGF-1 or IL-6 in all tested
myeloma cell lines, showing the highest response for strong
Akt activation in a milieu that corresponds to the tumour
microenvironment. Experiments using siRNA-induced knock
down of the isoforms indicated a central role for Akt3 during
myeloma cell migration and adhesion to stroma cells, high-
lighting for the first time a crucial implication for Akt3 during
myeloma progression. Further analyses on bone marrow of
myeloma patients are currently performed to elucidate the
clinical rationale of distinct Akt isoforms for targeted thera-
peutic intervention.
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The Epithelial cell adhesion molecule (EpCAM) is a calcium-
independent homophilic cell adhesion molecule and is over
expressed in a variety of tumours, such as breast and colon
cancer. EpCAM, a cell surface antigen with oncogenic features
can modulate cell-cell contacts by antagonizing E-cadherins and
therefore support invasion and metastasis.
To gain insights into molecular changes following EpCAM
overexpression, we decided to establish breast cancer cell line
models stably overexpressing EpCAM. Therefore, two EpCAM
negative human epithelial breast cancer cell lines, Hs578t and
MDAMB-231 were selected. Both cell lines Hs578t and MDA-
MB231 were transfected with the pIRESpuro3_EpCAM plas-
mid and after selection the resulting cell lines were named
Hs_EpCAM and MDA_EpCAM. Cells were also transfected
with the pIRESpuro3 empty vector and resulting cells were
named Hs_control and MDA_control, respectively. After
selection of stable lines, EpCAM gene expression was
compared to that of the positive control breast cancer cell lines
MCF-7 and SkBr-3. The localisation of EpCAM protein in
Hs_EpCAM and MDA_EpCAM cell lines was analysed by
immunofluorescence and confocal fluorescence microscopy.
Expression was compared with positive controls MCF-7 and
SkBr-3. Notably, cell density was very important for the
localization of EpCAM. Highly dense cultures showed high
membranous EpCAM staining, while cells lacking interactions
with neighbouring cells exhibited weaker membrane but
stronger cytosolic staining.
The findings obtained by analyzing EpCAM overexpressing
breast cancer cell line models suggest that EpCAM tumour
promoting function is specific for each distinct cell type and can
be mediated by different strategies depending on the cellular
microenvironment.
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Introduction: Dendritic cells (DC’s) are the most potent
antigen presenting cells that play an important role in cancer
immunity. The importance of DC’s in governing response to
therapies in colorectal cancer patients is unknown. Factors
released from the tumour microenvironment may inhibit DC
function, maturation and activation in the tissue. Circulating
levels of myeloid and plasmacytoid DC’sm a ya l s ob e
affected.
Aims: The aim of this study is to assess the levels of circulating
plasmacytoid DC’s (pDC) and myeloid DC’s (mDC) in colorectal
cancer patients with different tumour staging pre-surgery and post
surgery
Methods: Whole blood was obtained from 30 patients pre-surgery,
10 patients post-surgery and 11 healthy controls. Cells were
stained with Lin1-FITC, CD1c-PE, CD303-APC and their
corresponding isotype controls. Samples were analysed by flow
cytometry and levels of plasmacytoid and myeloid DC’s were
measured as percentage of total cell number. Statistical analyses
were performed using student t-test.
Results: Plasmacytoid dendritic cell populations were signifi-
cantly lower in cancer patients compared to healthy controls (p=
0.0001). Myeloid dendritic cell populations were also lower in
cancer patients. A decreasing trend was observed in plasmacytoid
DC levels with increasing stage, and this was statistically
significant for stage II (p=0.03, n=8) and stage III (p=0.004,
n=12) cancers. Myeloid DC numbers also showed a declining
trend with increasing stage. 5 patients showed an increase in
S149post-surgery circulating pDC levels compared to pre-surgery. 4
additional patients showed a decrease in pDC levels post-surgery,
and 1 patient had the same levels of pDC pre- and post-surgery.
A similar trend was seen for the myeloid DC population.
Conclusion: Colorectal cancer patients have significant lower
numbers of plasmacytoid DC, but not myeloid DC compared to
healthy individuals, and interestingly, this is associated with
severity of disease.
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Many similarities exist between the stroma at sites of wound
repair and reactive stroma in cancer. Common features include
an elevated stromal cell proliferation, altered expression of
matrix components, expression of several common stromal
markers, and neovascularization. Although emerging data points
to the fundamental role that carcinoma associated stromal cells
play in angiogenesis, little is known about specific mechanisms
and key regulatory components in prostate cancer or other
tumors. In this report, benign or malignant human prostate tissue
harvested by radical prostatectomy, and transplanted into SCID
mice implanted with testosterone pellets, demonstrate an explo-
sive burst of angiogenesis by human blood vessels between Days
6–14 after transplantation. The nascent vessels exhibited alter-
ations in structure and function similar to tumor blood vessels,
and leaked serum components into the interstitial tissue space
until the vessels matured by establishing interactions with
pericytes. The wave of human angiogenesis was preceded by a
striking increase in expression of VEGF-A in the human prostate
stroma. The over-expression of VEGF-A during the initial days
after tissue implantation, and the subsequent increase in micro-
vessel density, was concurrent with the appearance of a reactive
stroma phenotype, as determined using Masson’s trichrome stain
and immunohistochemistry analysis for the expression of α-
SMA, Vimentin, Tenascin, Calponin and Desmin. These results
suggest that the stromal present in the human prostate xenografts
undergo activation potentially comparable to what occurs in a
tumor microenvironment and suggest that VEGF-A is a
candidate regulator of reactive stroma generation. A better
understanding of the mechanism(s) of modulation of the human
prostate stromal activation could have significant implications
for more effective modeling of new forms of anti-angiogenic
therapies for prostate cancer, and for developing targeted
adjuvant therapies to improve the efficacy of androgen depriva-
tion therapy.
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CD44 is a cell surface receptor for the glycosaminoglycan
h y a l u r o n a n( H A ) .O v e r e x p r e s s i o no fH Aa n dC D 4 4i nb r e a s t
cancer correlate with poor prognosis and distant recurrence. In
vitro, CD44 signaling underpins breast cancer cell invasion and
cell adhesion. Initial experiments revealed that RNAi-mediated
suppression of CD44 alone markedly attenuated the magnitude
and rate of invasion demonstrated by MDA-MB-231 breast
cancer cells through collagen-enriched matrices. Therefore, the
objective of this study was to determine the proteolytic targets of
CD44 signaling in breast cancer cells that assist in promoting
localized invasion and intravasation. Urokinase plasminogen
activator (uPA) is a serine protease whose increased activity has
been implicated in the potentiation of cancer cell intravasation
and whose elevated expression also correlates with poor
prognosis in breast cancer. Our further experiments conducted
in the invasive breast cancer cell line MDA-MB-231 demon-
strates that HA-induced CD44 signaling increases the transcrip-
tion of the uPA gene and that of its cell-surface expressed
receptor (uPAR). Furthermore, immunoblotting confirms in-
creased expression of uPA and uPAR in HA-stimulated MDA-
MB-231 cells. Parallel assays studying the effects of HA upon
the endogenous inhibitors of the uPA system, PAI-1 and PAI-2
confirm an increased expression of PAI-1 but not PAI-2 in the
MDA-MB-231 cells. Further immunoblotting and substrate-
based activity assays confirm that the resultant impact of HA-
induced CD44-mediated signaling is to increase the cell-surface
associated uPA activity in these breast cancer cells. Our
continuing studies are aimed at demonstrating the link of this
CD44-promoted uPA activity in underpinning the CD44-
promoted invasion of collagen matrices and experimental models
of cross-linked collagen-enriched basement membranes, and
exploiting in vivo models to demonstrate the linkage of CD44
signaling and uPA activity to the enhanced rates of breast cancer
cell intravasation.
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S150As it is known that irradiation can influence cellular metabolism it
is conceivable that it can induce metabolic changes which lead to a
predisposition of certain cells to show enhanced survival,
migratory activity and metastasis. The aim of this study was to
investigate short term and long term irradiation effects on
proliferation and metabolism of melanoma cells in vitro and their
ability to form metastases in vivo.
B16-F10 melanoma cells were irradiated with different doses of
X-ray irradiation in the range of 1 to 20 Gy. One, two, and three
days (short term effects) and, furthermore, 7, 14 and 21 days (long
term effects) after treatment cells were analyzed concerning cell
growth, proliferation, viability, glucose and amino acid transport.
Additionally, we performed in vivo studies in a syngeneic mouse
model to analyze the capability of irradiated melanoma cells to
form lung metastases.
The analysis of short term effects showed decreased cell growth,
viability and arrest in the G2/M phase of the cell cycle while
glucose transport is increased. Long term effects involve recov-
ered proliferation, accompanied by increased glucose transport
and decreased viability and amino acid transport. In vivo studies
showed loss of metastasis immediately after irradiation and
reduced metastasis if cells were allowed to recover proliferation
before injection.
We conclude that melanoma cells as short term response to
irradiation show cell cycle arrest and impairment in growth and
viability. Three days after irradiation compensatory mechanisms
start, leading to recovered growth within three weeks. Studies
concerning metabolic properties indicate that a subpopulation of
surviving melanoma cells compensate for the initial irradiation-
induced damage possibly by metabolic modulations such as
increase in glycolysis. As metastasis in vivo is impaired beyond
recovered cell proliferation, the role of adjusted cell metabolism
and additional extrinsic factors is strongly suggested.
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Chronic Lymphoytic Leukemia (CLL) is an adult B cell leukemia
with highly variable clinical prognosis. CLL is divided into two
prognostic subgroups based on the expression of the tyrosine
kinase ZAP-70, as high ZAP-70 (ZAP-70+) expression correlates
with more aggressive disease and low/no ZAP-70 (ZAP-70-)
correlates with more indolent disease. CLL cells exhibit enhanced
survival properties in vivo yet rapidly die in cell culture. However,
coculture of CLL cells with stromal associated cells called Nurse-
Like Cells (NLCs) keeps the CLL cells alive in culture, suggesting
that the microenvironment plays a critical role in CLL survival.
One of the factors known to be secreted by NLCs that contributes
to survival in vitro is the chemokine, CXCL12. While CXCL12
clearly enhances CLL survival, relatively little is known regarding
its mechanisms of action or differences in effects on the ZAP-70
subsets. In order to elucidate the mechanisms by which CXCL12
contributes to CLL survival, we have directly probed known
survival signaling pathways, e.g. Akt and ERK1/2, and used
phosphoproteomics to determine novel signaling events that may
be important to this process.
Our results indicate that while CXCL12 stimulates Akt and
ERK1/2 activation in both CLL subgroups, the intensity and
duration of activation is enhanced in the ZAP-70+ CLLs,
especially for ERK1/2. Upstream signaling events of ERK1/2
also appear to be enhanced in ZAP-70+ cells. However,
expression levels and turnover rates of CXCR4, the receptor
for CXCL12, were not found to differ significantly between
the two subgroups. Additionally, while many similar down-
stream targets of Akt and ERK1/2 pathways appear to be
activated in both ZAP-70 subgroups, phosphoproteomics has
revealed some CXCL12-stimulation targets, e.g. HSP27, that
are characteristic of select patients, highlighting the underlying
heterogeneity of CLL and difficulties in fully understanding its
pathogenesis.
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Stromal fibroblasts contribute to tumor growth and drug sensitiv-
ity. PDGF receptor signaling is important for the stromal
recruitment and growth. Previous studies have suggested hetero-
geneity of PDGF receptor expression in tumor stroma. We
therefore investigated, by immunohistochemistry, the potential
prognostic and response predicative roles of stromal PDGF
receptors in breast cancer.
In a population-based cohort of breast cancers we found
associations between PDGF β-receptor status and clinico-
pathological characteristics. High stromal PDGFβ-receptor ex-
pression was significantly associated with high histopathological
grade, ER negativity and high HER2 expression. High stromal
PDGF β-receptor expression also correlated with significantly
shorter recurrence-free and breast cancer specific survival. The
prognostic significance of stromal PDGF β-receptor expression
was particularly prominent in tumors from pre-menopausal
women.
S151In an independent material, derived from a phase III study of
adjuvant tamoxifen, we analyzed the response-predicative role of
stromal PDGF β-receptor expression. When patients were divided
according to stromal PDGF receptor expression, it was noted that
the therapeutic benefit of tamoxifen was much more prominent in
the group with low stromal PDGF receptor expression. These
results suggest a previously unrecognized response-predicative
role of stromal PDGF β-receptor in breast cancer. The mechanistic
basis for this phenomenon is currently explored in co-culture
experiments where the potential PDGF-dependent influence of
fibroblasts on breast cancer cell sensitivity to tamoxifen is being
analyzed.
In summary our studies indicated novel prognostic and response-
predicative roles of stromal PDGF receptor expression, which
should be explored in the continued development of PDGF
receptor inhibitors and endocrine treatments.
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PDGF tyrosine kinase receptors activation has been involved in
multiple aspect of cancer growth. In solid tumors PDGF receptor
signaling appears to be most important for the pericytes and
fibroblasts of the tumor stroma. We have developed co-culture
assays to analyze the paracrine interactions between fibroblasts
(PDGFR+) and colorectal cancer (CRC) cells (PDGFR-). PDGF-
dependent effects of fibroblasts on the proliferation, migration,
invasion and response to EGFR inhibitor (Cetuximab) of CRC
cells (HT29, SW620 and LIM1215) were analyzed in different co-
culture models.
PDGF stimulation of fibroblasts increased the migration and
invasion of LIM1215 and HT29 CRC cells. The fibroblast-
induced migration of SW620 cells, which produce PDGFs, could
be blocked by PDGF receptor inhibitors targeting the co-cultured
fibroblasts. Furthermore, “priming” of matrigel with fibroblasts
indicated PDGF-dependent effects on the matrigel which facilitat-
ed CRC cell invasion. Finally, PDGF stimulated fibroblasts protect
CRC cells from the growth- and migration-inhibitory effect of
cetuximab.
Gene-expression profiling of control and PDGF stimulated fibro-
blasts has been performed to identify the molecular mediators of the
fibroblasts-derived paracrine effects on tumor cell migration and
invasion. Approximately 10 secreted proteins where found to be up-
regulated in the PDGF stimulated cells. Functional studies, with
antibodiesorsiRNA,havebeeninitiatedforaselectedsubsetofthese
genes.
In summary, these studies have identified novel PDGF
dependent paracrine effects on CRC cell proliferation, migra-
tion, invasion and drug sensitivity. The ongoing identification
of the molecular mediators of these paracrine effects should
potentially lead to novel prognostic, response-predicative and
therapeutic opportunities.
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It is necessary to understand mechanisms of androgen refractory
prostate cancer development and progression. We hypothesized that
enhanced chemokine signaling results in the recruitment of immune
cells to the prostate microenvironment from the bone marrow. A
chimeric mouse model with GFP-labeled bone marrow was used to
allow us to identify bone marrow cells recruited to the prostate. We
studied how bone marrow derived cells (BMDCs) contributed to an
androgen refractory response, specifically prostate regrowth. In a
similar mouse model we used GFP-labeled mesenchymal stem cells
(MSCs) to study this specific subset of BMDCs in response to
prostate regrowth. Host mice were castrated or left intact as a
control. Testosterone was given to the chimeric mice. The intact and
castrated control mice had a low number of BMDCs recruited to the
prostate. However, three and seven days following treatment with
exogenous testosterone resulted in a dramatic increase in BMDC
recruitment during prostate regrowth. Immunohistochemistry stain-
ing for F4/80 suggested that some of these BMDCs were
macrophage cells. GFP labeled MSC cells were also recruited to
the prostate at three days following treatment with exogenous
testosterone. Interestingly, even after four weeks the fully regrown
prostates retained BMDCs that appeared to be incorporated in the
epithelial compartment. Double immunofluorescence staining
showed that a subset of BMDCs gained the expression of p63, a
basal cell marker; androgen receptor and Foxa1, an endoderm
marker, in the prostate. This suggested that the incorporated cells
may have either differentiated or fused with resident cells. The
recruitment and eventual incorporation of BMDCs in the prostate
suggests a mechanism for exogenous cells in castration-resistant
prostate cancer growth.
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WhileNKcellswereoriginallyidentifiedbytheirabilitytokilltumor
cells in vitro, only limited information is available on NK cells
present in tumor microenvironment. Our objectives were to charac-
terize the phenotype and function of NK cells in human Non Small
CellLungCancers(NSCLC)patients,intumormicroenvironment,in
non tumoral lung tissue, and in the blood, and to investigate the
expression of NK cell receptor ligands on tumor cells.
NK cells are present both in tumoral and non tumoral lung tissues of
NSCLC patients. In the tumor, they are mainly localised in the
invasive margin, but outside tertiary lymphoidstructures (Ti-BALT –
“Tumor-induced Bronchus Associated Lymphoid Tissues”)t h a ta r e
induced in the tumoral area. Intratumoral NK cells are not cytotoxic
even after activation with IL-2, on the contrary to NK cells from
blood of the same patient, despite an activated phenotype defined by
NKp44 and CD69 expression. Consistent with this observation,
intratumoral NK cells display a highly significant decreased
expression of activating receptors such as NKG2D, NKp30,
NKp80, DNAM-1 and CD16. On the contrary, NK cells from non
tumoral lung tissue or blood of NSCLC patients have the same
phenotype than healthy donors. Analysis of NK cell receptor ligand
expression revealed that inhibitory receptors ligands such as HLA-G
and HLA-E are strongly expressed by tumor cells, but not by normal
tissue, whereas activating receptors ligands such as MICA/B and
ULBP1, 2, 3 are rarely expressed by tumor cells.
Altogether these results demonstrate for the first time that the NK cells
display an altered phenotype and function specifically in the tumor
microenvironment and that tumor cells express high levels of
inhibitory receptors ligands. This suggests a local induction of escape
mechanisms established by tumor cells and directed towards NK cells.
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The tumor stroma is known to interact with cancer cells to
promote growth and metastasis. Preliminary data from our
laboratory has identified differentially expressed proteins that
are either over-expressed or under-expressed in the tumor
stroma and tumoral tissue compared to surrounding ‘normal’
peri-tumoral tissue from the same patients with cholangiocar-
cinoma. A novel marker of myofibroblasts that may be
involved in stimulating myofibroblast proliferation, migration
and differentiation, periostin, was markedly increased in the
tumour stroma of these patients. Periostin is a unique
extracellular matrix protein, whose deposition is enhanced by
mechanical stress and the tissue repair process. Periostin
deposition in the stroma of invasive tumours has been
described in the literature. Stromal cell secretion of periostin
has only recently been shown to correlate with epithelial to
mesenchymal transition of human pancreatic cancer cells
indicating stromal cells influence on cancer development.
The significance of periostin and its secretion by stromal cells
in normal and neoplastic tissue has not yet been fully
clarified. We assessed the expression patterns of periostin in
a number of different human tumors by immunohistochemistry
and showed localised expression in the tumor stroma of lung,
colon, liver, renal, breast, stomach, pancreatic, thyroid, ovary,
uterine, prostate and skin cancers. Interestingly, increased
staining was also keen in non-neoplastic fibrotic kidney, skin
and liver tissue suggesting a possible role in epithelial to
mesenchymal transition in human tissue. Further investiga-
tions will be carried out to elucidate autocrine and paracrine
regulation of periostin in stromal and cancerous cells using
cell-based and animal-based models as well as human tissue
and to further our understanding of its role in tumour growth
and metastasis.
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Recent research has revealed tumor-associated macrophages
(TAMs) can facilitate the malignant progression of cancer, and
our aim is to determine the role of TAMs in two distinct
microenvironments: the brain and pancreas.
We utilize the RCAS-TVA model of gliomagenesis where somatic
cell gene transfer of PDGF-B into transgenic nestin-TVA;Ink4a/
ARF-/- mice induces brain tumors that recapitulate the histopa-
thology of human glioblastoma multiforme. Using immunohisto-
chemistry and flow cytometry we have shown that macrophages
are the predominant immune cell type within gliomas and that
TAM density correlates with tumor grade. Actin-GFP bone-
marrow transplants have shown that glioma TAMs derive from
both brain resident microglia and peripheral bone marrow-derived
cells. Microglia in the contralateral hemisphere opposite the tumor
are highly proliferative relative to TAMs and normal microglia.
Current studies aim to deplete macrophages from gliomas to
determine their role in tumor development and progression.
RIP1-Tag2 (RT2) transgenic mice express SV40-T-antigen under the
control of the rat insulin promoter leading to the development of
S153multiple pancreatic islet tumors. To determine the role of TAMs in the
pancreatic microenvironment, RT2 mice were crossed to CSF-1 null
macrophage deficient mice. There is a progressive increase in
macrophage density in wild-type RT2 tumors, and in line with a
tumor-promoting role of TAMs, both tumor number and tumor burden
are decreased in CSF-1 null RT2 mice. Histological invasion scoring
has revealed a more invasive phenotype of CSF-1 null RT2 tumors
relative to controls. This may be due to compensatory macrophage
recruitment via a CSF-1 independent mechanism, which is under
investigation.
In conclusion, while the source of TAMs may be dependent on
tissue context, macrophage recruitment is a critical step in cancer
development and progression in both the pancreatic and brain
tumor microenvironments.
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There is a growing appreciation of the importance of tumor-stroma
interactions for tumor progression and metastasis. In the tumor stroma,
macrophagesare very abundant and have been shown to enhance these
malignantprocesses.Wehaveusedanexperimentalmetastasisassayto
elucidate the significance of macrophages in promoting the two final
limiting steps of metastasis: target organ seeding and persistent growth.
Ourdatademonstratethatthepulmonaryseedingandpersistentgrowth
of Polyoma virus middle Tantigen induced mammary tumor cells are
correlated with host colony stimulating factor 1 (the major growth
factor for macrophages) gene copy number and the numbers of
macrophages recruited to lung metastasis. To further determine the
macrophage contributions, liposome encapsulated Clodronate was
used to deplete macrophages in vivo; this treatment reduced the
efficiency of both rate-limiting steps in the pulmonary lung metastasis
assay. FACS analysis revealed a recruitment of CSF-1R+CD11b
+Gr1- cells in the metastasis bearing lung. CD11b+cells were deleted
in vivo with diphtheria toxin (DT) treatment in mosaic animals
generated by bone marrow transplant using a transgenic mouse
expressing human DTR driven by the CD11b promoter as a bone
marrow donor. The deletion of CD11b+cells reduced the tumor
cell seeding efficiency and growth rate in lung. Further intact
lung 3D imaging study revealed that tumor-macrophage interac-
tion is critical for tumor cell extravasation. In addition, CCL2/
CCR2 signaling was found to be important for the recruitment of
these macrophages and critical for tumor cell seeding. Together
these data demonstrated the importance of a recruited myeloid
cell population displaying a distinct phenotype in tumor cell
extravasation, seeding and growth in a metastatic target organ
and revealed the potential of targeting CSF-1 and CCL2
signaling in blocking metastasis.
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Matrix-metalloproteinases (MMPs) are of essential importance for
tumor cell invasion and metastasis. Two of their members,
proMMP-2 and proMMP-9 are proteolytic enzymes involved in
the process of tumor invasion by mediating degradation of
basement membrane and remodeling of extracellular matrix. They
are secreted as latent pro-enzymes (proMMP-2 and proMMP-9)
which are activated by proteolytic cleavage and are inhibited by
forming complexes with a class of endogenous inhibitors of
MMPs, TIMPs. Imbalance between MMPs and TIMPs can lead to
cancer metastasis.
We analyzed the activity of proMMP-2 and proMMP-9, as well
as the activity of active MMP-2 and MMP-9 in breast cancer and
surrounding tissue of 24 patients (clinical stage I and II) by
gelatin zymography. In order to verify the activity of MMPs, we
performed MMP inhibition test on zymography. Expression of
TIMP-1 was assessed in tumor cell lysates by Western blotting
using anti-TIMP-1 antibody.
The analysis of activity of ProMMP-2 and ProMMP-9 shows
significantly higher activity in tumor tissue compared to surround-
ing healthy tissue. In our study we show that tumor tissue
compared to surrounding healthy tissue of patients shows a higher
activity of active forms of MMP-2 and MMP-9. Tumor tissue of
patients compared to surrounding healthy tissue shows lower
expression of TIMP-1, inhibitor of MMP-9 activity. We give data
of enzyme and pro-enzyme higher activity of MMP-2 and MMP-9
in breast cancer tissue of patients and lower expression of TIMP-1,
inhibitor of MMP-9 activity in breast cancer tissue. MMP-2 and
MMP-9 activation participate in processes associated with cancer
progression and understanding the processes of MMPs activation
and regulation may have significant benefits in clinical interpre-
tation. The reported higher MMP-2 and MMP-9 activity in breast
cancer tissue suggests a role of MMP-2 and MMP-9 in prognostic
stratification of breast cancer patients and in designing new
therapeutics.
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Adamts1 (a disintegrin and metalloprotease with thrombospondin
motifs1) is a protease known to remodel the extracellular matrix
(ECM) surrounding tumors through cleavage of proteins, such as the
extracellular proteoglycan versican. In breast cancers with highly
elevated metastatic activity Adamts1 is found to be upregulated, and
recent studies have identified Adamts1 is required for hormone
mediatedlymphangiogenesisintheovary.Inthisstudyweinvestigated
whether Adamts1 plays an essential role in mammary cancer
metastasis using the MMTV-PymT mammary tumor model.
Adamts1
−/−PymT mice displayed significantly reduced mammary
tumor burden compared to the wildtype littermates and increased
survival. Importantly the number and area of lung metastases was
significantly reduced in Adamts1
−/−/PymT mice. Histological exam-
ination revealed an increased proportion of tumors with ductal
carcinoma in situ in and a lower proportion of high grade tumors in
Adamts1
−/−/PymT mice compared to Adamts1
+/+/PymT mice. The
reduced tumour burden in Adamts1
−/−/PymT mice was associated
with an increased apotoptic index but not associated with alterations
in the proliferative index nor vascular density. Interestingly tumors
from Adamts1
+/+/PymT mice had increased levels of versican
compared to Adamts1
−/−/PymT mice but unaltered hyaluronan levels.
Overall, this study provides strong in vivo evidence that Adamts1 is
non-redundantly involved in breast cancer growth and metastasis. We
propose that Adamts1 promotes the remodelling of peritumoral ECM
facilitating the release of tumour cells from the primary tumour and
their invasion into blood and lymphatic vessels for ultimate
dissemination to distal sites.
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Brain metastasis indicates that melanoma reached its terminal
stage. Since efficient therapies for brain metastasis do not exist, it
is essential to identify why melanoma frequently metastasizes to
the brain and identify therapeutic targets.
Chemokines, essential constituents in the immune system, attract
leukocytes expressing respective receptors to insulted tissue sites.
Cancer cells expressing chemokine receptors have hijacked this
chemo-attraction mechanism to migrate to distant organs and form
metastasis in these organs.
To identify chemokine receptors that might be involved in
melanoma homing to the brain, we checked the expression of
chemokine receptors in cell lines of cutaneus melanoma and
melanoma brain metastasis.
Three lines of cutaneous melanoma and five lines of melanoma
brain metastasis were analyzed for the expression of 19 chemokine
receptors and for the expression of the cell-bound chemokine
CX3CL1. Five chemokine receptors (CCR3, CCR4, CXCR3,
CXCR7 and CX3CR1) and the chemokine CX3CL1 were
expressed both on cultures of cutaneous melanoma and of
melanoma brain metastasis.
No significant differences were measured between the expression
of these chemokine receptors by the cutaneous melanomas and the
melanoma brain metastasis.
Preliminary immunohistochemistry analyses performed with sec-
tions from primary cutaneous melanoma and melanoma brain
metastasis confirmed the expression of these chemokine receptors
in patient material.
We have at our disposal melanoma variants which grow in nude
mice either as local tumors or as brain metastasis. These 2 types of
variants were derived from the same patients having therefore, an
identical genetic background. The chemokine receptor profile of
the variants was similar to that of the local and metastatic
melanoma cell cultures mentioned above.
Ongoing work focuses on the functional significance of the chemo-
kine receptors expressed by brain-metastasizing melanoma cells.
This study was supported by the Dr. Miriam and Sheldon G.
Adelson Medical Research Foundation (Needham, MA, USA)
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The mechanisms of tumoral invasion in solid tumors are related to
angiogenesis, endothelial adhesion and cell migration and similar
mechanisms have been hypothesized for hemopathies, especially
acute leukemia. An increased medullary angiogenesis has been
observed on bone marrow biopsies of children with ALL (1).
However, no correlation between angiogenesis and the prognosis
of ALL has been clearly established. In our work, we focused on
pro-and anti-angiogenic markers (bFGF, VEGF, endostatin) in
S155urine and/or plasma of 39 patients at diagnosis. Lymphoblasts
mRNA expression (RT-PCR) has shown that VEGF and
endostatin partially originate from lymphoblasts, whereas
bFGF seems to have a stromal origin. Quantification in the
supernatant of lymphoblasts confirmed these findings in half
of the cases studied. Plasmatic and urinary levels of VEGF of
patients were not significantly higher than in controls, but
higher in relapsing patients (p<0.006). Patients’ urinary
bFGF levels were significantly higher at diagnosis than in
controls (545 vs 44 pg/mmol creatinine, p<0.005), but
interestingly bFGF levels were lower for patients with high
proliferation criteria. For a small subset of patients, we
cultured leukemic cells with and without fibroblasts and
observed a reduction of the apoptosis rate (annexin V test),
especially in patients with high urinary levels of bFGF.
Among the patients with a bFGF level within the normal
range, most cases showed no influence of fibroblasts on
apoptosis, suggesting that a subset of leukemias with a high
proliferation rate could have a growth independent of the
medullary microenvironment.
(1) Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E,
Folkman J. Spectrum of tumor angiogenesis in the bone marrow
of children with acute lymphoblastic leukemia. Am J Pathol 1997;
150:815–821.
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Bone metastasis occurs frequently in renal cell carcinoma
(RCC) patients leading to excessive osteolytic lesions. There
is increasing evidence that the bone marrow microenviron-
ment plays an important role in the homing of disseminated
tumor cells. However, little is known about the mechanisms
l e a d i n gt ob o n et r o p i s m .H e r e ,w ep e r f o r m e dc e l la d h e s i o n
and migration assays using RCC cell lines A498 and
CRL1611 and primary isolated RCCs to investigate the
influence of bone marrow components on cellular functions
of renal tumor cells. Cell-matrix adhesion assays revealed a
strong binding of RCC cells to extracellular matrix molecules
expressed in the human bone marrow including collagen type
I and IV, laminin isoforms, osteopontin or tenascin-C, which
were partly mediated by β1-integrins. Cell-cell adhesion
assays showed a moderate binding of RCC cells to primary
human osteoblasts. The attachment to stromal cell lines,
however, was significantly weaker. To investigate the influ-
ence of bone marrow cells on tumor cell migration, we
performed cell migration assays using conditioned media of
these cells. Wound healing assays with tumor cells showed
that osteoblasts, but not osteoclasts or stromal cells, secrete
factors which led to faster wound closure, indicating an
increased migration ability of the tumor cells. This was not
affected by hydroxyurea, a cell proliferation inhibitor, indi-
cating that these effects are due to migration. Microarrays
were performed using RNA isolated from RCC cells either
treated with osteoblast-conditioned or control medium. Culti-
v a t i o ni no s t e o b l a s t - c o n d i t i o n e dm e d i u mr e s u l t e di na nu p -
regulation of a cancer-associated cell membrane glycoprotein
which is currently analyzed in detail. These data demonstrate
that RCC cells preferentially interact with osteoblasts and
extracellular matrix components of the human bone marrow
and show increased migration ability in response to
osteoblast-derived factors suggesting a possible mechanism
for facilitated homing of RCC cells into bone.
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Changes in the immunological equilibrium and escape from
immune surveillance are critical events for the progression of
a developing tumor. Likewise, tumor derived vascular endo-
thelial growth factor C (VEGF-C) is known to stimulate
lymphatics at the tumor periphery and promote metastasis to
draining lymph nodes. CCL19 and CCL21 are produced by
both lymphatic endothelium and reticular stroma guiding
antigen presenting cells (APCs) to LN and driving co-
localization of CCR7
+ APCs and naïve T cells within the
lymph node. Furthermore, we recently demonstrated that
tumors use autologous CCL21 secretion and lymphatic function
to escape a growing tumor. To this end, we investigated how
lymphatic growth factors and lymph node chemokines influ-
ence the developing tumor-lymphatic microenvironment and
ensuing immune response. We engineered tumor cells to secrete
different levels of CCL21 and VEGF-C. Using in vitro co-
culture models and complementary in vivo studies we demon-
strate that several tumor cell lines express functional VEGFR-3;
hence tumor-derived VEGF-C could act autologously on tumor
cells to promote their invasion through a 3D matrix, by
increasing their motility and proteolytic activity. In addition to
peritumoral lymphatic expansion, tumor-secreted VEGF-C also
increased CCL21 production by lymphatic endothelium. In-
creased tumor volumes were observed in these VEGF-C-
overexpressing tumors compared with control counterparts
and coincided with a switch in the inflammatory compartment
S156towards a regulatory phenotype. A sustained loss of CCL21 at
the tumor site permitted an effective tumor specific immune
response to develop. These results indicate that modulation of
the tumor-lymphatic microenvironment not only promotes
metastasis through VEGF-C-CCL21 cross-talk strategies but
is also necessary for manipulation and control of the anti-tumor
immune response.
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Malignant glioblastomas are characterized by infiltration of
tumour tissue with brain macrophages that may consist up to
30% of tumour mass and create specific microenvironment
contributing to tumour progression. A relative proportion of
brain resident and peripheral monocyte/macrophages to glio-
mas is poorly defined. We generated chimeric mice with the
immune system reconstituted after irradiation with hematopoi-
etic GFP-bone marrow cells. The dsRed-GL261 glioma cells
were implanted to the brains of 16-weeks old C57BL/6
chimeric mice. Two weeks after implantation, tumour bearing
hemispheres were isolated and the number of CD11b
+CD45
low
microglial cells or CD11b
+CD45
high macrophages was deter-
mined by flow cytometry. The increase of the percentage of
microglial cells and macrophages was observed in tumor-
bearing hemispheres. We found that peripheral GFP
+ macro-
phages comprise above 60% of GFP
+ cells in the tumour.
Peripheral GFP
+ cells accumulated inside and around tumours.
A co-localization of Iba-1
+ cells (macrophages/microglia) with
GFP
+ cells has been detected by confocal microscopy. Counting
of double-stained cells revealed that above 50% of Iba-1
+ cells
are peripheral macrophages. To study a functional contribution
of microglia/macrophages to glioma growth, invasion and
pathogenesis, we employed osteopetrotic mice (op/op)w h i c h
possess a spontaneous mutation in the macrophage colony-
stimulating factor (M-CSF/CSF-1) gene. Mice homozygous for
the osteopetrosis mutation are viable but exhibit a generalized
macrophage deficiency, monocytopenia, deficient microglia/
macrophage responses and defective bone remodeling. The
studies of growth of GFP-GL261 glioma cells in op/op mice
will facilitate understanding of contribution of microglia/macro-
phages to glioma microenvironment and growth. Our studies
demonstrate that in addition to accumulation of brain resident
macrophages (microglia), also blood-borne macrophages mi-
grate to the tumour and consist of a significant population of
tumour-associated macrophages.
Studies supported by grant P-N/024/2006 from the Ministry of
Science and Higher Education.
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The Effect of Human Placental Explants on Breast Cancer
Cell Line MCF7; To stay or to STAT?
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Introduction: Pregnant women with breast cancer often present
with an advanced disease and have decreased estrogen receptor
(ER) levels. In spite of that, metastases are rarely found on the
placenta which suggests that the placenta is a nonsupportive
microenvironment for the cancer cells. Indeed, we have found
that MCF7 cells (ER positive, breast cancer cells) when
cocultured with first trimester placental explants had elevated
apoptosis, G1/G0 cell cycle arrest accompanied by cell
detachment and migration. The aim of the study presented here
w a st oa n a l y z ew h i c hM C F 7s i g n a l i n gp a t h w a y sw e r ea f f e c t e d
by the placenta.
Methods: MCF7-eGFP cells cultured on matrigel with or without
placental explants were separated from the placenta by cell sorting
and their mRNA was subjected to microarray analysis. ERa/
STAT3/mTOR expression and phosphorylation levels were ana-
lyzed in these cells.
Results: Trophoblast cells differentiate into extravillous tro-
phoblast cells (EVT) which migrate into the matrigel. The
effects (apoptosis/proliferation/detachment) were mainly ob-
served in MCF7 cells that were located near the EVT cells.
Microarray results have demonstrated significant changes in
genes related to cell adhesion, glycan, breast carcinoma
estrogen and JAK-STAT pathways. Decreased ERa and elevat-
ed pmTOR and STAT3 proteins detected by immunobloting
confirmed our findings at the transcript level. Moreover,
promoter analysis of significantly affected genes in this array
demonstrated an enrichment of motifs located at the transcrip-
tion start site that match annotation for ISRE (interferon-
stimulated response element), suggesting the activation of
interferon (INF) signaling.
Conclusion: Our results suggest that the placenta attenuates
MCF7 growth in its vicinity by modulating INF/STAT and
inducing detachment/migration and apoptosis. Published data
demonstrated that the above pathways may indeed stimulate
these processes. The involvement of these signaling pathways
in cell migration/apoptosis an dt h ef a t eo ft h ed e t a c h e dM C F 7
cells will be further studied.
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Identification of Secretory Stromal Gene Signature
of the Ovarian Tumor Microenvironment and Implications
for Ovarian Cancer Progression
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The stromal microenvironment provides structural support and
myriad signaling cues, which can significantly affect cell growth
and development. The tumor-associated stromal microenviron-
ment has been shown to play a key role in many cancers by
influencing tumor initiation, invasion and metastasis. Our objec-
tive was to identify specific genes that are differentially regulated
in the stromal component of high-grade late-stage serous ovarian
cancer that may contribute to ovarian cancer progression.
Microarray analysis of RNA isolated from 10 microdissected
normal ovarian fibroblasts, and the epithelial and stromal
component of 16 high-grade late stage serous ovarian cancers
revealed that 40 secreted proteins are overexpressed more than 5
fold by cancer-associated fibroblasts exclusively. Quantitative RT-
PCR validated the overexpression of several genes, including
sFRP2, by the cancer-associated fibroblasts. Clinical data corre-
lated stromal sFRP2 overexpression with poorer overall survival
and chemoresistance in patients with high-grade late stage serous
ovarian cancer, suggesting that sFRP2 promotes ovarian cancer
progression.
In vitro functional studies illustrate increased ovarian cancer cell
line growth in response to sFRP2.
Our results illustrate a direct and specific signaling linkage from
the tumor microenvironment to tumor cells that contributes to
tumor progression.
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Progression and Serves as Diagnostic and Poor Prognostic
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Cholangiocarcinoma (CCA) is a major health problem in
Thailand. It is well recognized to contain abundant fibrous
stroma with activated fibroblasts. Our group has recently
isolated primary culture CCA fibroblast (Cf) from CCA tissues
and revealed that Cf induced human biliary epithelial and CCA
cell proliferation. However, molecular mechanism of fibroblasts
in CCA remains unclear. Here, we indicated periostin (PN)
secreted from cancer fibroblasts as diagnostic and prognostic
factors, and had carcinogenic role in CCA. By comparing gene
expression profile of Cf and non-tumorigenic liver fibroblasts,
1,466 genes were up-regulated whereas 495 genes were down-
regulated in Cf. PN was verified up-regulated expression in Cf
by real time PCR and western blotting. Immunohistochemistry
of PN in CCA tissues (n=139) revealed that PN was solely in
tumor stromal fibroblasts. More than 80% of CCA cases had
low to high level of PN, but slight expression was found in
benign liver tissues and hepatocellular carcinoma. The overall
survival of CCA patients with high PN expression was
significantly lower than those who had low level (P=0.029).
Multivariate analysis indicated that high PN expression was an
independent poor prognosis factor (P=0.039). Spearman corre-
lation analysis indicated that PN mRNA level significantly
correlated with PN level in tissues (P=0.045). In addition, in
vitro study revealed that PN could induce CCA proliferation by
driving cells into S+G2/M of cell cycle. Taken together, it is
likely to conclude that high PN expression in CCA tissues can be
used as a diagnostic factor to distinguish CCA from hepatocel-
lular carcinoma. Fibroblast-derived PN in the tumor microenvi-
ronment may play important role in induction of cancer
progression and serves as a poor prognostic factor.
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The α2β1 integrin is a heterodimeric cell surface receptor for
collagen, laminin, and other extracellular matrix proteins.
Expressed on the epidermal basal layer and on several
inflammatory cell populations, the α2β1 integrin regulates
orderly, cellular proliferation and innate and adaptive immune
system function. Using the K14-HPV16 model of epithelial
carcinogenesis and the α2β1 integrin-null mouse, we evaluated
S158the α2β1i n t e g r i n ’s impact on squamous cell carcinoma (SCC)
development and progression. We hypothesized that the
integrin plays a role in SCC pathogenesis through keratinocyte
signaling within the local microenvironment or through chronic
inflammation.
Our data show that loss of the α2β1 integrin in K14-HPV16
mice does not alter SCC latency, prevalence, anatomic location,
or histologic grade. HPV-positive, α2β1 integrin-null animals
(HPV/KO), when compared with wild-type, HPV-positive (HPV/
WT) littermates, have: reduced tumor metastasis by 43%,
decreased Ki67
+ tumor cell proliferation (p=0.0059), fewer
tumor multiplicity, and decreased tumor, LYVE-1
+ lymphatic
vessels (p=0.021). Intratumoral HPV/KO lymphatics occupy
only 0.029±0.048% of the 20X field versus the 0.59 ± 0.92%
seen in HPV/WT tumors (p=0.031). Peritumoral LYVE-1
+
vessel area are less in HPV/KO mice (p=0.013). Mast cells
express the α2β1 integrin, use integrin-signaling mediated IL-6
secretion, and increase epithelial neoplastic change through
inducing chronic inflammation. Mast cells are decreased (p =
0.019) in HPV/KO mice ears at 6-months-of-age compared to
age-matched HPV/WT mice ears. Plasma IL-6 levels are
decreased in HPV/KO relative to HPV/WT, tumor-bearing
animals (p=0.014).
Our data demonstrate the α2β1 integrin plays a critical role in
regulating metastasis to regional lymph nodes; decreased
metastasis seen in HPV/KO mice may result from reduced
lymphangiogenesis or vessel function. Future studies focus on
the α2β1i n t e g r i n ’s role in regulating structure and function
of pathologic lymphatic vessels and determining whether mast
cell-lymphatic crosstalk alters lymphangiogenesis.
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in Tumor Blood Vessels and Supports Angiogenic Sprouting
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Angiogenesis and metastasis of tumors is strongly dependent
on the expression of proteases that cleave basement membranes
and extracellular matrix. Transcriptome analysis of normal and
tumor blood vessels in colorectal cancer revealed an over-
expression of MMP-11 in the tumor endothelium. These data
could be confirmed by immunohistochemistry clearly showing
immunoreactive MMP-11 in blood vessels of the tumor and
fibroblasts of the reactive stroma. Adenoviral overexpression of
MMP-11 did not affect proliferation of HUVECs, but signifi-
cantly supported angiogenic sprouting of endothelial cell
spheroids in a collagen matrix. In contrast to GFP, MMP-11
transfected cells increased cumulative sprout length and number
of sprouts/spheroid.
MMP-11 overexpressing B16F10 melanoma cells were generated
by the sleeping beauty transposase system and grafted into the
chorioallantoic membrane (CAM) of chicken embryos. In com-
p a r i s o nt om o c k - t r a n s f e c t e dc ells, MMP-11 overexpressing
B16F10 cells showed no increased proliferation in vitro, but a
significant higher rate of metastasis in the chicken embryo
xenograft assay. Our data support the hypothesis, that tumor
endothelial cells secret MMP-11 to support angiogenic sprouting
processes and metastasis of the tumor.
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Non-alcoholic fatty liver disease (NAFLD), encompassing stea-
tosis and progression to non-alcoholic steatohepatitis (NASH) are
liver disorders of increasing clinical significance. We hypothesize
that steatosis and steatohepatitis establish early permissive micro-
environments for metastatic seeding and tumor progression in the
liver. Specifically, we hypothesize that MMP12 (macrophage
metalloelastase) and MMP13 (collagenase-3) are important regu-
lators of tumor growth in the setting of NAFLD. MMP12 can
process latent TNF alpha and it is important for macrophage
migration and immune-mediated injury response. MMP13 can
cleave fibrillar collagens and is potentially involved in collagen
remodeling of fibrotic liver disease associated with NAFLD. Mice
in the C57Bl/6 background were fed a 42% fat diet for three
months to induce hepatic steatosis. Affymetrix microarray analysis
was performed on steatotic vs. normal liver to determine candidate
genes altered between these liver microenvironments. Of 715
significant changes noted in gene expression, the matrix metal-
loproteinases MMP12 and MMP13 were the most significantly
upregulated genes in the steatotic microenvironment. MMP12 as
well as MMP13 deficient mice both developed high fat diet
induced hepatic steatosis. To determine whether these MMPs
affected metastasis, normal and steatotic MMP deficient mice
underwent splenic injection experimental metastasis assays.
Preliminary data showed similar results between wildytpe and
MMP13 deficient mice. However, loss of MMP12 resulted in
decreased number of metastases compared to wildtype for steatotic
livers. Conclusions: Modulation of host factors is known to be
important in tissue/site specific susceptibility to cancer metastases.
The matrix metalloproteinases 12 and 13 were upregulated in the
condition of hepatic steatosis and MMP12 was found to effect the
establishment of metastatic tumors in this permissive microenvi-
ronment. Improved understanding of alterations to host factors in
S159the setting of NAFLD and their mechanisms of action may lead to
a better understanding of microenvironmental host response to
metastasis and tumor progression.
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Aims: Interactions between epithelial tumor cells and the
surrounding milieu are an essential regulatory component of
tumor development. Especially the contribution of the crosstalk
between epithelial tumor cells and tumor-associated fibroblasts
(TAFs) on tumor progression and metastasis formation is of
emerging interest. Therefore, we ask whether circulating TAFs
could be detected in the peripheral blood of tumor patients.
Methods: CD90 (Thy-1) is a putative marker of TAFs. A
fluorescence-scanning-cytometer (scan
R) was used to detect and
quantify vital CD90-positive cells in blood samples from
individual tumor patients. For further analysis CD90-positive cells
were separated from leukocyte fractions pooled from different
tumor patients using an immunomagnetic cell separation technol-
ogy (ROBOSEP®). The CD90-positive fraction was subsequently
analyzed by immunofluorescence and immunohistochemistry.
Results: Incell culture experimentsweestablished CD90 as a highly
specific marker for fibroblasts. The amount of CD90 positive cells in
unseparated blood samples varied from 0 up to 54,000 cells/ml and
changes over time. The CD90-positive cells were enriched immuno-
magneticallyfromthe leukocytefractionpooledfromtumor-patients.
By immunofluorescence we approved the cell vitality and verified
that the separated cells do not belong to the sub-population of CD34-
positive blood stem cells. Up to now more than 300 patients with
solidtumors(e.g.breast,bladder,kidney)weretestedforthepresence
of CD90-positive cells. Further analysis showed the expression of
CD29whichisinvolvedinmetastasisformationandCD105amarker
foractivatedfibroblastsinasubsetoftheCD90-positivecellfraction.
Conclusions: We could show for the first time that CD90-positive
cells circulate in the peripheral blood of breast cancer patients.
Ongoing studies should evaluate their suitability as diagnostic or
prognostic factor.
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VEGF receptor 1 (VEGFR1) expression by bone marrow-derived
cell (BMDC) populations associated with primary tumors as well
as the metastatic microenvironment has been reported
1,2. This
receptor has been used to describe cell populations of myeloid
progenitor or monocyte/macrophage lineage with pro-angiogenic
and metastatic function. However, the role of VEGFR1 activity in
these contexts remains unclear. In the present study, we tested the
effect of lentiviral-mediated knockdown of VEGFR1, specifically
within BMDCs, on the development of spontaneous metastases.
We report that downregulation of VEGFR1 expression in the bone
marrow had a modest effect on primary B16 subcutaneous tumor
growth and subsequent tumor cell seeding at early-metastatic sites,
yet drastically reduced the occurrence of micro- and macro-
metastatic foci. Microarray analysis of RAW 264.7 monocyte/
macrophages transduced with VEGFR1 shRNA showed the
upregulation of key anti-angiogenic factors, including CXCL4
(platelet factor-4) and pigment epithelial derived factor (PEDF).
Upregulation of these factors was drastically enhanced in VEGFR1-
deficient RAW cells and primary bone marrow-derived myeloid cells
lacking VEGFR1 when co-cultured withB16 tumor cells. Functional
analyses of VEGFR1-deficient BMDCs indicate these cells inhibit
endothelial cell survival in vitro. Additionally, co-injection of
VEGFR1-deficient myeloid cells with B16 tumor cells suppressed
subcutaneous tumor growth due to apparent defects in functional
vessel formation. These novel findings indicate that VEGFR1
expression controls the angiogenic activity of tumor-associating
myeloid cells by suppressing the expression of potent angiostatic
chemokines and that blocking this pathway can significantly inhibit
tumor metastasis. Our results clearly demonstrate a functional role
for VEGFR1 expression within BMDCs in promoting metastatic
progression by mediating an angiogenic microenvironment.
1 Kaplan, R. N. et al. VEGFR1-positive haematopoietic bone
marrow progenitors initiate the pre-metastatic niche. Nature 438,
820–827, (2005).
2 Lin, E. Y. et al. VEGF Restores Delayed Tumor Progression in
Tumors Depleted of Macrophages. Mol Oncol 1, 288–302, (2007).
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Background:
The suppression of the immune system is a crucial event in the
development of malignancy, particularly in cases of cancer relapse. It
S160has not, however, been common practice to evaluate the suppressive
influence of cancer cells on the immune system, even though the
soluble forms of RCAS1 and HAL-G can be detected in the blood
serum of patients suffering from gynecological malignancies, and
elevatedlevelsseemtoberelatedtocancerprogression.Certainly,the
participation of both these proteins in inhibiting the cytotoxic
immune response has been well documented. In our study, we took
serial measurements of the levels of both proteins over the course of
the applied therapy in order to determine their usefulness for
revealing the relationship between the applied therapy and the size
and degree of the tumor suppressive environment.
Methods:
We measured both the sRCAS1 and sHLA-G blood serum
concentration levels in a group of 85 patients treated for gynecolog-
ical malignancy. The group included 38 patients with ovarian cancer,
33 with endometrial cancer, and 14 with uterine cervical carcinoma.
We assessed the levels of these proteins using ELISA Kits through a
series of measurements taken before and after surgery.
Results:
In patients with both ovarian and endometrial carcinomas, the
blood serum concentration levels of both sRCAS1 and sHLA-G
were found to be statistically significantly higher before surgery
when compared with the levels following surgery. In the patients
treated surgically due to cervical carcinoma, the blood serum
concentration level of sRCAS1 was statistically significantly
higher before treatment as compared to after. No such differences,
however, were observed in the sHLA-G blood serum concentra-
tion levels of the women in this group.
Conclusion:
The detected levels of the blood serum concentration of sRCAS1
and sHLA-G may prove to be useful indicators of the status of the
tumor microenvironment.
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Tumor progression to a metastatic stage is accompanied by
profound changes in tumor cell phenotype. Tumor microenviron-
ment plays an important role in this process by regulating tumor
cell gene expression by variety of soluble and cell-associated
molecules. Cells in primary tumor dissemble established cell-cell
junctions, become more migratory, release tissue-remodeling
enzymes, and make new cell-cell contacts forming secondary
tumor masses (metastases). In epithelial tumors, these changes are
referred as epithelial-mesenchymal transition (EMT). Cadherins,
transmembrane proteins responsible for cell-cell interactions, play
a central role in EMT. Switch from E-to-N-cadherin in EMT has a
profound effect on tumor cell phenotype and behavior.
Here we described the unique pattern of cadherin switch in ovarian
tumors, namely, N-to-E-cadherin. Immunohistochemical staining of
80 cases of ovarian primary tumors and their metastases demon-
strated that (i) primary tumors expressed either N- or E-cadherin; (ii)
N-cadherin expression was dependent on differentiation state of the
tumor: N-cadherin in well-differentiated ovarian tumors was
replaced by E-cadherin in poorly differentiated tumors; (iii) ovarian
tumor metastases expressed exclusively E-cadherin.
To further investigate the role of E-cadherin in development of
metastaticphenotype,weexpressedafulllengthE-cadherincDNAin
E-cadherin-negativeSKOV3humanovariancarcinomacells.Several
E-cadherin expressing clones were studied as an in vitro model of
ovarian tumor metastases. E-cadherin expression resulted in more
aggressive phenotype characterized by new adhesion properties,
higher migration and invasion potential, increased proliferative
capacity and resistance to taxol (anti-cancer drug used in ovarian
cancer therapy).
We conclude that ovarian tumor progression is associated with
mesenchymal-epithelial transition, namely, with N-to-E-cadherin
switch. Given that expression of cadherins could be transcription-
ally and epigenetically regulated by various microenvironmental
signals, these results suggest the crucial importance of microen-
vironment in ovarian tumor progression.
This work was supported by grant from the Israel Cancer
Association and EU FP7 Health Research Grant number
HEALTH-F4-2008-202047.
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Glioblastomas are malignant brain tumours associated with poor
prognosis, due to the capacity of glioma cells to invade normal
brain tissue.During their migration, cancerous astrocytes interact
with other cancerous cells (homotype interactions) as well as with
normal motionless astrocytes (heterotype interactions), in partic-
ular through gap junctions. These interactions appear to strongly
influence the migration of glioma cells. We have developped a
cellular automaton where the strength of each type of interaction is
ajustable, in order to describe the migration of glioma cells.
From this automaton, we were able to derive a macroscopic
diffusion equation, where the diffusion coefficient is original
compared to other classical models, as it is non linear. We show
that the inhibition of homotype gap junctions leads to the increase
of cell migration, whereas when both homotype and heterotype
gap junctions are involved, their inhibition leads to a reduction of
migration. This result is in agreement with experimental data [5].
Our model also accounts for the variability of the expression of
connexin 43 (the major junctional protein in astrocytes) through
S161different tumours. We suggest that the various migrating behav-
iours observed among cells in a tumour correspond to different
expressions of connexin 43 and we propose a model for the “go or
grow” hypothesis, based on a differential connexin 43 expression.
[1] Aubert M et al, 2008, A model for glioma cell migration on
collagen and astrocytes, J. R. Soc. Interface, 5, 75.
[2] Deroulers C et al, Modeling tumor cell migration: From
microscopic to macroscopic models, 2009, Phys Rev E Stat
Nonlin Soft Matter Phys. 79, 031917.
[3] Oliveira R et al, 2005, Contribution of gap junctional
communication between tumor cells and astroglia to the invasion
of the brain parenchyma by human glioblastomas BMC Cell Biol.,
6, 7.
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Nerve growth factor (NGF) is increased during hepatic regener-
ation and carcinogenesis, but its role during hepatic metastasis is
unknown. A tissue-array collection of metastases from 24 patients
who had undergone hepatic excision of colorectal adenocarcinoma
metastases was used to investigate NGF and neurotrophin receptor
expression by cancer and stromal cells. NGF immunostaining of
cancer cells only occurred in 2 out of 24 patients with hepatic
metastases, while around 80% of patients had metastases with
NGF-expressing stromal cells. Conversely, high affinity TrkA
neurotrophin receptor immunoreactivity was mainly concentrated
in cancer cells, with low expression occurring in tumor stroma.
However, NGF immunostaining of tumor stroma and cancer cell
immunostaining with anti-ki67 antibodies did not correlate,
suggesting that NGF was not associated to metastatic cell
proliferation. Anti-alpha-smooth muscle actin antibodies revealed
that majority of metastasis-associated NGF-expressing cells had a
myofibroblast phenotype. Interestingly, NGF immunoreactivity
was unequivocally localized to desmin-expressing hepatic stellate
cells (HSC) —prototypic myofibroblast precursors—, and peri-
metastatic hepatocytes, located at the invasion front of metastases.
NGF-expressing hepatocytes had phenotypic features suggesting
epithelial-to-mesenchymal transition. A similar immunostaining
pattern was reproduced in the experimental hepatic colonization of
C26 and 51b colorectal cells. Consistent with in situ findings,
NGF increased by two-fold in the hepatic blood from metastasis-
bearing mice. NGF also significantly increased in the supernatant
of both HSC given tumor cell-conditioned medium(CM),and
hepatocytes given tumor-activated HSC-CM, but not tumor cell-
CM. Recombinant NGF dose-dependently increased chemotactic
migration, but not proliferation and adhesion of neurotrophin
receptor-expressing tumor cells in vitro. HSC migration-
stimulating activity of VEGF and tumor-activated hepatocytes
was also NGF-mediated as shown with anti-NGF antibodies. Our
results demonstrate that hepatocyte- and HSC-derived myofibro-
blasts secrete NGF in the hepatic metastasis microenvironment of
colorectal carcinoma and suggest that NGF contributes to hepatic
metastasis development through the specific activation of tumor
and stromal cell migration.
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Background:
Patient stratification becomes increasingly important for metastatic
cancer treatment. Initiation of metastasis involves invasion and
increased cell motility, which has many similarities to Epithelial-
Mesenchymal-Transition (EMT), including a loss of cell-cell
adhesion mediated by E-cadherin down-regulation.
Aim:
The aim of this study is to identify a set of genes that could be a
biomarker for metastatic risk to be used on tumor biopsies. More
specifically, a gene expression signature discriminating epithelial
from mesenchymal cell phenotypes.
Methods:
First we have focused on known genes related to EMT based on
literature. Second, we investigated whether we could identify
another unbiased set of genes, solely based on expression data of
cell lines, which can discriminate epithelial from mesenchymal
cells. A refined principle component analysis, based on this subset
of genes, identifies the weight of each gene in this signature.
Taking these weights together with their expression levels make
up a so-called composite gene expression measure. This has been
applied to data from clinical samples.
Results:
Identification of affected biological processes when comparing
epithelial with mesenchymal cell lines confirmed that cell-cell
adhesion is highly affected. Analysis on gene level revealed that a
set of 24 genes could clearly discriminate epithelial from
mesenchymal cell lines. The identified composite gene expression
measure clearly subdivided expression data from clinical samples
S162in 2 groups. Moreover, the composite gene expression measure
showed a correlation with the pathological grade available for the
clinical samples.
Conclusion:
This 24-gene signature revealed that clinical samples consisted of
two distinct subpopulations. This suggests that the composite gene
measure may predict whether a patient biopsy is enriched with
epithelial or with mesenchymal cells. It could also give an idea of
pathological grade of the sample making this signature a potential
biomarker for patient stratification allowing personalized therapy.
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The mammary epithelium is thought to be stabilized by cell-cell
adhesion mediated mainly by E-cadherin. Here we show that
another cadherin, Retinal (R)-cadherin, is critical for maintenance
of the epithelial phenotype. R-cadherin is expressed in non-
transformed mammary epithelium but absent from tumorigenic
cell lines. In vivo, R-cadherin was prominently expressed in the
epithelium of both ducts and lobules. In human breast cancer, R-
cadherin was downregulated with tumor progression, with high
expression in ductal carcinoma in situ and reduced expression in
invasive duct carcinomas. By comparison, E-cadherin expression
persisted in invasive breast tumors and cell lines where R-cadherin
was lost. Consistent with these findings, R-cadherin knockdown in
normal mammary epithelium stimulated invasiveness and disrupted
formation of acini despite continued E-cadherin expression.
Conversely, R-cadherin overexpression in aggressive cell lines
induced glandular morphogenesis and inhibited invasiveness,
tumor formation, and lung colonization. R-cadherin also sup-
p r e s s e dt h eM M P 1 ,M M P 2 ,a n dC o x2g e n ee x p r e s s i o n ,
associated with pulmonary metastasis. The data suggest that
R-cadherin is an adhesion molecule of the mammary epithelium
that acts as a critical regulator of the normal phenotype. As a
result, R-cadherin loss contributes to epithelial suppression and
metastatic progression.
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MUC1 is a prominent marker of breast cancer cells endowed with
signal transduction potential due to its cytoplasmic domain. In the
cell MUC1 undergoes alternative splicing and proteolytic process-
ing which may lead to both membrane bound and secreted forms.
Recent studies have identified the cleavage of the cytoplasmic tail
of MUC1, which generates a truncated membrane bound form, as
an important event in its signal transduction. In order to study the
signaling potential of MUC1 devoid of a cytoplasmic tail in the
establishment and maintenance of the tumorigenic phenotype we
have generated MUC1/G-TRUNC, a truncated genomic fragment
of the human MUC1, which encodes for both a truncated trans-
membrane form and a secreted form. To identify and dissect the
function of different structural features of this construct, we
generated additional MUC1 constructs, endowed with or devoid of
a cytoplasmic tail, either as genomic fragments or cDNA. All
constructs were transfected into DA3, highly malignant mouse
mammary tumor cells. Only cells transfected with MUC1/G-
TRUNC differed morphologically and phenotypically from paren-
tal DA3. Thus, presence of both truncated and secreted forms of
MUC1 leads to the potentiation of in-vitro measured tumorigenic
parameters and epithelial to mesenchymal transition (EMT). DA3/
G-TRUNC cells demonstrate ERK-dependent increased spreading
on fibronectin, and PI3K-dependent enhanced proliferation. In
spite of the enhanced transformation of DA3/G-TRUNC in
culture, and the maintenance of their tumorigenic phenotype
in immuno-compromised mice, these cells fail to grow when
implanted in immuno-competent mice unlike all other DA3 based
cell lines. This suggests a tumor abrogation mechanism dependent
on T-cells and on the interaction with the host microenvironment.
Different molecular forms of MUC1 generated through genetic or
proteolytic means may serve as a phenotype-determining regula-
tory mechanism. The role of cellular context and tumor microen-
vironment concomitantly determines the readout of the activation
of specific signaling pathways.
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The cell microenvironment, especially extracellular matrix (ECM)
proteins is considered to play an important role in the tumor cell
response to chemotherapeutic drugs. We have previously reported
that the highest non toxic dose of the antracycline drug,
doxorubicin, displays a marked antimigratory effect on human
fibrosarcoma HT1080 cells when cultured in a conventional way,
on tissue culture plastic (Int J Oncol. 2004; 24: 1607–15), which
was not observed when cells were grown on ECM proteins
(Cancer Sci. 2008; 99: 1699–705). The present study was
designed to investigate whether the cell microenvironment can
influence the antiinvasive effect of doxorubicin when these tumors
cells are grown in a 3 dimensional (3D) context which simulates a
natural microenvironment. For this purpose, we define migratory
S163parameters by time-lapse videomicroscopy, the integrin expres-
sion, and the activation state of FAK and GTPase RhoA, two
proteins involved in the formation of focal adhesion complexes
and cell movement. In 3D matrix, the highest non toxic dose of
doxorubicin does not affect cell migration and cell trajectories.
Concerning the integrin expression, and the activation state of
FAK and GTPase RhoA, protectory effect of microenvironnement
was also observed. In conclusion, this in vitro study demonstrates
the lack of antiinvasive effect of anthracyclines in a 3D
environment which is generally considered to better mimic the
phenotypic and morphological behaviour of cells in vivo.
Consistent with the previously shown resistance to the cytotoxic
effect in 3D context, our results shed more light on the importance
of the matrix configuration on the tumor cell response to
antiinvasive drugs.
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PPAR-g Ligands Inhibit Acquisition of Mesenchymal
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Tumors cells acquire metastatic capabilities by undergoing
epithelial-mesenchymal transition (EMT). In lung cancer cells,
we demonstrated that TGF-b-induced EMT confers a migratory
and invasive phenotype in-vitro and promotes metastasis in-vivo.
We have also shown that activation of nuclear hormone receptor,
peroxisome proliferator activated receptor (PPAR)-g with its
ligands, inhibits the growth and metastasis of lung cancer cells.
Many pathways have been implicated in PPAR-g mediated
inhibition of tumor progression, but the mechanisms by which
PPAR-g activation may inhibit metastasis are not clear. Here we
tested the hypothesis that PPAR-g activation may inhibit EMT
contributing to its anti-metastatic effects. Activation of PPAR-g by
synthetic ligands or by a constitutively active form of PPAR-g, did
not prevent TGF-β-induced E-cadherin loss or the fibroblastoid
morphology. However, the induction of mesenchymal markers
(vimentin, N-cadherin) and MMPs by TGF-b were significantly
inhibited. Consistently, activation of PPAR-g also inhibited EMT-
induced migration and invasion of A549 cells. It has been shown
that Zinc finger E-box binding homeobox 1 (Zeb1) regulates EMT
by repressing epithelial gene expression and inducing mesenchy-
mal gene expression. Here we demonstrate that activation of
PPAR-g inhibits TGF-b-induced Zeb1 expression but had no
effect on TGF-b-induced Smad phosphorylation or expression.
Furthermore, effects of PPAR-g ligands on Zeb1, vimentin and
MMP expression were attenuated by siRNA mediated knockdown
of PPAR-g indicating above responses are PPAR-g dependent.
Together our data demonstrates that PPAR-g activation regulates
EMT by selective inhibition of mesenchymal phenotype partly
through inhibition of Zeb1 expression and offers PPAR-g ligands
as potential therapeutics against tumor metastasis.
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PAR-1 has been studied to play a significant role in cancer
metastasis. PAR-1 is activated by thrombin and initiates the signal
transduction across the membrane to activate intracellular G
proteins, which regulate pathways for cell migration and adhesion.
The expression of PAR-1 was also reported about the association
with gastric cancer progression, however the regulation mechanism
(s) of PAR-1 is still unclear. Here, we demonstrated galectin-3
regulates the expression of protease-activated receptor1 (PAR1),
which promotes gastric cancer cell migration through its activation.
Galectin-3, a member of the β-galactoside-binding proteins, is also
involved in tumor metastasis but its roles also need to study.
When the expression of galectin-3 was knock-downed by small
interfering RNA (siRNA), the decrease of PAR-1 expression was
detected in MKN-28 gastric cancer cells. Not only PAR1 expression,
galectin-3 siRNA treatment also reduced MMP-1 and PAR-1 target
genes such as MMP-2 and MMP-9. Down-regulation of both of
galectin-3 and PAR-1 by its siRNA resulted in decrease of cell
migration and change of cell morphology to round shape. Over-
expression of galectin-3 showed the increased PAR-1 expression and
cell migration. However, its increasing induced by over-expression of
galectin-3 was blocked by PAR-1 silencing, suggesting that galectin-
3 promotes cell migration through PAR-1 up-regulation. To deter-
mine how galectin-3 modulates PAR-1 expression, we found out the
expectation siteof AP-1 binding on PAR-1 promoteranddetected the
interaction with galectin-3 and c-jun/fra-1. After galectin-3 silencing,
c-jun and fra-1 could not bind on PAR-1 promoter by ChIP assay.
Taken together, we suggest that galectin-3 increases cell motility
through up-regulation of PAR-1 expression, and galectin-3 can
serve as potential target molecule in the prevention and/or therapy
of gastric cancer metastasis.
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Hypoxia is a strong signal for cell migration and invasion in cancer.
The reversion-inducing cysteine-rich protein with Kazal motif
(RECK), a tumor suppressor, inhibits cancer cell migration and
S164invasion and is frequently silenced in aggressive tumor cells by
histone deacetylases. However, the effect of RECK silencing in
several cancer cells in a hypoxic microenvironment has not been
fullyidentified.HereweinvestigatedthathypoxiasuppressesRECK
expression and restoration of RECK by using the strategy of HDAC
inhibition inhibits cancer cell migration and invasion. HDAC
inhibitorsincludingtrichostatinA(TSA)completelyrestoredRECK
expression suppressed by hypoxia in the H-Ras MCF10A cell line
(human breast cancer) and the HT1080 cell lines (human fibrosar-
coma). TSA suppressed the activity of MMP-2 and MMP-9 induced
by hypoxia and significantly inhibited the hypoxia-stimulated
migration and invasion of both cancer cells. RECK overexpression
significantly inhibited the hypoxia-induced migration and invasion,
suggesting the inhibitory role for RECK in hypoxic conditions. We
also demonstrate that silencing of HDAC1 using small interfering
(si) RNA suppressed hypoxia-induced RECK downregulation. In
conclusion, the inhibition of HDAC successfully restored the
expression of RECK under hypoxic conditions. This resulted in
the inhibition of cancer cell migration and invasion through the
repression of MMP-2 and MMP-9 activity.
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The ability of tumor cells to migrate, invade and intravasate requires
the deregulation of interactions with adjacent cells and the extracel-
lular matrix. A major challenge of cancer biology is to observe the
dynamics of the proteins involved in this process in their functional
andphysiologiccontext.Toaddressthis,wedevelopedanE-cadherin
chimera fused tobothGFP and a FKBP-destabilization domain(DD)
thatconstitutivelytargetstheproteinforproteasomedegradationuntil
stabilizedbySHIELD-1,asmallmoleculethatbindsreversiblytothe
DD. This approach allows one to dynamically modulate E-cadherin
activity at the post-translational level by varying the levels of
SHIELD-1. Using the highly metastatic MDA-MB-231-LN cell line,
we demonstrate that in the absence of SHIELD-1, E-cadherin is
observed only in punctate cytoplasmic vacuole pools that co-localize
with 20S proteasome. Within 30 minutes of SHIELD-1 treatment, a
shift in localization to the plasma membrane is seen with concurrent
formation of cell-cell adherens junctions. SHIELD-mediated induc-
tion of E-cadherin significantly reduces cell migration and
invasion compared to un-induced MDA-MB-231LN cells
expressing the E-cadherin chimera and vector control MDA-
MB-231LN cell line. Using an experimental in vivo human
breast cancer metastasis model in the chick embryo, we observe
retraction of cell protrusions and formation of adherens junctions
in MDA-MB-231LN cells with SHIELD-1 treatment. Moreover,
cells transform from a spindle-shaped morphology into a
rounded morphology, resembling a mesenchymal-to-epithelial
morphological transition. Using this dynamic protein modulation
strategy with intravital imaging, we will be able to quantify the
impact of dynamic E-cadherin modulation in vivo during each
rate-limiting step of metastasis.
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Background: Tumor hypoxia is considered to be relevant for
several aspects of tumor pathophysiology, for tumor growth and
progression, and epithelial to mesenchymal transition (EMT). We
now report that hyperbaric oxygen (HBO) treatment induced
mesenchymal to epithelial transition (MET) in a dimetyl-α-
benzantracene induced mammary rat adenocarcinoma model, and
the MET was associated with extensive coordinated gene
expression changes and less aggressive tumors.
Methods: One group of tumor bearing rats was exposed to HBO
treatment (2 bar, pO2 = 2 bar, 4 exposures à 90 minutes), whereas
the control group was housed under normal atmosphere (1 bar,
pO2 = 0.2). Treatment effects were determined by assessment of
tumor growth, tumor vascularisation, tumor cell proliferation, cell
death and gene expression profile.
Results: Tumor growth was significantly reduced (~16%) after
repeated HBO treatment compared to day 1 levels, whereas
control tumors increased almost 100% in volume. A significantly
decrease in tumor cell proliferation and tumor blood vessels,
together with an increase in cell death, are consistent with tumor
growth reduction and tumor stroma influence after hyperoxic
treatment. Gene expression profiling showed that HBO induced a
MET with increased expression of cell attachment gene modules.
Conclusion: Hyperoxia induces a coordinated alteration of entire
gene modules of cell junctions, attachments and MET, which leads
to less aggressive DMBA-induced mammary tumors. This indicates
that oxygen per se might be an important factor in the “switch”
from EMT to MET in vivo. HBO treatment also attenuates tumor
growth and changes tumor stroma by targeting the vascular system,
having anti-proliferative and pro-apoptotic effect.
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Bone Morphogenetic Proteins (BMPs), members of the TGF-β
superfamily, has been reported to enhance migration, invasion,
and metastasis of various types of cancer cell lines, but its role in
the invasive phenotype of gastric cancer cells is not yet known.
Here, we was investigated a role and mechanism for BMP2-Akt-
Raf signaling as it relates to the metastatic potential of gastric
cancer. We found that stimulation of BMP2 in gastric cancer cells
enhanced cellular motility and invasiveness, but addition of BMP4
did not. Meanwhile, blockade of BMP2 pathway by Noggin (a
BMP signaling inhibitor) or anti-BMP2 neutralizing antibodies
inhibited BMP2-induced invasiveness of gastric cancer cells. The
phosphorylation of Akt and c-Raf was also enhanced by treatment
with BMP2, but not Noggin, anti-BMP2 neutralizing antibodies.
To investigate the functional relationship between BMP2 and
Akt signaling in regulating the metastatic progression of human
gastric cancer, we performed Matrigel invasion assay using
cells either transfected with kinase-dead Akt or treated with
either LY294002 or PD98059. Blockade of the Akt kinase
using kinase-dead Akt, LY294002, or PD98059 in the presence
of BMP2 significantly inhibited the gastric cancer cell
invasiveness in association with a decreased expression of
phospho-Raf. In addition, In addition, phosphorylation of
IκBα,I κBα degradation, and the nuclear translocation of NF-
κB was also enhanced by treatment with BMP2, but not
Noggin, BMP2 neutralization antibodies, LY294002, or
PD98059. Furthermore, we investigated whether the serum
BMP-2 level from patients had any association or tendency
with progression status of gastric cancer. No significant
difference in the mean serum BMP-2 levels was observed
between control and EGC (Early Gastric Cancer without lymph
node metastasis) groups. However, metastatic disease group
had significantly higher level of serum BMP than those of
control and EGC groups. Overall, BMP2 signaling pathway
promotes invasiveness of gastric cancer cells through activation
of PI3K/Akt-Raf-NF-κB pathway.
Poster No. 134
Highlighting the Peritumoral Areas of Human Skin Cancer
Biopsies by Infrared Spectral Microimaging
David Sebiskveradze
1, Cyril Gobinet
1,E l o d i eL y
1,M i c h e l
Manfait
1, Olivier Piot
1, Valeriu Vrabie
2, Pierre Jeannesson
1
1MéDIAN, CNRS UMR 6237 MEDyC, University of Reims
Champagne-Ardenne, Reims, France,
2CReSTIC, University of
Reims Champagne-Ardenne, Reims, France
Infrared micro-spectral imaging is an efficient label-free optical
method to analyze biological samples and to provide spatially
resolved information on the basis of their biochemical composi-
tion. Recent studies have shown its potential to detect and
characterize cancerous tissues in their early stages, independently
of visual morphology. Infrared micro-imaging could thus be
developed as a sensitive, nondestructive and objective diagnostic
tool in clinical oncology. The discrimination between tumoral and
peritumoral tissues relies on the highlighting of subtle infrared
spectral differences. For this, we developed an algorithm based on
fuzzy classification techniques which permits to automatically
identify both the tumoral areas and their normal counterparts. This
approach has been directly performed on formalin-fixed paraffin-
embedded tissue sections of human skin cancers (squamous cell
carcinoma and melanoma), without chemical dewaxing. The
constructed infrared colorcoded spectral images allow recovering
the different histological structures automatically. However, more
than reproducing classical histology, our algorithm can give access
to interesting information on the assignment of the infrared images
pixels to the tissular structures. For each pixel, fuzzy classification
provides with membership values, permitting to nuance their
assignment. Such data are very valuable for the pixels located at
the interface between tumoral tissue and its microenvironment.
Thus, heterogeneous transitional areas between tumor and envi-
ronmental normal tissue were identified for the examined tissue
sections. These areas cannot be identified on hematoxylin-eosin
staining or by conventional classification of infrared data, such as
K-means. They are characterized by a gradual increase of the
membership value of the pixels, from tumor to normal tissue to
reach a maximum. Then, this value sharply decreases at the edge
of the normal tissue. Experiments are underway to define the
molecular assignments of the spectral variations observed in these
peritumoral areas.
(DS is a recipient of a doctoral fellowship from INCa).
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Transforming growth factor (TGF-beta) is a pleiotropic cytokine
that plays a dual function in lung cancer, acting as suppressor at
initial stages of tumor growth, but becoming oncogenic at later
cancer stages.
Although recent studies have described a mechanism whereby the
TGF-beta induce mammary cancer cells to disrupt the capillary
walls and seed metastases to lung, the role of this cytokine in lung
tumor cell intravasation in the lung lymphatic vasculature
remained obscure.
In this study, we use in vitro models to describe that upon TGF-
beta exposure, H157 NSCLC, enhance their migration towards the
leukocyte chemokines MIP1-alpha with the concomitant induction
of its receptor CCR5 on NSLCL cells surface. These effects were
specifically blocked by DAPTA an inhibitor of CCR5 signalling
S166and by the TGF-beta inhibitor SB431542. Subsequently, we
observed that TGF-beta treated NSCLC showed also increased
adhesion and transmigration through the lymphatic vessels in the
presence of MIP1-alpha gradients.
Lastly, to provide a mechanistic support for TGF-beta mediated
tumor cell adhesion to this endothelium, we analyzed the
integrins and integrin receptors that showed modified expres-
sion after TGF-beta exposure, observing that there was an
induction of the integrins alphavbeta3 and alphavbeta5 in
NSCLC cells while that of their receptor, the protein L1 did
not change on lymphatic endothelial cells. After specific
blockade of these integrins and confocal microscopy analysis
we could definitively affirm that they intervene in NSCLC
adhesion to the lymphatic endothelium.
These results provide the first in vitro evidence of the implication
of TGF-beta induced CCR in the onset of the metastatic spread of
NSCLC through the lymphatics.
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Butyric acid is a short chain fatty acid (SCFA), a final product of
bacterial fermentation of dietary fibers in colon. Butyric acid
controls cell proliferation and apoptosis due to its action as a
histone deacetylase inhibitor; as such, butyrate and butyrate-
derived drugs are commonly used in cancer therapy with varying
success. Despite the high butyrate concentration in colonic lumen,
some colon cells are resistant to the butyrate effect and can give
rise to aggressive colon cancers. In the present report, we
characterize the effects of butyrate exposure on butyrate-resistant
colon cancer cells. In vivo, sub-cutaneous tumours formed by
butyrate pre-treated HCT15 (resistant colon cancer cells) prolifer-
ated more and were more angiogenic than tumours induced by
non-treated cells. Similarly, intravenous inoculation of butyrate
pre-treated HCT15 cells resulted in the formation of pulmonary
micro-metastases, while mice injected with non-treated cells did
not develop metastases. In vitro, we show HCT15 cells are able to
fully metabolise butyrate. Butyrate treatment regulated the
expression of angiogenic factor VEGF and its receptor KDR
(VEGFR-2) at the transcriptional level. Butyrate treatment also
induced the expression of b-oxidation acyl-dehydrogenases
(SCAD and MCAD), MMP2, MMP9, a2 and a3 integrins, and
reduced E-cadherin, suggestive of epithelial to, mesenchymal
transformation (EMT). These results suggest that butyrate resistant
colon cancer cells exposed to butyrate-rich microenvironment
undergo metabolic and phenotypic changes resulting in enhanced
proliferation, angiogenesis and metastasis. These results reveal the
mechanistic basis for the clonal selection of very aggressive and
butyrate resistant colorectal cancers.
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Fibroblasts in the tumor microenvironment promote cancer progres-
sion and invasion through various mechanisms. We previously
demonstrated that fibroblasts respond to interstitial flow (Ng et al.,
2005), and since flow is an important part of the tumor microenviron-
ment, we asked how flow affects tumor-fibroblast crosstalk and cancer
invasion. In a modified transwell assay with a 3-D matrix, fibroblasts
significantlyandsynergisticallyenhancedmelanomacellinvasiononly
with interstitial flow. This synergy depended on endogenous, but not
exogenous, TGF-β1. We therefore hypothesized that highly localized
gradients of TGF-β1 were driving this synergistic response, and that
the fibroblasts responded to these gradients to help direct tumor cell
invasion. Cell-localized gradients could be generated by interstitial
flow and secreted proteases, as we previously showed (Fleury et al.,
2006). Interstitial flow alone increased fibroblast migration by 3-fold;
in the presence of tumor cells, flow enhanced fibroblast migration 6-
fold. This migration was TGF-β1-dependent. Fibroblasts produced
most of the TGF-β1, as tumor cell-fibroblast gels contained 113 pg of
TGF-β1, compared to 15 pg in tumor cell only gels. To generate an
autologous TGF-β1 gradient, fibroblasts would need to activate latent
growth factor, possibly via matrix metalloproteinases (MMPs).
I n h i b i t i n gM M Pa c t i v i t yr e s u l t e di na4 7 %d e c r e a s ei nf l o w -
stimulated fibroblast migration, and a 40% reduction in fibroblast /
flow-mediated tumor cell migration. These results suggest that
fibroblasts secrete latent TGF-β1, activate it via MMPs, and generate
a gradient in the direction of interstitial flow. Further, these data
support the notion that fibroblasts chemotact up autocrine TGF-β1
gradients and direct tumor cell invasion. This behavior represents a
previously undescribed mechanism by which tumor cells could
migrate to lymphatic vessels, towards which interstitial flow is
directed, leading to lymph node and organ metastases.
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S167The tumor-stroma crosstalk is a dynamic process fundamental in
tumor development. In hepatocellular carcinoma (HCC), the
progression of malignant hepatocytes frequently depends on
transforming growth factor (TGF)-beta provided by stromal cells.
TGF-beta induces an epithelial to mesenchymal transition (EMT)
of oncogenic Ras-transformed hepatocytes and an upregulation of
platelet-derived growth factor (PDGF) signaling. To analyze the
influence of the hepatic tumor-stroma crosstalk onto tumor growth
and progression, we co-injected malignant hepatocytes and
myofibroblasts. For this, we either used in vitro activated p19
ARF
myofibroblasts or in vivo activated myofibroblasts derived from
physiologically inflamed livers of Mdr2/p19
ARF double null mice.
We demonstrate that co-transplantation of myofibroblasts with
Ras-transformed hepatocytes strongly enhances tumor growth.
Genetic interference with the PDGF signaling decreases tumor cell
growth and maintains plasma membrane-located E-cadherin and
beta-catenin at the tumor-host border, indicating a blockade of
hepatocellular EMT. We further generated a collagen gel-based
three dimensional HCC model in vitro to monitor the
myofibroblast-induced invasion of micro-organoid HCC sphe-
roids. This invasion was diminished after inhibition of TGF-beta
or PDGF signaling. These data suggest that the TGF-beta/PDGF
axis is crucial during hepatic tumor-stroma crosstalk, regulating
both tumor growth and cancer progression.
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The activation of Sonic hedgehog (Shh) signaling is involved in
the progression and invasion of various tumors, including gastric
carcinoma. Epithelial-mesenchymal transition (EMT) and matrix
metalloproteinases (MMPs) have been implicated in facilitating
the invasion and metastatsis. Herein, we investigated the impact of
phosphoinositide 3-kinase (PI3K)/Akt pathway and MMPs activ-
ity on the Shh/Gli-mediated EMT and invasion of gastric cancer
cells. We found that stimulation of N-Shh in gastric cancer cells
enhanced cellular motility and invasiveness and induced a full
EMT process characterized by Snail induction and E-cadherin
down-regulation. Accompanying EMT, Shh also induces increased
expression and activity of MMP-9. Meanwhile, blockade of Shh/
Gli signaling by Cyclopamine (a Shh signaling inhibitor), anti-Shh
neutralizing antibodies, or Gli siRNA also restored these changes
of EMT markers and activity of MMP-9 and inhibited N-Shh-
induced invasiveness of gastric cancer cells. The phosphorylation
of Akt was also enhanced by treatment with N-Shh, but not
cyclopamine, anti-Shh neutralizing antibodies, or Gli siRNA.
Blockade of the Akt kinase using DN-Akt or LY294002 in the
presence of N-Shh significantly inhibited the Shh-induced
EMT, activity of MMP-9, and invasiveness. Furthermore,
knock-down of MMP-9 by its siRNA results in an decrease
in invasiveness of gastric cancer cells treatment with N-Shh.
Immunohistochemistry on gastric tumor biopsies showed
that the levels of Gli, E-cadherin, MMP-9 and phosph-Akt
expression were enhanced in cases of metastatic gastric cancer
than in cases of primary gastric cancer. Moreover, the strong
correlation between Gli and E-cadherin, MMP-9 or phospho-
Akt expression was also observed in lymph node metastasis
specimens. These data indicate that Shh/Gli signaling pathway
promotes EMT and invasiveness of gastric cancer cells
through activation of PI3K/Akt pathway and upregulation of
MMP-9.
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CD44 is a transmembrane adhesion molecule and principal
receptor for hyaluronan (HA). Expression of CD44 has been
documented to have a key role in breast cancer metastasis. We
conducted an immunohistochemistry (IHC) study of CD44s
expression in breast cancer tissue microarrays (TMAs) and found
that CD44s expression significantly associated with node positive
tumours (p=0.0209) and distant recurrence (p=0.0427). Further-
more CD44 expression was associated with the basal phenotype of
breast cancer (p=0.018). Basal breast cancers are known to have a
poor prognosis and the aim of this study was to gain insight into
the role of CD44 in the poor prognosis of basal breast cancers. For
this we used a subclone of the basal-like breast cancer cell line
MDA-MB-231 that specifically metastasises to bone. Bone
homing MDA-MB-231BO cells displayed increased CD44,
alpha5 and beta1-integrin expression relative to the parental cells
and were more adherent to bone marrow endothelium (BMEC)
and fibronectin. HA-induced CD44 signaling increased beta1-
integrin expression and activation and induced phosphorylation of
the cytoskeletal proteins cortactin and paxillin. HA-induced
paxillin phosphorylation was attenuated by depletion of CD44
S168and cortactin using RNAi and following administration of
neutralizing antibodies to beta1-integrin receptors, suggesting that
it is a downstream target of CD44-promoted, integrin-mediated
signaling. Inhibition of this signaling cascade by RNAi-mediated
depletion of CD44, cortactin or paxillin or by addition of
neutralizing antibodies against beta1- and alpha5beta1-integrins
attenuated MDA-MB-231BO cell adhesion to BMECs and the
alpha5beta1-integrin substrate, fibronectin. Furthermore IHC
confirmed alpha5 and beta1-integrin expression in breast TMAs
and correlated CD44 expression with alpha5 expression (p=
0.044). We propose this CD44 induced, integrin-mediated signal-
ing pathway contributes to the efficient extravasation of basal
breast cancer cells across endothelial barriers and their colonisa-
tion of the metastatic niche.
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The tumor stroma of solid tumors harbours many different cell
types that are contributing to an intense crosstalk with the cancer
cells and thereby promote tumor growth and progression. One of
the major cell types of the tumor stroma are cancer-associated
fibroblasts (CAFs). CAFs attract increasing attention because of
their critical contributions to tumor development and metastasis.
Using an integrative approach we identified several novel factors
in CAFs derived from prostate cancer patient biopsies. For one of
the soluble factors identified, the chemokine CXCL14, we
describe a novel, tumor- promoting activity when expressed by
CAFs.
Analyses of matched normal and tumor tissue revealed up-
regulation of CXCL14 in cancer-associated fibroblasts of a
majority of prostate cancer. Fibroblasts over-expressing CXCL14
promoted the growth of prostate cancer xenografts, accompanied
by increased tumor angiogenesis and macrophage infiltration.
Mechanistic studies demonstrated that autocrine CXCL14-
stimulation of fibroblasts enhance migration and proliferation of
fibroblasts. CXCL14- producing fibroblasts, but not recombinant
CXCL14, enhanced in vitro proliferation of prostate cancer cells
and in vivo angiogenesis. Furthermore, expression profiling led to
the identification of several molecules that putatively mediate
CXCL14- action in the fibroblasts.
These studies thus identify CXCL14 as a novel autocrine
stimulator of fibroblasts, with multi-modal tumor-stimulatory
activities. In more general terms, our findings emphasize the
importance of CAFs in tumor growth and suggest a novel
mechanism whereby cancer-associated fibroblasts achieve their
pro- tumorigenic phenotype. The generic strategy used for the
identification of these novel stimulators of prostate cancer growth
is predicted to also be applicable in other tumor types.
Östman and Augsten, Curr Opin Genet Dev. 2009 19: 67–73.
Augsten et al., Proc Natl Acad Sci U S A. 2009 106: 3414–3419
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Pancreatic cancer is one of the most aggressive neoplasms with an
extremely low survival rate. Because most pancreatic carcinoma
patients miss the opportunity for complete surgical resection at the
time of diagnosis, radiotherapy remains a major component of
treatment modalities. However, pancreatic cancer often shows
resistance to radiation therapy. Ionizing radiation (IR)-induced
aggressiveness is emerging as one of the important mechanisms
responsible for limited benefit of radiation therapy in pancreatic
cancer, but the identity of downstream effectors responsible for
this effect remains poorly investigated.
Here we report that IR promotes pancreatic cancer aggressiveness
through up-regulation of the heparanase. Heparanase is a
predominant mammalian enzyme capable of degrading heparan
sulfate (HS), the main polysaccharide component of the basement
membrane and other types of extracellular matrix (ECM).
Cleavage of HS by heparanase leads to disassembly of ECM,
enables cell invasion, releases HS–bound angiogenic and growth
factors from the ECM depots, and generates bioactive HS
fragments. We found that clinically relevant doses of IR augment
invasive ability of pancreatic cells in vitro and in vivo via
induction of heparanase. Our results indicate that effect of IR on
heparanase expression is mediated by Egr1 transcription factor.
Moreover, specific inhibitor of heparanase enzymatic activity
abolished IR-induced invasiveness of pancreatic carcinoma cells
in vitro, while combined treatment with IR and the heparanase
inhibitor, but not IR alone, attenuated orthotopic pancreatic tumor
progression in vivo.
The proposed up-regulation of heparanase by IR represents a new
molecular pathway through which IR may promote pancreatic
tumor aggressiveness, providing explanation for the limited
benefit from radiation therapy in pancreatic cancer. Our research
is expected to offer a new approach to improve the efficacy of
radiation therapy and better define target patient population in
which such approach could be particularly beneficial.
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Incidence of neoplasia is known to increase with age while tumor
growth and metastatic spread proceed, paradoxically, at a slower
rate in aged as compared to young patients. Although not a
general feature, this intriguing phenomenon is observed in many
human and experimental tumors. We have shown this particular
behavior in the AKR lymphoma and B16 melanoma.
Understanding the mechanisms of this interesting phenomenon is
of importance, particularly in view of the possibility that these
mechanisms may eventually suggest modalities for age- adjusted
anti- tumoral therapy. We have previously shown that one such
mechanism is increased tumor cell apoptosis in the old animals. In
the present study we tried to verify whether the induction of tumor
cell apoptosis in the aged depends on the malignancy of the tumor.
We used variants of malignancy of the AKR lymphoma and tested
the degree of apoptosis in young and old mice in several such
variants. According to various cellular (Apoptag staining, DNA
flow cytometry) and molecular (ladder type DNA fragmentation,
Bcl-2, Fas receptor and caspase expression) characteristics of
apoptotic cells, we found that tumor cell apoptosis was increased
in tumors of old as compared to those of young mice in all
variants. This age-dependent increased apoptosis was however
inversely proportional to AKR lymphoma malignancy.
Our results may indicate that the inhibitory capacity of the old
organism tumor microenvironment is limited by the aggressive-
ness of the tumor. We have previously found that low malignancy
variants of AKR lymphoma are more prone to apoptosis than high
malignancy variants. It is therefore expected that inducing tumor
cell apoptosis as a therapeutic modality in the old can be more
effective at early stages of tumor development than at late ones.
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to the Desmoplastic Reaction in Breast Cancer: A New Link
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In a variety of tumours, such as breast carcinomas, a desmo-
plastic response, characterized by the presence of a dense
collagenous stroma comprising fibroblast-like cells, is observed
and is thought to contribute to tumour progression. Peritumoral
fibroblasts are composed of several subpopulations that are
morphologically undistinguishable and their origins remain
debated. Most of the studies have focused on the activation of
fibroblasts present in the interstitium (the so-called myofibro-
blasts) and very little attention has been given to adipocytes,
although it is obvious that in breast, early local tumour invasion
results in immediate proximity of cancer cells to adipose tissue.
We demonstrate here that the tumour cells modify both the
mature and precursors components of the surrounding adipose
tissue leading to the accumulation of an activated population
with morphological features of fibroblast cells. Using an original
2D system, where an insert separates the two cell populations,
we first demonstrate that mature adipocytes cocultivated with
breast tumour cells for 5 to 8 days exhibit a loss of lipid content,
a decrease in differentiation markers (shown by qPCR and
Western blots) and underwent morphological changes into
fibroblast-like cells associated to cytoskeleton reorganization.
Tumour cells were also able to profoundly inhibit the adipo-
genesis of pre-adipocytes grown in adipogenic conditions.
Interestingly, this population of adipocyte-derived fibroblasts
(ADF) exhibit a profibrotic phenotype (with enhanced fibronec-
tin and collagen I production) and enhanced migratory capaci-
ties. Ongoing experiments are performed in our laboratory to
assess the presence of these ADF in human breast tumours. Our
results might provide an explanation for the poor prognosis
observed in localised breast cancer in obese women, since the
nature of the desmoplastic reaction and the secretion pattern of
the ADF might be profoundly altered in this physiopathogical
condition.
Poster No. 145
The Endothelial KSHV GPCR Signaling Pathways
is Active in Human Kaposi Sarcoma
Julie Dwyer
1,2, Mamta Sumbal
1,2, Armelle Le Guelte
1,2,
Laetitia Douguet
1,2, Nina Fainberg
3, J. Silvio Gutkind
3,
Philippe A. Grange
4, Nicolas Dupin
4,J u l i eG a v a r d
1,2
1Institut Cochin, Universite Paris Descartes, CNRS (UMR 8104),
Paris, France,
2INSERM, U567, Paris, France,
3Oral and
Pharyngeal Cancer Branch, National Institute of Dental and
Craniofacial Research, National Institute of Health, Bethesda,
Maryland, USA,
4UPRES-EA1833 Laboratorie de Recherche en
Dermatologie, Centre National de Reference Syphilis, Paris,
France
Kaposi Sarcoma (KS) are opportunist tumors, associated with the
herpes virus-8 infection, also named as Kaposi Sarcoma Herpes
Virus. KS development is indeed highly favored by immune-
depression, such as AIDS malignancies. Although KS incidence is
reduced in HIV-infected patients through the use of antiretroviral
tri-therapies, recent epidemiological data show that KS is the
second most frequent tumor in AIDS patients in western countries.
KS are multiple tumor lesions, highly angiogenic, highly
S170inflammatory, and involved in neoplastic cells as well as
transformation of the microenvironment most likely through
paracrine effects. Recently, it has been demonstrated that the
expression of the viral G protein coupled receptor (vGPCR) in the
endothelial compartment is sufficient alone to recapitulate forma-
tion and progression of Kaposi Sarcoma in mice; making this
model and this viral protein in particular, a powerful tool to study
the pathology of KSHV. However, the functional effects of
vGPCR expression on endothelial homeostasis are far from being
addressed. Here we show that vGPCR expression in endothelial
cells induces an increase in paracellular permeability through a PI
(3)Kinase/Rac pathway and involves the activation of the kinase
PAK. This leads to the further phosphorylation of VE-cadherin
and the subsequent remodeling of endothelial junctions. Impor-
tantly, this signaling pathway was also found active in 12 out of 14
KS samples analyzed. Our results suggest that endothelial vGPCR
signaling mechanisms are functional in KS microenvironment,
placing endothelial transformation as a key cellular target for
therapeutic intervention.
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Colorectal cancer (CRC) is the second most common cause of
cancer deaths in the western world. We have previously shown a
correlation between high macrophage infiltration and improved
survival in CRC. Tumour associated macrophages (TAMs) play
complex roles in tumourigenesis since they can both prevent and
promote tumour progression. According to a suggested hypoth-
esis classically activated M1 macrophages mainly act to prevent
tumour progression and metastasis, whereas alternatively
activated M2 macrophages instead have mainly tumour pro-
moting functions.
We have applied an immunohistochemical approach to determine
the degree of M1 and M2 macrophage infiltration in clinical
specimens of CRC and related the results to various clinico-
pathological variables. A total of 434 consecutive CRC specimens
collected over the period 1995 through 2003 were stained for
iNOS (M1 marker) and CD163 (M2 marker). The average
infiltration along the invasive tumor margin was semi-
quantitatively evaluated using a four-graded scale. We observed
a statistical correlation between the amount of iNOS (M1) and
CD163 (M2) positive cells (p<0.001). Furthermore, patients
harbouring iNOS high tumours had a significantly better prognosis
than iNOS low tumours. An inverse association between tumour
stage and the amount of iNOS positive macrophages (p<0.001)
was found. Accordingly, the prognostic significance for iNOS
macrophages was lost when including tumour stage in the
multivariate analysis. In vitro cell culture models using primary
human monocytes or a monocytic cell line (MonoMac6) were
used to study the functional roles of M1 and M2 macrophages in
tumour cell migration and invasion In conclusion, our results
support the view that TAMs are important in tumour progression
and for patient outcome.
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the Growth of Neoplastic Cells in vitro
Bratko Filipič
1, Evgen Šooš
2, Hrvoje Mazija
3, Srečko Koren
1
1Institute of Microbiology and Immunology, Medical Faculty,
University of Ljubljana, Ljubljana, Slovenia,
2Kloštar Ivanić,
Croatia,
3Department of Avian Diseases with Clinic, Veterinary
Faculty, University of Zagreb, Zagreb, Croatia
The Holocene started by withdrawal of pleistocene glacier. The
holocene sants containing uniform holocene minerals occured.
Grained show unusual biological/microbiological activity, like
antifungal against Peronospora sp., Phytophthora sp.
The entity of the patent invention lies in the use of the holocene
grain wash-out and different Human Interferons and combinations
between them in the prevention of growth and multiplication of
Human neoplastic cells in vitro.
1)
Grain samples (»Svijetli« (Light), »Tamni« (Dark)) and
Human Interferons: HuIFN-αN3 (Human leukocyte Interfer-
on) (1000 I.U./ml) (reference value) and rHuIFN-α2 (1000 I.
U./ml) (reference value) were used. Samples from river Drava
sants, near Koprivnica, grained by »Star mix« technology
giving fine grain with 60–80 μms i z ew e r eu s e d .T h e
following wash-out (»suspensions«) were prepared: (1) 10%
Monoethylene-glycole, (2) 10% PBS (Phosphate buffer sa-
line).CaCo-2 (Colon cancer carcinom) cells were used and
WISH (Human amniotic cell line) cells as control. Cells were
treated either with grain wash-out (Monoethylene glycole,
PBS), HuIFN-αN3, rHuIFN-α2 or with different combinations
between them in ratio: 1:1, 1:2, 2:1. The 50% cell growth
inhibition test was used. The meaning of the data: The higher
is the dillution till well giving 50% cell growth inhibition,
beter is the substance. The conclusions:(1)The holocene grain
wash-out (10% suspension) show the AP (Antiproliferative)
activity against CaCo-2 cells in vitro.(2)The AP actvitiy of
Monoethylene glicole wash-out is higher than these obtained
f r o mP B S( 3 ) T h eo b t a i n e dA Pa c t i v i t yc a nb ee n h a n c e du pt o
4x by combination with HuIFN-αN3 but not with rHuIFN-α2.
(4)For the optimal enhancement of Holocene grain wash-out
AP activity in vitro different natural subtypes contained in
HuIFN-αN3 are needed.
1)Kesteli B., Filipič B., Šooš E. (2007): Ways of use of natural
extracts of Holoce- ne minerals and Interferons on the growth of
neoplastic cells.(In Croatian) IPO; Republic of Croatia, Patent
No.: P20080400A
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It is widely acknowledged that cancer progression and behavior is
affected by the microenvironment [1]. Furthermore, substantial
evidence exists that demonstrates the dependence of the drug
response in cancer cells on cues of the surrounding environment,
such as dimensionality [2] and ECM composition [3]. Such
insights partially explain the discrepancies between observed drug
efficiency in vitro and in vivo. This work aimed to use controlled
engineered cell environments to improve the understanding of the
role of external cues on drug response.
We used a microwell array, previously developed in our group
[4], which enables the culture of cells in a 3D environment
with control of cell cluster size down to the single cell level.
It also allows the control of the biochemical interface with the
cells. Initially we studied the influence of dimensionality on
the response to taxol on the breast carcinoma cell line,
MCF-7.
Cancer cells cultured in microwells showed an increased resis-
tance to taxol in comparison to cells cultured on flat substrates. A
similar change in drug response was observed for cells in cell-
derived fibronectin matrices. These results in two 3D systems, of
different complexity, demonstrate that dimensionality is an
important factor for determining the responsiveness of cells to
drugs. In addition, the results showed that the microwell array can
be used as an in vivo mimic, and is therefore a promising tool for
the screening of anti-cancer drugs.
References:
1. Bissell, M. J., Differentiation, 70, 537–546, 2002. 2. Serebriiski
et al., Matrix Biology, 27, 1074–1077, 2007. 3. Aoudjit, F. et al.,
Oncogene, 20, 4995–5004, 2001. 4. Ochsner, M. et al., Lab Chip,
7, 1074–1077, 2007.
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Background: Colorectal cancer is one of the leading causes of
cancer deaths in western countries, with death generally resulting
from metastatic disease. In recent years, the importance of the
tumor microenvironment, including tumor-associated fibroblasts,
has paid increasing attention.
Aim: To analyze the effect of Fibroblast activation protein
(FAP)-expressing fibroblasts on colon cancer cell migration
and invasion in experimental cell studies. We also investigated
the expression pattern of FAP in tumor-associated fibroblasts
during transformation from benign to malign colorectal
tumors.
Methods and results: In immunohistochemical analyses, FAP
was expressed in fibroblasts in all carcinoma samples examined
(n=61), whereas all normal colon (n=12), hyperplastic polyps (n=
16) or adenoma (n=55) samples were negative for FAP. In in
vitro studies, conditioned medium from HCT-116 colon cancer
cells, but not LT97 adenoma cells, induced FAP expression in
colon fibroblasts. FAP-expressing fibroblasts increased the
migration of colon cancer cells in Boyden chamber experi-
ments, and when co-cultured with FAP-expressing fibroblasts in
a three-dimensional organotypic cell culture model, the inva-
sive behavior of the cancer cells was increased. In contrast,
FAP-expressing fibroblasts did not increase the invasiveness of
the adenoma cell line. Conditioned medium from FAP-
expressing fibroblasts increased the invasion in colon cancer
cells, indicating an involvement of mechanisms other than the
protease activity of membrane-bound FAP. Further cell culture
analysis showed that FGF1-expression is increased in FAP-
expressing fibroblasts.
Conclusions:W ed e m o n s t r a t ean o v e lf u n c t i o nf o rF A P -
expressing fibroblasts. Our findings also suggest that FAP may
be a potential diagnostic marker for early invasion in colorectal
cancer.
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The genetic instability of tumors ensures a changing landscape
of mutated or over-expressed tumor associated antigens
(TAAs). The presence of tumor-specific lymphocytes in
tumors is evidence that TAAs are targets for T-cell immunity.
In spite of this, established tumors rarely generate endogenous
immunity leading to successful tumor eradication. A key
reason for poor TAA immunity is that the tumor microenvi-
ronment becomes progressively more immunosuppressive as
the tumor develops, inhibiting anti-tumor immune activity. The
S172immunosuppressive milieu within tumors is largely brought
about by the presence of T-regulatory cells (Tregs), which
maintain self-tolerance by directly inhibiting T-cells, NK cells
and dendritic cells. Depletion of Tregs enhances antitumor
immune responses, however, it also affects the number of T-
effector cells. Previous studies indicate that intratumoral
injections of CpG-ODN strongly reduces the levels of Tregs
within the tumor, and that the decrease in Tregs is mainly
mediated by IL-6. Since IL6 promotes growth of some human
cancers, alternate pathways to inactivate Tregs were sought
through microarray analysis, resulting in gene candidates that
can be exploited to modulate the function of Tregs. Chemo-
kine (C-C motif) ligand 1 (CCL1) was expressed by Tregs and
its neutralization both inhibited Treg conversion and suppres-
sive function without affecting the function of T-effector cells.
The combination of CpG-ODN and anti-CCL1 treatments
induce complete rejection of tumors in BALB-neuT tolerant
mice. Tumor rejection was coincident with changes in the
lymphocyte composition in the tumor microenvironment.
Tumors of CpG+anti-CCL1 treated mice have decreased in
Treg numbers and a concomitant accumulation of tumorcidal
cells within the tumor. We propose that neutralization of
CCL1 can be used as an adjuvant to anti-tumor immunother-
apy, as a means of reversing Treg dependent immunosuppres-
sion within the tumor.
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Prostate cancer (PCa) is one of the most common and lethal
diseases among men. Although early cancer is often curative,
subsequent metastatic spread of tumor cells renders the disease
untreatable. Treatment failure is also due to a poor understand-
ing of the contribution of the tumor microenvironment to
disease progression. We find that a number of PCa cells secrete
heat shock protein 90 (Hsp90). This extracellular Hsp90
(eHsp90) acts in a manner distinct from the intracellular
chaperone and has been implicated in regulating cell motility
in other models. Interestingly, we find that eHsp90 expression
correlates with cancer aggressiveness. Consistently, the more
aggressive and metastatic PCa cells secreted several fold more
eHsp90 relative to their weakly tumorigenic matched counter-
parts. Interference with this pathway by antibody or drug-
mediated neutralization of native eHsp90 dramatically impaired
tumor cell migration, thereby implicating eHsp90 in a consti-
tutive pathway culminating in cell migration. Concomitant with
inhibition of eHsp90, the activation of downstream mediators
such as FAK, Src, and ERK were attenuated. The multifunc-
tional receptor LRP1 (LDL-receptor Related Protein-1) has
been proposed as the receptor for eHsp90. We find that
silencing of LRP1 similarly reduced PCa signaling and
migration, implicating an eHsp90-LRP1 signaling axis in PCa
development. Addition of Hsp90 to prostate stromal cells,
which lack Hsp90 secretion, potently stimulated ERK activa-
tion and cell motility, implicating paracrine effects. ERK
activation was inhibited by pretreatment with an inhibitor of
MMP activity, suggesting that eHsp90 modulates ERK signal-
ing and MMP activity to modulate cell migration. We propose
that PCa aggressiveness may be due in part to increased
secretion of eHsp90, which then activates the stroma to further
support tumor growth.
Poster No. 152
IL-6 Promotes Pancreatic Cancer Progression by Intractions
of Fibroblasts
Hidenobu Kamohara
1, Takatoshi Ishiko
1, Hiroshi Takamori
1,
Hideo Baba
1
1Department of Gastroenterological Surgery, Kumamoto Univer-
sity, Graduate School of Medical Sciences, Kumamoto, Kuma-
moto, Japan
Introduction:
IL-6 has pleiotropic function and are produced by various
immunnocompetent cells, as well as cancer cells. Some studies
have been demonstrated IL-6 play an important role in evading host
immune surveillance in tumor microenvironment, but interactions of
fibroblasts has not been fully understood. Therefore, the aim of this
study is to reveal role of fibroblasts in pancreatic tumor microen-
vironment. Especially, we evaluate induction and biologicial
function of IL-6 in pancreatic carcinoma cells after the stimulation
with various cytokines and fibroblast associated factors.
Methods and Results:
All 7 tested cell lines expressed gp130 and IL-6Ralpha mRNA, 2
cell lines (Hs7667 and Capan1) expressed IL-6 mRNA in serum
free condition by RT-PCR and Northern blotting. Hs766T cells
were stimulated with or without cytokines. Northern blotting
revealed TNFalpha and IL-1beta upregulated IL-6 mRNA, but not
IL-6, IL-8 and LIF. IL-6 did not affect cell proliferation by WTS
assay, but promoted cell motility and chemoinvasion significantly.
To identify IL-6 expression by interaction between pancreatic
carcinoma cells and fibroblasts, we used two established fibro-
blastic cell lines (MRC-9 and WI-38)isolated from human
embryonal lung tissues. Serum free conditioned medium (CM)
were collected after incubation for indicated periods. Hs766T
produced CM (Hs766T-CM)induced IL-6 and IL-8 mRNA in
MRC-9 and WI-38 cells. MRC-9 CM and WI-38-CM did not
affect in Hs-766 T cells. Co-culture between Hs766T and MRC-9
cells induced IL-8 mRNA drastically.
S173Conclusion:
Communication of pancreatic carcinoma cells with fibroblasts affect
IL-6 expression and that could contribute to pancreatic cancer
progression. Regulation of IL-6 expression in tumor microenviron-
ment would be important for pancreatic cancer therapy.
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Anti-angiogenic effects of the proteasome inhibitor bortezomib
were analyzed in vivo using tumor xenografts in the chicken
chorioallantoic membrane (CAM) assay. Bortezomib’s inhibitory
effects on CAM vascularization were abrogated in the presence of
distinct tumor xenografts suggesting a soluble inhibitory factor
secreted by tumor cells. Using size-exclusion and ion-exchange
chromatography as well as mass spectroscopy. GRP-78, a
chaperone protein of the unfolded protein response, normally
expressed and retained in the endoplasmatic reticulum was
identified as being responsible for bortezomib inhibition. In fact,
a variety of bortezomib-resistant solid tumor cell lines (PC-3,
HRT-18), but not bortezomib-sensitive myeloma cell lines (U266,
OPM-2) were found to secrete high amounts of GRP-78. In fact,
recombinant GRP-78 confered bortezomib resistance to endothe-
lial cells and knock down of GRP-78 in PC-3 cells resulted in loss
of bortezomib resistance. Preliminary data using immunoprecipi-
tation and proteasome activity assays suggest that the mechanism
of action of GRP-78 induced bortezomib resistance is not due to
direct interference with the compound or the proteasome but rather
further downstream due to inhibition of apoptotic signalling. In
conclusion, distinct solid tumor cells secrete GRP-78 thereby
gaining resistance to bortezomib. These findings describe a
hitherto unknown mechanism of resistance to proteasome inhib-
itors and may offer a novel strategy to increase the susceptibility
of solid tumor cells to bortezomib.
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Breast cancer is the most common cancer affecting women in the
United States and other countries. In individuals with breast
cancer, the frequency of bone metastasis is much higher than other
organ metastases. Breast cancer cells secrete osteolytic factors,
such as parathyroid hormone-related protein (PTHrP), interleukin
(IL)-1β, -6 and -11. These factors stimulate stromal/osteoblastic
cells to over-express receptor activator of nuclear factor-kappa B
ligand (RANKL), which is required to induce osteoclast forma-
tion/activation. Over-expression of RANKL results in increased
osteoclast formation and bone resorption. The subsequent bone
resorption induces the release of various growth factors from the
bone matrix, such as transforming growth factor (TGF)-β, insulin-
like growth factor (IGF)-Iand -II. The released growth factors
stimulate the proliferation of cancer cells. The interaction between
tumor cells and bone cells, called to ‘vicious cycle’, is crucial for
the initiation and promotion of skeletal metastasis. We found that
platycodin D (PD), a major constituent of triterpene saponins
found in the root of Platycodon grandiflorum, inhibited the
viability of human breast cancer MDA-MB-231 cells, in a dose-
dependent manner. However, PD did not influence the secretion of
osteolytic factors in MDA-MB-231 cells and RANKL/OPG ratio
in osteoblasts treated with conditioned media of MDA-MB-231
cells. PD suppressed RANKL-induced osteoclast formation/acti-
vation through down-regulation of c-Fos and nuclear factor of
activated T cells 1 (NFATc1) in mouse bone marrow-derived
macrophage (BMM) cells. PD also induced apoptosis in osteo-
clasts. Consistent with the in vitro effect, PD showed the
inhibitory effect on tumor growth and tumor-induced bone
destruction in vivo. Taken together, our results indicate that PD
may block breast cancer-induced osteolysis by decreasing the
viability of cancer cells and inhibiting RANKL-induced osteoclast
formation.
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The tumor stroma is believed to contribute to some of the most
malignant characteristics of epithelial tumors. However, signaling
between stromal and tumor cells is complex and remains poorly
understood. Here we show that the genetic inactivation of Pten in
stromal fibroblasts of mouse mammary glands accelerated the
initiation, progression and malignant transformation of mammary
epithelial tumors. This was associated with the massive remodel-
ing of the extra-cellular matrix (ECM), innate immune cell
infiltration and increased angiogenesis. Loss of Pten in stromal
fibroblasts led to increased expression, phosphorylation (T
72) and
recruitment of Ets2 to target promoters known to be involved in
these processes. Remarkably, Ets2 inactivation in Pten stroma-
deleted tumors ameliorated disruption of the tumor microenviron-
ment and was sufficient to decrease tumor growth and progression.
Global gene expression profiling of mammary stromal cells
identified a Pten-specific signature that was highly represented in
the tumor stroma of breast cancer patients. These findings identify
the Pten-Ets2 axis as a critical stroma-specific signaling pathway
that suppresses mammary epithelial tumors.
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Human erythropoietin (EPO) is a hormone produced by the kidney
that circulates into the bloodstream. EPO binds to its specific
receptor (EpoR) on the surface of erythroid progenitors inducing
their proliferation, survival and differentiation into mature eryth-
ocytes. Functional EpoR expression, together with EPO produc-
tion, has also been documented in nonhematopoietic sites
including some tumors. Since recombinant human erythropoietin
(rHuEPO) is widely used in cancer patients to correct anemia
several studies have evaluated its role in tumors. It has been
suggested that EpoR may contribute to the development of these
tumors. We focused on the study of the effect of rHuEPO in
cervical cancer cell lines. Expression of EpoR was detected in cell
lines HeLa, SiHa and C33 by flow cytometry. rHuEPO signifi-
cantly increased proliferation of all cell lines. Pre-incubation with
a neutralizing anti-EPO antibody, or with Lovastatin abated
rHuEpo-induced proliferation. We also detected that rHuEPO
promotes the growing of HeLa tumors in athymic female mice.
Interestingly we observed that rHuEPO actived several members
of the JAK/STAT pathway. Our data suggest that rHuEPO plays a
critical role in proliferation of cervical cancer.
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Introduction:
The development of bone metastasis from breast cancer is a
common and fatal complication of the disease. Understanding the
biological mechanisms underpinning this process will be vital to
the development of effective treatment modalities. The develop-
ment of bone metastasis involves a complex series of events
including bone homing, migration and invasion. We have
developed a innovative co-culture system composed of breast
cancer cells grown in association with bone stromal cells (BSCs)
derived from orthopedic bone reamings from cancer free patients.
This system enables in-vitro study of the interactions of breast
cells and benign bone stromal cells. We have shown that primary
bone derived stromal cell cultures are superior to HS68 fibroblast
cultures in stimulating migration of MCF-7 and MDA-MB-231
breast cancer cells in transwell migration assays. We performed
gene expression microarray analysis to detect the differences in
gene expression patterns between BSCs and HS68 cells.
Materials and Methods:
Total RNA was isolated from cultures of HS68 and BSCs.
Affymetrix HU133 Plus 2 GeneChip® arrays were used to analyze
gene exprssion. Six isolates of BSCs were compared with three
isolates of HS68 cells.
Results:
There were 471 differentially expressed genes using stringent
criteria. Bioinformatics analysis indicated these genes were signif-
icantly more likely to cluster into developmental process pathways
P=1.4E–10. Several messages coding for secreted molecules were
also identified including Hepatocyte growth factor.
Conclusions:
The bone derived stromal co-culture system coupled with gene
expression profile analysis is a powerful method to study the
microenvironmental interactions leading to breast metastasis to
bone.
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The tight contact between mural cells (vascular smooth muscle
cells and pericytes) and the underlying endothelium stabilizes a
mature blood vessel and renders the endothelium quiescent. In
tumors, contact between mural cells and endothelial cells is
decreased and abnormal, which allows tumor vessels to be leaky
and proliferative. However, the mechanism by which tumors
prevent proper association between mural cells and the endothe-
lium is unknown. Since gap junction communication between
mural cells and endothelial cells plays an important role in vessel
communication and mural cell differentiation, we sought to
determine the effects of tumors on the gap junction protein
Connexin 43 (Cx43) on vascular cells. Here we demonstrate that
short term treatment of mural cells with media conditioned by
breast tumor cells stimulates a rapid and sustained inactivating
phosphorylation of Cx43 at the protein kinase C (PKC) site
Ser368, and that Cx43 is phosphorylated at this site on the
vasculature of xenograft tumors. We found that longer term (24
hours) treatment of mural cells with media conditioned by breast
or brain tumor cells leads to downregulation of Cx43 protein
levels in mural cells, while media conditioned by actively
proliferating monocytes lacks this activity. The decrease in
Cx43 protein results both from decreased mRNA expression
and proteasomal degradation of the protein. We have further
demonstrated that functional Cx43 is required for mural cell-
induced endothelial quiescence, as control siRNA transfected
mural cells can reduce proliferation of co-cultured endothelial
cells, while mural cells in which Cx43 has been knocked down
by siRNA lack this activity. Our data are consistent with the
notion that tumor cells can induce angiogenesis by disrupting or
preventing junctional contacts between endothelial cells and
mural cells, thus releasing endothelial cells from mural cell-
induced quiescence. Vascular Cx43 may therefore represent a
novel target for anti-angiogenic or vascular normalization
strategies.
Supported in part by NIH CA138727.
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Breast cancer is the most frequent and the second most lethal
cancer affecting women in Canada. The skeleton is a common site
for breast cancer metastasis; however, the reasons for this are not
fully understood. We have used mouse models to isolate 4 T1
breast cancer cell populations that aggressively metastasize to
bone and have compared them to cells that are weakly bone
metastatic. Through gene expression profiling, we have identified
ccn3 (nov), which is expressed at higher levels in the aggressively
bone metastatic cells versus those that weakly metastasize to bone.
We have verified that our bone metastatic breast cancer cells
overexpress ccn3 mRNA and that elevated levels of CCN3 protein
are detected in the conditioned media of the bone metastatic 4 T1
sub-populations.
To determine the relevance of CCN3 expression in human breast
cancer, we have interrogated ccn3 expression in publically
available gene expression datasets and have observed a correlation
between ccn3 expression and the luminal sub-type. These results
are interesting in light of the fact that breast cancers that
metastasize to the bone are most likely to be of the luminal
subtype. Finally, we have performed immunohistochemical stain-
ing of CCN3 in bone metastases derived from patients with breast
cancer and have found that CCN3 is expressed in every lesion (20/
20). Together, these data implicate CCN3 as an interesting target
associated with breast cancer bone metastasis.
Given the osteolytic nature of the bone metastases that develop in
our 4 T1 breast cancer model, we wished to test the hypothesis
that CCN3 plays a causal role in promoting the formation of
osteolytic lesions through the inhibition of osteoblast differenti-
ation. Using primary cultures of mouse bone marrow cells, we
confirmed that a recombinant CCN3 protein impaired osteoblast
differentiation. We are now investigating potential signaling
pathways through which CCN3 may function to impair osteo-
blast differentiation and tip the balance towards enhanced
osteoclastogenesis.
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Tumor microenvironment plays a major role in cancer progression
and activated fibroblasts, among them cancer-associated fibro-
S176blasts (CAFs), are key components of the tumor stroma. Nemosis
is a novel type of fibroblast activation induced by cell-cell
clustering. Formation of a fibroblast spheroid causes overexpres-
sion of genes involved in inflammation and tumor progression,
resembling the expression pattern found in CAFs.
We used paired normal skin fibroblasts and cancer-associated
fibroblasts and primary and recurrent oral squamous cell
carcinoma (SCCs) cells. Nemosis response, as observed by
induction of COX-2 and VEGF, HGF/SF and FGF7 and CAF
markers a-SMA, FSP1 and FAP differed between these fibroblast
populations. One of the normal fibroblast strains, FB-43,
upregulated COX-2 in nemosis, but FB-74 cells did not. In
contrast, CAF-74 spheroids expressed COX-2 but CAF-43 cells
did not. Alpha-SMA protein was expressed in both CAF strains
and in FB-74 cells, but not in FB-43 fibroblasts; its mRNA levels
were downregulated in nemosis. FSP1 mRNAwas downregulated
in normal fibroblasts, but not in CAFs, whereas FAP was
upregulated in all fibroblasts. Growth factor mRNA levels were
upregulated to variable degree. CAFs increased the colony
formation of primary tumor UT-SCC cell lines, but normal
fibroblasts inhibited the anchorage-independent growth of recur-
rent UT-SCC cells.
These results clearly demonstrate that fibroblasts obtained from
different individuals vary in gene expression and this is
reflected in their capability to respond to nemosis. Nemosis,
an in vitro model of fibroblast activation, may have its in vivo
counterpart in cancer-associated fibroblasts and is a valuable tool
in studying the variations between fibroblasts obtained from
different individuals. Work on nemosis may also reveal new
therapeutic means to modulate unwanted inflammation and
tumor progression.
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Several recent data showed that deprotected telomeres can
suppress oncogenesis by engaging senescence or apoptosis,
providing an explanation for the up-regulation of telomerase
observed in the vast majority of human cancers. Interestingly,
an increased dosage of TRF2, a key factor to preserve
telomere protection and acting independently of the telomer-
ase pathway, is also observed in various human malignancies
and contributes to carcinogenesis in mice. However, very little
is known on the role of TRF2 in cancer. We demonstrate here
that a reduced activity or expression of TRF2 in human tumor
cells can impair their ability to form xenografts in immuno-
compromised mice without engaging a cell intrinsic program
of proliferation arrest. Strikingly, this antitumor effect does
not correlate with overt telomere deprotection, DNA damage
response and senescence. These data suggest that cell extrinsic
mechanisms limit tumor formation upon TRF2 inhibition. We
further demonstrate that the anti-tumor properties of TRF2
inhibition rely on activation of natural killer (NK) cells. These
findings suggest that the overexpression of TRF2 observed in
different types of human cancer contributes to bypass innate
immunosurveillance. Consequently, TRF2 emerges as a mul-
tifunctional oncogenic protein and a promising therapeutic
target.
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Natural killer T (NKT) cells are potent modulators of anti-tumour
immunity. Their protective effects can be achieved upon their
activation by glycolipid ligands presented in the context of the
CD1d molecule. These CD1d-binding glycolipid antigens have
been described as potent therapeutic agents against tumours,
infections, as well as autoimmune diseases. On the other
hand, their repeated administration can result in NKT cell
anergy and serious adverse effects. Immunoregulatory and
therapeutic effects of glycolipid ligands depend on their
structure and modes of administration. Therefore more studies
are needed for optimization of the particular therapeutic
settings. This study was focused on tumour-inhibitory effects
of 12 carbon acyl chain β-galactosylceramide (C12 β-D-
GalactosylCeramide) on the growth of HPV16-associated
neoplasms transplanted in the syngeneic mice. Treatment of
tumour bearing mice with β-galactosylceramide 3–14 days
after transplantation of tumour cells significantly inhibited
growth of the MHC class I-positive (TC-1), as well as MHC
class I-deficient (TC-1/A9) HPV16-asssociated tumours.
Moreover, administration of β-galactosylceramide after surgi-
cal removal of TC-1 tumours inhibited growth of tumour
recurrences. Similar results were obtained in the treatment of
the tumours after chemotherapy. Beta-galactosylceramide
treatment turned out to be also synergistic with immunother-
apy based on administration of IL-12-producing cellular
vaccines. These results suggest that β-galactosylceramide,
whose antitumour effects have not been studied in detail,
can be effective for treatment of minimal residual tumour
disease as well as an adjuvant for cancer immunotherapy.
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Solid tumors comprise tumor cells and surrounding stromal cells,
mostly of hematopoietic origin. Cancer cells and infiltrating
leukocytes communicate through a complex network of pro-
inflammatory molecules; among them critical are the transcrip-
tion factor NF-kB and the inflammatory mediator TNF-α, which,
through a multifaceted interaction, eventually promote cancer
development and progression, at least in some tumor types. We
have investigated the role of TNF-α in HER-2/neuT (NeuT)
transgenic mouse model of mammary carcinogenesis spontane-
ously developing carcinomas during life time. Bone-marrow
transplantation (BMT) experiments from TNF-α KO mice into
NeuT recipients significantly delay the onset and reduce the
number of affected mammary glands, indicating that the relevant
source of TNF-α fostering tumor promotion is of BM origin.
BMT experiments performed at different time points during
tumor progression (8, 15, 20 weeks of age) indicate that TNF-α
is critical in early steps of mammary tumorigenesis but still
active also at later time points when carcinomas in situ and
invasive carcinomas are already present. Analysis of tumor
organization and vasculature points out significant differences
in the two types of chimera: wild type-transplanted mice show a
well-differentiated nest-like growth pattern, branching fibrovas-
cular stromal meshwork with structured vessels, and limited foci
of epithelial necrosis, whereas tumors from TNF-α-KO-trans-
planted mice display a disorganized structure with gross stromal
axes and defective vascularization; extended necrosis, involving
also the stroma and perivascular areas, is present. Immunohisto-
chemistry for leukocyte infiltration indicates that the lack of
TNF-α alters the number and localization of some leukocyte
subtypes, in particular CD206+ cells that are highly represented
throughout the stroma of tumors from wild type chimeras, and
scarce in tumors from TNF-α deficient chimeric animals. From
this work we expect to uncover the role of TNF-α in the various
phases of mammary transformation and progression and to
identify the best time window to neutralize its activity using
specific monoclonal antibody.
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Background: Even though colorectal cancer patient prognosis
depends to a large extent on tumor stage, complementary markers
are needed. It is well-known that a high degree of infiltrating
lymphocytes in and around the tumor improve patient prognosis.
Recently the CpG Island methylator phenotype (CIMP), charac-
terized by a high degree of hypermethylation, has been associated
with disease outcome. Furthermore, patients with tumors display-
ing microsatellite instability (MSI) have a better prognosis
compared to microsatellite stable (MSS) tumor patients. A high
degree of infiltrating lymphocytes is a common feature of MSI
tumors, whereas the level of inflammatory response is not well
established in CIMP-high tumors.
Aim: To characterize the level of lymphocytic infiltration in
CIMP-negative, CIMP-low, and CIMP-high tumors and relate
findings to patient prognosis.
Methods: CIMP-status was determined in 499 colorectal cancer
patients with quantitative real-time methylation-specific PCR
(MethyLight). Immunohistochemistry (anti-CD3) was used to
quantify t-lymphocytes infiltrating the tumor (TIL) and tumor
stroma (in tumor front and centre).
Results: A high level of infiltrating lymphocytes was associated
with a better prognosis independent of tumor stage and in all
subgroups of colorectal cancer based on CIMP- and MSI-status. In
CIMP-low tumors, a high degree of lymphocytes in the tumor
centre was associated with an excellent prognosis (5-year cancer
specific survival 91.3%). 5-year cancer specific survival in MSI
tumors with a high degree of lymphocytes in the tumor front was
91.1%, while the prognosis of patients with MSI tumors with
lower degrees of lymphocytic infiltration was similar to MSS
tumors (60.0 and 60.2%, respectively).
Conclusion: The survival advantage of a higher level of infiltrating
lymphocytes is more distinct in certain subgroups of colorectal
S178cancers based on CIMP- and MSI-status. These findings may
facilitate a refined assessment of patient prognosis.
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The importance of the immune infiltrate in the prognosis of
human cancers is now clearly established. In a retrospective
study on non-small cell lung cancer (NSCLC), we have
previously shown that high density of tumor-induced tertiary
lymphoid structures is associated with patients’ long-term
survival. We thus wanted to explore the structural and cellular
organization of these structures that we called Ti-BALT
(Tumor-induced Bronchus-Associated Lymphoid Tissue) and
their relevance in local immune responses against cancer. We
used fresh human lung tumor specimens from surgical
resection of NSCLC, as well as slides from paraffin-
embedded and frozen biopsies. The expression of relevant
molecules was assessed on fresh tumor-infiltrating lympho-
cytes by multicolor flow cytometry, and on biopsy slides by
enzymatic and fluorescent immunohistochemistry. By Laser-
microdissection, specific RNA from frozen slides was isolated
for RT-PCR analysis. We showed that the Ti-BALT T cells are
predominantly CD4+ central memory T cells and CD8+ naive
T cells. These cells all express the CD62L marker and are in
close contact with PNAd+High Endothelial Venules. We
investigated the role of the chemokine system in lymphocyte
migration by assessing chemokine receptor (CKR) presence on
T cells subsets and found significant differences of CKR
expression according to the subset. To confirm the potential
role of the CKR expressed, local chemokines expression was
measured on micro-dissected Ti-BALT.
We characterized T lymphocytes populations found in tumor-
induced tertiary lymphoid structures and found several ligand-
receptor interactions potentially implied in their migration to these
structures. Knowing how these structures are organized will help
to understand their prognostic value in lung cancer.
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Experimental and epidemiological studies indicate a strong
link between persistent inflammation and tumor progression,
and human colorectal cancer (CRC) represents a paradigm in
this connection. Major players of the cancer-related inflamma-
tion are chemokines and their receptors. Fractalkine (CX3CL1)
is a peculiar chemokine, existing both as a soluble and a
membrane-anchored protein. Its unique receptor, CX3CR1, is
expressed on monocytes, NK, and T cells. In this study we
provide evidence that CX3CL1 is expressed in human
colorectal carcinoma and may modulate tumor malignant
behaviour. CX3CL1 mRNA expression, evaluated in 30 CRC
samples was strongly up-regulated in tumor tissues in
comparison to normal colonic mucosa. CX3CL1 protein
expression has been evaluated by immunohistochemistry in
172 CRC samples, classified by tumor stage, confirming a
strong positivity by tumor cells. On the same series of
samples, the expression of CD3 and CD68 is being investi-
gated by immunohistochemistry and the density of tumor-
infiltrating T lymphocytes and macrophages will be associated
with the expression score of CX3CL1, as well as with clinical
outcome of patients. Intriguingly, the receptor CX3CR1 was
found expressed also by tumor cells, with a heterogeneous
pattern of positivity. To better characterize the significance of
the CX3CL1/CX3CR1 interaction in CRC, a multi-cellular
tumor spheroids (MTS) in vitro assay was performed, with CRC
cell lines characterized by the expression of Fractalkine and its
receptor. Preliminary results indicate that both CX3CL1 and
CX3CR1 are expressed by all the MTS forming cells, and that
CX3CL1 is predominantly expressed by cells at the periphery of
the spheroids. These data indicate a role of CX3CL1 and
CX3CR1 within cancer cell interaction and in the cancer cells-
immune cells cross-talk.
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Pancreatic cancer is the 6
th leading cause of cancer deaths in the
European Union. The most common malignancy is pancreatic
ductal adenocarcinoma (PDA), which is almost uniformly lethal.
Epidemiological and molecular studies exhibit a robust link
between chronic inflammation and pancreatic cancer. Tissue injury
due to premature activation of digestive enzymes is a well-
described cause of hereditary chronic pancreatitis. These patients
have a 100-fold increased risk of developing PDA.
Hallmarks of PDA and chronic pancreatitis are the replacement of
pancreatic parenchyma with fibrotic tissue and the accumulation
of immune cells with suppressive phenotypes (myeloid derived
suppressor cells and regulatory T cells (Treg)). The fibrotic stroma
is thought to originate from pancreatic stellate cells (PSC), a rare
cell type in the healthy pancreas that, when activated, takes on a
myofibroblastic phenotype. However, their physiological function
and whether they are involved in creating the immunosuppressive
microenvironment is unknown. Pancreatic stellate cells are (in
conjunction with hepatic stellate cells) the major storage for
vitamin A. Retinoic acid is an essential component for peripheral
Treg priming. Immunoregulatory function has been ascribed to
hepatic stellate cells. We hypothesize that PSC are tissue sentinels
with antigen-presenting function responding to tissue injury by
inducing an immunosuppressive response. We show that PSC
express Toll-like receptors (TLR) and upon activation upregulate
co-stimulatory molecules and MHCII in a mouse model of acute
pancreatitis. PSC may thus be able to sense danger associated
molecular patterns (DAMP) and respond by priming Treg.
Therefore, the default program for non-infectious activation of
PSC may be to curb excessive immune responses preventing an
autoimmune attack. However, this protective program suitable for
resolving acute tissues distress may be devastating in circum-
stances of repetitive irritation such as during chronic inflammation
and pancreatic cancer precluding an immune response against the
developing tumour.
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Despite the important role of Th17 cells in the pathogenesis of
many autoimmune diseases, their presence and role in cancer
remain unclear. In this work, we investigated the presence of these
cells and their related cytokines in a new syngeneic model of
primary intraocular B-cell lymphoma (PIOL) which is a subtype
of non Hodgkin lymphomas. This model was chosen because
there is no resident lymphocyte in a normal eye, so it is easier to
characterize the different lymphocyte subsets recruited by the
tumor. The lymphomatous B-cell line A20-IIA1.6 (H2
d) was
injected in the posterior chamber of immunocompetent BALB/c
mice (H2
d) and flow cytometric analysis were performed to study
the tumor growth and the immune infiltrate. Concomitantly to the
presence of prepolarized Th1 lymphocytes and CD4+Foxp3+
cells, Th17 cells were found and characterized by the intracellular
expression of IL-17 and IL-21, but no IFNg. At the molecular
level, RT-PCR analysis demonstrated the ocular expression of the
messengers for IL-17, IL-21 and IL-23. Interestingly, IL-17
protein level measured by cytometric beads array showed an
inverted correlation with the tumor burden. These data demon-
strate that a local infiltration of IL-17 and IL-21 secreting cells
occurs in a tumoral context, and it seems that Th17-related
cytokines counteract the tumor development. Thus, use of Th17
cells or their related cytokines should be considered as a new
therapeutic approach for non Hodgkin B-cell lymphomas and
particularly with an ocular localization.
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Ulcerative colitis (UC) and Crohn’s disease (CD) are the major
chronic inflammatory bowel diseases (IBD) affecting the gastro-
intestinal tract (GI). UC primarily affects the mucosal lining of the
colon, whereas CD affects the whole GI. Defective mucosal
barrier triggers invasion of commensal enteric bacteria into the gut
layers that result in aggressive immune responses. Feeding mice
for several days with Dextran Sodium Sulfate (DSS) polymers in
the drinking water induces acute colitis characterized by bloody
diarrhea, ulceration, body weight loss and infiltration with
granulocytes/mononuclear cells, reflecting human’s symptoms.
The present study was designed to explore the ability of the anti-
inflammatory immunomodulator, ammonium tichloro [1,2-
ethanediolato-O,O’] tellurate (AS101) to attenuate the severity of
DSS-induced murine colitis. C57BL/6 mice received 3.5% w/v
DSS in the drinking water for 7 days followed by 5 days of regular
autoclaved water. Daily treatment with AS101 starting either
concomitantly with DSS or 2 days later, significantly reduced
occult and visible blood score vs. the DSS+PBS group. Further-
S180more, both treatment modes with AS101 significantly ameliorated
the stool consistency score and prevented the decrease in body
weight. Colon length, being much reduced in diseased mice was
normalized in AS101-treated mice. Histopathology examination of
the distal colon revealed destruction of the crypt structure in PBS-
treated mice. Furthermore massive mononuclear cell infiltration
into the mucosa and submucosa were found. In comparison, the
colons of AS101-treated mice exhibited normal appearance.
Treatment with AS101, either before or after disease onset,
significantly reduced the inflammatory cytokine IL-17 in the
colon while only AS101 given concomitantly with DSS also
reduced colonic INF-γ.
These results collectively propose that inhibition of colon IL-17,
and not that of INF-γ, plays an important role in attenuating
murine colitis by AS101 and suggest that treatment with AS101
may be an effective therapeutic approach for controlling human
IBD.
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The activating NK cell receptor NKG2D recognizes a number of
evolutionary conserved ligands, which are expressed on many trans-
formed but not on most normal cells. We analyzed the expression of
NKG2D ligands in Ewing’s sarcoma (EWS) and found expression in
the majority of the tested cell lines, providing opportunities for
NKG2D based immunotherapy of EWS. We report the construction of
achimericNKG2Dimmunoreceptorbylinkingtheextracellularligand
domain of NKG2D in reverse orientation to an IgG1-Fc/CD28/
CD3zeta transmembrane signaling platform creating a chimeric type I
transmembrane immunoreceptor. Primary human T cells transformed
with this chNKG2D molecule expressed by either a lentiviral vector or
electroporated mRNA recognize and efficiently lyse murine B cells
expressing ULBP2 or MICA. Also, ligand specific stimulation of the
lentivirally transduced Tcells resulted in efficient long term expansion
and enhanced expression density of the chNKG2D receptor. Coculture
of EWS cell lines with either lentivirally transduced or mRNA
transfected activated human T cells resulted in chNKG2D specific
cytokine secretion and revealed high susceptibility of EWS to CD8+
and CD4+ T cell mediated cytotoxicity. These data provide the basis
for further exploring the potential of a chNKG2D based immunother-
apy of EWS.
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Our previous work showed that successful anticancer chemother-
apy is dependent on CTL and IFN-γ while specific CTL priming
triggered by dying tumor cells is dependent on IL-1β. Here, we
demonstrated that after chemotherapy and radiotherapy, IFN-γ-
producing CTL infiltrated much more intensively into tumor bed
of tumor regressors compared with that of tumor progressors and
untreated control. Meanwhile, tumor infiltrating γδ cells potently
produced IL-17 but not IFN-γ and they were the major source of
IL-17 in tumor beds of treated mice, especially in regressing tumor
bed. Furthermore, the IL-17 producing γδ TILs have dominant
preferential usage of Vγ4 and Vγ6. Interestingly, IFN-γ produc-
tion by CD8+ TILs is closely correlated with IL-17 production by
γδ TILs. Neutralizing IL-17 resulted in failure of chemotherapy in
MCA205 tumor model. As we know, γδ T cells from naïve LN
potently produce IL-17 upon PMA/IO stimulation. We also
discovered that these γδ T cells could vigorously produce IL-17
in response to IL-1β or/and IL-23 without TCR ligation ex vivo.
Moreover, IL-1β and IL-23 are much more enriched in treated
tumor bed. Our data suggested that γδ Tcells play a pivotal role in
the success of chemotherapy by shaping and modulating host
immune response to cancer through producing IL-17.
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Candida albicans is an opportunistic fungal pathogen and a major
cause of morbidity in cancer patients whose immune system is
compromised. Candida albicans infection involves host production
of inflammatory cytokines such as interleukin (IL)-18 and tumor
necrosis factor (TNF)-alpha, whose augmentations have already
been correlated with metastatic occurrence of most common
cancer types. However, whether the concurrent infection of this
S181fungal pathogen during cancer cell dissemination affects metasta-
sis occurrence is unclear. In this study, a well-established murine
model of TNFalpha/IL-18-dependent hepatic melanoma metastasis
was used to study whether Candida albicans isolated from patients
with systemic candidiasis can alter the ability of murine B16
melanoma (B16M) cells to colonize the liver. We demonstrated
that Candida albicans increased the metastatic efficiency of B16M
cells in the liver, irrespective of fungus injection route. Prometa-
static effects were abrogated with antifungal ketoconazol treat-
ment, and occurred when hepatic colonization of cancer cells took
place 12 hours after Candida albicans injection. Pre-infection
status also enabled a low-metastatic dose of B16M cells to
metastasize in the liver at levels indistinguishable from normal
mice receiving a highly-metastatic cancer cell dose. Candida
albicans also accelerated the growth of established micrometa-
stases, when mice received the fungus 4 days after cancer cell
injection. Circulating candida albicans adhered to hepatic sinusoi-
dal endothelium (HSE). They also induced TNFalpha production
from HSE in vitro, which in turn enhanced endothelial cell
adherence for cancer cells. Similar results were obtained when
HSE cells were incubated with mannoprotein extracts from the
same Candida albicans strains instead of live Candida albicans,
suggesting that Candida albicans produced the remote activation
of HSE via soluble mannoproteins. The HSE response to soluble
mannoproteins occurred via specific mannose receptors, and the
microenvironment generated by activated HSE may facilitate the
ability of cancer cells to metastasize into Candida albicans-
susceptible sites acting as premetastatic niches.
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The degree of cytotoxic T lymphocyte infiltration is highly
correlated with the clinical outcome of cancer patients. Tumor
antigen specific T lymphocyte migration from the circulation into
tumor tissues is tightly controlled by endothelial cells expression
of multiple receptors such as integrins and vascular selectins.
Analysis of tumor endothelium / leukocyte interaction could allow
the development of novel approaches to improve the number of
tumor infiltrating lymphocytes and immune therapy. Our group
has more than 15 years expertise in the molecular characterisation
of High endothelial venules (HEVs), specialized post-capillary
venules found in lymphoid tissues that mediate high levels of
naïve T lymphocyte recruitment from the blood. HEV-like vessels
that are similar to HEVs from lymphoid tissues, also appear in
chronically inflamed tissue and have been proposed to participate
in the amplification and maintenance of chronic inflammation in
auto-immune diseases. In collaboration with the Institute Claudius
Regaud, we recently identified in human tumor tissues from
melanoma, ovary and breast carcinoma patients, venules with
HEV-characteristics. Like their lymph node counterparts, tumor
HEVs display a cuboidal shape and express functional PNads
(Peripheral node adressins) allowing the recruitment of CD62L
+
lymphocytes. In a mouse tumor model, induction of HEV-like
vessels has been shown to allow naive lymphocyte recruitment,
priming, and eradication of tumor cells. Therefore, although
detrimental in chronic inflammatory diseases, presence of HEV-
like vessels could be beneficial in human cancer. Indeed, we
observed that within human tumors, HEV-like vessels were
present in areas of effector memory CD8
+ T lymphocytes
infiltrates in close contact with mature dendritic cells. A better
understanding of the molecular mechanisms controlling HEV
phenotype and functions may have important applications in
cancer therapy for enhancing lymphocyte recruitment into
tumors.
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Bacterial infections of the prostate are increasingly recognized as a
potential risk factor for development of proliferative diseases as benign
prostate hyperplasia and cancer. A phase of infection-induced
inflammation is believed to precede the malignant state. We and others
have identified the Gram-positive facultative anaerobic bacterium
Propionibacterium acnes as a frequent inhabitant of prostate tissue.
Currently, we are investigating P.acnes prevalence in prostatectomy
tissue, genetic variance of isolates from prostate contra other loci, and
the inflammatory and proliferative effects of the bacterial infection.
Here we present result obtained from experimental infections of
cultivated prostate epithelial cells and rat prostate.
The bacterial infection was shown to induce a strong TLR2 mediated
inflammatoryresponseasseenasup-regulationandsecretionofIL-6,
IL-8, GM-CSF, TNF-α, G-CSF, andCCL2. In a rat prostate infection
model,theP.acnes infection induced strong inflammation, as seen as
recruitment of lymphocytes. 4 weeks post infection, foci of intense
inflammation and remaining bacteria could still be visualized. The
S182tissue in close proximity to the infested areas exhibited increased
proliferative activity, scored as brdU incorporation.
We are presently collecting P. acnes from prostatectomy samples,
urethra and perineal skin from 100 patients, and can preliminary
score the frequency of infection, both in cancerous and benign
prostate tissues to 60%. Given the high prevalence in human
prostates, we suggest that bacterial infections, and especially
Propionibacterium acnes, contribute to prostate inflammation and
thus contribute to a proliferation stimulating environment that
facilitate the transition of prostate epithelium into higher rate of
proliferation and thus disorders as hyperplasia and cancer.
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Background: Pancreatic cancer, one of the most deadly human
malignancies, is characterized by an extensive stroma, which
includes fibroblasts, inflammatory cells and vascular components.
Among the inflammatory cells, the components of the adaptive
immune system, T- and B-lymphocytes, are abundantly repre-
sented. The contribution of the adaptive immune system in cancer
is controversial, with evidence supporting its role as a protective
mechanism against tumor growth, and some contradicting evi-
dence indicating that lymphocytes contribute to maintaining a
chronic inflammatory environment that favors tumor progression.
In pancreatic cancer, clinical studies have shown that the quantity
and class of lymphocytes located within a tumor correlate with
patient survival. Studies in the Kras mouse model of pancreatic
cancer that closely recapitulates the human disease have shown
that regulatory T cells represent the majority of the infiltrating
lymphocytes during pancreatic tumorigenesis, leading to the
assumption that anti-tumor immune activity is absent in pancreatic
cancer.
Objective: Functional studies addressing the role of the adaptive
immune system in pancreatic cancer are currently missing. We
set out to investigate how lymphocytes affect pancreatic
tumorigenesis.
Results: We generated Kras mice that are Rag deficient (Kras;
Rag-), and thus lack all T- and B- lymphocytes and compared
them with Rag positive littermates (Kras;Rag+).
Surprisingly, Kras;Rag- mice showed earlier onset and higher
number of pancreatic cancer precursor lesions compared to Kras;
Rag+control animals. Our data indicates that absence of lympho-
cytes has a tumor-promoting effect in pancreatic cancer. We are
currently investigating whether an immuno-surveillance mecha-
nism is present in the early stages of pancreatic cancer, or whether
a different mechanism is responsible for the faster tumor
progression in Kras;Rag- mice.
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Objectives: The type, density, and location of immune cells in
colorectal cancer have a prognostic factor superior and indepen-
dent to the criteria related to the anatomic extent of the tumor
(Galon et al., Science 2006). The aim of the study was to analyze
the balance between the cytotoxic and helper T-cells in colorectal
cancer and the impact on disease-free survival.
Methods: The tumor microenvironment was investigated in 107
frozen colorectal tumor samples by analyzing the expression of
immune-related genes by Low-Density-Array on real-time PCR
Taqman 7900 HT. Infiltrating cytotoxic T cells, Treg, Th1, Th17
cells of colorectal cancer patients were quantified by immunohis-
tochemical analyses of tissue microarrays containing tissue cores
from the center and from the invasive margin of the tumor. For
pairwise comparisons of parametric and non-parametric data and
for survival analysis, the Student’s t-test,Wilcoxon rank-sum test
and Logrank test were used, respectively.
Results: We first investigated the expression of cytotoxic, Th1,
Th2, Treg and Th17 genes. Hierarchical clustering of a
correlation matrix revealed functional clusters of genes associ-
ated with Th17 (RORC, IL17A), Th2 (IL4, IL5, IL13), Th1
(Tbet, IRF1, IL12Rb2, STAT4), and cytotoxicity (GNLY,
GZMB, PERF1). High-IL17A mRNA expression level was
most frequent at early stages of tumor progression. Patients
with high expression of the Th17 cluster had a poor prognosis
whereas patients with high expression of the Th1 cluster had
prolonged disease-free survival. In contrast no prediction of the
prognosis was associated with the Th2 clusters. The combined
analysis of cytotoxic/Th1 and Th17 clusters gave a better
discrimination for relapse. In situ analysis of IL17+ cells and
CD8+ cells using tissue-microarray confirmed with these
results.
Conclusion: Functional clusters associated with Th1 and Th17
cells have opposite effect on patients survival and bring
complementary information.
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Increasing evidences suggest that chronic inflammation contrib-
utes to cancer development and progression. One of the
underlying mechanisms is proposed that tumor cell-derived
inflammatory and immunosuppressive cytokines contribute to
tumor immune escape and resistance to immunotherapy. Toll-like
receptors (TLRs) have been implicated in tumor progression and
metastasis. Our previous study showed that calcium/calmodulin-
dependent protein kinase II (CaMKII) promoted TLR-triggered
proinflammatory cytokine in macrophages. hCaMKIINa, a novel
CaMKII inhibitory protein identified by us, suppressed the growth
of colon cancer cell by inducing cell cycle arrest in vitro and in
vivo. Thus we wonder whether hCaMKIINa-mediated CaMKII
inhibition affects TLR4-triggered cytokine production of colon
cancer cells for immune escape. In this study, we demonstrate that
TLR4 is expressed on human colon cancer cell lines. TLR4
ligation promotes production of immunosuppressive cytokines IL-
8 and VEGF. Overexpression of hCaMKIINa inhibits TLR4-
triggered production of IL-8 and VEGF; H282R, constitutive
activated CaMKII, significantly promotes TLR4-triggered IL-
8 and VEGF secretion. In addition, we also observe that
hCaMKIINa inhibits LPS-mediated activation of p-ERK1/2 and
LPS-mediated TLR4 expression in SW620 cells. Furthermore,
hCaMKIINa-mediated inhibition of ERK1/2 is necessary for
suppression of TLR4-triggered IL-8 and VEGF secretion. These
results suggest that hCaMKIINa-mediated CaMKII inhibition
might play important roles in the suppression TLR4-triggered
metastasis and immune escape of human colon cancer cells by
inhibiting immunosuppressive cytokine production.
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Inducible CD4
+CD25
−IL-10
+TGF-β
+ regulatory T cells (Tr1) are
generated upon encountering cognate antigens. In cancer patients,
the Tr1 frequency is increased; in tumor and blood. However, the
mechanisms used by these cells to mediate suppression are not yet
defined. The ectonucleotidases, CD39 and CD73, convert ATP
into adenosine which binds to the A2a receptors on effector T
cells, inhibiting their functions. We reported that these ectonu-
cleotidases are expressed in human nTreg and tumor cells. Here,
we evaluated the effects of tumor-derived adenosine on the Tr1
generation and Tr1-mediated immune suppression. Tr1 were
generated in co-cultures containing sorted CD4
+CD25
neg T cells,
autologous dendritic cells, low doses of IL-2, IL-10 and IL-15
(10 IU/mL each) and irradiated CD73
+ MDA tumor cells or
CD73
neg MCF-7 tumor cells. Proliferating Tr1 were tested for
expression of the nucleotidases by multiparameter flow cytometry
and their suppressor function assessed in assays with CFSE-
labeled autologous CD4
+CD25
neg responder cells (RC). ATP
hydrolysis was measured in luciferase-based ATP detection
assays. Adenosine in cell supernatants was analyzed by mass
spectrometry. Tr1 generated in the co-cultures expressed CD39
and CD73. The CD73
+ tumors induced differentiation of the
highest numbers of ectonucletidase+Tr1 (p<0.01) relative to
CD73
neg tumors. The Tr1 generated with CD73+ tumors mediated
the highest suppression of RC proliferation (p<0.01), hydrolyzed
exogenous ATP at the highest rate (p<0.05) and produced high
amounts of adenosine (p<0.05). ARL67156, an inhibitor of
CD39, and ZM241385, A2A receptor antagonist, blocked Tr1-
mediated suppression (p<0.01–0.02). Tumor-derived adenosine
favors the generation of immunosuppressive CD39+ and CD73+
Tr1 cells, which have higher enzymatic activities relative to Tr1
cells generated in the CD73
neg tumor environment. The data
suggest that adenosine plays a major role in the induction of Tr1
cells, which also utilize adenosine to mediate suppression in the
tumor microenvironment.
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Peptide-targeted nanoparticles offer an attractive multivalent
platform for in vivo molecular imaging of the tumor microenvi-
ronment. While random combinatorial peptide libraries have
shown considerable promise for the identification of peptide
ligands, conventional screening strategies are labor intensive and
time consuming. Here, we describe the identification of novel
peptide ligands specific to avb3 integrin using a novel “beads on a
bead” screening approach that significantly accelerates the
identification and isolation of positive peptide hits from combina-
torial peptide libraries. As a proof of principle, we took advantage
of the tendency of 2µm magnetic beads coated with the protein
target (avb3 integrin) to associate differentially with the much
larger 90µm Tentagel beads coated with RGD (high affinity),
KGD (low affinity) or AGD (no affinity) peptides. Positive bead
hits were isolated from the negative library beads using a
neodymium magnet, and specificity was validated by incubating
S184with avb3-expressing MDA435 (positive control) and avb3-
knockdown MDA435 (negative control) tumor cells. The hit
peptides were cleaved and sequenced “on bead” using a novel
MALDI-TOF/MS technique developed in-house. We demonstrate
here that the protein-coated magnetic beads associated with the
library beads in an affinity-dependent fashion, and that the
accuracy of this method is greater than 98%. A random
combinatorial peptide library was screened for avb3 integrin-
binding peptides, and a number of novel high-affinity peptides
were identified that did not contain the RGD motif. Therefore, we
expect that they may be useful to develop molecular imaging
agents that do not interfere with avb3 integrin function.
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Overexpression of cell-cycle regulating cyclin-dependent kinases 4
and 6 (Cdk4/6) and deregulation of Cdk4/6-pRb-E2F pathway are
common aspects in human tumors. The aim of our study was the
evaluation of pyrido[2,3—d]pyrimidin-7-one derivatives (CKIA
and CKIE) concerning their efficacy and suitability as small
molecule Cdk4/6 inhibitors and, after iodine-124 ([
124I]CKIA) or
fluorine-18 ([
18F]CKIE) radiolabeling, as radiotracers for Cdk4/6
imaging in tumors by positron emission tomography (PET).
CKIA and CKIE were analyzed concerning their biological
properties (effects on cell growth, cell cycle distribution, Cdk4/6
mediated pRb-Ser
780 phosphorylation, mRNA expression of pRb
affected genes E2F-1 and PCNA) and radiopharmacological
properties (cellular radiotracer uptake and PET studies) using
human tumor cell lines HT-29, a colorectal adenocarcinoma cell
line, FaDu, a head and neck squamous cell carcinoma cell line,
and THP-1, an acute monocytic leukemia cell line, as well as
phorbol ester TPA-activated THP-1 cells, as model of tumor-
associated macrophages.
CKIA and CKIE were identified as potent inhibitors of Cdk4/6-
pRb-E2F pathway due to decreased Cdk4/6 specific phosphory-
lation at pRb—Ser
780 and downregulation of E2F-1 and PCNA
mRNA expression in HT-29, FaDu and THP-1 tumor cells. This
resulted in arrest of these tumor cell lines in G1 phase of the cell
cycle and growth inhibition. Otherwise, in non-proliferating TPA-
activated THP-1 macrophages no change of cell-cycle distribution
after treatment with CKIA and CKIE was observed. Furthermore,
TPA-activated THP-1 macrophages showed lower Cdk4 mRNA
and protein levels, than other tumor cell lines. In vitro radiotracer
uptake studies using [
124I]CKIA and [
18F]CKIE demonstrated
tumor cell uptake, which could be blocked with both nonradio-
active CKIA and CKIE. However, THP-1 macrophages showed
similar radiotracer uptake like other tumor cells. Preliminary small
animal PET studies in mouse tumor xenograft models further
analyzed the hypothesis that radiolabeled Cdk4/6 inhibitors are
suitable tracers for molecular imaging of tumors.
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The central core of solid tumors are characterised by a high
number of apoptotic and dead cells. This is due to two factors.
First, tumor cells proliferate uncontrollably, and those cells ≥200
µm from a blood vessel die because of lack of oxygen. Second,
the relative paucity of macrophages to dying tumor cells results in
slow clearance and thus prolonged residency of apoptotic cells in
the tumor core. When the tumor is subjected to chemotherapeutics,
anti-hormonal agents or radiotherapy, tumor apoptosis increases.
The degree of apoptosis correlates with the sensitivity of the tumor
to the given treatment. Observing tumor cell apoptosis could
therefore assist clinicians in evaluating treatment efficacy.
GSAO (4-(N-(S-glutathionylacetyl)amino)phenylarsonous acid) is
a synthetic tripeptide trivalent arsenical that rapidly concentrates
in dying and dead cells. Upon fluorescent, infrared or radioactive
labelling, GSAO serves as a novel and effective imager of cell
death, both in vitro and in vivo. Radiolabelled
111In-DTPA-GSAO
and its derivative PENAO bind specifically to dead and dying
cells in a wide variety of immortalized tumor cell lines treated
with various cytotoxic agents. Inhibition of apoptotic cell death by
Z-VAD-FMK decreased binding of
111In-DTPA-GSAO. Analysis
of fluorescently labelled GSAO by flow cytometry revealed that
GSAO accumulates in the late stages of apoptosis following loss
of plasma membrane integrity. GSAO is retained in the cell via
binding to cytoplasmic proteins, and this is mediated by cross
linking of closely spaced di-thiols.
In vivo imaging of
111In-DTPA-GSAO in mice bearing Lewis
Lung Carcinoma and Colon Carcinoma (CT-26.WT) tumors reveal
binding to dead and dying cells in both treated and untreated
tumors.
111In-DTPA-GSAO uptake was quantitatively greater in
treated versus untreated tumors and was also greater than
99mTc-
Annexin V in the same animal. Kidney and liver accumulation of
111In-DTPA-GSAO was several fold less than
99mTc-Annexin V.
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S185Cholangiocarcinoma is an adenocarcinoma of the liver which has
increased in incidence over the last thirty years in many countries
to reach similar levels to other liver cancers. Diagnosis of this
disease is usually late and prognosis is poor, therefore it is of great
importance to identify novel markers and potential early indicators
of this disease as well as molecules that may be potential
therapeutic targets. We have used a proteomic approach to identify
differentially expressed proteins in peripheral cholangiocarcinoma
cases and compared expression with paired peri-tumoral histolog-
ically normal liver tissue from the same patients. 2-D electropho-
resis using DIGE labelling of the proteins with cyanine(Cy)3 and
Cy5 was used to identify differentially expressed proteins. Overall,
of the approximately 2400 protein spots visualised in each gel,
172 protein spots showed significant differences in expression
level between tumoral and peri-tumoral tissue with p<0.01. Of
these, 100 spots corresponding to 147 different proteins were
identified by mass spectroscopy: 76 proteins were over-expressed
whereas 71 proteins were under-expressed in tumoral samples
compared to peri-tumoral samples. Several of the identified
proteins have potential roles in control of cancer or stromal cell
proliferation and survival and of control of angiogenesis. Among
the over-expressed proteins were pigment epithelium derived
factor (PEDF), 14,3,3 protein, periostin and a-smooth muscle
actin. Immunohistochemical studies were carried out on samples
from the same patient population and confirmed increased
expression of 14-3-3 proteins in adenocarcinoma cells while a-
smooth muscle actin and periostin were shown to be overex-
pressed in the tumor stroma. Double labeling showed that these
latter two proteins were colocalised in stromal myofibroblasts.
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Despite increasing evidence that estrogen signalling plays a major
role in both the development and progression of prostate cancer,
very few studies have focused on estrogen related genes in
hormone refractory prostate cancer (HRPC). The aim of the study
was to compare on both tumoral and stromal cells the expression
of genes related to androgen and estrogen metabolism in paired
samples of prostate cancers collected before androgen deprivation
therapy (ADT) and after hormonal relapse.
The study included 55 patients treated only by ADT for prostate
cancer, and for whom tissues were available before treatment
induction and after recurrence. Gene expressions were analysed
using immunohistochemistry performed on tissue microarray,
using antibodies directed against: androgen receptor (AR),
phosphorylated AR (pAR), estrogen receptor alpha (ERA),
estrogen receptor beta (ERB), 5 alpha reductase 1 and 2,
aromatase, BCAR1 (involved in antiestrogen resistance in breast
cancer), and the proliferation marker Ki67. Expressions were
compared using Friedman and Wilcoxon paired tests. Predictive
expressions of overall survival and the time to hormonal relapse
were analysed using Log-rank and Cox tests.
When compared to hormone sensitive samples, tissues collected after
hormonal relapse were characterized by increased expression of
Ki67, AR, pAR (p<0.001), and BCAR (p=0.03), and by lower
staining for 5AR2 (p=0.002), ERB (p=0.016), and aromatase (p<
0.001). Shorter time to hormonal relapse was associated with high
expressions of aromatase and BCAR on diagnosticbiopsies,together
withlowstromalstainingforERA.Overallsurvivalwassignificantly
shorter when tissues collected after relapse displayed both high
proliferation index and low ERA expression in stromal cells.
These results demonstrated a dysregulation of proteins involved
not only in androgen pathways but also in estrogen synthesis and
signalling during the development of HRPC. The survival
advantage of ERA staining in HRPC underlines the importance
of steroid signalling via the microenvironment in prostate cancer.
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Aim: Multidrug resistance (MDR) and metastasis are the main
causes of treatment failure in prostate cancer (CaP) patients.
CD147 activates proteinases and angiogenic factors in the tumour
microenvironment, stimulates hyaluronan production and interacts
with CD44 to regulate MDR and MCT transporters. CD44 is a key
receptor for hyaluronan, critical for cell signalling and drug
resistance. We investigated the expression of CD147, CD44, and
transporter (MDR1) and MCT proteins in CaP progression.
Methods: CD147, CD44s and v3-10, MDR1, MCT1 and MCT4
expression was studied in human metastatic CaP cell lines (PC-
3 M-luc(MDR), PC-3 M-luc, Du145, LN3, DuCaP) and primary
CaP tumours, lymph node metastases and normal prostate, using
immunoperoxidase, immunofluorescence and microscopy. Cell
line dose-response and sensitivity (IC50) to docetaxel was
measured with MTT, and correlated with CD147, CD44, MDR1,
and MCT expression.
S186Results: PC-3 M-luc (MDR), PC-3 M-luc and Du145 cells
expressed high level CD147, CD44, MDR1 and MCT. In contrast,
DuCaP cells showed no CD147 or CD44, but weak MCT
immunostaining. LN3 cells expressed strong CD147 and MCT,
weak CD44v and MDR1, and no CD44s. Docetaxel sensitivity
was positively related to CD44, CD147, MDR1 and MCT
expression. Strong heterogeneous CD147, CD44, MDR1, MCT
expression was found in high grade primary tumours (Gleason
score >7). Heterogeneous co-localization of CD147 with CD44,
MDR1 and MCT was found in PC-3 and Du145 cells, and in high
grade tumours.
Conclusions: Metastatic CaP cell lines and primary CaP displayed
overxpression of CD147, CD44, MDR1, MCT proteins. Inter-
actions between these proteins could contribute to the develop-
ment of CaP drug resistance and metastasis. Selective targeting of
CD147 and CD44 to block their activity (alone or combined) may
limit tumour metastasis, and increase drug sensitivity by modify-
ing expression of MDR and MCT proteins.
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Subtractive hybridization, and more recently, whole genome
expression arrays have advanced our understanding of differential
gene expression in neoplastic compared to normal tissues, leading
to identification of several important oncogenes as well as tumor
suppressor genes. We hypothesized that such changes in gene
expression would not only result in differential protein expression
profiles, but would also ultimately result in detectable differences
in the ionic composition of normal, dysplastic, and neoplastic
tissues. In a blinded fashion, we utilized atomic absorption (AA)
to analyze the metallic ion composition (iron, zinc, copper,
chromium, magnesium, and manganese) in normal human
esophagus, low grade dysplasia, intestinal metaplasia (Barrett’s
esophagus), high grade dysplasia, and carcinoma. Normal esoph-
ageal epithelium consistently displayed the lowest concentration
of all metallic ions analyzed. Samples representing esophageal
carcinoma contained elevated concentrations of all six ions (p<
0.025). Copper and manganese levels were consistently able to
discriminate between normal esophagus and all categories of
dysplasia (p<0.004 and p<0.045, respectively) including low
grade dysplasia. Thus, in cases where the histology of a biopsy is
indeterminate, metallic ion composition may serve to identify
epithelial dysplasia at an early stage. Results from these studies
are being analyzed in light of whole genome expression arrays to
identify candidate genes responsible for mediating changes in
ionic profiles and their relationship to the carcinogenic process.
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The main problem of radiotherapy is that some cancer cells
acquire radioresistance after radiation. Remodeled tumor micro-
environment(TME) is an inevitable consequence following irradi-
ation, however, its cardinal gene expression remains unknown. We
aimed to find out screen and validate surrogate genes of TME
alteration related to radiation resistance(RR) to improve the poor
prognosis of head and neck squamous cell carcinoma(HNSCC),
which demands radiotherapy.
Head and neck cancer cell lines (SCC15, SCC25 and QLL1) with
acquisition of RR until 60 Gy of cumulative dosages were
established. Combined results of cDNA array and proteomics
demonstrated differential expression profiles to compare with
corresponding control group, non-irradiated HNSCC cell lines.
Protein levels were verified retrospectively in tissue samples with
locoregional failure after radiotherapy, and compared with other
cell lines using western blot, immunofluorescence (IF).
On combined cDNA array and proteomics, NM23A was signifi-
cantly overexpressed in RR cell lines. NM23A was also strongly
expressed in tissue samples with RR. NM23A was predominantly
accentuated along the tumor margin. IF revealed high expression
of NM23A and partly translocation of protein into nucleus in
SCC25, QLL1. This nuclear shuttling was also noted in other cell
lines, including HeLa, CaKi-1, PC-3, but downregualted in sk-ov-
3, and T-24. E-cadherin, HGF precursor, MMP(metrix metallo
proteinase), EIF(eukaryotic translation initiation factor), EBP1
(erbB3 binding protein) and casein kinase 1 were significantly
upregulated in radiation resistant cell lines.
NM23A was one of the surrogate markers to be related to RR and
partly translocated into nucleus when upregulated.
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Aberrant gene function and altered patterns of gene expression are
key features of cancer. Growing evidence shows that the acquired
S187epigenetic abnormalities participate with genetic alterations to
cause this dysregulation. Patterns of DNA methylation are
profoundly altered in neoplasia and simultaneously include
genome-wide losses of, and regional gains in, DNA methylation
We purpose in understanding how epigenetic alterations partici-
pate in the earliest stages of neoplasia, and discuss the strategies to
control cancer.
The explosion in our investigations of epigenetic cancer biology
how alterated chromatin organization modulated DNA hypome-
thylation background has highlighted the importance of epige-
netic mechanisms in the initiation and progression of human
cancer. In this connection on the base of date obtained have been
resumed that extrachromosomal satellite DNA organization is
the pivotal microenvironmental feature in the initiation of
epigenetic cancer biology that triggeres the heterochromatic
chromocenters formation and the consequently heteropicnosis as
the pivotal macroenvironment in the progression of epigenetic
cancer cell biology. Taken together we conclude that epigenetic
genome-wide DNA methylation is the strategy from the crucial
extrachromosomal constitutive heterochromatin development to
control cancer.
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The matrix metalloproteases (MMPs) are endopeptidases in-
volved in the degradation of the extracellular matrix (1).
Correlations between MMP expression and increased metastatic
potential of various solid tumours have been documented (2).
Childhood acute lymphoblastic leukaemia (ALL) is character-
ized by its capacity to infiltrate different organs which can be
the cause of relapses. We analyzed the expression of MMP-2,
-9, -14 and TIMP-1 and -2 in a prospective study on 86
children with newly diagnosed ALL (73 B- and 13 T-lineage)
and 9 children at relapse with B-ALL. Cellular expression
(membrane bound and intracytoplasmic content) of MMPs and
TIMPs was analysed by flow cytometry, and secreted MMPs
were analysed by zymography and quantified by ELISA.
Although weakly expressed on the cell surface, MMP-2 and
MMP-9 were present in the cytoplasm of all ALL cases, with
an average of 40% positive cells. MMP-14 expression was
higher on B-ALL cells at relapse, as compared to B-ALL at
diagnosis (p<0.05). In B-ALL, the percentage of lymphoblasts
containing intracytoplasmic MMP-9 was significantly higher in
patients with peripheral infiltration than in patients without (p<
0.05), suggesting a possible role for gelatinases in peripheral
organ infiltration. Nine children died and their lymphoblasts
secreted higher levels of MMP-9 than children who recovered
(p<0.05). ROC curve and Kaplan-Meier curve analysis show
that a high secretion of MMP-9 (> 2450 pg/ml/10
6 cells) is
associated with a lower overall survival rate, suggesting that the
secretion of MMP-9 is an independent prognostic factor in
childhood B-ALL.
1. Malemud CJ. Matrix metalloproteinases (MMPs) in health and
disease: an overview. Front Biosci 2006; 11: 1696–1701.
2. Deryugina EI, Quigley JP. Matrix metalloproteinases and
tumour metastasis. Cancer Metastasis Rev 2006; 25: 9–34.
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Our research is focused on the development of effective
therapeutics preventing cancer progression and metastasis. In
tumor microenvironment, TGF-β cytokines promote tumor inva-
sion, angiogenesis and bone metastasis. However, TGF-β is also a
potent tumor-suppressor that inhibits cell growth and induces cell
death. This dual role of TGF-β in cancer is an impediment in the
development of anti-TGF-β therapies. The present study describes
a molecular pathway underlying pro-oncogenic TGF-β activities
in carcinoma cells.
The study investigated molecular pathways contributing to the
metastatic potential of breast, prostate and lung carcinoma cell
lines. Expression profiles and functional assays revealed that
TAK1 kinase is required for TGF-β induction of MMP9, VEGF
and COX2 in the metastatic cell lines. Disruption of TAK1
signaling reduces the metastatic potential of breast cancer MDA-
MB-231 cells, affecting tumor invasiveness and angiogenesis. The
biochemical assays showed that disruption of TAK1 reduces
NFkB activity but not ERK nor p38MAPK signaling. Thus, TAK1
plays a central role in the cross-talk of TGF-β and inflammatory
NFkB pathways.
Cancer-induced bone lesions present a significant complication
for patients with breast cancer. To investigate if TAK contributes
to osteolytic bone lesions, we used the intra-cardiac injection
model with MDA-MB-231 cells. Control and dominant-negative-
TAK1 cells were injected in the left ventricle of SCID mice. The
X-ray and immuno-histochemistry assays revealed bone lesions
in nearly 80% of mice in the control group but none in the
dn-TAK group, indicating a critical role of TAK1 in bone
metastases.
Our discovery provides a novel therapeutic target in cancer
progression and metastasis. The current research is directed
toward the development of TAK1 kinase inhibitors and to the
identification of the molecular components of the TGF-β-TAK-
NFkB axis.
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Antibody-based therapeutics represent a major class of drugs
which have contributed greatly to an improvement in treatment for
patients suffering from many forms of cancer. The major
characteristics which make antibodies attractive as therapeutics
are their increased specificity, long half life and reduced toxicity.
Traditionally antibodies have been developed against targets such
as membrane receptors or ligands where they evoke an agonistic
or antagonistic response. More recently some groups, including
ours, have explored their application in targeting biomarkers
present in the tumour microenvironment, which may originate
from more than one tumour associated cell type.
Cathepsin S (CatS) is a lysosomal cysteine protease which has been
implicated in tumour cell invasion and angiogenesis in a range of
different tumour types. CatS is normally restricted to the lysosomes of
professional antigen presenting cells, however in tumourigenesis, the
protease is secreted into the tumour microenvironment where it is
involved in extracellular matrix remodelling. We have developed an
antibody which specifically targets and inhibits CatS and have
demonstratedefficacyinarangeofinvitroandinvivotumourigenesis
models. The CatS inhibitory antibody significantly impaired invasion
of a range of tumour cell lines by the Boyden Matrigel invasion assay
and also disrupts capillary-tubule formation in the in vitro HUVEC
and ex vivo rat aortic ring angiogenesis assays. Live-cell proteolysis
assays have demonstrated that the perturbation of tumour invasion
occurs as a result of the inhibitory antibody blocking CatS mediated
collagen degradation. Furthermore, administration of the CatS
antibody resulted in the inhibition of tumour growth, metastasis
and neovascularisation in various xenograft tumour models.
In conclusion, this data highlights the potential of specifically
targeting CatS within the tumour microenvironment and indicates
that the CatS inhibitory antibody is an exciting experimental
therapeutic which has great clinical potential.
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Microglia (brain macrophages) are prominent in the stromal
compartment of malignant gliomas. Recent evidence suggest that
tumor-infiltrating cells release a variety of growth factors, cytokines/
chemokines and enzymes that support tumor growth, angiogenesis,
and invasion. Current understanding of molecular mechanisms of
glioma pathology permits to identify microglia-glioma interactions
as a novel therapeutic target. We demonstrated that cyclosporin A
(CsA) affects growth/survival of cultured glioblastoma cells,
interferes with glioma-microglia interactions and impairs tumorige-
nicity. In the present study we investigated efficacy and mechanisms
mediating antitumor effects of CsA in vivo, with particular attention
to drug influence on density and morphology of brain macrophages
and level of pro/anti-inflammatory cytokines.
EGFP-GL261 glioma cells were injected into the striatum of
C57BL/6 mice and tumor-bearing mice received CsA (2 or 10 mg/
kg/i.p.) every 2 days starting from the 2nd or the 8th day after
implantation. CsA-treated mice had significantly smaller tumors
than control mice. When the treatment was postponed to 8th day,
only the higher dose of CsA was effective causing 66 % tumor
volume reduction. Glioma implantation caused a massive accumu-
lation of brain macrophages within tumor. CsA-treated mice showed
a diminished number of tumor-infiltrating, amoeboid brain macro-
phages (Iba1-positive cells). TUNEL staining revealed DNA
fragmentation within infiltrating macrophages and glioma cells after
CsA treatment. Production of ten pro/anti-inflammatory cytokines
was determined using FlowCytomix immunoassay in total extracts
from tumor-bearing hemisphere. Elevated IL-10 and GM-CSF
levels were found in tumor-bearing hemisphere in comparison to
naive controls. CsA treatment reduced significantly IL-10 and GM-
CSF levels in brains of tumor-bearing mice. Altogether, our findings
demonstrate that targeting of cytokine production, brain macro-
phage infiltration and their interactions with glioma cells is effective
strategy to reduce glioma growth and invasion.
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Vascular Endothelial Growth Factor (VEGF) is a crucial regulator
of neo-angiogenesis in cancer, promoting endothelial cell prolif-
eration and migration. Microtubules, through their dynamic
instability, control cellular processes such as division and
migration that sustain tumor growth and dissemination. We have
previously shown that microtubule-targeting agents (MTA) pro-
duce their anti-migratory/anti-angiogenic effects on endothelial
cells through an increase in microtubule dynamics, a decrease of
EB1 comets at microtubule plus ends and lower microtubule
stabilization at adhesion sites (1–3). It is likely that external cues
S189from the tumor microenvironment are integrated at the level of
microtubules to regulate these processes. To test this hypothesis,
we analyzed the effect of VEGF on microtubule and EB1
dynamics in primary human endothelial cells. Autocrine VEGF
inhibition using a VEGF trap strongly increased in interphase
microtubule dynamic instability (+ 43%). Consistently, exoge-
nously added VEGF (10 ng/ml) suppressed microtubule dynamic
instability (− 29%). Interestingly, the suppression of microtubule
dynamics occurred through their plus end stabilisation at
paxillin-containing focal adhesions. Moreover, VEGF in-
creased EB1 comet length at microtubule plus end by 32 %,
without any change in its expression level. Differential post-
translational modifications of EB1 were detected by 2D
electrophoresis and western blotting. Their characterizations
are under investigation by mass spectrometry. In conclusion,
our results show (i) that microtubules integrate signals from
the tumor microenvironment, (ii) that VEGF and MTA have
opposite effect on microtubule and EB1 dynamics supporting
the clinical benefit of the therapeutic combination of VEGF
inhibitors and MTA, and (iii) suggest a potential role of EB1
protein in angiogenesis.
1- Pasquier E, et al Cancer Res 2005. 2- Pourroy B, et al Cancer
Res 2006. 3- Honoré S, et al Mol Cancer Ther.2008.
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Tumor angiogenesis is crucial to support tumor cells growth and
allow them to form metastasis [1]. Endothelial progenitor cells
(EPC) are key players that influence tumor neovascularisation
being directly incorporated into the tumor vessels [2]. Subse-
quently, we use progenitors of endothelium as vehicles for killer
genes to be expressed preferentially in tumors [3]. This needs to
determine the chemokines network that guides the progenitor and
stem cells toward tumor.
Here, we study mice model of melonama (B16F10 cells) and
primitive endothelial precursors isolated from mice embryo
(MAgEC – Murine Aorta-gonad-mesonephros Endothelial Cells).
To investigate the potential of B16F10 cells to stimulate MAgECs
migration we applied two in-vitro methods with usage of
fluorescence and pseudo confocal video microscopy, applied to
dynamic phenomena using shear stress conditions and time lapse
measurements on long term experiments. The first method was
based on transwell inserts and visualization of MAgEC invasion
through Matrigel. In the second one, 3D tumor spheroids were
formed and migration of MAgEC through collagen gel towards
spheroids was investigated. This allows to study the chemokine
activity as we showed that CCL21 augments MAgEC sensitivity
and migration potential. Such “education” may be important in
cell based therapy against tumor.
In vivo studies indicated the applicability of such 3D model. By
imaging using the near infra red cell tracking combined to
bioluminescence we showed the active migration and localisation
of the endothelial precursor cells in the sites where the tumor cells
metastasize. This was confirmed by applying several methods
including MRI (Magnetic Resonance Imaging), near-infrared
fluorescence imaging and flow cytometry to detect and quantify
the efficacy of the EPC seeking into tumor sites.
[1] Folkman J, N Engl J Med., 285:1182–1186 (1971)
[2] Peters BA et al. Nat Med., 11(3):261–2 (2005)
[3] Gao D, Nolan DJ, Mellick AS, et al. Science. 319(5860), 195,
(2008)
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The Epstein-Barr virus (EBV) is associated with several malignant
diseases which can be distinguished by their patterns of viral latent
gene expression. The latency II (lat.II) program is limited to the
expression of the non-immunodominant antigens EBNA-1, LMP-
1 and LMP-2, and is particularly associated with Hodgkin’s
disease, nasopharyngeal carcinomas and peripheral T/NK-cell
lymphomas. Knowing that CD4
+ T lymphocytes may play a
crucial role in controlling these EBV malignancies, we favoured
an immunotherapeutic approach, based on the stimulation of a
specific CD4
+ T cell response.
We used the TEPITOPE software to predict promiscuous MHC class
II epitopes derived from the latency II antigens EBNA-1, LMP-1 and
LMP-2. The predicted peptides were then submitted to peptide-
binding assay on HLA II purified molecules, which allowed the
selection of 6 peptides (EBNA-1: 3, LMP-1: 1, LMP-2: 2) with a
highly promiscuous capability of binding. The peptide cocktail was
highly immunogenic in Aβ°-DR1 transgenic mice, leading to a
specific cellular and humoral Th1 response. Every peptides used in
the cocktail or individually were also recognized by human CD4
+
memory T cells from healthy donors expressing various HLA II
genotypes and from patients with Hodgkin’sl y m p h o m a( H L ) .W e
have then generated peptide-specific CD4
+ cell lines, and assessed
their cytotoxic potential to lyse lymphoblastoid cell lines (LCLs,
S190Lat.III), or other EBVexpressing cell lines such as Tcell line (NC5,
Lat.II) and monocyte cell lines (TE1, Lat.II). Finally, any changes in
CD4+CD25+ regulatory Tcell activity were observed in response to
the peptide cocktail; avoiding the risk of aggravation of the pre-
existing immuno-suppressive microenvironment, already known in
EBV
+ associated malignancies.
Thus, this promiscuous peptide cocktail could be used in
immunotherapeutic approaches against EBV latency II malignan-
cies. It could be used as peptide-based vaccine or cellular therapy,
with the hope of controlling the residual disease after classical
treatment or to decrease the risks of relapse.
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Prostate cancer is the most commonly diagnosed non-skin
carcinoma and one of the leading causes of cancer-related
mortality of men in western society. Presently there are no
therapies available for advance and metastatic prostate cancer.
Oncolytic viral therapy may be used as a new and alternate
therapy to current treatments and provides an opportunity to
efficiently direct cell death to primary and metastatic cancer cells
while sparing normal cells. Vesicular Stomatitis Virus (VSV) is an
oncolytic virus which is able to replicate in cells with a defective
interferon (INF) response. Here, we examined the effect of a
mutated VSV (AV3 strain), which expresses luciferase and has an
enhanced INF-sensitivity, on the viability of prostate tumours that
develop in prostate-specific PTEN null transgenic mice. Prostates
of PTEN knockout and control mice were injected with 5x10
8 pfu/
ml of VSV(AV3) and monitored for luminescence over a 96 h time
period using the IVIS-Xenogen machine to track the viral
distribution. Both real time qPCR and plaque analysis indicated
viral presence and replication in prostate tissues of PTEN null
transgenic mice while little to no replication is seen in control
mice. TUNEL analysis of paraffin embedded tissues demonstrated
that VSV(AV3) is capable of selectively infecting and killing
malignant prostate cells while sparing normal cells, specifically at
the 48 h time point. This cancer-specific cell death was not due to
infiltration of neutrophil into the prostate tumours of PTEN null
mice as previously reported in an orthotropic mouse model.
However, an increase in macrophage and B-lymphocyte infiltra-
tion into the prostates of PTEN null mice is seen when compared
to control mice. In summary, our data demonstrates that VSV may
be used as a potential oncolytic viral therapy to target prostate
cancer.
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Recent evidence strongly suggests that cancer progression is
dependent on the microenvironment consisting of stromal and
inflammatory cells. Interactions of tumor cells with endothelium
in a microvasculature of distant organs determine the outcome of
metastasis. Previously, we could show that L-selectin deficiency
reduced the recruitment of myeloid cells, and attenuated
metastasis. Here we provide evidence for the molecular
mechanism involved in the tumor cell-mediated activation of
endothelial cells leading to formation of a metastatic niche.
Selectin-mediated cell-cell interactions of tumor cells with
platelets and leukocytes induce endothelial activation associated
with a production of inflammatory chemokines. Enhanced
expression of the key chemoattractant for monocytic cells is
associated with metastatic progression. Inhibition of monocyte
recruitment strongly reduced survival of tumor cell and metas-
tasis. Our findings demonstrate that the selectin-dependent
endothelial expression of chemokines contributes to the forma-
tion of a permissive metastatic microenvironment.
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HT10, a taurocholic acid-conjugated low molecular weight
heparin derivative is a novel angiogenesis inhibitor. We aimed
for designing a new angiogenesis inhibitor with tumor homing
capability by introducing the active targeting moiety to
previously developed HT10. The end-amine low molecular
heparin was conjugated to Apopep-1, the apoptosis-targeting
peptide, mediated by succinimidyl-4-[N-maleimidomethyl]cy-
clohexane-1-carboxylate and then HT-Apopep was completed
by adding taurocholic acid. The intravenous administration of
HT-Apopep in MDA-MB231 human breast cancer-bearing mice
S191for 14 days resulted in significantly reduced tumor size
compared to vehicle-treated control. The antitumor effect of
HT-Apopep was dose-dependent and superior to unmodified
HT10 and moreover, to bevacizumab, a humanized anti-VEGF
monoclonal neutralizing antibody. Immunohistochemical analy-
sis of tumor tissues demonstrated that HT-Apopep decreased
the number of CD34-positive erythrocyte-filled blood vessels
and Ki67-positive proliferating cells in tumor. These results
suggest that combining the angiogenesis inhibitor with active
targeting moiety improves antitumor efficacy and HT-Apopep
is a promising candidate for cancer therapeutics with tumor
homing antiangiogenic activity.
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Background: Tumor microenvironment alters biological response
of tumors, which might lead to alteration of tumor response to
radiation. Understanding the influence by different microenviron-
ment seems to be the basic step in developing novel antitumor
strategies. In this study, we investigated how biological response
of a tumor differs by different microenvironment.
Materials and Methods: A syngeneic murine tumor model was
established for hepatocarcinoma, HCa-I, which shows high radio-
resistance (50% tumor cure probability with higher than 80 Gy)
and early metastasis to the lung. Tumor cells (1X10
5) were
injected to male C3H/HeJ mice liver (orthotopic) or thigh muscle
(heterotopic). The mice were observed for the tumor growth and
metastasis. Tumor tissues were analyzed for CD31 and VEGF by
immunochemical staining. VEGF was also analyzed in mice
serum for response to radiation of 10 Gy.
Results: Tumor growth rate was faster in orthotopic than
heterotopic in early time and became similar at 15 days. Number
of metastatic lung nodules was much higher in orthotopic than in
heterotopic (number of nodules per mouse; 136 vs 1). Endothelial
cell marker, CD31, was increased in orthotopic than in heterotopic
tumors by 6 fold and 7.4 fold in 9 and 15 days, respectively.
Expression of VEGF was also increased in orthotopic than in
heterotopic tumors by 2.3 fold and 2 fold in 9 and 15 days,
respectively. The analysis of serum VEGF response showed a
biphasic pattern; at 1 day after radiation it decreased in both
orthotopic and heterotopic tumors. However, at day 3 after
radiation, serum VEGF decreased (2.6 fold) in orthotopic tumor
in contrast to increase (1.3 fold) in heterotopic tumors.
Conclusions: The present study showed different biological
response of tumors by different microenvironment in tumor
growth, metastasis, and related biological markers. It might be
applicable to preclinical studies in developing novel therapeutic
strategy.
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Metastasis continues to be the leading cause of mortality for
patients with cancer. Several years ago it became clear that
chemokines and their receptors could control the tumor progress.
CXCR3 has now been identified in many cancers including
osteosarcoma and CXCR3 ligands were expressed by lungs which
are the primary sites to which this tumor metastasize. This study
tested the hypothesis that disruption of the CXCR3/CXCR3
ligands complexes could lead to a decrease in lungs metastasis.
The experimental design involved the use of the CXCR3
antagonist, AMG487, and two murine models of osteosarcoma
lung metastases. Following tail vein injection of osteosarcoma
cells, mice that were systematically treated with AMG487
according to preventive or curative protocols had a significant
reduction in metastatic disease. Treatment of osteosarcoma cells in
vitro with AMG487 led to decreased migration, decreased matrix
metalloproteinase activity, decreased proliferation/survival and
increased caspase-independent death. Taken together, our results
support the hypothesis that CXCR3 and their ligands intervene in
the initial dissemination of the osteosarcoma cells to the lungs and
stimulate the growth and expansion of the metastatic foci in later
stages. Moreover, these studies indicate that targeting CXCR3
may specifically inhibit tumor metastasis without adversely
affecting antitumoral host response.
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Tumor-related activities that seem to be operationally induced
by the division of function, such as inflammation, neoangio-
genesis, Warburg effect, immune response, extracellular matrix
remodeling, cell proliferation rate, apoptosis, coagulation
S192effects, present itself from a systems perspective as an
enhancement of complexity. We hypothesized, that tumor
systems-directed therapies might have the capability to use
aggregated action effects, as adjustable sizes to therapeutically
modulate the tumor systems’ stability, homeostasis, and
robustness.
We performed a retrospective analysis of recently published data
on 266 patients with advanced and heavily pre-treated (10% to
63%) vascular sarcoma, melanoma, renal clear cell, cholangiocel-
lular, and hepatocellular carcinoma, hormone-refractory prostate
cancer, gastric cancer, and multivisceral Langerhans’ cell histio-
cytosis enrolled in ten multi-center phase II trials (11 centers).
Each patient received a multi-targeted systems-directed therapy
that consisted of metronomic low-dose chemotherapy, a COX-2
inhibitor, combined with one or two transcription modulators,
pioglitazone +/− dexamethason or IFN-alpha. These treatment
schedules may attenuate the metastatic potential, tumor-associated
inflammation, may exert site-specific activities, and induce long-
term disease stabilization followed by prolonged objective
response (3% to 48%) despite poor monoactivity of the respective
drugs. Progression-free survival data are comparable with those of
reductionist-designed standard first-line therapies. The differential
response patterns indicate the therapies’ systems biological
activity. Understanding systems biology as adjustable size may
break through the barrier of complex tumor-stroma-interactions in
a therapeutically relevant way: Comparatively high efficacy at
moderate toxicity. Structured systems-directed therapies in meta-
static cancer may get a source for detecting tumor-associated
complex aggregated action effects as adjustable sizes available for
targeted biomodulatory therapies.
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Previous work from our laboratory has used quantitative immu-
nohistochemistry (IHC) to show limited distribution from tumour
blood vessels of the auto-fluorescent drugs doxorubicin and
mitoxantrone. Analysis of the distribution of other anticancer
drugs is more difficult because most are not fluorescent, and they
are not recognized directly by available antibodies. Here we
investigate the use of IHC to determine the distribution of markers
of drug effect, and compare that to the distribution of the
fluorescent drugs mitoxantrone and AQ4N/AQ4. AQ4N is an
inactive pro-drug that is selectively bioreduced in hypoxic
environments to the cytotoxic metabolite, AQ4; it is structurally
related to mitoxantrone, and like mitoxantrone binds with high
affinity to DNA, and inhibits topoisomerase II. We have shown
that AQ4N/AQ4 accumulates selectively in hypoxic regions of
tumours (Tredan et al, Cancer Res 2009;69:940–7) Here, we use
quantitative IHC to analyse the spatial distribution of the
following molecular markers of drug effect in relation to blood
vessels (recognized by an antibody to CD31) and regions of
hypoxia (recognized by an antibody to EF5) of tumours treated
with mitoxantrone alone, AQ4N alone, or these drugs in
combination: cleaved caspase 3 (a marker of apoptosis), gamma-
H2AX (a marker of DNA damage) and Ki67 (a marker of cell
proliferation). Preliminary data show that compared to controls,
mitoxantrone treatment causes perivascular apoptosis, while
AQ4N-treated tumours have greater levels of apoptosis farther
away from blood vessels. Similarly, gammaH2AX staining is
increased in drug-treated tumours compared to untreated tumours,
and AQ4N-treated tumours show greater gammaH2AX activation
farther away from blood vessels. Quantitative statistical analysis of
the distributions of markers of drug effect in relation to tumour
blood vessels and to regions of tumour hypoxia is in progress, and
will be compared to the fluorescence distributions of mitoxantrone
and AQ4N/AQ4.
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Preventing and eradicating metastases in target organs requires to
better understand the mechanisms involved in the homing and/or
development of metastases. There is mounting evidence that
chemokines-receptors play a critical role in determining the
metastatic progression of tumors. Our study consisted in investi-
gating the role played by CXCR7 in metastatic colon cancer,
receptors that we found significantly over-expressed in biopsies of
CRC patients compared to healthy colon. To address this question
in vivo, we have developed two protocols of treatment based on
the systemic antagonism of CXCR7 with ChemoCentryx com-
pounds. On the one hand, a curative treatment of tumor-bearing
mice with CXCR7 antagonists was performed to evaluate their
therapeutic potential to eradicate pre-established colon cancer
metastases. On the other hand, a preventive treatment with these
S193compounds were given to the mice prior to tumor inoculation in
order to assess their ability to prevent the metastatic spread of
colon cancer cells to lung and liver. Our approach based on the
administration of pharmacologic antagonists within animal cancer
models using either murine or human cancer cells enabled us to
show that CXCR7 are a key factor in the dissemination and the
progression of colon cancer metastases into the lungs. Our in vitro
studies performed on cancer cells suggest that the anti-tumor
effects of pharmacologic blockers could reside in the inhibition
of the migratory and growth/survival ability of the cancer cells
induced by the corresponding chemokines (CXCL11 and
CXCL12). Interestingly, however, we show that both preven-
tive and curative CXCR7 antagonisms fail to reduce the extent
of liver metastasis, thus suggesting that such receptors do not
appear to play a major role in the metastatic process within this
target organ.
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Liver and lung metastases are the predominant cause of
colorectal cancer (CRC) related mortality. Recent research has
indicated that CXCR3/chemokines interactions that orchestrate
hematopoetic cell movement are implicated in the metastatic
process of malignant tumors, including that of CRC cells to
lymph nodes. To date, however, the contribution of CXCR3 to
liver and lung metastasis in CRC has not been addressed. To
determine whether CXCR3 receptors regulate malignancy-related
properties of CRC cells, we have used CXCR3-expressing CRC
cell lines of human (HT29 cells) and murine (C26 cells) origins
that enable the development of liver and lung metastases when
injected into immunodeficient and immunocompetent mice,
respectively, and assessed the effect of CXCR3 blockade using
AMG487, a small molecular weight antagonist. In vitro,
activation of CXCR3 on human and mouse CRC cells by its
cognate ligands induced migratory and growth responses, both
activities being abrogated by AMG487. In vivo, systemic
CXCR3 antagonism by preventive or curative treatments with
AMG487 markedly inhibited the implantation and the growth of
human and mouse CRC cells within lung without affecting that
in the liver. Also, we measured increased levels of CXCR3 and
ligands expression within lung nodules compared to liver tumors.
Altogether, our findings indicate that activation of CXCR3
receptors by its cognate ligands facilitates the implantation and
the progression of CRC cells within lung tissues and that
inhibition of this axis decreases pulmonary metastasis of CRC
in two murine tumor models.
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Adhesion of therapeutic and diagnostic delivery vehicles to the
endothelial lining is influenced by endothelial activation, which
leads to tissue-specific differences in endothelium and
corresponding differences in the expression of specific cell
surface molecules. Elevated expression of E-Selectin, Vascular
Cell Adhesion Molecule-1 (VCAM-1), and Inter-Cellular Adhe-
sion Molecular-1 (ICAM-1) on tumor-associated endothelia are
targets for blood borne drug delivery vehicles. The realization
that blood-borne delivery systems must overcome a multiplicity
of sequential biological barriers has led to the fabrication of a
multistage delivery system (MDS) designed to optimally
negotiate vascular transport, localizing preferential at patholog-
ical endothelia, and delivering both therapeutic and diagnostic
cargo. The MDS is comprised of stage one nanoporous silicon
particles that function as carriers of second stage nanoparticles.
We have successfully fabricated an MDS with targeting and
imaging capabilities by loading iron oxide nanoparticles into the
porous silicon matrix and capping the pores with a polymer coat.
The polymer also provides free amines for attachment of
targeting ligands. Tissue samples from mice that were intrave-
nously administered the MDS support the in vivo stability of the
multi-particle system by demonstrating co-localization of silicon
and iron oxide particles. Mice with breast cancer xenografts
show dark contrast in the tumor by magnetic resonance imaging
following injection with the MDS, supporting accumulation of
iron oxide nanoparticles in the tumor. Transmission and scanning
electron microscopy have been performed to view the luminal
surface of the tumor endothelium following administration of the
MDS.
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Studies report that soy isoflavones inhibit growth in a number of
carcinoma cell lines and may enhance radiotherapy. We investigated
the interaction of a soy isoflavone diet (ISF) and radiation (XRT) on
PC-3 human prostate xenograft tumors in mice. The PC-3 cell line
is androgen-insensitive, does not express p53 or PTEN tumor
suppressor genes, and overexpresses Akt, a major prosurvival
pathway. Methods: Male nude mice on a soy-free control diet were
injected with PC-3 prostate cancer cells into the hind flank. On day
5, half the mice were placed on a diet containing 0.5% soy
isoflavone concentrate (ISF). On day 9, half the mice from each diet
group were randomly irradiated to 2 Gy (XRT). Tumor sizes were
monitored biweekly. Resected tumors were fixed in formalin and
paraffin-embedded. Immunohistochemical staining was performed
using antibodies against Akt, phosphorylated-Akt (phosAkt),
TUNEL, VEGF, CD34, PCNA and vimentin. Results: The ISF
and XRT treatments, respectively, each significantly inhibited
xenograft tumor growth, with combination ISF+XRT (2 Gy) having
additive inhibitiory effects. ISF and XRT, individually, produced
inhibition of proliferation (PCNA), induction of apoptosis
(TUNEL), and decreased angiogenesis (VEGF, CD34). In contrast,
ISF decreased phosAkt in tumor cells, whereas XRT upregulated
phosAkt, possibly as a prosurvival response to low dose radiation.
In addition, XRT alone increased staining for vimentin in tumor
cancer cells, a mesenchymal marker, and tumors were more
invasive. The combination of ISF+XRT, however, suppressed
phosAkt, as well as the transition to vimentin staining. Thus, soy
alters the tumor microenvironment to sensitize to radiation killing,
as well as suppress mesenchymal activation by XRT. Conclusions:
Evidence shows that dietary soy isoflavones (ISF) inhibit xenograft
tumor growth in mice, and also act as an adjuvant agent to sensitize
to radiotherapy through distinct mechanisms within the tumor
microenvironment. (Support from NIH and the Maren Foundation)
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Activin receptor-like kinase-1 (ALK1) is a TGF-beta type I
receptor found on remodeling blood vessels. ALK1 mutations are
associated with the hemorrhagic disease Hereditary Hemorrhagic
Telangiectasia indicating its role in the regulation of angiogenesis.
We developed a soluble ALK1 receptor, ACE-041, by fusing the
extracellular domain of ALK1 to the Fc region of IgG1, to
examine the potential of ALK1 inhibition as a novel anti-
angiogenic therapy. ACE-041 binds circulating ligands and
prevents their signaling through ALK1. RAP-041, the murine
analog, was also developed for testing in rodents. Bioactivity was
evaluated in cell based assays and the effect of ACE-041 on
neovascularization was evaluated in vitro using a cord formation
assay. The addition of ACE-041 reduced ALK1 signaling through
both SMAD 1/5/8 phosphorylation and Id-1 expression, confirming
that ACE-041 abrogates ALK1 signaling. In vitro stimulation of
endothelial cells induces their rearrangement into vessel-like
structures (cords). The addition of ACE-041 significantly inhibited
their rearrangement (45%), suggesting an important role of ALK1 in
neovascularization. Antiangiogenic activity of RAP-041 was dem-
onstrated in vivo in a modified Basement Membrane Extract plug
assay, in a chick chorioallantoic membrane assay (CAM) and in an
epiphyseal hypertrophy assay. RAP-041 showed anti-tumor activity
in several tumor models including a modified CAM assay and an
orthotopic breast cancer model. RAP-041 treatment decreased
tumor volume (up to 80%); tumor weight (up to 81%) with
immunohistochemical staining demonstrating a reduction in blood
vessels (decreased CD31). Taken together, these results suggest an
important role of ALK1 in blood vessel formation and demonstrate
the anti-angiogenic properties of ACE-041. In conclusion, ACE-
041, a soluble ALK1-Fc fusion protein, is a novel anti-angiogenic
compound being developed for use as a cancer therapy.
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Anti-VEGF therapy has shown promising results in cancer
treatment but its in vivo mechanism of action is, to this date,
poorly understood. Bevacizumab shows a synergistic effect when
administrated with chemotherapy but has failed as a single-agent
and, even more intriguingly, the intravenous injection of the
VEGF monoclonal antibody has been reported to increase serum
VEGF [1–4]. We have built an in silico model that comprises three
compartments: blood, healthy and tumor tissues. This whole-body
model includes molecular interactions involving VEGF, inter-
compartmental transport (microvascular permeability and lym-
S195phatic removal) and clearance from the plasma. We show that the
introduction of an anti-VEGF agent disrupts the VEGF distribu-
tions in tissues and blood. We predict that the increase in serum
VEGF can be explained by the extravasation of the anti-VEGF
agent, followed by a net flow of VEGF complexed with the anti-
VEGF agent from the tissue to the blood. Such findings can lead
to a better understanding of the pharmacokinetics of anti-VEGF
therapy, will aid in the optimization of drug dosage regimens, and
the molecular design of therapeutic agent carriers.
1. Segerstrom L, Fuchs D, Backman U, et al. Pediatr Res 60: 576–
81, 2006.
2. Willett CG, Boucher Y, Duda DG, et al. J Clin Oncol 23: 8136–
9, 2005.
3. Yang JC, Haworth L, Sherry RM, et al. N Engl J Med 349:
427–34, 2003.
4. Gordon MS, Margolin K, Talpaz M, et al. J Clin Oncol 19:
843–50, 2001.
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Peripheral Proopiomelanocortin Expression Inhibited the Lung
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Malignant melanoma is a highly lethal that metastasis of
melanoma cells to distant organs represents the primary cause
for cancer mortality, underscoring the demand of novel therapeutic
alternatives. Proopiomelanocortin (POMC) is the precursor of
various anti-inflammatory peptides including α-melanocyte-
stimulating hormone (α-MSH). We have recently demonstrated
the potential of systemic POMC expression via adenovirus gene
transfer suppresses the growth of primary B16-F10 melanoma and
prolongs the survival of tumor-bearing mice. In this study, we
investigated whether POMC gene transfer also held promise for
management of metastatic melanoma. In cell cultures, POMC
gene delivery potently inhibited the motility and invasiveness of
B16-F10 melanoma cells. Such inhibition was correlated with
the reduced Rho activity and downregulation of Rho-ROCK
signaling proteins including RhoA, RhoB, ROCK-I and ROCK-
II. Besides, POMC gene transfer also disrupted the epithelial-
mesenchymal transition (EMT) of melanoma cells through
E-cadherin up-regulation and α-SMA down-regulation. To
evaluate the anti-metastatic efficacy in vivo, C57BL/6 mice were
intravenously administrated with luciferase-engineered B16-F10
cells at day 1, treated with adenovirus vectors at day 2, and
monitored for development of lung metastasis at day 14 by
counting lung foci and bioluminescence. It was found that
POMC-treated mice exhibited significant reduction in lung
metastasis. Therefore, the present study demonstrated for the
first time the anti-metastatic potential of peripheral POMC
expression for control of metastatic melanoma via perturbing
EMT and Rho/ROCK pathways.
Poster No. 209
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Denileukin diftitox (DD; ONTAK
® - Eisai Inc.), a recombinant fusion
protein that combines IL-2 with the membrane and catalytic domains
of diphtheria toxin, binds to and potently kills cells that express the
IL-2 receptor (IL-2R). One component of that receptor is CD25. High
level IL-2R expression is a characteristic of immunosuppressive
regulatory T lymphocytes (Tregs), which many types of solid tumors
are known to utilize for immune evasion. We found that a 1–2 hour
exposure to DD dose-dependently depleted CD4+CD25+FoxP3+
murine splenocytes or CD4+CD25
hiFoxP3+ human blood leukocytes
in vitro, while largely sparing CD4+CD25- splenocytes. The same
brief DD exposure that led to depletion of Tregs (as measured by
flow cytometry) also inhibited suppressive activity of murine Tregs
(as measured by suppression of [
3H]thymidine uptake) towards
stimulated non-Treg T cells. In vivo exposure to DD at 4.5µg/mouse
(Q7dx2) led to stasis of established subcutaneous CT26 colon tumors
in BALB/c mice. Of interest, we also found that DD at 4.5µg/mouse
(Q7dx2) was completely without anti-tumor effect towards CT26
tumors if tumors were implanted in immunocompromised nude mice.
Transcriptional profiling of excised tumors from DD-treated and
untreated mice revealed a strong immune activation response to DD
treatment. In syngeneic mouse models of solid tumors, we conclude
that DD exerts its major anti-tumor effect against T cells, and in
particular against Tregs.
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Acquisitionofmigratorycapacityofprostatecancercellsisanessential
event for metastatic disease progression; however, the molecular
mechanism underlying acquisition of a metastatic capacity remains
unresolved. Clusterin (CLU) is a secreted chaperone protein, over-
expressed in many cancers that has been previously reported as up-
S196regulated during Castration Resistant progression of prostate cancer
(CRPC). We used an antibody array to identify changes in protein
expression and phosphorylation of PC3 prostate cancer cells in which
CLU expression was suppressed by siRNA knockdown. We observed
that CLU siRNA knockdown leads to decreased focal adhesion kinase
(FAK) phosphorylation as well as its downstream targets. FAK is a
member of a family of non-receptor protein-tyrosine kinases that acts
as a key regulator of cell migration and whose expression level
correlates with CRPC progression. Validating the antibody array
results, we confirmed that CLU siRNA knockdown decreases FAK
phosphorylation in PC3 cells without affecting total FAK levels by
immunoblot analysis. We have gone on to show that CLU siRNA
treatment suppresses serum- and VEGF-inducing FAK phosphoryla-
tion, and attenuates PC-3 cell migration and invasion capacity in
wound healing and matrigel invasion assays. All together, these
observations implicate CLU as an important regulator of cell motility
and FAK activation in PC3 cells.
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Our recent study in murine prostate cancer cells, TRAMP-C1, found
that radiation therapy (RT) by either 25 Gy in a single dose or 60 Gy
with 15 fractions in 3 weeks resulted in the development of chronic
and persistent hypoxia, which allured the aggregation of CD68
positive TAMs to these regions. To further study the distribution of
tumor-infiltrating cells in the irradiated tumors, flow cytometry and
immunohistochemistry were used to characterize the distribution and
association of these cells in TRAMP-C1 tumors with hypoxic and
necroticregions following RT. Tumor-infiltrating cells in control, un-
disturbed tumors were randomly located and no specific distribution
pattern can be identified. In irradiated tumors, except the aggregation
of CD68 positive macrophages at chronic hypoxia region, we further
foundthatCD11bandGr-1positivecellswereconcentratedincentral
necrotic region and F4/80 positive macrophages were distributed
along the junction of necrotic and chronic hypoxic region. Flow
cytometryassaydemonstratedthattotalCD11bcellswerenotaltered,
but there are more CD11b and Gr-1 positive cells in the necrotic
region of irradiated tumor than control tumor, no matter the size of
tumor or necrotic area. The re-distribution pattern of different
subsets of CD11b positive cells into different microenviron-
ments in irradiated tumors suggest irradiated tumors form sub-
component which has factor(s) to attract specific subset of
CD11b positive cells. The illustration of the role and function
of these cells in particular regions may provide a new strategy
to improve the effectiveness of radiation therapy. (This work is
supported by grants of NHRI-EX98-9827BI and NTHU-
98N2425E1 to Chi-Shiun Chiang)
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Dysregulation of the Met receptor tyrosine kinase and of its
cognate ligand Hepatocyte Growth Factor / Scatter Factor (HGF/
SF) occurs frequently in cancer, and Met overexpression indicates
poor prognosis in several cancers such as breast and head and
neck. HGF/SF binding triggers signalling that promotes cancer
cell migration, proliferation and invasion. We have generated Met-
binding single-chain fragment variable (scFv) antibodies by phage
display, using the ‘McCafferty’ library, which has a diversity of
10
10 clones. After two rounds of biopanning, 76/182 clones bound
Met in ELISA, of which 72 were found to be unique. Preliminary
data indicates isolation of several clones capable of inhibiting
HGF/SF-induced scatter of the pancreatic cancer line BxPC-3.
Affinity maturation and selection strategies directed towards
antibodies that bind the same epitopes as HGF/SF may yield
clones with higher activity. Met-blocking scFv may be useful for
cancer therapy.
This work is funded by Cancer Research UK / Cancer Research
Technology.
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Introduction
The pO2 is a crucial factor affecting the response of tumors to
irradiation and other cytotoxic treatments. It has been predicted
that modification of oxygen consumption is much more
efficient at alleviating hypoxia than modification of oxygen
delivery.
Arsenic has been reported to have anti-tumor effect in acute
promyelocytic leukemia and in solid tumors. As2O3 seems also to
inhibit mitochondrial respiratory function in human leukemia
cells. Thus, we hypothesized that As2O3 could be an important
modulator of tumor oxygenation by affecting the oxygen
consumption of tumors.
Materials and methods
The effect of As2O3 (5 mg/kg) was studied in TLT tumor model.
Local pO2 was measured in vivo using low frequency EPR (1) and
19F-relaxometry (2). The oxygen consumption rate was measured
in vitro using high-frequency EPR. At the maximum pO2 (after
1 h30) perfusion and radiation sensitivity were also studied by
Patent Blue staining assay and regrowth delay experiment after X-
Ray irradiation (10 Gy), respectively (Fig.4).
S197Results
The administration of As2O3 increases significantly the pO2 in
TLT tumors, an effect that was not observed for the control group
(Fig.1). The results were confirmed by
19F NMR. The increase in
pO2 induced by As2O3 was not due to an increase in tumor
perfusion as shown by the Patent blue staining assay (Fig.2). As
t h ei n c r e a s ei np O 2 was not due to an increase in perfusion, the
tumor oxygen consumption was investigated. The administration
of As2O3 significantly decreased the oxygen consumption
(Fig.3). Finally, the irradiation (10 Gy) of tumors showed a
regrowth delay that was significantly increased in arsenic-treated
mice.
Conclusion
As2O3 is an important modulator of pO2 by decreasing
oxygen consumption and enhances the response of tumors to
radiotherapy.
References
(1) Gallez et al, NMR Biomed. 2004, 17,240–262. (2) Jordan et al,
MRM 2009, 61, 634–638.
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It is now established that adipose tissue secretions, i.e.
adipokines, may play a role in mammary carcinogenesis
development. We have shown that two major adipokines, leptin
and adiponectin, had stimulating and inhibiting effects on cell
proliferation respectively and were expressed in mammary
adenocarcinoma
1,2. At present, we evaluated Zinc-α2-
glycoprotein (ZAG) expression, which is known to be overex-
S198pressed in prostate tumors
3, in tumor or healthy breast tissue and
examined whether it was correlated with that of major adipo-
kines (leptin, adiponectin), usual tumor biomarkers (sex steroids
receptors, i.e. estrogen (ER) and progesterone; Ki67 proliferation
factor; cErb2 growth factor receptor), or apoptosis markers (Bcl2
and Bax).
Biopsies (n=55) of human ductal breast carcinoma (Jean-Perrin
Anti-Cancer Center) and mammary tissues (n=6) of healthy
women (Edouard-Herriot Hospital), were used to investigate
ZAG expression by immunohistochemistry (ABC technique,
biotin-avidin-peroxidase). Statistical analysis was realized with
Spearman correlation.
ZAG expression was detected in ductal carcinoma and in normal
epithelial adjacent tissue (87% and 94% of cases studied
respectively) but was not found in normal tissue of healthy
women. In cancer tissue, its expression was positively correlated
to leptin receptor (p=0.01, r=0.459) and negatively to adiponectin
receptor (p=0.03, r=−0.371) and ER (p=0.04, r=−0.279). We did
not show statistically significant correlation between ZAG and the
other studied markers.
These preliminary results suggest both a close relationship
between ZAG expression and pathways involving major adipo-
kines or estrogen and, that ZAG may be a potential breast cancer
biomarker, which requires further investigations.
1 Caldefie-Chézet F, Biochem Biophys Res Commun, 2005;
2Jardé
T, Proc Nutr Soc, 2008;
3Hale LP, Clin Cancer Res, 2001.
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Background:
It is well known that chronic infections affect the microenviron-
ment with a high proportion of cancer incidence.In Egypt, chronic
infection with hepatitis C,HCV, is a widespread infection among
Egyptian population, and has been associated with increased
incidence of Hepatocellular Carcinoma,HCC, and in some studies
with increased risk of non-Hodgkin lymphoma,NHL.P53 protein
plays an important role in the maintenance of genome stability in
mammalian cells;it acts in many processes including cell-cycle
checkpoint, DNA repair, apoptosis, and angiogenesis. Mutations
of P53 have been reported as common mutations in solid tumors,
including HCC and NHL, and have been implicated in drug
resistance, aggression and poor prognosis. Circulating free DNA
(CFDNA) has been shown to be a good source of liver tissue
derived DNA in African and Asian patients with chronic liver
disease or HCC.
Objective:
We have examined the presence of p53 mutations from exons 5 to
9 in CFDNA of patients with HCC or chronic liver disease, and of
patients with NHL from Alexandria,Egypt, in two separate case-
control studies.
Results:
The DNA concentrations were significantly higher in HCC
patients compared to HCV individuals. TP53 249 mutations were
shown in 5% of CFDNA and 10% of tumors of HCC,with
underlying HCV. Also, concentrations of CFDNA were signifi-
cantly higher among NHL patients compared to the negative
control individuals. Mutations of p53 determined in NHL cases
(30%) were of Arg-176(1/20:5%), Phe-238(1/20:5%), Ser-249(2/
20;10%), Lys-249(1/20:5%) and Phe-250(1/20:5%).No mutations
were detected among controls.
Conclusion:
Our findings of higher DNA concentrations with some p53
mutations in CFDNA from cancer patients that match the previous
reported p53 mutations from tumor DNA may hold promises that
CFDNA may serve as a convenient source of tumor-derived DNA
to serve as a promising tool of a non-invasive, low-cost new
strategy for earlier detection, diagnosis and follow-up of the
disease.
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Solid tumours maintain a barrier that prevents 1) adequate delivery
of anti-tumour drugs and 2) immune cells penetrating the tumour
microenvironment and exerting their effects. In clinical trials, this
is reflected by the large proportion of patients where systemic anti-
cancer vaccines or adoptive transfer of anti-cancer immune cells
ultimately fail to induce a strong anti-tumour response. In a mouse
model where SV40 Large T antigen is expressed in the β cells of
the pancreas (RIP1-Tag5), studies have shown that the inflamma-
tory environment and the tumour vasculature can be modulated as
to allow T cell penetration and tumour rejection [1–3]. Recently, a
peptide was identified (CRGRRST) that specifically homes to
RIP1-Tag tumour vessels [4]. We have used this peptide to
produce fusion proteins using the TNF family members, TNFa and
LIGHT (LIGHT; Homologous to Lymphotoxins, shows inducible
expression, and competes with herpes simplex virus glycoprotein
D for HVEM, a receptor expressed by T lymphocytes). These
compounds are of particular interest for tumor-targeting because
of their documented anti-tumor effects and their potential but
unexplored dual actions on tumor stroma and immune effector
cells. The activity of our fusion proteins was verified in vitro using
FACS analysis, followed by demonstration of specific homing to
RIP1-Tag5 tumour vessels after systemic injection in mice. We
S199show here that TNFa and LIGHT targeted to the tumour
microenvironment simultaneously activate the tumour stroma and
CD8+ effector cells, and therefore result in enhanced T cell influx
that ultimately leads to tumour destruction.
References
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Background:
In the tumor microenvironment, activation of tumor-stromal
interactions is considered to play a critical role in Prostate Cancer
(PCa) progression. Hedgehog signaling, a developmental pathway
implicated in cancer, has been associated with resistance to
cytotoxic treatment in human samples. Thus hedgehog signaling
inhibition is a candidate therapeutic target for combination with
maximal androgen ablation. Selection of preclinical models of
PCa relevant to the human disease is imperative for development
of applicable therapeutic strategies.
Materials and methods:
Xenografts generated by our research team from castrate-resistant
PCa specimens were used to screen gene expression of key
components in hedgehog signaling. Tumors were examined for the
RNA and protein expression of Shh, Gli1, Gli2, Smo, Ptch1 and
Sufu by Real Time RT-PCR and IHC in both (human) prostate
cancer cells and in host (mouse) derived stromal cells.
Results-Conclusions:
118b is an androgen independent xenograft, not expressing AR,
inducing bone formation in the surrounding stroma. This
xenograft has a striking overexpression of hedgehog signaling
including nuclear expression of Gli1 and Gli2. Xenografts A10,
137, 117, 115 and 79 are expressing AR and some extent of
hedgehog signaling. All studied models showed differential gene
expression of hedgehog signaling components in stromal com-
partment compared to tumor cells. Notably, A10 when grown in
castrate host has increased expression of the transcription factors
Gli1 and Gli2 and the ligand Shh, in the stromal compartment as
compared to growth in non-castrate (vide infra). This experiment
recapitulates the human condition based on our translational
results and therefore might be the most well suited model to test
the effect of hedgehog signaling inhibition on blocking androgen-
resistant growth.
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Recent data have expanded the concept that the tumor microen-
vironment, largely arranged by inflammatory cells, is an indis-
pensable participant in the neoplastic process. Tumor-associated
macrophages represent the major component of the stroma of
many tumors, including brain tumors - gliomas, and their high
content correlates with malignancy and poor patient prognosis. We
have demonstrated that glioma cells release soluble factors which
induce accumulation and a non-inflammatory activation of brain
macrophages associated with pro-invasive function of these
cells
1, 2. Proteomic analysis of glioma-conditioned medium
(G-CM) using HPLC fractionation followed by a tandem mass-
spectrometry revealed that one of these factors is Osteopontin
(OPN), a metastasis-associated small integrin-binding ligand N-
linked glycoprotein family member. Interference with OPN
binding to integrins using a blocking RGD peptide, abolished
morphological alterations of brain macrophages induced by G-
CM. We demonstrate that Osteopontin was abundantly expressed
in rat C6 glioma cells, but not in non-transformed glial cells.
Using pharmacological inhibitors of many signaling pathways, we
found that MEK1/2-ERK and NFκB signaling pathways are
S200responsible for the high expression of OPN in glioma cells. To
evaluate the role of OPN in glioma pathology, Osteopontin
expression was efficiently silenced with the commercial siRNA
(Qiagen). Silencing of Osteopontin had no impact on proliferation
and survival of transfected glioma cells. Furthermore, the
migration rate of glioma cells (evaluated with a wound healing
assay), as well as glioma invasiveness (determined with the
Matrigel invasion assay) were not affected by siRNA OPN.
Altogether, our studies indicate that tumor-derived OPN does not
affect properties of tumor cells itself, but may be a crucial factor
mediating interactions between glioma and tumor-associated brain
macrophages and involved into pathogenesis of gliomas.
1. Sliwa et al. Brain 2007. 130:476–89.2. Wesolowska et al.
Oncogene 2008. 27:918–30.
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The transdifferentiation of hepatic stellate cells (HSC) into
myofibroblasts is a key event for the development of stroma and
angiogenesis during hepatic metastasis development, although
regulatory pathways involved in HSC activation are unclear.
Discoidin domain receptor 2 (DDR2) is a tyrosine kinase receptor
for fibrillar collagen expressed by activated HSC during hepatic
fibrosis. Mice lacking DDR2 gene (DDR2
−/−) have an enhanced
susceptibility to carbon-tetrachloride-induced hepatic fibrosis,
suggesting that DDR2-dependent genes are anti-fibrogenic. There-
fore, we hypothesized that tumor stroma formation by trans-
differentiated HSC may be enhanced by DDR2 deficiency,
predisposing hepatic tissue to colon carcinoma metastasis.
Experimental hepatic MCA38 colon carcinoma metastasis occur-
rence and development significantly increased in DDR2
−/−
compared to DDR2
+/+ mice. Immunohistochemical analysis
showed that hepatic metastases in DDR2
−/− mice had higher
density of HSC-derived myofibroblasts (dual desmin/alpha-
smooth muscle actin-expressing cells), neoangiogenic vessels
(CD31-expressing cells) and proliferating cells (ki67-expressing)
than in DDR2
+/+ littermates. Consistent with in vivo findings,
secretion of endothelial cell adhesion- and migration-stimulating
factors, and of MCA38 cell proliferation-stimulating factors
significantly increased by 50% in the supernatants of DDR2
−/−
HSC primary cultures, compared to those from wild-type HSC.
These secreted factors further increased by 20% in the super-
natants of DDR2
−/− HSC cultures pretreated with MCA38 cell-
conditioned media. Moreover, compared to wild-type HSC, gene
profiling of DDR2
−/− HSC showed increased expression of a
cluster of genes, associated with inflammation and extracellular
matrix remodeling, that have been clinically correlated with
hepatic metastasis occurrence, such as IL-10, TGFbeta,
syndecan-1, integrin-a2, thrombopoietin and BMP7. These
results demonstrate that DDR-2 deficiency predisposes hepatic
tissue to colon carcinoma metastasis. The mechanism may
depend on a special prometastatic microenvironment operating
in the absence of certain DDR2-dependent factors that prevent
tumor cell adhesion and proliferation, and endothelial cell
migration.
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Background:
Clinical experience has shown limited benefits when anti-
angiogenic agents that target VEGF are used alone, but greater
effects when combined with chemo-therapy. Transient vascular
normalization has been proposed to explain this unexpected
combination effect (Jain, Science 2005;307:58–62), which
involves reduced vascular permeability, destruction of immature
vessels and increased pericyte recruitment at specific times
following anti-VEGF therapy. The resulting improvement of
tumor blood flow and oxygenation, and reduction in interstitial
fluid pressure, might improve chemotherapy delivery. Evidence to
support vessel normalization remains inconsistent. Here we
evaluate the effect of aflibercept, a potent soluble receptor for
VEGF (undergoing clinical trials), for its effect on vascular
physiology and delivery of doxorubicin to solid tumors.
Hypothesis:
During a certain window of time, aflibercept will increase
functional blood vessels, decrease hypoxia, and improve delivery
and therapeutic effects of doxorubicin.
Methods:
Mice with A431 human squamous cell cancer xenografts were
killed at 8, 24, 72 hours and 7 days following administration of
aflibercept or its diluent; they received EF5 (to identify hypoxic
regions), doxorubicin, and DiOC7 (a marker of blood flow) at
2 hours, 10 minutes and 1 minute respectively prior to death.
Excised tumors were frozen, sectioned and stained for blood
vessels (with anti-CD31) and hypoxia. The distribution of
doxorubicin relative to functional blood vessels was quantified
by immunohistochemistry as described previously (Primeau et al,
Clin Cancer Res 2005;22:8782–8). Therapeutic effects of doxoru-
bicin, with or without prior VEGF-Trap, were studied by growth
delay.
S201Results:
The table below summarizes median values of various outcomes.
Studiestoquantifythedistributionofdoxorubicin,anditstherapeutic
effects are in progress, and will be reported at the meeting.
Conclusions:
These results suggest a transient improvement in vessel functionality
and reduction in hypoxia between 24 and 72 hours in tumors treated
with aflibercept lending support for normalization of vessels.
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Extensive clinical evidence and mouse models of tumorigenesis
support the critical role of the microenvironment in promoting
tumor growth and metastasis. We have identified a novel role for
extracellular matrix enzyme lysyl oxidase-like 2 (LOXL2) in the
creation of the pathologic microenvironment of oncologic and
fibrotic diseases through modulation of matrix tension. Our
analysis of human tumors and liver fibrosis revealed widespread
and conserved expression of LOXL2 by activated fibroblasts and
neovasculature. The inhibition of LOXL2, but not LOX, with a
specific monoclonal antibody was efficacious in both primary and
metastatic xenograft models of cancer, as well as CCl4-induced
liver fibrosis. Inhibition of LOXL2 resulted not only in a
substantial reduction in fibroblast activation and recruitment,
desmoplasia, and vascularization, but also in significantly de-
creased production of pro-angiogenic growth factors and cyto-
kines such as VEGF and SDF1, as well as reduction of collagen
production and LOXL2 expression itself. Tumor cells in anti-
LOXL2 treated animals showed significant increases in necrosis
and pyknosis. Anti-LOXL2 therapy using a monoclonal antibody,
while highly specific, revealed a broad spectrum of pleiotropic
effects that impacted tumor viability. The anti-LOXL2 monoclonal
antibody outperformed small molecule pan-lysyl oxidase inhibitor
b-aminoproprionitrile (BAPN) in all analyses. Unlike BAPN, this
antibody acts as a substrate-independent inhibitor of LOXL2, and
represents a new therapeutic approach with broad applicability in
oncologic and fibrotic diseases. In addition, targeting the genet-
ically more stable stromal cells of the tumor microenvironment
offers the potential for reduced likelihood of drug resistance.
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By microarray supervised analysis on a dataset obtained from breast
carcinoma patients treated with docetaxel as neoadjuvant therapy, the
foremost variable identified has been SerpinB5, a serine-protease-
inhibitor, using disease-progression as supervised variable. SerpinB5
resulted 13 times more expressed in non-responsive in comparison to
S202responsive tumors (p<0.0001). Real Time PCR on 30 core biopsies
from patients treated in our Institute with neoadjuvant therapy,
revealed 3 times higher SerpinB5 expression in non-responder
patients in comparison to responders (p=0.002).
To understand the role of SerpinB5 in response to therapy we
infected breast carcinoma cells MCF7 with SerpinB5 (MCF7-Ser).
Tumors from nude mice xenografted with MCF7-Ser presented
reorganized accumulation of collagen fibers. Immunofluorescence
analysis by confocal microscopy showed a dramatically decreased
localization of doxorubicin (DXR) within tumors from MCF7-Ser
in comparison to mock cells, suggesting that resistance to
chemotherapy in patients with SerpinB5 overexpressing breast
carcinomas could derive from less drug diffusion.
To investigate the importance of extracellular matrix amount in
drug diffusion and efficacy, we injected HER-2-overexpressing
cancer cells in nude mice, mixed or not with Matrigel. Matrigel-
mixed tumors resulted significantly (p<0.01) more resistant to
DXR and showed lower apoptosis levels compared to those
without Matrigel. Analysis by imaging mass spectrometry and
immunofluorescence revealed lower uptake of DXR, confirming
that dense matrix could be responsible for tumor chemoresistance
through drug diffusion inhibition.
Using hydrophilic liposome based DXR formulation, DXR has
been detected also in Matrigel-mixed tumors, suggesting that the
less free drug diffusion could be due to its physical-chemical
properties. Accordingly treatment with hydrophilic-drug Trastu-
zumab resulted more effective in tumors from Matrigel-mixed
cells and the presence of the bio-drug, analyzed by immunoflu-
orescence and radioimmune localization assay, was higher in
tumor cells surrounded by dense extracellular matrix.
In conclusion extracellular matrix accumulation impacts drug
diffusion according to drug physical properties.
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While the roles of tumor-associated macrophages (TAMs) in
brain tumors are extensively studied recently, the distinct roles of
subtypes of TAMs on tumor progression or caner therapy remain
unclear. To define the roles of different subtypes of TAMs within
brain tumors, the spatial distribution of CD11b-positive or CD68-
positive TAMs within GL261 murine glioma cells grown
intracranially in C57/BL6 mice were first examined. We found
that CD11b-positive TAMs within the highly cellular tumor were
mainly distributed along the tumor border. On the other hand, the
CD68-positive TAMs were more centered in tumor core. This
indicates that intracranial growing tumors may have two distinct
subtypes of TAMs and they may have different origins. To further
address this question, bone marrow-derived monocytes from GFP
mice were i.v. injected into GL261 tumor-bearing mice. One
week after the transplantation, a patch of GFP positive cells were
found to be co-localized with CD11b staining in brain tumor
region under confocal microscopy. These cells have apparently
characteristic of macrophage with kidney-shaped nuclei. These
data indicate that not only local microglia proliferation and
migration into the tumor, furthermore, the peripheral monocytes
can also infiltrate into the brain tumor. To further dissect the
origins of CD11b-positive and CD68-positive TAMs within brain
tumors, the bone marrow transplantation model is currently
undertaken.
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Cells usually respond intrinsically to the perception of DNA
damage by initiating the DNA damage response (DDR) that leads
to cell-cycle arrest and repair. For instance, critical shortening or
chromatin alterations of telomeres activates DDR, thereby induc-
ing senescence or apoptosis. Interestingly, the DDR pathway does
not only lead to cell-cycle arrest, repair and senescence but also to
an inflammation environment and to the activation of innate
immune responses that remove senescent cell from the organism.
Therefore, genome integrity is kept in check by both intrinsic and
extrinsic mechanisms suggesting unexpected links between DNA
alterations, immunity, aging and cancer
[1].
Many unknowns remain in the description and understanding of
these extrinsic responses to genome injury and in particular in
their role during oncogenesis. Our laboratory recently provide
evidence that the essential telomere protein TRF2 controls a DDR-
independent extracellular anti-tumor program via activation of
natural killer cells
[2].
We investigate here the function of the TRF2-interacting protein
Apollo, which is an ortholog of the Artemis factor. We found that
TRF2 and Apollo prevent cells to enter into senescence by
preventing breakage during telomere replication. In particular, the
expression of a mutated form of Apollo abolishing its 5′-
exonuclease activity but preserving its telomeric location does
not complement the damaged telomeres resulting from a dimin-
ished expression of endogenous Apollo. Moreover, the expression
of this nuclease-dead allele of Apollo or of a dominant-negative
form of TRF2 triggers the DDR pathway at chromosome ends but
also at an interstitial telomeric DNA region. We propose that
TRF2 regulates an Apollo-mediated nucleolytic processing of
S203telomere structures prone to break DNA during replication. We
will discuss the possibility that the overexpression of TRF2 and
Apollo observed in different types of human cancers protects
malignant cells from intrinsic and extrinsic anti-cancer barriers
suggesting that these proteins would be valuable therapeutic
targets to modulate tumor-microenvironment.
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